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Conventional treatments for prostate cancer have significant limitations making it difficult to 
control the disease. Cyclopropabenzindoles (CBI) are more biologically potent, stable and 
synthetically accessible analogues of cyclopropapyrroloindole (CPI) anti-tumour antibiotics, 
such as duocarmycin-SA and CC1065. A polymeric prodrug carrying a CBI drug attached to 
the polymeric backbone through a PSA-cleavable linker peptide has two modes of selectivity: 
activation by PSA and the EPR effect. To synthesise a 5-amino-seco-CBI analogue, 2,4-di-
nitronaphthalen-1-ol gave di-Boc-1-iodonaphthalene-2,4-diamine in five steps (triflation, 
SNAr displacement with iodide, reduction (loss of iodine), protection and restoration of the 
iodine. For the amino-seco-CBI, it was important to discriminate between N2 and N4. Acidic 
removal of the Boc-group(s) resulted in deiodination. NMR investigations showed an 
unexpected Wheland-like cationic intermediate. N3 of naphthalene-1,3-diamine was 
selectively trifluoroacetylated and N1 was masked with Boc. Electrophilic iodination gave an 
orthogonally protected 1-iodonaphthalene-2,4-diamine. Allylation at the trifluoroacetamide 
was followed by free radical cyclisation with TEMPO trap. Removal of the trifluoroacetyl 
group allowed coupling to 5-(2-(dimethylamino)ethoxy)-1H-indole-2-carboxylic acid. 
Reductive removal of 2,2,6,6-tetramethylpiperidine, substitution of the exposed hydroxy 
group with chloride and removal of the Boc-group gave the amino-seco-CBI drug, 5-amino-1-
chloromethyl-3-(5-(2-dimethylaminoethoxy)indole-2-carbonyl)-2,3-dihydro-1H-
benz[e]indole. A DNA-melting assay confirmed that it binds very strongly to dsDNA causing 
a 13 deg. C increase in melting temperature. The drug was a highly potent cytotoxin in vitro, 
with IC50 = 18 nM against LNCaP prostate cancer cells. The polymeric prodrug system 
involved the synthesis of the pentapeptide SSKLQ. The amide side chain of glutamine can be 
masked as the nitrile and this can be quantitatively hydrated to the -carboxamide of L-Gln 
with hydroperoxide. The pentapeptide was coupled to 4-methoxynaphthalen-1-amine and to 
poly(ethylene glycol) as a model polymeric prodrug system. Efficient release of the model 
drug from the polymeric prodrug by PSA will allow this polymeric prodrug system to be 
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The walnut-sized prostate gland is the site of two of the most commonly encountered medical 
problems in elderly men; benign prostatic hyperplasia (BPH) and prostate cancer (PCa). The 
prostate gland is part of the male reproductive system lying in front of the rectum just beneath 
the bladder and surrounding the upper part of the urethra. 
 
1.1 Prostate development 
The development of prostate gland starts around the 10th week of gestation triggered by 
production of testosterone by the foetal testis around week 8. Binding of α-
dihydrotestosterone to androgen receptors in surrounding mesenchymal tissue causes the 
initial growth of prostate buds from the urogenital sinus (UGS). These outgrowths undergo 
extensive morphogenesis during the latter days of foetal growth. Influence of androgens 
during the postnatal stage results in further differentiation and development of the secretory 
role of the prostate. The posterior part of the prostate is the glandular region, whilst the 
anterior section of the prostate is entirely fibromuscular in nature.1  Up to 40% of PCa occurs 
in the anterior section of the prostate gland.2  
 
1.2 Zones of the prostate 
The prostate consists of four anatomical zones based on biological and histological concepts. 
The zones originate from the prostatic urethra and have different features.3  
 
1.2.1 Peripheral zone 
The peripheral zone (PZ) is the outermost area and consists of relatively small and round 
uniformly distributed acini. It has a fibromuscular stroma made up of a meshwork of loosely 
arranged smooth muscle fibres separated by numerous collagen fibres and irregular spaces. 
This zone consists of columnar secretory cells with small uniform basal nuclei and regular 
luminal border. The PZ makes up about 70% of the glandular part of the prostate. The 
majority of prostate carcinoma occurs in this zone. 3, 4 
 
1.2.2 Central zone 
The epithelium of the central zone (CZ) consists of a stroma containing muscle fibres closely-
packed together and extending to the borders of the acini. The acini in the central zone are 
large and relatively rectangular in cross section and are separated by the stroma. Irregularly 
2 
 
arranged secretory cells with large nuclei are seen in this zone. There are fewer stromal 
components in CZ compared to PZ and transition zone (TZ). About 25% of the glandular 
prostate that surrounds the ejaculatory duct is the central zone. The zone is said to be resistant 
to cancer and other disease.3, 4  
 
1.2.3 Transition zone 
The transition zone rests next to the urethra and its morphology resembles that of the 
peripheral zone. The acini are uniformly distributed and the stroma consists of compactly 
arranged smooth muscle and collagen fibres. The zone grows with age and is frequently the 
site for benign prostatic hyperplasia.3, 4 
 
1.2.4 Periurethral zone 
This zone contains underdeveloped small ducts and acini. Muscle and collagen fibres in the 
periurethral region are compactly arranged. It makes up just a small fraction of the transition 
zone.3  
 
1.3 Functions of the prostate gland 
The prostate gland has a range of functions including its participation in the control of urine 
output from the bladder through its mass and musculature. It also aids in the transmission of 
seminal fluid during ejaculation. As an exocrine gland, it contributes to the seminal plasma by 
secreting a thick, milky-white fluid which is liquefied by prostate-specific antigen (PSA), an 
enzyme also secreted by the prostate. The liquefied milky fluid becomes part of the semen. 
This fluid contains small molecules and enzymes like coagulase and fibrinolysin which help 
fertility and are involved in coagulation. Prostatic secretion reduces the acidity of urethra and 
helps to keep sperm viable. The secretion also help improves the motility of sperm. Prostatic 
acid phosphatase produced by the prostate is directly involved in the nutrition of sperm cells 
by hydrolysing phosphorylcholine to choline. The prostate helps with the rapid metabolism of 
testosterone to dihydrotestosterone and appears to be responsible for the high level of zinc in 
the seminal plasma which acts as an antibacterial agent helping to protect sperms.5, 6  
 
1.4 Prostate conditions 
The prostate gland is prone to a number of medical conditions but mainly, benign prostatic 
hyperplasia (BPH), prostatitis and prostate cancer (PCa).  
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1.4.1 Benign prostatic hyperplasia (BPH) 
Benign prostatic hypertrophy is defined as an increased in number of parenchymal cells and 
occurs almost exclusively in the transition zone of the prostate gland.7 The condition is 
associated with age and around 60% of men aged 60 years and above have a degree of 
prostate enlargement. Causes are unknown but BPH is thought to be associated with hormonal 
changes, food and lifestyle. Symptoms include increased urinary frequency and weakened 
urinary flow as the enlargement places pressure on the bladder and the urethra. Treatment 
options include lifestyle changes, medications and surgery. BPH does not necessarily increase 
one’s chance of getting prostate cancer.8-10  
 
1.4.2 Prostatitis  
Prostatitis is the inflammation of the tissues of the prostate gland. This can be due to infection 
(acute) or idiopathic in origin (chronic). Infection is mainly due to E. coli. It is estimated that 
one in seven men will develop at least one episode of prostatitis in their lifetime. Unlike other 
prostate conditions, prostatitis affects men of all ages (~10%) with majority of incidence 
present in those in their 40s. Symptoms include pelvic pain and pain on urination. It is 
managed with medications (e.g. antibiotics and pain killers).11-13  
 
1.4.3 Prostate cancer 
In the UK, prostate cancer (PCa) is the most common cancer in men. Early intervention is 
critical for successful treatment but most men do not seek help until it is too late.14  
 
1.4.3.1 Incidence 
There is a 40% lifetime risk of developing prostate cancer for a male born in the Western 
world. The risk of becoming symptomatic is, however, only 10%.15 About 14% of male 
cancers are prostate cancers in developed countries compared to 4% of male cancers in less-
developed countries. Prostate cancer is the most common solid tumour in Europe accounting 
for an incidence rate of 214 cases per 1000 men.16  About 190,000 new cases of prostate 
cancer are recorded in Europe yearly.17 There are 21,400 new cases of PCa diagnosed in the 
UK annually, a rate of 74 cases per 100,000.15 In England and Wales, one in thirteen men is 





1.4.3.1.1 Age-adjusted incidence 
PCa is rare under the age of 40 and the incidence increases exponentially with age. Age-
adjusted incidence rates vary worldwide, with the highest rate found in African Americans 
(185.4 per 100,000 person-years) whilst the lowest incidence is found in Asian countries (e.g. 
China, India, Thailand, Pakistan, and Shanghai; 3-7 per 100,000 person-years). Incidence 
rates in Europe vary (15-100 per 100,000 person-years) and are highest in Western Europe. 
Incidence data from African countries is sparse with incidence apparently ranging 2-37 per 
100,000 person-years).19, 20  
 
1.4.3.2 Mortality 
Prostate cancer is the second most common cause of deaths in men in most developed 
countries.16 Higher mortality rates are recorded in Western nations compared to the lower 
mortality in low-risk Asian countries (Figure 1)20.  
 
Carribean nations with large populations of men of African descent have the highest rate of 
mortality (30.3-47.9 per 100,000 person-years) and mortality in Asian countries (South 
Korea, Philippines and Japan) is the lowest (1.6-4.4 per 100,000 person-years).19 The disease 










































































































































Figure 1: Age-adjusted prostate cancer mortality rates per 100,000 men in various countries for the year 2000.20 
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death rate since 1985 in most countries.16 Death rates have trebled in the last thirty years in 
England and Wales.18  
 
1.4.3.3 Aetiology  
Seventy-seven loci suspected to be associated with PCa development have been identified.21  
Prostate cancer is thought to be due to a series of genetic mutational events which begins with 
the loss of tumour suppressive genes like p53 and p21. Mutation of p53 occurs in up to 64% 
and that of p21 up to 55% in prostate tumours. The gene, p73, which has significant 
homology with p53, also appears to be mutated in many prostate cancers. The most mutated 
tumour suppressor gene in prostate cancer is MMAC1 / p10 and this may be responsible for 
acquisition of the metastatic phenotype. Over-expression of mutant p53 and bcl-2 family 
proteins (regulates apoptosis), as well as amplification of the androgen receptor, appears to be 
related to the development of the hormone-refractory phenotype of prostate cancer.18 The 
genes RNASEL and MSR1 are linked to some familial clusters of PCa. RNASEL encodes for 
a ribonuclease enzyme responsible for the degradation of cellular and viral DNA upon 
infection and MSR1 encodes for subunits of a macrophage scavenger. Four brothers with PCa 
were found to carry RNASEL alleles with the base substitution 795G→T, whilst, in another 
four of the six affected brothers, it was found that they carried RNASEL alleles with a base 
substitution 3G→A.7 Defective MSR1 alleles have been found to be linked to familial PCa and 
also sporadic PCa cases.7 Germline mutation in BRCA2, which has a tumour suppressor role, 
can also increase the relative risk of prostate cancer by 4.65.21-23  It is estimated that between 
0.8-2% of men with early-onset prostate cancer have BRCA2 mutation.23 A genetic variant 
linked with prostate cancer in European and Africans has been identified on chromosome 
8q24. This genetic variant occurs at high frequency in African Americans which could 
explain why the incidence of prostate cancer is high in this group of people. Other important 
aetiological factors include diet, pattern of sexual behaviour, alcohol, and ultraviolet radiation 
exposure.17   
 
1.4.3.4 Risk factors 
A range of risk factors are implicated in the development of PCa. Some of these risk factors 




Prostate cancer incidence increases exponentially with age, an increase faster than for other 
malignancies.19 There is an increase in risk from 0.005% among individuals aged < 39 years 
to a risk of 2.2% for those aged 40-59 years and 19.7% in those aged 60-79 years. Studies 
suggests that a 50-year-old male has a lifetime risk of 42% for showing histological evidence 
of PCa, a 9.5% risk of developing the disease and a 2.9% risk of dying from the disease.20  
 
1.4.3.4.2 Family history and genetic susceptibility 
The risk of PCa at least doubles if one first-line relative has the disease, increasing by 5-11-
fold if two or more first-line relatives are affected. About 9% of individuals with PCa have 
true hereditary PCa which is defined as having three or more relatives affected or having at 
least two relatives who developed the disease before the age of 55.16 Men with positive family 
history tend to be diagnosed earlier (~6 to 7 years) than those whose first degree relatives are 
not affected by the disease. Studies suggest that 5-10% of all PCa cases and up to 40% of PCa 
occurring in men < 55 years may be due to heredity.20 Men with family history of breast 
cancer (mutated  BRCA1 and BRCA2 genes) have been linked to an increased risk of PCa.23  
 
1.4.3.4.3 Diet and physical activities  
Exercise has a tendency to decrease the risk of prostate cancer with smoking increasing the 
risk. The relationship with consumption of alcohol is, however, unknown. Body-mass index 
and lean body mass are positively correlated to the risk of prostate cancer. Intake of tomatoes 
(containing the antioxidant lycopenes) and cruciferous vegetables (containing the antioxidant 
sulforaphane) is found to reduce risk to the disease. Diets poor in selenium and Vitamin E can 
also increase the risk of PCa. Consumption of soya products with high concentrations of 
phyto-oestrogens has a protective effect against prostate cancer.7, 17 Other environmental 
factors implicated in PCa are high intake of saturated fat and exposure to radiation.18  
Increased total fat intake, animal fat intake and consumption of red meat have been linked 
with increased risk of prostate cancer. Meats cooked at high temperatures or grilled on 
charcoal grills produce heterocyclic aromatic amine and polycyclic aromatic hydrocarbon 
carcinogens (e.g. 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine) which caused prostate 




Studies have shown that farmers and other agricultural workers have a 7-12% increased risk 
of prostate cancer. This could be due to chemicals encountered in agriculture, such as 
fertilisers, solvents pesticides and herbicides which have a variety of poorly characterised 
effects. Furthermore, people working in heavy industries, rubber manufacturing and 
newspaper printing may be at increased risk, suggesting that exposure to certain chemicals or 
other factors may increase the risk of prostate cancer.19  
 
1.4.3.4.5 Sex steroid hormones 
There is little evidence to suggest that overexposure to androgens causes human PCa. 
However, men castrated before puberty tend to have atrophic prostates, which are not prone to 
PCa.7, 25  Relatively high levels of testosterone have been found in African-American men, 
which might explain the higher incidence of PCa compared to Caucasian men.25 Studies in 
animals have demonstrated that testosterone can promote or even initiate the development of 
PCa. An explanation given is that through the action of aromatase, testosterone is converted to 
oestrogens which act as a carcinogen similar to its effect in the development of breast cancer. 
Supporting this is the fact that several countries with high rates of PCa also have a high breast 
cancer rates. Caucasians tend to have lower oestrogen levels, compared to African-Americans 
who have higher PCa rate. Administration of 17β-oestradiol to adult male Wistar rats 
increased prostatic inflammation.7, 26  
 
1.4.3.4.6 Infections and inflammation 
Men with prostatitis display a relative risk of 1.3 towards developing PCa. Men at young ages 
with high levels of PSA, (probably indicating damage or dysfunction to the prostate 
epithelium by infection), tend to be at higher risk. A study has shown that men between 40-50 
years whose PSA level is greater than 0.6 ng mL-1 have a relative risk of 3.8 of developing 
PCa.  When the prostate of mice is exposed to bacteria and viruses, this triggers immediate 
inflammatory response and subsequent PCa precursor lesions. Sexually transmitted diseases 
have been epidemiologically associated with increased risk to PCa. Epstein-Barr virus and the 
murine retrovirus XMRV have been detected in PCa cells and tissues.7, 27 Other risk factors 





Figure 2 shows the different factors that influence the development of PCa.7, 24 Inflammation 
of the prostatic epithelium is implicated in the carcinogenesis of PCa. Initial damage to 
prostate epithelium maybe due to: 
 Infection ; 
 Reactive oxygenative species (ROS);  
 Reactive nitrogen species (RNS); 
 Dietary carcinogens; 
 Oxidative stress. 
    
All these lead to genomic damage. The damage to the prostatic epithelium results in the 
appearance of lesions termed proliferative inflammatory atrophy (PIA), a precursor to 
prostatic intraepithelial neoplasia (PIN) and PCa. Epigenetic silencing (GSTP1), telomere 
shortening and activation of c-Myc gene expression trigger the pathogenic steps of PCa. 




















• Genetic changes and 
genetic instabilities











• Continued accumulation 
of genetic changes
Figure 2: Pathogenesis of prostate cancer.7,  24 
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all PCa cases, seems to occur at the very initiation of transformation between proliferative 
inflammatory atrophy and prostatic intraepithelial neoplasia or prostate cancer. GSTP1 is a 
glutathione S-transferase gene responsible for deactivating electrophilic carcinogens. 
Silencing of this gene by hypermethylation leaves cells with increased vunerability to 
carcinogens. Changes in DNA caused by epigenetic gene silencing may be the very earliest 
changes in the somatic genome.7, 28, 29 Telomere is involved in stabilising chromosomes by 
preventing deleterious recombination and loss of DNA sequences. Telomere consists of 
repeated DNA sequence (5’-TTAGGG-3’) bound to telomere-binding protein at the end of 
linear chromosomes. The DNA length of telomere can be shortened during cell division due 
to incomplete replication or as a result of oxidative damage. In normal cells, critically short 
telomeres trigger the initiation of apoptosis or an irreversible cell cycle arrest. This telomere 
length monitoring system is said to be inactivated in cancer cells leading to critically short 
telomeres. This give rise to genetic instabilities such as chromosomal fusion, breakage and 
rearrangement since telomere can no longer perform its function of stabilising chromosomes. 
PIN and PCa have been shown to display telomere shortening especially in the luminal 
epithelial cells.7, 30-32 The overexpression of the oncogenic transcription factor, c-Myc protein, 
is observed in PIN lesions and prostatic adenocarcinomas.33 Further epithelial damage occurs 
until an epigenetic gene mutation results in creating a transformed cell. Continual epigenetic 
and genetic instability leads to metastatic carcinoma. Formation of fusion transcripts between 
TMPRSS2 (an androgen-regulated differentiation gene) and oncogens such as ERG and 
ETV1 occur. This results in tumour cells opting out of androgen-regulated differentiation 
which normally suppress cell proliferation. Amplification and overexpression of androgen 
receptors increases the sensitivity of PCa cells to low levels of androgens thereby making 
them resistant to androgen deprivation.24  
 
1.4.3.6 Diagnosis 
Procedures used in the diagnosis of PCa include:  
 Digital rectal examination (DRE);  
 PSA blood test; 
 Trans-rectal ultrasound (TRUS);  




1.4.3.6.1 Digital rectal examination 
DRE involves the physical examination of the prostate gland to detect signs of tumour 
growth. When the volume of prostate tumour is about 0.2 mL or larger, it may be detected by 
DRE as most PCa are located in the peripheral zone of the prostate.16  Tumours arising in the 
anterior to the midline of the prostate (up to 40%) is not detected by this diagnostic method. 
Only tumours located at the posterior and lateral part of the prostate can be detected by DRE. 
The chance of detection of tumours < 1.5 cm is only 41%.2 The prostate gland is assessed for 
nodules, hardening and thickening of tissue. DRE alone can sometimes determine the need for 
further investigations.25  
 
1.4.3.6.2 PSA blood test 
PSA is a kallikrein-like serine protease exclusively secreted by the epithelial cells of the 
prostate. PSA levels greater than the reference range (Table 1)35 is indicative of prostate 
disease. The higher the level of PSA in serum, the greater the chance of being diagnosed with 
PCa.  
 Table 1: Age specific reference ranges for PSA     
Increases in serum PSA levels do not occur 
exclusively in PCa. Other prostate conditions 
such as BPH and prostatitis can result in high 
PSA levels. Furthermore, some diagnosis of 
PCa has been made despite low levels of PSA. 
Serum PSA level is therefore not an absolute 
diagnostic tool for PCa.16 For instance, if the 
usual cut of level of 4 ng mL-1 PSA level is used to determine when further investigations are 
needed, the specificity of the PSA serum test is only 40%. This means if men with PSA level 
> 4 ng mL-1 undergo biopsies, about 60% will not be diagnosed as PCa patients. Futhermore, 
only 30% of men with PSA range of 4-10 ng mL-1 are diagnosed to have PCa. Patient with 
organ confined PCa tend to give a false negative PSA test results (< 4 ng mL-1) and 15% of 
men with PSA levels < 4 ng mL-1 will have PCa.34, 35 Due to these limitations, several 
modifications of serum PSA value have been described with the aim of improving specificity 
of PSA in the early detection of PCa.16 The age-adjusted PSA levels has been suggested to 
take into account the effect of age on PSA levels (Table 1). The free / total PSA (fPSA / 
tPSA) ratio is the modification most widely used in clinical practice to discriminate between 
BPH from PCa.16 Men with PCa tend to have a relatively decreased fPSA / tPSA ratio as a 
 
Age (years) 
Normal PSA range (ng mL-1) 















result of lower proportion of fPSA whilst in BPH, the total detectable PSA is lower and hence 
the fPSA / tPSA ratio higher.35 The ratio is mainly used to assess the risk to PCa in men 
whose PSA levels lie between 4 and 10 ng mL-1 with a negative DRE.16  
 
1.4.3.6.3 Trans-rectal ultrasound and needle biopsy 
TRUS is used to obtain images of the prostate. Abnormal ultrasonic features include hypo-
echoic areas, loss of differentiation of zones, asymmetry and capsular distortion.27 TRUS is 
increasingly used to guide transrectal core biopsies which involve examination of the 
histopathological or cytological of specimens from the prostate gland.17, 25  
 
1.4.3.6.4 Grading and clinical staging 
Grading and staging of PCa is used to ascertain the level of tumour development and to help 
decide on treatment choice. The Gleason grading system (1 → 5) of prostate cancer is based 
on the extent of glandular differentiation. The sum of two of the most common patterns of 
tumour growth gives the Gleason score. This ranges from 2, being the least aggressive to 10, 
the most aggressive.16, 18 The most frequently used method to describe the spread of prostate is 
the TNM (Tumour, Lymph Nodes and Metastasis) staging classification.18 Table 2 gives the 
























Table 2: Gleason grading and TNM staging of prostate cancer.18, 35  
Gleason grading  TNM staging 
Grade 1: Well differentiated 
carcinoma with uniform gland 
pattern. 
Grade 2: Well differentiated 
with glands varying in size and 
shape. 
Grade 3: Moderately 
differentiated carcinoma with 
either (a) irregular acinae often 
widely separated or (b) well 
defined papillary / cribriform 
structures.  
Grade 4: Poorly differentiated 
carcinoma with fused glands 
widely infiltrating the prostatic 
stroma. 
Grade 5: Very poorly 
differentiated carcinoma with 
no or minimal gland 
formation. Tumour cell masses 
may have central necrosis. 
T1: Tumour not palpable nor visible by imaging 
(a) Incidental finding in < 5% of resected tissue 
(b) Incidental finding in > 5% of resected tissue 
(c) Tumour identified by needle biopsy  
T2: Tumour confined to prostate 
(a) Involving half lobe or less 
(b) Involving more than one half of one lobe 
(c) involving both lobes 
T3: Tumour extends through the prostatic capsule 
(a) Extracapsular extension 
(b) Tumour invades seminal vesicles 
T4: Tumour is fixed or invades adjacent structures 
other than seminal vesicles 
(a) Invades bladder neck and/or external sphincter 
and/or rectum 
(b) Invades levator muscles and/or is fixed to pelvic 
wall 
N1: Metatases in regional lymph node(s) 
M1: Distant metastases 
(a) Non-regional lymph nodes 
(b) Bone 
(c) Other sites  
 
1.4.3.7 Presentation 
Initial stages of PCa are often asymptomatic and are increasingly diagnosed at routine PSA 
testing and DRE. Symptoms are experienced when about 80% of the tumour has locally 
advanced or metastasised. Lower urinary tract symptoms are the most common complaint. 
Renal failure at presentation can occur due to locally advanced tumour obstructing the ureters. 
Pain and pathological fracture can result from metastasis to the bone. Metastasis to the spinal 
cord can cause spinal cord compression which leads to symptoms such as urinary and faecal 
incontinence and limb weakness. Haematuria may occur secondary to infection or damage to 
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the prostate gland. Weight loss, cachexia, perineal pain and signs of lymphatic obstruction in 
the form of lymphaoedema can occur in advanced disease states.18, 27 
 
1.4.3.8 Management  
The management of PCa is dependent on the stage of the disease. The slow progression of 
PCa means that majority of men can live with the disease without the need for treatment. A 
range of treatment regimens are available to treat patient with varying degree of disease 
progression. 
 
1.4.3.8.1 Localised prostate cancer 
This refers to tumour confined within the prostate gland. A risk category based on PSA level, 
Gleason scores and clinical staging is assigned to men with localised PCa. This helps to 
determine the risk of recurrence and to decide which treatment options are recommended to 
patients. 
 
1.4.3.8.1.1 Watchful waiting and active surveillance 
Watchful waiting and active surveillance involve no active treatment until progression of 
disease occurs. In watchful waiting, initiation of treatment is dependent on symptomatic 
progression (symptom-guided treatment), whilst in active surveillance (active monitoring), 
serial PSA monitoring and TRUS guided biopsy are carried out, allowing regular re-
assessment of risk category to inform when treatment should be initiated.16, 25, 34  
 
1.4.3.8.1.2 Radical prostatectomy 
This involves the surgical removal of the prostate, seminal vesicles and pelvic nodes if 
necessary. This treatment option is thought to be the best curative method for men with 
localised PCa. Radical prostatectomy is proven by a randomised controlled trial to reduce the 
development of metastases and reduce mortality. Side-effects include impotence (> 29%) and 




1.4.3.8.1.3.1 External beam radiotherapy (EBRT) 
This involves delivery of external radiation to the prostate tumour in daily fractions over 4-8 
weeks. Intensity-modulated radiotherapy with / without image guiding is the gold standard of 
EBRT. It involves incremental delivery of radiation of upto 86 Gy to the tumour whilst 
reducing radiation risk to surrounding organs. Radiation toxicity to the bladder and bowel is 
common as these can fall within the field of radiation. Damage to the neurovascular system 
may result in erectile failure.16, 25, 27, 34  
 
1.4.3.8.1.3.2 Brachytherapy 
This is a form of radiation therapy involving permanent implantation of radioactive seeds 
(low dose rate) or temporary implantation of radioactive wires (high dose rate) directly into 
the prostate under ultrasound control. Side-effects include impotence (50-60%), urinary 
incontinence (up to 30%) and bladder damage (10-20%).25, 27, 34  
 
1.4.3.8.1.4 Experimental local treatment  
Heating the prostate gland using High-frequency ultrasound (HiFU) or freezing the prostate 
gland using cryotherapy are used to eradicate prostate cancer.16, 34  
 
1.4.3.8.2 Metastatic prostate cancer 
Metastatic prostate cancer has a poor outlook with 90% mortality within 5 years. Androgen 
withdrawal either surgically or medically can control the disease for several years.27, 34  
 
1.4.3.8.2.1 Hormonal therapy 
About 20-30% of prostate tumours will not respond to this form of treatment. Androgen 
deprivation is achieved through orchidectomy or the use of luteinizing hormone-releasing 
hormone (LHRH) agonists to reduce testosterone levels to castration levels (< 50 ng dL-1) 
(Figure 3). Anti-androgens acts at the receptor level in prostate cancer to counteract the effect 
of testosterone. The combination of androgen deprivation and the use of anti-androgens 






1.4.3.8.2.2 Bilateral orchidectomy 
Reduction of testosterone levels is achieved by removal of both testes. Common side-effects 
are hot flushes, loss of libido and impotence.25  
 
1.4.3.8.2.3 Luteinizing hormone-releasing hormone (LHRH) receptor agonists (e.g. 
busereline, gosereline) 
These are used to reduce the level of testosterone by over-stimulating the LHRH receptors in 
the pituitary gland to stop release of luteinising hormone via a negative feedback mechanism 
(Figure 3). The long-term effect of these drugs is to down-regulate LHRH receptors.36 This 
leads to the reduction of testosterone to castration levels within 2-4 weeks. However, about 
10% of patients fail to achieve castration levels of testosterone. Reduction in tumour size 
occurs as well as slowing of the progression of tumour growth. These agents, however, do not 
eradicate the disease. The initial action of these drugs result in rapid increase in testosterone 
levels which can result in worsening of symptoms (e.g. increased bone pain, spinal cord 
compression). It is therefore recommended to start these drugs together with anti-androgens 
for two weeks to reduce the risk of symptom flare-ups. Side-effects of LHRH receptor 


























agonists include reduction in sex drive and impotence which are reversible on cessation of 
medication.16, 25  
 
1.4.3.8.2.4 LHRH antagonists (e.g. degarelix) 
These agents competitively inhibit LHRH receptors in the pituitary gland to bring about 
reduction of LH and therefore testosterone. One advantage over LHRH agonists is that, these 
agents do not cause initial surge in testosterone levels and therefore need not to be given 
together with anti-androgens. Castration levels of testosterone is said to be achieved within ~3 
d. Serious life-threatening side-effects have been associated with some of these agents.16  
 
1.4.3.8.2.5 Androgen receptor antagonists 
Androgen receptor antagonists inhibit the effects of testosterone by blocking androgen 
receptors on the prostate gland (Figure 3). There are two classes of this group of agents 
namely, steroidal and non-steroidal anti-androgens.25  
 
Steroidal anti-androgens (e.g. cyproterone acetate): This group of drugs are derivatives of 
hydroxyprogesterone and therefore have progestational properties. In addition to peripherally 
inhibiting androgen receptors, these drugs inhibit the release of LH and also suppress adrenal 
activity thereby reducing testosterone levels.16  
 
Non-steroidal anti-androgens (e.g. bicalutamide): These drugs only inhibit androgen receptors 
without inhibiting the secretion of testosterone.16  
  
Side-effects of these agents include breast enlargement, breast pain and hepatotoxicity. These 
agents also do not eradicate the disease but only serve to slow the progression.16, 25  
 
1.4.3.8.3 Hormone-refractory prostate cancer 
There is no known curative therapy for hormone-resistant PCa. Treatment is symptomatic and 
aims to improve quality of life and survival. A combination of docetaxel and prednisolone is 
licensed for treatment of this form of PCa. Docetaxel belongs to the taxane family and brings 
about apoptosis of cancer cells through inhibition of microtubule depolymerisation.34, 37 This 
therapy also affects highly proliferating cells such as those of the bone marrow and intestinal 
epithelium as well as the tumour cells. This lack of selectivity results in immunosuppression 
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and gastrointestinal disorders. The side-effects are such that the use of docetaxel may not be 
possible if the cancer has progressed to a stage where it is causing significant symptoms. 
Those who cannot tolerate docetaxel are usually treated with the combination of mitoxantrone 
and prednisolone.25, 34 Cabazitaxel is also licensed to be used with prednisolone / prednisone 
to treat hormone-refractory PCa. It is normally used in patients who have been on doctaxel 
containing regimen in the past. Hypersensitivity is a common side-effect with this new drug.37   
 
The newly licensed drug, abiraterone (Figure 4) is a selective 
inhibitor of androgen biosynthesis which acts by irreversibly 
blocking CYP17A1 an enzyme involved in the synthesis of 
testosterone. It is licensed in the UK for use with prednisone / 
prednisolone for the treatment of metastatic castration-resistant 
PCa in men whose disease has progressed on or after a docetaxel-
based chemotherapy regimen.37, 38 Sipuleucel-T is a cellular 
vaccine designed to stimulate immune response against prostatatic acid phosphatase 
expressing prostate cancer cells.37, 39 The radioisotope radium-223 and the anti-androgen, 
enzalutamide are also in use to manage hormone resistance PCa.40  
 
Ongoing trials are investigating different agents to treat PCa. These include inhibitors of 
intratumoural androgen synthesis (e.g. orteronel), inhibitors of angiogenesis (e.g. 
cabozantinib, tasquinimod) and immunomodulatory agents (e.g. ipilimumab).37, 39 Second-line 
hormonal therapy with oestrogens or estramustin phosphate may give partial response but has 
not been shown to improve survival.27 
  
1.4.3.9 Novel therapeutic approaches 
The lack of curative therapy for PCa and the many downsides with current therapies resulting 
from their non-selectivity has driven researchers to look into alternative therapies. The 
naturally occurring cyclopropapyrroloindole (CPI) anti-tumour antibiotics are represented by 
CC-1065 and duocarmycin SA. This family also includes duocarmycin A and yatakemycine, 
which are all derived from the fermentation cultures of Streptomyces sp.41  
 
They are very potent cytotoxics with IC50s against mammalian cell lines (e.g. leukaemia, 
pancreatic, renal and prostate tumour cell lines) in the picomolar range (Figure 5).42, 43Li et 
al.43 have shown that in contact with L1210 cells for 3 d, the dose of CC-1065 required for 




50% inhibition of growth (ID50) is 0.017 ng mL-1 (24.2 pM). These compounds contain a 
cyclopropapyrroloindole (CPI) DNA-alkylating pharmacophore (Figure 5) and derive their 
biological activity through selective alkylation in the minor groove of duplex DNA offering a 
new mode of cancer treatment.41, 44, 45  
  
These drugs, however, have proven to have too many toxic side-effects precluding them from 
clinical developments. For instance, admininistration of a single dose of CC-1065 to healthy 
mice resulted in delayed deaths (50-90 d) caused by hepatotoxicity.46 The downsides of the 
natural products have led to the synthesis of many analogues (adozelesin, carzelesin, KW-
2189, and bizelesin). Although these analogues show promising anticancer activities in 
animal model, all have failed in clinical trials in humans due to myelotoxicity.47-49  
 
1.4.3.9.1 Mechanism of the anti-tumour antibiotics  
The pharmacophore of these compounds can be divided into the alkylating subunit and the 
DNA-binding non-alkylating subunit (Figure 5). The anti-tumour antibiotics effect a sequence 
selective alkylation of double-stranded DNA. 
  
  
Figure 5: Structures of selected natural anti-tumour antibiotics. 
 
(+) Duocarmycin SA 
IC50 (L1210) = 10 pM 
(+) Duocarmycin A 
IC50 (L1210) = 200 pM 
(+) CC-1065 IC50 
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(+) Yatakemycin      







Binding to the DNA is aided by the non-alkylating subunit and occurs in the AT-rich regions 
of the minor DNA groove. Initial binding is via hydrophobic interactions and van der Waals 
forces. The binding causes a twist in the tumour antibiotic allowing alignment of adenine N3 
with the electrophilic strained cyclopropane ring. A reversible stereoelectronically-controlled 
covalent addition of adenine to the least substituted carbon of the cyclopropane ring occurs 
resulting in the formation of a drug-DNA adduct (Figure 6).  
 
The seco (non-cyclised) analogues generate the reactive cyclopropane ring in situ via 
Winstein-cyclisation before reacting with the DNA (Figure 7). Alkylation at adenine accounts 
for 86-92% (duocarmycin A), 90-100% (duocarmycin SA) and 80-90% (CC-1065) of DNA 
alkylation. Minor guanine-N3 alkylation has been detected.50-52  
 
1.4.3.9.2 Inhibition of macromolecular synthesis and enzymes 
Li et al.43 investigated the biological and biochemical effect of CC-1065 on L1210 leukaemia 
cells. It was found that CC-1065 inhibited DNA synthesis ten times more than RNA synthesis 
with protein synthesis being the least inhibited. A concentration of 5.7-8.5 nM was required to 
inhibit 50% of DNA synthesis whilst a concentration of 63.9-85.3 nM was needed to inhibit 
50% of RNA synthesis.43 A similar pattern was observed when the effect of CC-1065 was 
studied on the B16 cell line.53 More than 90% of DNA inhibition in L1210 cells occurred at 
Figure 7: Proposed mechanism for seco-CPI. 
Figure 6: Alkylation of CC-1065 by adenine N3. 
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CC-1065 concentration of 14.2 µM. The effect on enzymes directly or indirectly involved in 
DNA synthesis was also investigated. It was found that inhibition of dThd kinase was about 
40% at drug concentration of 7.1 µM whilst inhibition of DNA polymerase α was 74% at 1.4 
µM.43 The thermal melting of calf thymus DNA (∆Tm) was increased by ≥ 31 deg. C at DNA-
drug ratio of 6:9. It was shown that 80% of CC-1065 binds strongly to calf thymus DNA 
when the CC-1065:DNA ratio was 0.01. Further cytotoxicity studies on L1210 indicated that 
DNA-bound CC-1065 was far less cytotoxic than the free CC-1065. L1210 cells exposed to 
CC-1065 at a final concentration of 56.8 pM, experienced 85% growth inhibition. However, 
pre-mixing CC-1065 with as low as 0.02 µg mL-1 calf thymus DNA, 10 min before adding to 
L1210 cells, resulted in significant reduction in growth inhibition. This effect was dependent 
on the concentration of calf thymus DNA used. At 0.5 µg mL-1, the observed percentage 
growth inhibition markedly reduced to ~4%.43  
 
1.4.3.9.3 Apoptotic cell death 
Cell death by the CPI anti-tumour antibiotics is thought to be through apoptosis.  Wrasidlo et 
al.42 microscopically examined Molt-4 leukaemia cells after exposure to duocarmycin and 
observed shrinkage and blebbing of the cells with no evidence of lysis. Exposure of Molt 4 
and L1210 cells to duocarmycin (10 nM) also revealed characteristics typical of apoptotic cell 
death including chromatin condensation, fragmentation of nucleus and disintergration of 
affected cells (50-60%) into apoptotic bodies. Analysis of DNA isolated from Molt 4 cells 
showed intense endonuclease mediated internuclosomal DNA fragmentations.42, 54 This has 
led to the proposal that sequence alkylation of DNA at internucleosomal sites is responsible 
for triggering a sequence of signalling pathways that eventually lead to apoptotic cell death.42  
 
Propidium iodide stained flow cytometric analysis of cells treated with analogues of the anti-
tumour antibiotics has also confiremed the likelihood of cytotoxicity through apoptosis. Flow 
cytometry is used to detect extensive DNA cleavage in cells which is characteristic of 
apoptotic cells. P815 mastocytoma cells incubated with a range of analogues of the anti-
tumour antibiotics displayed a high level of DNA cleavage when analysed.55-59  
 
1.4.3.9.4 Structure-activity relationship 
 A range of studies using the natural CPI anti-tumour antibiotics as well as its analogues 
especially the CBI (1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indole-4-one) analogues (Figure 
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8) have helped established the relationship between the pharmacophore of these agents and 
their acivitities. 
  
1.4.3.9.5 DNA-alkylation selectivity 
Thermally induced depurination and strand cleavage of labelled DNA after exposure to agents 
have made it possible to identify sites of alkylation and the relative selectivity of the anti-
tumour antibiotics. Sequence selectivity is controlled by the non-covalent binding in the 
minor groove of AT-rich regions of the DNA and the steric accessibility to the alkylation site 
which accompanies deep penetration into the AT-rich minor groove. The natural enantiomers 
(7bR, 8aS) bind to adenine in the 3’ → 5’ direction across adjacent bases.  Each adenine N3 
alkylation site is flanked by two 5’-A or T bases. The (+)-duocarmycins and (+)-CC-1065 
prefer the sequence 5’-AAA > 5’-TTA > 5’-TAA > 5’-ATA. The duocarmycins bind over 3.5 
base pairs whilst CC-1065 binds over 5 base pairs. The fourth 5’ base was more likely to be A 
or T rather than C or G.60-62  
 
The unnatural enantiomers (−) of the duocarmycins and CC-1065 alkylates DNA in 5’ → 3’ 
direction. This reverse orientation is required for adenine alkylation of the least substituted 
cyclopropane carbon. (−)-Duocarmycin SA alkylates DNA at 10 × the concentration required 
for the natural enantiomer whilst (−)-CC-1065 has been shown to alkylate DNA at a rate and 
efficiency comparable to the natural enantiomer.51, 61 Studies have shown that some simplified 
(−)-CPI analogues either failed to alkylate DNA or did so at a considerably higher 
concentrations. This effect is also correleated to in vitro cytotoxicity.63, 64 The adenine 
alkylation site for the unnatural enantiomers is flanked by a 5’ and 3’ A or T bases. The 
sequence preference of (−)-duocarmycin SA is 5’-AAA > 5’-AAT > 5’-TAA > 5’-TAT and 
that of (−)-CC-1065 is 5’-AAA > 5’-TAA > 5’-AAT > 5’-TAT. The second 3’ base from the 
alkylation site is preferred to be A or T.51, 61 The sequence-selective alkylation is dependent 
on the minor groove shape and size chararacteristics of an AT-rich sequence which allows 
shape-selective and shape-dependent catalysis. Nucleosomal DNA has been reported to be 
accessible, recognised and selectively alkylated by these agents.65 Taq DNA polymerase stop 
Figure 8: Alkylating subunits for CPI and CBI analogues. 
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assays have shown that analogues of these drugs stop activity of the enzyme at adenine rich 
sites confirming the alkylating site of these agents.56, 58  
 
1.4.3.9.6 Stereoelectronic control of ring opening of cyclopropane 
Adenine-N3 alkylation by the CPI anti-tumour antibiotics has been shown to occur almost 
exclusively at the least substituted secondary carbon of the cyclopropane ring. This 
regioselectivity was investigated by Boger et al.66 using the CBI (1,2,9,9a-
tetrahydrocyclopropa[c]benz[e]indole-4-one) analogues of the natural products. It was 
observed that the difference in alignment of the cyclopropane bond from the quaternary 
carbon to the secondary cyclopropane carbon and to the tertiary carbon was important in 
determining the site of reactivity (Figure 9).66-68  
 
For N-Boc-CBI [(8bR,9aS)-tert-butyl 4-oxo-9,9a-dihydro-1H-benzo[e]cyclopropa[c]indole-
2(4H)-carboxylate)], (Figure 9)66 the molecular orbital of the secondary cyclopropane carbon 
(C8b-C9) is aligned perpendicularly to the plane of the cyclohexadienone and, consequently 
overlaps with the developing -system of the phenol product. This is in contrast to the bond 
extending to the tertiary cyclopropane carbon (C8b-C9a) which is almost in plane (13) with 
the cyclohexadienone and orthogonal to the developing -system of the incipent phenol 
product. This effect is due to having a five-membered ring fused to the cyclopropane ring. 
The perpendicular alignment favours nucleophilic attack at the least substituted cyclopropane 
carbon. This selectivity is due to the stereoelectronic control, rather than the intrinsic 
electronic preference for ring expansion which would place a developing positive charge on a 
preferred tertiary carbon versus a secondary carbon. Besides, SN2 reactions prefer addition to 
the least substituted carbon. Furthermore, breaking of the longer and therefore weaker C8b-C9 





With N-Boc-CBQ (9bR,10aR)-tert-butyl 5-oxo-1,2,10,10a-tetrahydrobenzo[f]cyclo-
propa[d]quinoline-3(5H)-carboxylate) (Figure 9), the plane of the cyclohexadienone equally 
bisects the cyclopropane ring with bonds to the secondary (C9b-10) and tertiary (C9b-C10a) 
carbons equally aligned (29) with the -system. Thus the available cyclopropane bonds are 
equally aligned for cleavage. Solvolysis of N-Boc-CBQ therefore occurs with nucleophilic 






























Further evidence to support the role of the fused five-member ring is given by N-Boc-CNA 
(10bR,11aS)-tert-butyl 6-oxo-2,3,11,11a-tetrahydro-1H-cyclopropa[c]naphtho[2,1-b]azepine-
4(6H)-carboxylate) (Figure 10) which has a seven-membered ring fused with the 
cyclopropane ring.  
 
The cyclopropane ring of this compound is nonideally conjugated with the -system but in 
addition rises above the plane of the cyclohexadienone resulting in a better steroelctronic 
alignment of the more substituted carbon for nucleophilic attack. Acidic solvolysis of this 
compound (Figure 10) resulted in the formation of a single compound with a solvolytic half-
life (pH 3) of 0.03 h, compared to 133 h for N-Boc-CBI. Further analysis of the product 
showed that nucleophilic addition to the cyclopropane ring occurred exclusively at the tertiary 
cyclopropane carbon rather than the least substituted carbon resulting in the ring expansion 
product.68, 69 
 
1.4.3.9.7 Functional reactivity and biological activity 
The acid-catalysed activation of the anti-tumour antibiotics towards their alkylation of DNA 
led to suggestions that a linear relationship existed between reactivity and cytotoxicity. It was 
expected that increased electrophilicity of the cyclopropane ring would lead to increase 
cytotoxicity. Studies, however, reveal that the reverse is true. Agents with higher predicted 
stability show greater cytotoxicity. A direct relationship has also been established between 
stability towards solvolysis (pH 3) and biological potency. These observations are likely to be 
due to the requirement for sufficient stability for effective delivery of the agents to their 
Figure 10: Acidic solvolysis of N-Boc-CNA using CF3CO2H (0.12 eqv.) in H2O/THF.69 
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intracellular target balanced against the need for sufficient reactivity to alkylate DNA once 
they reach the target.68, 70  
 
The high solvolytic stability and the consequent high cytotoxicity of the natural anti-tumour 
antibiotics have been attributed to the fused five-membered ring to the cyclopropane ring. X-
ray structures  of N-Boc-CBI and N-Boc-CBQ (Figure 9)66, 68 show longer cyclopropane bond 
lengths in N-Boc-CBQ compared to N-Boc-CBI. This longer bond length of N-Boc-CBQ 
despite its cyclopropane ring being fused with the less strained six-membered ring is said to 
be due to the idealised conjugation of the ring with the cyclohexadienone -system. The ideal 
alignment of the cyclopropane ring with the plane of cyclohexadienone, when viewed at 90 
rotation, helps with this conjugation (Figure 9). When compared to N-Boc-CBI, the 
constraints by the fused five-membered ring pulls the cyclopropane ring down and to the side, 
placing the cyclopropane ring at 20 away from the plane of cyclohexadienone. This causes 
non-ideal alignment and non-ideal conjugation of the cyclopropane ring. This difference is the 
cause of the observed longer cyclopropane bond lengths, weaker bond strengths, higher 
solvolytic reactivity (63 ×) and therefore lower cytotoxicity (50 ×) of N-Boc-CBQ (IC50 
L1210 = 4 µM) compared to N-Boc-CBI (IC50 L1210 = 0.08 µM).61, 66, 68  
 
1.4.3.9.8 Influence of the stability of vinylogous amide on reactivity 
 
It has been established that the vinylogous amide (Figure 11) of the alkylation subunit 
contributes to the unusual stability of the anti-tumour antibiotics. Investigations to ascertain 
the effect of destabilising the conjugation of the vinylogous amide showed that the degree of 
conjugation of the cyclopropane and its reactivity is not only due to the geometrical alignment 










Figure 12: Effects of destabilising the vinylogous amide conjugation. 
 
A typical C-N (c) bond length of a fully conjugated vinylogous amide is 1.312-1.337 Å. A 
reduction in vinylogous amide conjugation (e.g. increased dihedral angle χ1) results in an 
increased bond lengths of the cyclopropane ring (Figure 12). This diminished vinylogous 
amide conjugation also causes the cyclopropane bonds to be aligned at a more idealised 
conjugation with the -system of the cyclohexadienone and, therefore, increases reactivity. In 
vitro cytotoxic studies confirmed the correlation between solvolysis reactivity and cytotoxic 
potency.61, 68, 71  
 
Investigation of 1,2,9,9a-tetrahydro-1H-cyclopropa[c]benz[e]inden-4-one 
(CBIn) (Figure 13) which contains a five-membered carbocyclic skeleton 
lacking the vinylogous amide nitrogen further revealed the importance of this 
amide. CBIn proved to be 3200 × less stable than its nitrogen containing CBI 
counterpart at pH 3 and more reactive (×103-104-fold) at pH 7 where the 
nitrogen containing CBI is stable. Solvolysis studies revealed no dependency 
on acid concentration between pH 4-12, demonstrating that alkylation rate of these agents is 
independent on pH.68  










































1.4.3.9.9 Linking amide 
  
The importance of a rigid N2 substitution was demonstrated by comparing the above 
compounds (Figure 14).68 Substituting the linking amide with a methylene group results in 
full vinylogous amide conjugation and an increased stability of the compound. The solvolysis 
half-life at pH 3 for CBI-CH2-TMI is 3.6 y compared to 230 h for CBI-TMI. Despite this high 
stability towards solvolysis which is usually correlated to high cytotoxicity, the absence of the 
linking amide causes a decrease in DNA alkylation efficiency (> 106-fold) and a decrease in 
potency (104-105-fold).71, 72 Replacing the linking amide with the more electron-withdrawing 
thioamide also causes disruptions of the vinylogous amide leading to increased solvolysis 
reactivity (t1/2 160 h versus 230 h), reduced alkylation efficiency (× 10-100) and reduced 
cytotoxicity (IC50 L1210 = 1.1 nM vs 0.02 nM) compared with CBI-TMI. This goes on to 
establish the linking amide as the optimum linkage unit. 71 
 
With the loss of the linking amide in CBI-CH2-TMI, this should lead to a more basic C4 
carbonyl and therefore, higher acid-catalysed reactivity. However, this was not the case, 
further suggesting that reactivity of these agents is pH independent. The results highlight an 
essential role for the linking amide in the mechanism of DNA alkylation and the need to have 




IC50 (L1210) 0.02 nM 
t1/2 (pH 3)     230 h 
DNA alkylation easily 
detected at 25C,  
10-6 M, 24 h 
Figure 14: Effects of N2 substitution. 
CBI-TMI CBI-CH2-TMI 
IC50 (L1210) 14000 nM 
t1/2 (pH 3)     31000 h (3.6 years) 
No DNA alkylation 
detected after 14 days, 
at 37C, 10-4 M  
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1.4.3.9.10 Effect of relocating the C4-carbonyl group 
To investigate the proposal that the DNA alkylation 
selectivity of these agents is due to an acidic 
activation of the C4 carbonyl group by a 
strategically positioned phosphate group, Boger et 
al.67 synthesised a series of iso-CIs and iso-CBIs 
(Figure 15) and analysed their structure-activity relationships.  Structural studies of the DNA-
agent adducts show that the C4 carbonyl of the natural anti-tumour antibiotics projects out of 
the minor groove and lies on the surface of the complex, making it accessible to the phosphate 
backbone. In contrast, the location of the C4 carbonyl in iso-CI and iso-CBI will lead to 
projection into the minor groove, where it is inaccessible to the phosphate backbone.  
Solvolysis studies showed that iso-CBI was less stable and 5 × more reactive than CBI. The 
increase in reactivity was attributed to the diminished vinylogous amide conjugation caused 
by relocation of the C4 carbonyl group. An X-ray structure showed an increase of the N2-C2a 
bond length diagnostic of diminished vinylogous conjugation. Evaluation of the DNA 
alkylation properties of iso-CI and iso-CBI, however, showed that their reactivity was 
comparable to those of duocarmycin A and CC-1065. Nucleophilic addition to the 
cyclopropane ring of the iso-CBI also occurred with exclusive addition to the least-substituted 
carbon. The selectivity of alkylation of the iso-analogues was also similar to their natural 
analogues. These observations, therefore, do not support the idea that selectivity of alkylation 
is due to sequence-dependent protonation by the DNA phosphate backbone of the C4 
carbonyl but supports the proposal that selectivity is determined by the non-covalent binding 
to the AT-rich region of the minor groove of the DNA and the steric accessibility to the 
adenine N3 alkylation site.52, 67  
 
1.4.3.9.11 Importance of the cyclopropane ring 
Lajiness et al. synthesised an analogue of duocarmycin with modification 
to the cyclopropane ring. N-Boc-CbBI (Figure 16) was found to be very 
stable, being unreactive to solvolysis even at pH 1. This increased stability 
was due to increased vinylogous amide conjugation, confirmed by the 
diagnostic shortening of the N2-C2a bond length. Reduction of ring strain 
energy and the non-ideal alignment of the cyclobutane with the 
cyclohexadienone compared to cyclopropane in N-Boc-CBI also contributed to this increased 
stability. A cytotoxicity assay, however, showed a 106-fold reduction in cytotoxicity 
Figure 16: Structure 
of N-Boc-CbBI 
Figure 15: Structures o iso-CI and iso-CBI. 
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compared to the natural products. This further confirmed the parabolic relationship between 
solvolysis and cytotoxicity.70   
 
These observations in the analogues of the anti-tumour antibiotics has led to the proposal that 
DNA alkylation is facilitated by DNA-binding induced conformational change of the anti-
tumour antibiotics, which disrupts the vinylogous amide stabilisation and, in turn, activates 
the cyclopropane ring for nucleophilic attack. When the agent is bound to DNA, it adopts a 
helical conformation which complements that of the minor groove of DNA. The result is a 
twisting of the χ1 bond which disrupts the vinylogous amide stabilisation effect and 
consequently enhances reactivity. 1H NMR spectra of DNA-bound duocarmycin SA show a 
44 ± 2 twist between the alkylating subunit and the non-alkylating subunit. Most of this twist 
is due to the χ1 (20-35) dihedral angle and is greatest within the narrow AT-rich minor 
groove. This explains the preferential selective alkylation of these agents in this region.69, 72  
 
1.4.3.9.12 Reversibility of alkylation 
A variety of experiments initially failed to show reversibility of DNA alkylation by CC-1065. 
The stability of the CC-1065-DNA adduct is considered to be essential to the extreme potency 
of this agent. Studies have, however, shown that CC-1065-DNA adduct is reversible in non-
aqueous experimental conditions. The difficulty of not observing the akylation reversibility of 
some CPI agents in aqueous media is partly attributed to their insolubility. In aqueous media, 
eventhough reversal of alkylation might occur, the agent stays bound to the DNA. This 
encourages re-alkylation at the same site without dissociation.73  
 
Warpehoski et al.73 investigated the reversibility of alkylation of DNA by CPIs. CPI agents 
were treated with calf-thymus DNA to obtain the CPI-drug covalent adduct. The reversibility 
of this adduct was then studied in 0.25 M sodium phosphate buffer (SPB), pH 8.4. A slow 
recovery rate of CC-1065 from the drug-DNA adduct was observed. At higher temperature 
(55°C) in a mixture of butanol and 0.25 M SPB, pH 8.4, about 20% of CC-1065 was extracted 
into butanol after 20 h. At 80°C, CC-1065 was recovered efficiently by extraction into 
butanol.  Studies on adozelesin (a CPI analogue)-DNA adduct at 37°C for 24 h gave a 40% 
recovery and at 55°C gave 30% recovery in 1 h.73 Cytotoxicity studies with CPI-DNA 
adducts showed that adozelesin-drug adduct was quite potent (40 pM) compared to the free 
adozelesin (3 pM). This is consistent with the significant reversibility of the adozelesin-DNA 
adduct. The CC-1065-DNA adduct, however, showed no cytotoxicity at doses 60 times that of 
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CC-1065. This further proves that, although reversibility of CPI-DNA is possible, this adduct 
is irreversible under conditions used for cell growth.73 The unnatural enantiomers form less 
stable adducts with DNA and therefore are more easily reversible.52  
 
Lee et al.74  have also shown that the interaction between bizelesin (a CPI analogue) and DNA 
is reversible. The reversibility was observed to increase with temperature (up to ~80C), ionic 
strength and pH. It was also observed that single-stranded DNA-drug adducts undergo 
depurination in preference to reversal of alkylation. This suggests that conditions that result in 
instability of DNA (e.g. high temperatures) promote the depurination pathway.74  Scheme 1 
shows two decomposition pathways observed for a DNA-CPI adduct. Above 90°C, the 
depurination pathway-B which precedes DNA strand cleavage, predominates.73  
  
1.4.3.9.13 Limitations of the natural anti-tumour antibiotics 
The drawbacks to the natural anti-tumour antibiotics are two-fold; their extreme systemic 
toxicity and their structural complexity which makes them difficult to synthesise. McGovren 
et al.75 showed that CC-1065 caused lethal delayed hepatotoxicity at therapeutic 
antineoplastic doses. It was observed that non-tumour-bearing mice died approximately 50 d 
after a single intravenous dose of 12.5 µg Kg-1 and as much as 70 d after 10 µg Kg-1 was 
Scheme 1: Thermal decomposition of DNA-CPI adduct. A; reversal of alkylation, B; depurination. 
31 
 
given intraperitoneally. Higher intravenous doses caused death within 12 d with hepatic 
necrosis, compared to changes in hepatic mitochondrial morphology when lower doses were 
given. A subtherapeutic dose of 9 pg Kg-1 also caused delayed deaths (50-90 d) in healthy 
mice. This delayed lethality was mainly due to hepatotoxicity and peritonitis. Bone marrow 
depression was also observed. Changes in mitochondrial morphology and function probably 
due to binding of mitrochodrial DNA to CC-1065 have been implicated in the delayed 
toxicity. Doses of CC-1065 which did not cause delayed toxicity had little anti-tumour 
activity. Delayed toxicity at very low doses was also seen in rabbits suggesting that this effect 
is not limited to mice. Death in rabbits was associated with lesions in the liver and kidney.46, 75 
The use of agents (N-acetyl-L-cysteine) said to protect mice from lethal toxicities from DNA 
alkylating agents failed to have any effect on CC-1065 lethality.75  
 
There has been great research into CC-1065 and its analogues in other to understand its 
structure and activity relationship. Analogues of CC-1065 with modification of the alkylating 
subunit also result in delayed death.76 The delayed death effect was initially attributed to the 
presence of two ethylene moieties in the non-alkylating subunit of the molecule (Figure 17).45  
  
Wang et al.49  found that analogues of CC-1065 without the ethylene groups but possessing a 
terminal amide moiety also caused delayed death in animals. Replacing the terminal amide 
group with fluorine resulted in a compound that did not cause delayed death.49  
 
Duocarmycin SA is said to be the most stable and most potent member of the anti-tumour 
antibiotics lacking the fatal toxicity characteristic of CC-1065.51 This has led to a drive 
Delayed death
Alkylating subunit Non–alkylating DNA binding subunit
Figure 17: CC-1065 structure and activity relationships. 
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towards the total synthesis of this compound. Preliminary biological and physiological tests 
by Nagamura et al.,47 however, discovered that duocarmycin SA exhibited an in vivo anti-
tumour activity only at very narrow range of doses against murine sarcoma 180 and showed 
very poor water solubility. At a maximum tolerated dose of 0.10 mg Kg-1, duocarmycin SA 
caused a reduction in tumour volume by 0.21, relative to the control. However, at half this 
dose, no anti-tumour activity was observed.47  
 
The natural anti-tumour antibiotics are all associated with toxic side-effects mainly 
myelotoxicities. The toxicity of these natural anti-tumour antibiotics, their limited availability 
and their structure complexities have led to the synthesis of analogues with similar 
cytotoxicities but better in vivo profiles. Approaches to this include:  
 Modification of the alkylating subunit; 
 Simplification of non-alkylating DNA binding subunit; 
 Design and synthesis of prodrugs. 
 
1.4.3.9.14 Modification of the CPI alkylating subunit 
Modifications of the alkylation subunit of these agents have been extensively studied, 
primarily to establish the structure-activity relationships. Figure 18 shows a range of 
analogues of the original cyclopropapyrroloindole (CPI) alkylating subunit of the natural anti-
tumour antibiotics. The presence of ring-A is essential, since, when absent as in N-Boc-CI, 
biological activity is reduced. This is likely to be due to the reduced conjugative stability 
provided by the fused aromatic system.67 Cytotoxicity seems to be also dependent on the 
steric bulk at C6 comparing (+) N-Boc-CPI to (+) N-Boc-DSA. A range of studies have 






1,2,9,9a-Tetrahydrocyclopropa[c]benz[e]indole-4-one (CBI)-based analogues of the anti-
tumour antibiotics have been shown to be more stable (4 ×), biologically more potent (4 ×) 
and considerably more synthetically accessible than the corresponding agents incorporating 
the natural CPI alkylation subunit.70, 77, 78 Boger et al. synthesised CBI-Indole2 and compared 
its properties with the CPI analogue, CPI-Indole2 (Figure 19). The CBI analogue proved to be 
4 × more stable to acid-catalysed solvolysis and consequently 4 × more potent than CPI-
Indole2. The rate and intensity of DNA alkylation was also higher for the CBI analogue. 
Preliminary studies of in vivo anti-tumour activity revealed significant activity of CBI-Indole2 
at dosage levels for which there was little activity by CPI-indole2. These observed differences 
are attributed to the enhanced availability of CBI-indole2 due to its increased stability.78  CBI-
trimethoxyindole (CBI-TMI) (IC50 = 20 pM) has also been shown to be as cytotoxic as 
duocarmycin SA (IC50 = 10 pM) in L1210 leukaemia cells.44  




The 5-amino analogues of the CBI have gained popularity due to the ability to form more 
stable carbamate prodrugs (Figure 20). They have been shown to possess similar biological 
activity as their hydroxy counterparts. Carbamate prodrugs of the 5-hydroxy-CBIs have been 
reported (e.g. carzelesin) which are labile in plasma, releasing the corresponding phenol non-
specifically. By providing more stable prodrug, 5-amino-CBI should persist in the plasma but 







Synthesis and evaluation of (+)-5-amino-CBI-TMI showed that it had almost an identical 
cytotoxicity when compared to its 5-hydroxy counterpart (Figure 20). The amino derivative 
was also shown to undergo exclusive alkylation at adenine.44, 79  
Cell type 5-Hydroxy-CBI-TMI 5-Amino-CBI-TMI 
AA8 0.21 ± 0.06 0.21 ± 0.03 
UV4 0.09 ± 0.004 0.14 ± 0.01 
EMT6 0.13 ± 0.01 0.13 ± 0.01 
Figure 20: Cytotoxicity (IC50s in nM, 4 h exposure, ±SE) for nitrogen-substituted seco-CBI-TMI analogues. 
Average of two or more determinations. 
Figure 19: CBI and CPI alkylating subunits. 
CBI CPI






















1.4.3.9.16 Modification of the non-alkylating subunit 
The rate of alkylation of DNA and the cytotoxicities of the simplified analogues of the natural 
anti-tumour antibiotics lacking the non-alkylating subunit tend to be lower. This suggests an 
important role for the non-alkylating subunit in terms of enhancing the rate of alkylation and 
potency. Many modifications have been made on the non-alkylating subunit with the aim to 
understand the structre activity relationship and to obtain compounds with better solubility 
and lower toxicity.52  
 
Increasing cytotocity is obsereved with increase in size and length of the non-alkylating 
subunit.67 In saying this, (+)-CBI-indole2 exhibits cytotoxic potency comparable to (+)-CC-
1065.77 Studies into the effect of the three methoxy groups of the 5,6,7-trimethoxindole (TMI) 
group of the duocarmycins, has shown that the substituent at C5 is more important than those 
at the other positions (Figure 20). C5 methoxy substituents alone provide fully active agents, 
with little or no input from the C6 and C7 methoxy group. NMR structures of DNA-bound 
duocarmycin and its analogue lacking the three methoxy groups showed that the presence of 
the methoxy group at C5 increases the twist in the DNA-bound agent.52 Further studies into 
the effect of C5 substitution was made by Parrish et al.50 It was observed that a variety of 
substituents in this postion had different effects on potency. For instance, when C5 had a 
hydroxy-substituent, there was a 4-fold reduction in potency but 5-fold increase in 
cytotoxicity was observed when the C5 substituent was an ethoxy group.50, 67  
 
Investigations to find ways of improving the cytotoxicity and aqueous solubility of these 
agents led to Millbank et al.80 synthesising a series of amino-seco-CI analogues with varying 
non-alkylating subunit. One of the non-alkylating subunit was dimethylaminoethoxyindol-2-
carboxylic acid (DMAI) which retains a 5-alkoxy substituent for enhanced cytotoxicity and 
also contains a dimethylaminoethyl group to improve solubility. Biological and solubility 
assays showed that the analogue with the DMAI subunit was more potent across a range of 
cell lines compared to the analogue with C5 methoxy group. Solubility was also considerably 







Figure 21: Effects of DMAI non-alkylating subunit. a Solubility in 0.1 M phosphate buffer (pH 7.0) at room 
temperature. b IC50; concentration of drug to reduce cell numbers to 50% of controls following a 4 h drug 
exposure. Average of 2-5 determinations ± SEM. 
 
1.4.3.9.17 Prodrugs 
The anti-tumour antibiotics are unquestionably very potent. However, these agents lack 
intrinsic selectivity for tumour cells over normal cells. This undesired toxicity limits the 
efficacy of these agents. The design and synthesis of prodrugs to selectively deliver these 
agents to tumour cells is therefore very important.  
 
1.4.3.9.17.1 Tumour-activated produgs 
Design of agents selectively activated within the target reduces toxicity and increases 
targeting. Tumour-activated prodrugs involve the design of non-toxic prodrugs where the 
therapeutic effect of the drug is masked until activated by unique phenotypic differences 
within the tumour environment. This activation can be enzymatic, chemical, spontaneous or a 
combination of these and allows the prodrug to undergo selective cellular metabolism.82, 83 In 
general, tumour-activated prodrugs (TAPS) consists of a trigger, a linker and an effector 
(Figure 22).  
 
R Sol (µM)a                                        IC50 (µM)b 
       AA8                 UV4                EMT6                 SKOV3 
5-OMe 
 
23 0.31 ± 0.07 0.047 ± 0.001 0.23 ± 0.01 0.67 ±0.04 




The trigger controls selectivity and is joined to the effector which is the active agent through a 
linker.82, 83 In order for this strategy to work, there are a number of requirements the prodrug 
has to meet:84  
 Relatively stable in vivo;  
 Less molar toxicity compared to active drug; 
 High volume of distribution into tumour tissues; 
 Efficient selective activation. 
 
1.4.3.9.17.2 Enzyme-based activation of prodrugs 
Enzyme based activation of prodrugs includes antibody-directed enzyme prodrug therapy 




This concept introduced by Bagshawe in 198786  is a promising approach to selective delivery 











Figure 22: Model for tumour-activated prodrugs.82,83 
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specific antibody which localises the enzyme at the tumour. A prodrug is then administered 
which acts as a substrate for the enzyme, resulting in the release of free drug at the tumour site 
thereby ensuring selective delivery of the drug.52, 87  
 
Tietze et al.81 developed a prodrug of a duocarmycin analogue, the activation of which 
depended on the ADEPT concept (Figure 23). The cytotoxic potency of the prodrug was very 
low (IC50 = 3600 nM), compared to that of the prodrug  in the presence of the activating 
enzyme β-galactosidase (β-Gal) (IC50 = 0.75 nM).81  
 
This approach to selective delivery of drugs is, however, very complex as two separate agents 
and a time interval between their administration are required for their efficacy.52 The ADEPT 
approach also tends to be expensive and the selected monoclonal antibody and enzyme must 
be able to cope with possible immune response.88  
 
1.4.3.9.17.2.2 GDEPT 
This concept is similar to ADEPT, the difference being that the activating enzyme is 
introduced to the tumour through a gene delivered by a vector. Once expression of the 
enzyme occurs, a prodrug can be given, which is then selectively activated in the tumour. 
Ideally, the enzyme needs to be expressed exclusively at the tumour site compared to normal 
tissues or blood. The concentration and catalytic activity of the enzyme should also be 
sufficient to activate the prodrug under physiological conditions. A bystander effect is also 
desirable to kill neighbouring cells since not all tumour cells will express the enzyme. This 
requires that, after activation of the prodrug, the active drug kills both the tumour cells in 
Figure 23: Activation of a duocarmycin analogue via the ADEPT concept.81 
Prodrug
(+)-(1S, 10R), R = β-Gal, IC50 = 3600 nM






which activation occur as well as neighbouring tumour cells. The enzyme can be of non-
mammalian origin or human origin where the enzyme is expressed at low concentration or is 
absent from the tumour cells. For enzymes of non-mammalian origin, the major drawback is 
their immunogenicity. With the human enzymes, their presence in normal tissues precludes 
selective activation unless modifications are made to the substrate requirements of the 
enzyme.89   
 
1.4.3.9.17.2.3 PMT 
Prodrug monotherapy involves the exploitation of an intrinsic enzyme which is up-regulated 
in malignant tissues to selectively activate a prodrug.85 Endoproteases are frequently up-
regulated in tumour tissues as a consequence of tumour expansion or are sometimes a 
necessity for tumour expansion. One such enzyme is the prostate-specific antigen (PSA), 
which is exclusively expressed within the prostate and is able to cleave short peptide 
sequences, making it a good target for PMT. Peptide-conjugated prodrugs can therefore be 
designed to be activated by PSA to achieve selectivity.82  
 
1.4.3.9.17.3 Prostate-specific antigen (PSA) 
Prostate-specific antigen also known as human kallikrein 3 (hK3) is a serine protease with 
chymotrypsin-like specificity.90, 91 PSA (Mw 33,000) is a single-chain glycoprotein.92 The 
enzyme is secreted by normal and malignant cells of the prostate gland and leaks into 
circulation in higher proportion in prostate cancer. The level of PSA is elevated in prostate 
tumours and is more proteolytically active compared to normal prostate tissues which lack 
detectable PSA enzyme activity.82 The majority of the enzyme molecules that leak into 
circulation are complexed with protease inhibitors present in serum which are at a 104-105-
fold molar excess. These inhibitors include α-1-antichymotrypsin (ACT), α-2-macroglobulin 
(A2M) and α-1-trypsin inhibitor (API).35, 93, 94 The protease inhibitors bind in such a way as to 
cover the active site of the enzyme, thereby inhibiting enzymatic activity (Figure 24).95 This 




About 1-10% of the enzyme that leaks into circulation in prostate cancer patients is said to be, 
however, free and active.93 The function of PSA is to dissolve the gel formed after ejaculation 
and thereby permit movement of sperm in the female genital tract.35 The enzyme achieves this 
via selective cleavage of semenogelin at specific amino-acid sequences.96 Isolation of the 
digestive fragments of seminogelin by PSA has made it possible to produce PSA cleavage 
maps for human semenogelin I. It was observed that the peptide bond between Gln and Ser at 
positions 349 and 350 in semenogelin I was the most readily cleaved bond. Modifications of 
the amino-acid residues surrounding this bond led to the synthesis of a heptapeptide (N-
glutaryl-(4-hydroxyprolyl)-Ala-Ser-cyclohexylglycyl-Gln-Ser-Leu-OH) which is selectively 
cleaved by PSA.97 Studies have shown that the peptide His-Ser-Ser-Lys-Leu-Gln-OH 
(HSSKLQ) is also a PSA-specific peptide substrate that is efficiently and selectively cleaved 
by the enzymatic activity of PSA.98 With this knowledge, one can design a peptide prodrug 
that is activated by PSA within the prostate to achieve selective delivery of the drug to 
prostate tumour.  
 
1.4.3.9.17.3.1 PSA-cleavable prodrugs 
Based on the PSA-cleavage map for semenogelin I and II, Denmeade et al.99 synthesised a 
range of small peptides (≤ 7 amino-acids) and coupled their carboxyl terminus to 7-amino-4-
methyl coumarin (AMC). This allowed monitoring of cleavage of the constructs by PSA, 
which results in increased fluorescence due to the release of the coumarin. The six-amino-acid 
Figure 24: PSA protein binding.95 
41 
 
sequence HSSKLQ proved to be a good substrate with high degree of specificity for PSA 
over other peptidases. It also showed a good stability in sera even in men with elevated PSA 
levels and in human plasma, compared to other sequences especially those with tyrosine at the 
cleavage point which proved to be better substrates for other serine proteases, such as 
chymotrypsin and elastase. The only other enzyme with the ability to hydrolyse this peptide 
sequence significantly apart from PSA is cathepsin B, an intracellular lysosomal protease. 
This enzyme is, however, not significantly present in the extracellular fluid of normal cells 
but is substantially elevated around cancerous cells including prostate cancer cells. Hydrolysis 
by cathepsin B therefore provides another mode of selective cleavage of this peptide sequence 
within prostate tumours. The shorter amino-acid sequence SKLQ-AMC showed a higher Km 
but had the same Kcat:Km ratio and same serum stability when compared to HSSKLQ-AMC. 
SKLQ-AMC was also less soluble. The amino-acid sequence KLQ showed detectable 
cleavage whilst the two amino-acid sequence LQ-AMC showed no detectable cleavage at 5 
mM concentration.99  
 
Covalent linkage of the PSA cleavable peptide N-glutaryl-(4-hydroxyprolyl)-Ala-Ser-
cyclohexylglycyl-Gln-Ser-Leu-OH) to doxorubicin led to the creation of a prodrug 
hydrolysed by PSA. In the presence of PSA-secreting prostate cells, the prodrug was 
hydrolysed to release leucyl-doxorubicin and, subsequently, doxorubicin, both of which are 
cytotoxic to tumour cells. Incubation of this prodrug with non-PSA-producing prostate cells 
resulted in less cytotoxicity compared to doxorubicin. The use of both the prodrug and 
doxorubicin at their maximally tolerated dose in nude mice showed that the prodrug was 
fifteen times more effective at inhibition of tumour growth than conventional doxorubicin. An 
eight-to-nine-fold molar equivalent dose of this prodrug could be administered in vivo without 
additional toxicity compared to doxorubicin.82, 97 In vitro activity studies of the prodrug 
against human PSA-producing prostate cancer cells (LNCaP) proved that the concentration 
required to kill 50% of tumour cells was twenty-fold  lower (EC50 = 5 nM)  than that required 
in non-PSA-producing prostate cancer cells such as DuPRO and PC3 (EC50 = > 100 nM). 
This suggested that the activation of the prodrug was PSA-specific. The prodrug also reduced 
the weight of LNCaP tumours by 90% compared to doxorubicin which reduces tumours 
weight by just 6%. The concentration of doxorubicin in tumour from the prodrug was also 
higher than that from doxorubicin indicating the enhanced selective delivery of the drug to the 
target.96, 97  
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Denmeade et al.100 also developed a PSA-activated thapsigargin prodrug, consisting of a 
primary amine-containing thapsigargin analogue coupled to PSA-specific peptide HSSKLQ. 
It was observed that not only was this prodrug effective against PSA-producing prostate 
cancer cells in vitro but also it had the ability to induce apoptosis in both lowly and highly 
proliferating cells.100  Prostate cancer cell lines PC3 and DU145, however, have demonstrated 
the capacity to develop resistance to the cytotoxic effect of thapsigargin.101 5-
Fluorodeoxyuridine has, in the same way been coupled to HSSKLQ and showed to have a 
remarkable inhibitory effect on tumour cells with little toxicity when given intravenously.91  
 
Kumar et al.94 developed  paclitaxel prodrugs by coupling to PSA-cleavable peptides 2’-Mu-
HSSKLQ or 2’-MuSSKYQ via an ethylenediamine (EDA) linker to give  2’-MuSSKLQ-
EDA-paclitaxel or to 2’-MuSSKYQ-EDA-paclitaxel respectively (where Mu = 
morpholinocarbonyl protecting group). These compounds proved to be stable to degradation 
both in plasma and serum showing < 3% and < 2% degradation, respectively. The prodrug 
also showed improved solubilities (up to 70 mg mL-1, ~38 mM) compared to paclitaxel 
(0.00025 mg mL-1, ~0.29 µM). The half-life of the compounds in the presence of PSA was 10 
h for 2’-MuSSKLQ-EDA-paclitaxel and 6 h for 2’-MuSSKYQ-EDA-paclitaxel. Incubation of 
2’-MuSSKYQ-EDA-paclitaxel with a range of cell lines for 96 h showed a 3-5 fold increment 
in cytotoxicity (IC50 ~1µM) in CWR22Rv1 PSA-producing prostate cell line than in the non-
PSA-producing cell lines Du145 and TSU (Figure 25).94  
 
























1.4.3.9.18 Self-immolative linkers 
Insertion of a linker between the trigger and effector of a prodrug system is sometimes 
necessary. Directly linking the trigger to the effector (the parent drug molecule) in a prodrug 
system can reduced enzyme accessibility to the trigger due to steric hindrance caused by the 
bulky parent drug molecule resulting in lower rate of enzymatic hydrolysis.102-104 After 
cleavage by the requisite enzyme, the linker-drug conjugate undergo self-immolation to 
release the drug. Elimination and intra-molecular cyclisation are among the most widely used 
self-immolation mechanisms (Figure 26). The rate of self immolation depends on: 
 Nucleophilicity of the trigger group; 
 The leaving ability of the drug; 
 And the size of the ring formed. 
  
The pKa of the masked nucleophile is essential to the rate of cyclisation. Aliphatic amines 
which are usually adopted as the trigger group, have a pKa of 9-11 and normally requires 
higher than physiological pH for optimal cyclisation. A study comparing hydroxylamine 
which has a lower conjugate acid pKa (~5.9) to aliphatic amine demonstrated that having a 
hydroxylamine as the trigger group resulted in a faster release of drug. This is explained by 
the fact that, at physiological pH, the majority of the aliphatic amine will be present in its 
protonated state, with reduced nucleophilicity compared to the hydroxylamine.103  
 
1.4.3.9.18.1 ADEPT based linkers 
Using the ADEPT concept to investigate the effect of having a linker between the trigger and 
effector components in a prodrug system, Schuster et al. developed a β-D-galactosidase 
activatable prodrug of a duocarmycin analogue (Figure 27).102  
  




The prodrug was shown to be stable over 24 h at pH 7.4 and 37C with no cleavage of 
carbamate bonds and no generation of the free drug. The IC50 of the prodrug was 29 nM 
whereas in the presence of β-D-galactosidase the IC50 was 1.3 nM. The IC50 of the prodrug in 
the presence of the enzyme is comparable to the IC50 of the free drug (0.75 nM). This suggests 
that in the presence of the enzyme there is an efficient cleavage of the glycosidic bond and 
subsequent self-immolation to generate the free drug. DNA alkylation studies showed that the 
prodrug was not reactive towards DNA. Even at higher prodrug to DNA ratio of 3:1, the 
prodrug did not alkylate DNA.102  
 
1.4.3.9.18.2 PMT based linkers 
The design of prodrugs to be activated by exopeptidases (especially carboxypeptidases) 
allows cleavage of peptide-based prodrugs directly from the C-terminal of short peptides. 
Endopeptidases on the other hand, cleave between amino-acids leaving pendant amino-acids 
attached to the drug.105 The PSA-recognised sequence His-Ser-Ser-Lys-Leu-Gln↓Aaa is 
cleaved by PSA at the point shown ↓. PSA, being an endopeptidase, tends not to release drugs 
directly from the C-terminal of short peptides.104, 105 This means that attachment of drug 
directly to the cleaving point of the amino-acid sequence can result in inefficient release of the 
drug since drug molecules are still attached to one or more amino-acid units which may or 
may not affect the desired pharmacological activity of the drug.100, 105 For example, the 
doxorubicin prodrug developed by DiPaola et al.96  was released as Ser-Leu-doxorubicin by 
the action of PSA. It was then left to aminopeptidases to produce the biologically active-
forms Leu-doxorubicin and doxorubicin.96 To address the problem whereby the presence of a 
Figure 27: β-D-galactosidase activatable CBI prodrug. 
45 
 
pendant amino-acid(s) attached to the released drug would diminish activity, self-immolative 
linkers can be interposed between the drug (effector) and the PSA-recognised peptide 
sequence (trigger). In this system, after the release of the linker-drug unit, the linker 
decomposed spontaneously to expel the drug.106  
 
1.4.3.9.18.3 Non-peptide linkers 
Kumar et al.94 synthesised a series of paclitaxel prodrugs linked to a PSA-cleavable peptide 
via the self-immolative linkers 4-aminobenzyl alcohol (PABA) and ethylenediamine (EDA). 
The half-life for hydrolysis by PSA of PAB-containing prodrugs ranged from 12-14 h 
releasing the PSA-cleavable peptide and free paclitaxel.  
 
The cleavage product PABA-paclitaxel was not detected, demonstrating an instantaneous self-
immolation of the linker to release the drug after PSA activation. The PABA linker was, 
however, unstable to non-specific hydrolysis in serum and plasma. This was attributed to the 
weak carbonate bond between PABA and paclitaxel. The EDA linker contains a carbamate 
bond with paclitaxel and proved to be stable in serum and plasma. The EDA containing 
prodrugs also showed improved PSA hydrolysis with a half-life 6-10 h.94  
 
1.4.3.9.18.4 Dipeptide-based linkers 
Dipeptide-based linkers are cyclisation-based linkers that undergo intra-molecular cyclisation 
to release the drug. These linkers consist of a masked nucleophile that attacks the carbonyl of 
the –C(O)-X-Drug function after the action of the enzyme to cleave the trigger.83  
 
1.4.3.9.18.4.1 Proline-based dipeptide linkers 
Investigations into antibody-drug conjugates led to the development of a novel linker by 
Manabe et al.104 consisting of Gly-Pro dipeptide which forms a diketopiperazine when 
cyclised. The formed diketopiperazine is normally stable and non-toxic. This linker was 
incorporated into plasmin-cleavable paclitaxel prodrugs and biologically evaluated. Prodrugs 





were found to be cleaved by plasmin within 24 h. A prodrug with a Gly-L-Pro linker released 
39% of paclitaxel whilst only 15% of paclitaxel was released after 3 h when the linker was 
substituted with Gly-D-Pro. Plasmin-cleavable paclitaxel prodrug without the linker showed 
only 9% of drug release after 3 h.104  
 
Brady et al.107 also designed a vinblastine prodrug with the dipeptide, Ser-Pro, as the self-
immolative linker. After the enzyme (PSA) cleavage, the linker undergoes intra-molecular 
cyclisation to form diketopiperazines (DKP), releasing the drug in the process (Scheme 2).83  
 
The proportion of the dipeptide linker in the cis-amide 
conformation determines the rate of DKP formation 
(Figure 29). Most peptide sequences adopt the 
energetically favourable trans conformation; however 
proline is unique that as a tertiary amide, it can readily 
adopt a cis-amide conformation. The presence of proline 
increases the proportion of the dipeptide adopting the cis-
amide conformation, thereby increasing the rate of DKP 
formation and therefore the release of the active drug.83, 104 
The enhanced reactivity is due to the fact that the cis-amide conformation places the exposed 
nucleophile in close proximity to the electrophile unlike the trans-amide conformer.    
 


















Scheme 2: Mechanism of drug release by cyclisation-based linkers. 
47 
 
1.4.3.9.18.4.2 Pseudoproline based linkers 
The pseudoprolines such as 5,5-dimethyl-4-thiaproline (Dmt) and 5,5-dimethyl-4-oxaproline 
(Dmo) (Figure 30) have been used in place of proline and found to force peptides into 100% 
cis-amide conformation.106, 108 These peptides have mostly included S-Dmo or R-Dmt.106, 108 It 
has been shown that Dmt dipeptides in the L,S diastereomeric series cyclise faster (e.g. L-Val-
S-Dmt: t1/2 pH 8.0 =15 min, pH 7.0 = 45 min) compared to those in the L,R series (e.g. L-Val-
R-Dmt: t1/2 pH 8.0 = 1600 min, pH 7.0 = > 2700 min).105, 106  An attempt by Suaifan et al.105 
to incorporate Dmt in a peptide chain as the dipeptide, L-Val-S-Dmt, proved impossible since 
cyclisation into DKP was faster than coupling of L-Val-S-Dmt to other amino-acids. This 
effect was even observed when the amino group of L-Val was in the protonated form.105 
Furthermore, it has been shown that generation of  Dmt within a growing peptide chain (i.e. 
Aaa-Cys → Aaa-Dmt) is not possible as reaction only occurs at the sulfur.105 
 
Dmo has been frequently used as a masked form of serine to avoid solubility and aggregation 
problems that arise during peptide synthesis. It can be constructed within a peptide chain by 
treatment of Aaa-Ser or Aaa-Thr with 2,2-dimethoxypropane under acidic conditions.109 This 
cyclic amino-acid causes peptides to adapt the cis-amide conformation and should encourage 
cyclisation and self-immolation after release from a prodrug system when used as a self-
immolative linker.105, 110, 111 With an appropriate selection of a self-immolative linker, drug 
release should be rapid at the tumour site and reduce the diffusion of the linker-drug 
intermediate outside the tumour site causing non-specific delivery of the drug. 
 
1.4.3.10 Enhanced permeability and retention effect (EPR) 
Differentiating between normal cells and tumour cells is one of the main challenges facing the 
development of selective chemotherapeutic drugs. EPR is one of the few tumour specific 
characteristic that allows selective delivery of macromolecules to tumour sites. The EPR 
effect has been showen to be universal for solid tumours. In an effort to increase nutrient and 
oxygen supply, tumours undergo extensive angiogenesis resulting in hypervasculature. The 
vascular system and the lymphatic drainage system become defective and impaired. There is 
an increase in permeability mediators such as bradykinin and nitric oxide as part of the 
Figure 30: Structures of R-Dmt and S-Dmo. 
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mechanism to increase nutrient and oxygen to tumour cells. The process results in tumour 
tissues being supplied with leaky blood vessels compared to normal cells (Figure 31).112, 113  
 
To enhance further the selective delivery of drug to tumour cells, the enhanced permeability 
and retention effect (EPR) can be exploited. Macromolecules are preferentially taken up by 
solid tumours due to the poor tissue drainage and increased tumour permeability of tumour 
tissue (Figure 31). Macromolecules delivered to the interstitial space of tumour tissues are 
cleared very slowly leading to accumulation at higher concentration of macromolecules over a 
prolonged period. Exploitation of these abnormalities of the tumour vasculature can deliver 
drugs selectively to tumours leading to enhanced therapeutic benefits as well as fewer 
systemic side-effects.112, 114  
 
Most of the anticancer agents in use are of low molecular weight, exhibiting short plasma 
half-lives and high overall clearance. The small size of these molecules means they diffuse 
quickly into both normal tissues and tumour tissues. This result in relatively small amounts of 
drug reaching the tumour site calling for a higher dose to be administered which in turn 
results in increased side-effects.115 Developing drugs linked to a macromolecule with 










Figure 31:  Anatomical differences between normal and tumour tissues.114 
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1.4.3.10.1 Drug-polymer conjugates 
Conjugation of polymer to drugs with low molecular weight is one means of exploiting the 
EPR effect. Various polymers have been used as carriers of anti-cancer drugs, such as 
doxorubicin. An optimal polymeric drug carrier system would ideally be water-soluble, 
biocompatible and non-toxic. The use of polymeric carrier systems not only improves water 
solubility but also improves bio-distribution and plasma clearance of the drug.115, 116  
 
Seymour et al.,117 investigating the biodistribution of N-(2-hydroxypropyl)methacrylamide 
(HPMA) co-polymer-conjugated doxorubicin, observed that it showed a preferential 
localisation in tumour tissues 10-15 times more than that achieved using free doxorubicin 
administered at equal doses (5 mg of doxorubicin per Kg). The selective delivery of this 
polymer-conjugated doxorubicin meant that toxicity was low allowing elevated doses  (18 mg 
of doxorubicin per Kg) to be administered which achieved levels of drug in the tumour, 45-
fold higher than that resulting from the standard dose of free doxorubicin (5 mg Kg-1). The 
polymeric doxorubicin also showed a lower volume of distribution and longer plasma half-life 
than free doxorubicin.117  
 
Vasey et al.118 undertook a phase 1 clinical and pharmacokinetic study on doxorubicin bound 
to N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer through a lysosomally cleavable 
peptide linker. It was found that, despite the administration of higher doses, typical 
anthracycline-like toxicities were attenuated. For instance, with prophylactic 5HT3 antiemetic 
administration, nausea and vomiting was found not to pose any problem. Furthermore, only 
8% of patients (3 of 36) experienced grade 2 alopecia and there were no incidences of 




To enhance the delivery and solubility of a PSA-cleavable peptide prodrug of a potent 
thapsigargin analogue-L12ADT, Chandran et al.119 conjugated the peptidyl prodrug with 
HPMA copolymer (Figure 32). 
  
Stability studies which incubated the polymeric prodrug in human plasma did not show 
appreciable levels of L12ADT suggesting that the prodrug is stable to non-specific hydrolysis. 
PSA hydrolysis studies showed that the prodrug was cleaved by the enzyme to release the 
active drug. Cytotoxic assay was undertaken using the human prostate cancer cell line 
CWR22R. This cell line was shown to produce low percentage of enzymatically active PSA 
(≤ 5% active) in vitro. Therefore, in the absence of exogenous PSA, the polymeric prodrug 
did not show any cytotoxicity. Addition of exogenous active PSA (final concentration of 5 µg 
mL-1), however, showed a concentration-dependent growth inhibition. In vivo studies to 
evaluate the uptake and release of active drug involved administering the polymeric prodrug 
to mice bearing the PSA-producing CWR22R-H xenografts. Intravenous doses of the 
polymeric prodrug were given either as a single injection or 4 × daily. After a single dose, a 
~3-4 fold higher in concentration of L12ADT was detected in tumour tissues, compared with 
plasma or skeletal muscle. After four consecutive doses, the plasma concentration of the 
released drug was similar to the concentration observed when single dose was administered 
(Figure 33).119  




On the other hand, the concentration of drug in the tumour (~350 nM) was ~15-fold higher 
than in plasma and and 3.5-fold higher than the concentration in skeletal muscles. This 
confirmed the viability of the EPR effect by developing a small molecular weight drug into a 
macromolecule enabling increased tumour targetting.119  
 
1.4.3.10.2 PEGylated prodrugs 
Polyethylene glycol (PEG) (Figure 34) is an amphiphilic molecule with its hydroxy end-
groups easily derivatised. This allows easy coupling of PEG to other molecules. In aqueous 
environment such as the plasma, each ethylene oxide monomer within PEG is able to bind to 
2-3 water molecules. This layer of water molecules formed around PEG is said to be 
responsible for its ability to keep away cells and proteins from its surface giving the polymer 
properties such as:  
 Reduced immunogenicity; 
 Reduced antigenicity; 
 Resistance to enzyme degradation. 
 
The degradation product of low molecular weight (MW) PEG (< 400 Da) is said to be toxic 
whilst no evidence of such toxic metabolites has been observed from higher MW PEG (> 
1000 Da). Due to the good safety profile of high MW PEG, these have been used in food, 
pharmaceutical and cosmetic products. In vivo clearance of PEG is through urine and faeces 






























Figure 33:  Levels of L12ADT at 24 h after i.v. injection of HPMA-SSKYQL-12ADT into nude mice bearing 




PEGylated proteins possess better clinical features compared to unmodified proteins. These 
include resistance to proteolysis, increased solubility, improved chemical / thermal stability 
and being shielded from the immune system. PEGylation also prolongs the circulation of 
these agents, a feature attributed to the reduced clearance of these agents from the circulation 
system by kidney filtration. PEGylation often results in marked reduction in potency of drugs 
and can therefore be exploited in the development of a prodrug if PEG is released as part of 
the activation process.116, 120, 121 For instance water soluble PEGylated paclitaxel-7-carbamates 
showed 103 less activity than the free paclitaxel in vitro and were non-toxic in mice.122  
 
PEG has also been used to develop prodrugs of small cytotoxic molecules in other to exploit 
the EPR system for selective delivery. These drugs include taxol, campothecin and 
doxorubicin. PEGylation results in the properties of PEG being transferred to the conjugated 
drugs leading to improved properties such as increased solubility and improved 
pharmacokinetics.121 A PEG-peptide-doxorubicin prodrug (Figure 35) designed to be 
activated by lysosomal thiol-dependent protease (triosomes) was synthesised by Veronese et 
al.123 PEG of molecular weight of 5-20 kDa was used. In vitro assay showed that the PEG-
peptide-doxorubicin was 10-100 fold less toxic (IC50 = > 2µg mL-1) than free doxorubicin 
(IC50 = 0.24 µg mL-1) against B16F10 cells. Conjugates with higher MW PEG had a longer 
circulation in the blood after intravenous injection due to reduced renal clearance compared to 
free doxorubicin. This led to increased tumour targeting leading to higher tumour doxorubicin 
concentration. All PEG conjugates had a longer plasma half-life.  
 
 




Despite the highest MW PEG conjugate showing greater tumour levels, the PEG5KDa had the 
most favourable tumour to heart ratio which is important in the case of doxorubicin since 
cardiotoxicity is a known dose-limiting toxicity. It was also observed that release of the drug 
by lysosomal enzymes was dependent on the peptide linker and had little dependency on the 
PEG carrier.  In vivo studies using mice bearing subcutaneous B16F10 murine melanoma, 
showed that PEGylated peptidyl doxorubicin was more active than free doxorubicin which 
showed no significant anti-tumour activity.123  
 
The use of a polymeric-peptide-prodrug system to achieve selective delivery to prostate 
tumour allows dual targeting based on EPR effect and protease activation. The EPR effect 
ensures that macropolymeric prodrug selectively accumulates in tumour tissues. Activation of 
the prodrug by PSA occurs in the extracellular fluid surrounding tumour cells. Prodrugs are 
therefore not required to penetrate tumour cells before being activated. The presence of active 
drug within the extracellular fluid will allow a bystander cytotoxic effect on both PSA-
positive and negative cancer cells since not every cell in the tumour will be required to 
produce PSA before coming into contact with the active drug. This has a potential to reduce 
the chances of resistance developing.119  
 
 













n Lysosomally cleavable peptide
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2 Aims and objectives 
2.1 Aims 
The project aims to develop a polymeric prodrug system, which will deliver highly potent 
drugs selectively to prostate tumours. The Enhanced Permeability and Retention effect (EPR) 
ensures that water-soluble polymers, such as PEG, accumulate in solid tumours (e.g. prostate 
cancer).112, 114  Prostate-Specific Antigen (PSA) has been shown to be catalytically active only 
in the prostate.35, 93, 94 Conjugating a drug to a polymer via a PSA-cleavable peptide will create 
a polymeric prodrug system with two modes of selectivity. The polymeric prodrug system 
that this project aims to develop will consist of a CBI anti-tumour antibiotic analogue 
precursor (seco-CBI) 3 attached to PEG through a PSA-cleavable peptide (SSKLQ) with or 
without a molecular clip (Leu-R-Dmo) to form the polymeric prodrugs 1 or 2 (Figure 36).  
  
2.2 Objectives 
The project will proceed in three stages: 
 Chemical synthesis and cytotoxic evaluation of the proposed CBI drug to be delivered 
selectively; 
 Synthesis and evaluation of an advanced model to test PSA-triggered release of the 
CBI drug; 
Figure 36: Proposed seco-CBI and the corresponding polymeric prodrugs. 
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 Assembly and in vitro preliminary evaluations of the polymeric prodrug for PSA-
triggered delivery of the CBI drug. 
 
The proposed CBI drug comprises of a CBI alkylating subunit and 5-(2-
dimethylaminoethoxy)indole-2-carboxylic acid (DMAI) as the non-alkylating DNA-binding 
subunit. DMAI is involved in extra non-covalent binding to the minor groove of DNA. CBIs 
have been extensively studied and have shown to be more stable, more potent and more 
synthetically accessible than the corresponding CPIs.70, 77, 78 The proposed CBI drug is a 
modification of a 5-hydroxy-CBI drug synthesised by Tietze et al.124 to allow linkage to the 
peptide delivery system through an exocyclic nitrogen rather than oxygen. This will allow an 
amide to be formed with the PSA-cleavable peptide, which will be more stable than would the 
corresponding ester. Substituting the 5-OH with an amine has been shown not to be 
deleterious to the activity of the CBI drug.44, 79 The DMAI non-alkylating subunit 127 is 
chosen for ease of synthesis (Scheme 3). The tertiary amine also has the advantage of 
enhancing water solubility as the corresponding salt.52, 81 The indole core of 127 will be 
synthesised using a Fisher-like indole synthesis. An alkoxy substituent will then be introduced 
at the C5 position of the indole. 
  
Synthesis of the CBI drug will be achieved via the key naphthalene intermediate 67 which 
will be accessed through nitrated naphthalene derivatives. Reduction of the nitro groups 
Scheme 3: Synthesis of the alkylating subunit of proposed seco-CBI drug. 
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followed by orthogonal protection of the amino groups and substitution of the 1-position with 
iodine will give 67. The ideal protection at the ortho-amino group of 67 will be small and 
more electronegative than the protection at the para-amino group. This will enable selective 
alkylation at the ortho-amino group with either 2R,3S-3-methyl-2-(4-nosyloxymethyl)oxirane 
or allyl bromide to give 4 or 104, respectively. The homochiral nosylate reagent will be 
synthesised using Sharpless epoxidation to give the epoxy alcohol, followed by 
functionalisation of the hydroxy group into the nosylate. A metal-mediated cyclisation of 4 
will form the pyrrolidine ring of 5. Efforts will be made to introduce an extra methyl group at 
position-10 of the CBI drug 3 using this synthetic route (Figure 36). This methyl group 
through steric hinderance will be expected to reduce reactivity of the seco-CBI by preventing 
direct alkylation at C10. This will contribute to the expected reduction in the cytotoxicity of 
the prodrug compared to the spirocyclised active drug.125 The hydroxy group of 5 will then be 
converted to the chloride using a Mitsunobu-like reaction with retention of configuration. 
Deprotection of the N3 protecting group will then allow coupling to the DMAI non-alkylating 
subunit to give 7. With 104, free-radical cyclisation with TEMPO trap will be explored to 
synthesise the pyrrolidine ring. The 2,2,6,6-tetramethylpiperidine will then conveniently act 
as a protecting group of the hydroxy group of 105. Removal of the N3 protecting group and 
coupling to the non-alkylating subunit will be followed by reductive removal of the 2,2,6,6-
tetramethylpiperidine group to unmask the hydroxy group. Substitution of the hydroxy with 
chloride will give the protected seco-CBI 135. Removal of the remaining protection on the C5 
amino group of 7 and 135 will give the final seco-CBI. 
 
DNA alkylation studies will be carried out on the synthesised seco-CBI to ascertain the effect 
on the melting temperature on calf-thymus DNA. This will inform the extent of DNA 
alkylation and also the effect of the drug upon DNA alkylation. The degree of shift in the 
DNA-melting temperature of calf-thymus DNA will show the potency of the seco-CBI. An 
MTS cytotoxicity assay will also be carried out on prostate cancer cell lines using 3 as well as 
the protected precursors 7 and/or 135. Cytotoxicity tests on 7 and/or 135 will help predict the 
effect of conjugating the seco-CBI drug 3 to the peptide to form a prodrug. 
 
An advanced model to test PSA-triggered release of the synthesised CBI will firstly involve 
synthesis of a non-cytotoxic model drug with an aromatic amine group and coupling to the 
peptide, Ser-Ser-Lys-Leu-Gln, which contains the amino-acid sequence Ser-Lys-Leu-Gln, 
claimed to be the minimal sequence required for recognition and cleavage by PSA.99 The 
peptide-model drug conjugate will be incubated with PSA and the mixture examined by 
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HPLC to measure the rate of release of the model drug. This will give an insight into whether 
PSA can cleave the aromatic amine model-drug directly from the peptide as reported.99 If the 
release is poor, the molecular clip, Leu-Dmo (2,2-dimethyl-1,3-oxazolidine-4-carboxy, 
analogue of proline) will be inserted between the peptide and model drug. This will allow 
PSA (an endopeptidase) to cleave between Gln and Leu-Dmo and release the Leu-Dmo-
model-drug. The molecular clip is designed to then detach spontaneously, releasing the free 
drug. 
 
Following on from this, the peptide-model drug complex will be linked to poly(ethylene 
glycol) at the N-terminal of the peptide. This polymer has extensive use in prodrug 
development due to its non-toxicity, non-immunogenicity and excellent pharmaceutical 
properties.120-122 The polymer comes in a variety of molecular weights but for the purposes of 
exploiting the EPR effect, molecular weight of 20,000 Da will be used.114 Preliminary trials to 
couple the peptide-model drug to the polymer will, however, involve PEG of 5,000 Da 
molecular weight. The polymer comes as the diol, with both ends having a hydroxy group and 
in a version where one of the ends is capped with a methyl group. This will give the 
possibility of attaching the peptide–model-drug to one or both ends of the polymer after 
functionalising the hydroxy group(s) into a nosylate. The polymeric-peptide-model-drug 
conjugate will then again be subjected to enzymatic assay for release of the model drug. 
 
Once the polymeric prodrug concept has been proven, coupling of the synthesised CBI drug 
to the PSA-cleavable peptide will take place followed by assessment of cytotoxicity of the 
peptide-CBI drug complex against a range of prostate tumour cell lines. Cytotoxicity assay in 
non-PSA-producing cell lines such as Du145 and TSU will inform on the toxicity of the CBI 
prodrug whilst cytotoxicity assay in PSA-producing cell lines such as LNCaP and 
CWR22Rv1 will inform on the PSA-mediated release of the CBI drug.94 The peptide-CBI 









3 Results and discussion 
The limited range of chemotherapeutic treatments for prostate cancer and the lack of intrinsic 
selectivity of most of these drugs has created a need to develop more selective novel agents to 
target prostate tumour. The anti-tumour antibiotics CC-1065 and the duocarmycins belong to 
a class of agents with high cytotoxicity to various tumours including prostate tumour cell 
lines.42 These agents have been, however, precluded from clinical use due to toxic effects such 
as myelosuppression and delayed death in the case of CC-1065.45, 47-49, 75  These compounds 
are also not easily synthetically accessible.  
  
Scheme 4: Retrosynthesis of proposed polymeric prodrug system. 
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1,2,9,9a-Tetrahydrocyclopropa[c]benz[e]indole-4-one (CBI)-based analogues of the anti-
tumour antibiotics have been shown to be more stable (4 ×), biologically more potent (4 ×) 
and considerably more synthetically accessible than the corresponding agents incorporating 
the natural cyclopropapyrroloindole (CPI) alkylation subunit.70, 77, 78 Synthesis of the CBI-
analogue will be followed by developing of a polymeric prodrug system for selective delivery 
to prostate tumours. The proposed polymeric prodrug 1 or 2 (Scheme 4) consists of a seco-
CBI drug attached to one or both ends of the water-soluble polymer, PEG, via a peptide linker 
designed to be cleaved selectively by PSA. PSA has been shown to be able to cleave aromatic 
amines (e.g. 7-amino-4-methylcoumarin) directly from PSA-cleavable peptides.99 Direct 
attachment of drug to the PSA-cleavable peptide 2 will therefore be investigated. However, 
direct attachment of drug to the cleavage point of the peptide linker sometimes results in 
inefficient release of the drug. For instance, a peptide prodrug of doxorubicin was released as 
leucyl-doxorubicin.82, 97 To avoid situations where pendant amino-acid(s) attached to drugs 
can be deleterious to the activity of the drug, insertion of a self-immolative molecular clip 
between the PSA-cleavable peptide and the drug 1 will be investigated. In this way, 
enzymatic cleavage is followed by self-immolation of the pendant molecular clip to release 
the active drug. The synthesis of the polymeric prodrug system began with the synthesis of 
the proposed CBI drug followed by biological assay to investigate the potency of the drug and 
finally the synthesis of the prodrug. 
 
3.1 Synthetic approaches to the CBI “warhead”  
There are various approaches to the synthesis of the CBI analogues of the natural anti-tumour 
antibiotics. The synthesis of CBI is divided into two parts namely; the synthesis of the 
alkylating subunit (“warhead”) and the synthesis of the non-alkylating subunit. Access to the 
alkylating subunit has proven much more challenging than the non-alkylating subunit. Most 
of the difficulties have centred on efforts to functionalise the pyrrolidine ring of the 
benz[e]indole core to introduce a hydroxymethyl group. The hydroxy group can be 
subsequently substituted to a better leaving group such as chlorine, which is necessary for 
spirocyclisation to form the highly reactive cyclopropane ring. The majority of the 
investigations into the synthesis of CBI alkylating subunit have involved the 5-hydroxy 
analogues. Below is a review of some of the synthetic approaches adopted in the synthesis of 
the CBI “warhead”. 
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3.1.1 Synthesis of the key intermediate of the 5-hydroxy-CBI derivatives  
  
Boger et al.126 developed a synthetic route to access the 5-hydroxy analogue of the CBI 
alkylating subunit (Scheme 5). Starting from the commercially available 1,3-
dihydroxynaphthalene 8, reacting with ammonia gave 1-hydroxy-3-naphthylamine, followed 
by Boc-protection of the amine to give 9. Orthogonal benzyl protection at the hydroxyl group 
followed by electrophilic bromination with N-bromosuccinimide gave the key intermediate 
10.126 Introduction of a range of alkylating groups at the N2 position allows the synthesis of 
the pyrrolidine ring of the CBI alkylating subunit.  
 
3.1.2 Post- and pre-cyclisation functionalisation of the CBI pyrrolidine ring  
 
Initial efforts to synthesise the hydroxymethylindoline 12 involved post-cyclisation 
functionalisation of the pyrrolidine ring to introduce the hydroxymethyl group (Scheme 6). 
Treatment of the sodium salt of 10 with 3-bromopropyne followed by a 5-exo-dig aryl 
Scheme 5: Synthesis of tert-butyl (4-(benzyloxy)-1-bromonaphthalen-2-yl)carbamate 10. Reagents and 
conditions: i. liquid NH3, −78C → 130C, 1100 psi, 16 h; ii. Boc2O, dioxane, 100C, 4 h, iii. BnBr, K2CO3, n-
Bu4NI, dry DMF, N2, 23C, 8 h; iv. NBS, conc. H2SO4, THF, N2, −60C, 5 h. 
Scheme 6: Pre- and post-functionalisation of CBI pyrrolidine ring. Reagents and conditions: i. NaH, 
HC≡CCH2Br, THF / DMF, N2, 24C, 3 h; ii. Bu3SnH, AIBN, benzene, N2, 80C, 1 h; iii. BH3.SMe2, THF, Ar, 
0-24C, 3 h then H2O2, NaOH, 0 → 45C, ~1 h; iv. Ph3P, CCl4, CH2Cl2, Ar, 24C, 10 h; v. BrCH2CH=CMe2, 
NaH, DMF, Ar, 0 → 24C, 8 h; vi. 3% O3/O2, Me2S, CH2Cl2 / MeOH, −78 → 24C, 3 h; vii. Ph3PClCH2OTHP, 
THF/HMPA, −78C → 24C, n-BuLi, 24 h; viii. Bu3SnH, AIBN, benzene, Ar, reflux, 1 h, ix. MeOH, 
Amberlyst 15, 45C, 6 h. 
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radical–alkyne cyclisation when treated with tri-butyltin hydride and azobisisobutyronitrile 
(AIBN) gave the unstable 1-methylenebenzindoline 11. Hydroboration-oxidation of 11 gave 
the hydroxymethylindoline 12 and chlorination was effected with triphenylphosphine and 
carbon tetrachloride to give 13. Challenges faced with this synthetic route include partial / 
complete isomerisation of methylenebenzindoline to 1-methylbenz[e]indole on 
chromatographic purification. Besides, the cyclisation reaction proved very reliant on reaction 
time and the concentration of tri-butyltin hydride used and therefore stringent adhesion to 
reaction conditions was required.127  
 
Another way of accessing the hydroxymethylindoline involves pre-functionalisation of the 
alkylating group before cyclisation (Scheme 6). This method has the advantage of avoiding 
the challenges faced with post-cyclisation functionalisation.126 Boger et al.128 alkylated 10 
with 1-bromo-3-methyl but-2-ene to give 14. Ozonolysis with subsequent reductive workup 
gave 15. Treatment of 15 with [(2-tetrahydropyranyloxy)-methylene]triphenylphosphorane 
introduced a vinyl ether group to give 16. Free-radical cyclisation was effected with tri-
butyltin hydride and AIBN. Removal of the tetrahydropyranyloxy protecting group afforded 
the hydroxymethylindoline 12. Substitution of the hydroxy group of 12 with chlorine gives 13 
as the alkylating subunit to be coupled to the non-alkylating subunit. This synthetic route, 
however, has the constraint of having to incorporate the hydroxy functionalisation into the 
acceptor alkene before cyclisation and also requires carefully defined reaction conditions 
(ozonolysis) and subsequent Wittig reaction with a functionalised 
methylenetriphenylphosphorane. An easier and simpler synthetic route to 12, will be to 
incorporate functionality during cyclisation.128 
 
3.1.3 In situ functionalisation of the CBI pyrrolidine ring 
 
Scheme 7: Synthesis of CBI pyrrolidine ring with TEMPO trap. Reagents and conditions: i. NaH,
BrCH2CHCH2, DMF, 0 → 25C, 3 h; ii. Bu3SnH, TEMPO, benzene, N2, 70C, 105 min; iii. Zn, AcOH / 
THF / H2O (3:1:1), 70C, 2 h. 
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The functionalisation of the pyrolidine ring during cyclisation works better with iodine at C1 
in contrast to bromine at this position.128 O-Benzyl protection and electrophilic iodination of 9 
gave 17 (Scheme 7). Alkylation of 17 with 1-bromoprop-2-ene gives 18. Treatment of 18 with 
tri-butyltin hydride and TEMPO gives 19 with the incorporated protected hydroxy 
functionality. Reduction of the tetramethylpiperidine by reductive cleavage of the N-O bond 
exposes the hydroxy group, which can be subsequently substituted with chlorine to give 13. 
This method avoids the need of pre- or post-cyclisation functionalisation to introduce the 
hydroxy group, since the TEMPO trap incorporates this functionality during cyclisation.128  
 
3.1.4 Metal-mediated cyclisation 
Tietze et al.81 synthesised the CBI alkylating subunit 23 in their investigation into the design 
of a prodrug based on the ADEPT concept (Scheme 8). Alkylation at the N2 position of 17 
with (2R,3S)-2,3-epoxy-1-nitrobenzenesulfonyloxybutane) afforded 21 followed by a metal-
mediated cyclisation to give 22 with the hydroxy functionality revealed during the reaction. 
Using the Appel reaction, the hydroxy group of 22 was replaced with chlorine to give 23. 
Removal of the Boc group of 23 allowed coupling to a range of non-alkylating subunits.  
 
This synthetic route offers the prospect of enantiopure synthesis. The methyl group at 
position-10 of 23 was introduced in order to reduce the chance of direct reaction of the seco-
compound with the DNA which would be detrimental to the design of prodrugs. The design 
of prodrugs with these agents relies on the reduced reactivity of the seco-analogue compared 
to the spirocyclised CBI. By introducing the methyl group at position-10, the primary alkyl 
chloride was transformed into a secondary, sterically hindered chloride, discouraging inter-
molecular reaction.125 The introduction of the extra methyl groups results in a new stereogenic 
centre absent in the natural products. It has been observed that, when the two stereogenic 
centres of CBI drugs incorporating the alkylating subunit 23, are syn (1S/10S or 1R/10R) the 
seco-CBI drug possesses a low toxicity and is not suitable for development as a prodrug, 
whilst the anti-orientation (1S/10R or 1R/10S) leads to the appropriate properties.124 
Scheme 8: Synthesis of CBI pyrrolidine ring via metal-mediated cyclisation. Reagents and conditions: i. 
NaH, (2R,3S)-2,3-epoxy-1-nitrobenzenesulfonyloxybutane, DMF, 25C, 1.5 h; ii. MeLi, CuCN, −78 → 25C, 
~2.25 h; iii. PPh3, CCl4, CH3CN, −18 → 0C, 3 h. 
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Furthermore, a CBI incorporating the (+) (1S,10R) diastereoisomer of 23 has been found to be 
more active (IC50 = 0.75 nM) compared to the (−) (1R,10S) diasteroisomer (550 nM) against 
human bronchial carcinoma cells (A549).81, 124, 129  
 
3.1.5 Synthesis of the 5-amino CBI derivatives 
A CBI prodrug incorporating the alkylating subunit 13 (Scheme 6) with the 5-hydroxy group 
functionalised as O-galactoside prodrug showed an unexpected high cytotoxicity [(IC50 = 4.8 
nM (A549)] in the absence of the activating enzyme (β-D-galactosidase) compared to the 
activated analogue (IC50 = 0.15 nM (A549)]. This observation was partly attributed to non-
enzymatic cleavage of the galactoside and highlights the need for a more stable prodrug.125 
Carzelesin, a 5-hydroxy-CPI carbamate prodrug, is labile in plasma, rapidly releasing the 
active drug. Preparation of a more stable prodrug that persists in the plasma but allows 
specific release within the tumour by localised enzyme(s) is desirable.44 The 5-amino-CBI 
derivatives are said to possess the same biological properties as the hydroxy-CBI. One 
advantage of the amino-CBI is their ability to form more stable amide prodrugs.79 The 
synthesis of the amino-seco-CBIs are, however, very challenging. The synthesis of such an 
amino-CBI was carried out by Yang et al.79 Starting with 2,4-dinitronaphthalen-1-ol, they 
undertook a sequence of synthesis [triflation, SNAr displacement with iodide, reduction (with 
loss of iodine), protection with Boc2O and restoration of the iodine)] to access 25 (Scheme 9).  
 
Discriminating between the two nitrogens of 25, however, proved difficult. Non-selective 
allylation of 25 was therefore undertaken followed by free-radical cyclisation with TEMPO 
entrapment. Removal of the TEMPO group followed by substitution of the hydroxy group 
with chlorine gave 27. The final steps in the synthesis of the amino-CBI involved removal of 
the N3-Boc protecting group and coupling of the alkylating subunit to the non-alkylating 
subunit followed by removal of the 5-allyl group, a step which proved challenging.79 A 
Scheme 9: Synthesis of 5-amino CBI derivative. Reagents and conditions: i. (CF3SO2)2O, Et3N, CH2Cl2, 0C 
then rt, 2 h; ii. NaI, EtOAc, reflux, 2 h; iii. SnCl2, EtOAc, reflux, 30 min, basic workup then Boc2O, THF, 
reflux, 5 h; (iv) NIS, TsOH, 1:1 THF/MeOH, −78C then rt over 4 h; v. NaH, then CH2=CHCH2Cl; vi. TEMPO, 




synthetic route which allows easier discrimination between the nitrogens is, therefore, highly 
desirable. Efforts will be made in the present study to distinguish between the N2 and N4 
amines of 25 to afford a more selective alkylation at the N2 amine which will enhance the 
efficiency in the synthesis of the proposed CBI drug. 
 
3.2 Synthesis of the alkylating subunit of the proposed CBI drug  
  
The synthesis of the proposed CBI drug has two parts, namely, synthesis of the alkylating 
subunit and synthesis of the non-alkylating subunit. The synthesis of the alkylating subunit 
proceeds via a naphthalene derivative 67 with an iodo-substituent at position-1 and 
orthogonally masked amines at positions-2 and -4 (Scheme 10). Selective alkylation at the N2 
of 67 with the appropriate group will allow a cyclisation reaction to be performed to generate 
the five-membered pyrrolidine ring. There will be two approaches to this. Firstly, enantiopure 
synthesis will be attempted by alkylating N2 with an enantiopure epoxide followed by metal-
mediated cyclisation to give 5 (Scheme 3). The second approach will be based on racemic 
synthesis by adopting free-radical cyclisation to give 105 (Scheme 3) after introducing an 
allyl group at N2 of 67. Deprotection at the N2 of 5/105 will then allow coupling to the non-
alkylating subunit to give the proposed CBI drug. The masked amine at position-5, once 
deprotected will be coupled to a poly(ethylene glycol) via a PSA-cleavable peptide linker to 
form the polymeric prodrug.  
 
 
Scheme 10: Retrosynthesis of the alkylating subunit of the proposed CBI drug. 
65 
 
3.2.1 Mono-nitration of naphthalen-1-ol 
  
An initial attempt was made to synthesise 2-nitronaphthalen-1-ol 29 (or 4-nitronaphthalen-1-
ol 30) by mononitration of naphthalene-1-ol 28 (Scheme 11). The expected nitration at the 2- 
or 4-positions of naphthalen-1-ol was based on the ortho/para-directing effect of the 
mesomerically electron-donating hydroxy group. Furthermore, since nitro groups are 
mesomerically electron-withdrawing and deactivating, it was expected that dinitration should 
proceed slowly if at all. The rationale was to introduce a nitro group at one of these positions 
of naphthalen-1-ol 28 and then to reduce to the amine and protect this group. A second nitro 
group would then be introduced, reduced and protected with a different (orthogonal) 
protecting group. This will help to avoid the issue of selectivity which arises when using a 
dinitro-naphthalen-1-ol. This approach, however, was unsuccessful as multiple nitration 
occurred with formation of many products, which were impossible to separate. A new 
approach was adopted to access naphthalen-1-ol derivatives with orthogonally protected 
amino groups at the 2- and 4-positions. 
 
 
Scheme 11: Attempted mononitration of naphthalene-1-ol. Reagents and conditions: i. H2SO4, HNO3, 









3.2.2 Selective nitration of 4-aminonaphthalen-1-ol  
  
4-Aminonaphthalen-1-ol hydrochloride 31 presents a molecule with an amino group already 
present at position-4 (Scheme 12). Introduction of a second amino group at position-2 after 
protection of the 4-amino group will give an intermediate with orthogonal amino groups. 
Benzyloxycarbonyl (Cbz) protection of the amino group of 4-amino-naphthalen-1ol 31 was 
undertaken using benzyl chloroformate in the presence of a base to give 32. Selective 
protection of the amino group over the phenolic group is based on the superior nucleophilicity 
of the amino group under mildly basic conditions and also due to the stable carbamate product 
formed. The presence of an amide-like protection at the 4-amino group also had a secondary 
purpose. Both the hydroxy and amino group of 31 are ortho/para directing. Protection of the 
amino group therefore serves to deactivate somewhat the directing effect of the amino group, 
thereby allowing selective nitration at the position ortho to the phenolic group. Selective 
nitration at the position ortho to the hydroxy group of 32, however, proved difficult. The 
rationale was that once nitrated, the nitro group could then be reduced and the resulting amine 
protected with an orthogonal protecting group after substituting the hydroxy group with 
iodine to give the key intermediate 67. Attempts to nitrate benzyl N-(4-hydroxynaphthalen-1-
yl)-carbamate 32 using nitric acid as a mild nitrating agent resulted in a product mixture that 
included 34. This suggested that dinitration as well as oxidative deamination had occured. The 
use of one equivalent of potassium nitrate, together with trifluoroacetic acid, as a source of the 
nitronium ion was investigated. Nitration of 32 with this reagent, however, resulted in 
oxidative deamination as well, but without nitration at the desired position to give 35. Direct 
Scheme 12: Nitration of 4-amino-naphthalen-1-ol. Reagents and conditions: i. KOBut, benzyl chloroformate, 
 −70C to r.t., N2, 16 h; ii. HNO3, 0C to r.t., 3 h; iii. CF3CO2H, KNO3, −20C, 30 min. 
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nitration of the starting material 4-aminonaphthalen-1-ol hydrochloride 31 was undertaken 
with the rationale that, once in acidic medium, the amino group will stay protonated, 
deactivating nitration at the position ortho to the amino group and thereby allowing selective 
nitration at position-2. This effort also resulted in the oxidised product 35 without the desired 
nitration. Scheme 13 shows the proposed mechanism for the oxidative deamination.  
  
Nucleophilic attack on the generated nitronium ion by the phenolic group of 31 results in 
nitration at the phenolic oxygen to give 36. Delocalisation of electrons from the amino group 
results in an elimination process which releases nitrous acid / nitrite ion. Hydrolysis of the 
iminonaphthalenone salt 38 with loss of ammonia produces naphthoquinone 35. In the case of 
using excess nitric acid as the nitrating agent, the reaction proceeds further with the 
naphthalene ring undergoing an electrophilic substitution with the nitronium ion to give 34. 
The fact that 35 was obtained when one equivalent of the nitronium species was used (KNO3), 
suggests that nitration at the phenolic group and the subsequent oxidative deamination 
precedes nitration of the naphthalene ring. These challenges faced with this synthetic route led 
to investigation into other ways of accessing the key intermediate 67 in the synthesis of the 
proposed CBI drug. 
 
Scheme 13: Proposed mechanism of oxidative deamination of 31. 
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3.2.3 Attempted nucleophilic displacement of triflate group with iodide in 4-(tert-
butoxycarbonyl)amino-2-nitronaphthalen-1-yl trifluoromethanesulfonate (38) 
With the commercial availability of 2,4-dinitronaphthalen-1-ol 24 as the dye Martius Yellow, 
the question was asked if selective reduction of one of the nitro groups could be achieved. If 
possible, then protection of this amino group followed by substituting the hydroxy group with 
iodine and then subsequent reduction / protection of the remaining nitro group will give 
access to the key intermediate 67. An extensive literature search suggested that selective 
reduction of the 4-nitro group was possible.130  
 
The nitro group at position-4 of 2,4-dinitronaphthalen-1-ol 24 was selectively reduced under 
ethanolic acidic conditions with tin(II) chloride (3 equivalents) to give 40 (Scheme 14). The 
temperature of the reaction had to be controlled to less than 30C in order to avoid over 
reduction. The phenolic group appears to be involved in the protection of the ortho-nitro 
group from reduction. Similar reduction of 1-methoxy-2,4-dinitronaphthalene led to a product 
mixture of nitro-amines.130 A stabilising effect by coordination or hydrogen-bonding between 
the phenolic group and the 2-nitro group [(precluding simultaneous co-ordination of Sn(II)] 
may be responsible for the non-reduction of the ortho-nitro group of 24. 4-Amino-2-
nitronaphthalen-1-ol 40 was treated with di-tert-butyl dicarbonate and a catalytic amount of 4-
dimethylaminopyridine (DMAP) at room temperature. This surprisingly resulted in the 
acylation of the phenolic group rather than of the amino group to give 41 in a yield of 17%. 
The 4-dimethylaminopyridine acts to activate di-tert-butyl dicarbonate as a better electrophile. 
In this instance, it seems also to have acted as a base to deprotonate the acidic phenolic group 
which was made more acidic by the adjacent electron-withdrawing nitro group. This meant 
that the phenoxide generated was more nucleophilic than the amino group and, at room 
Scheme 14: Attempted substitution of triflate group with iodide. Reagents and conditions: i. SnCl2.2H2O, 
EtOH, conc. aq. HCl, < 30C, 17 h; ii. Boc2O, DMAP, N2, CH2Cl2, r.t., 30 min; iii. Boc2O, THF, N2, 16 h; 
iv. (CF3SO2)2O, pyridine, N2, 0C to r.t., 1 h; v. NaI, DMF, 80C, 2 h. 
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temperature, reaction of the phenolic group is favoured over the amino group. The low yield 
of 41 is partly due to the unstable nature of the carbonate group formed by acylation of the 
phenol. The reaction was repeated without 4-dimethylaminopyridine (DMAP). Using di-tert-
butyl dicarbonate and heating under reflux gave the desired product 42. Treatment of 42 with 
trifluoromethanesulfonic anhydride in the presence of pyridine as a solvent and base 
converted the phenolic group into a triflate 43. The use of excess base in this reaction was 
essential since trifluoromethanesulfonic acid is generated in the reaction and might deprotect 
the acid-labile BocNH. The triflate group serves as a better leaving group to aid the next step 
of the synthesis which was to undertake a nucleophilic substitution of the triflate with iodine. 
It was also hoped that the presence of the nitro group will activate the molecule to 
nucleophilic substitution. This nucleophilic aromatic substitution (SNAr) takes place via the 
addition and elimination mechanism and not by direct substitution. It is essential to have an 
electron withdrawing group ortho and/or para to the leaving group in order to accommodate 
and stabilise the negative charge from the nucleophile through inductive effect or conjugation. 
The importance of this requirement is best shown by comparing the 13C NMR of the 
carbocation and carbanion intermediates of benzene131 (Figure 37).  
 
As can be observed from Figure 37, the chemical shift for the meta-carbon of both ions differs 
only slightly from the chemical shifts corresponding to the benzene carbons. However, there 
is a significant downfield shift for the ortho- and para-carbons of the benzene cation and a 
significant upfield shift for the ortho- and para-carbons of the benzene anion. It is very clear 
from these results that the ionic charges are delocalised mainly on the ortho- and para-
carbons. This means that, in nucleophilic aromatic substitution, the electron-withdrawing 
activating group, such as the nitro group of 43, must be on the ortho- or para-carbons to have 






any stabilising effect on the generated anion.131 Several attempts using a range of reaction 
conditions, however, failed to give the iodinated product 44. Sodium iodide and potassium 
iodide were used as sources of the iodide, different dry solvents were investigated (ethyl 
acetate, dimethylformamide, dimethylsulfoxide) and a range of temperatures (≤ 90C) were 
tested. In all these circumstances the phenolic product 42 was obtained. Scheme 15 shows the 
proposed mechanism for this reaction and also the mechanism of the desired SNAr reaction.  
  
It appears that the single nitro electron-withdrawing group does not make the 1-position 
sufficiently electrophilic for nucleophilic attack by the iodide ion. The lack of sufficient 
electron-withdrawing groups on the aromatic ring of 43 allows an alternative reaction. The 
iodide attacks the best remaining electrophile in the molecule, which is the triflate sulfur. 
 
3.2.4 Reduction of the aryl triflate 
Following the failure to substitute the triflate group of 43 with iodine, attempts to remove this 
group reductively to form 46 were investigated (Scheme 16). Iodine could then be introduced 
through electrophilic substitution with N-iodosuccinimide. Deoxygenation of phenolic 
hydroxy groups is challenging due to their stability. The triflate group increases the leaving 
ability of the aryl oxygen of 43.132 Mori et al.132 have shown that dissolving magnesium in 
methanol, in the presence of palladium on charcoal as the catalyst, can reduce aryl triflates to 
generate the corresponding arenes. The source of hydrogen in this reduction is the acidic 
hydrogen atom of the methanol. Methanol was chosen due to the enhanced reactivity of 
magnesium with this solvent. Other protic solvents (e.g. ethanol, propan-2-ol) capable of 
being hydrogen donors failed to produce a reaction.132 Mori et al.132 have proposed that the 
reaction proceeds via an initial single-electron transfer from Pd0 to the aromatic ring of the 
Scheme 15: Proposed mechanisms of iodination of 43 and regeneration of 42. 
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aryltriflate to give a radical anion. Elimination of trifluoromethanesulfonate (OTf) anion gives 
rise to an aryl radical. A second single electron transfer from PdI to the aromatic ring takes 
place to give an aryl anion followed by protonation from methanol to give the deoxygenated 
product together with PdII which is reduced back to Pd0 by the magnesium.132 This synthetic 
method was adopted in the efforts to reduce the triflate group of 43 (Scheme 16). 
 
Compound 43 in methanol was treated with palladium on charcoal and magnesium and stirred 
at room temperature overnight. The isolated product from this reaction was, however, the 
regenerated phenolic compound 42. This again suggested a nucleophilic attack at the sulfur 
atom as observed with the attempted iodination of 43 (Scheme 14), where the iodide ion 
attacked the sulfur atom to give 42. This problem was encountered by Mori et al.132 in their 
investigations. It was reported that the use of excess reagents and the addition of ammonium 
acetate helped overcome this problem as well as accelerating the reaction.132 Ammonium 
acetate dissociates into acetic acid and ammonia in situ. The acetic acid facilitates the 
dissolution of magnesium in methanol which in turn enhances the reduction of PdII to Pd0 by 
magnesium. Coordination of ammonia to the Pd0 accelerates the single-electron transfer 
process to the aryl triflate.132 Adopting this method for 43, however, failed to give the desired 
product.  
 
The use of triethylammonium formate as a reducing agent to cleave the C-O bond of aryl 
triflates has been reported by Peterson et al.133 This method was shown to be efficient with 
aryl triflates with electron-withdrawing groups as well as with electron-donating groups.133 
The hydrogen donor in this reaction is the formate. Triphenylphosphine reduces palladium(II) 
acetate in situ to generate bis(triphenylphosphine)palladium(0). Insertion of palladium(0) 
between the aryl-triflate bond occurs through oxidative addition. Triflate is then displaced by 
formate ion followed by loss of carbon dioxide generating aryl-palladium(II) hydride. 
Reductive elimination results in the deoxygenated aryl product and regeneration of the 
catalytically active palladium species [(palladium(0)].134 Compound 43 was treated with 
triethylamine, formic acid, palladium(II) acetate and triphenylphosphine. Isolation and 
Scheme 16: Attempted reduction of the triflate group of 43. Reagents and conditions: i. Mg, Pd/C(10%), 
MeOH, r.t., Ar, 16 h; ii. PPh3, Pd(OAc)2, Et3N, formic acid, DMF, 65C, 1 h. 
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purification of product again showed that the phenol 42 was regenerated. The idea of 
substituting the triflate of 42 with iodide in two steps was, therefore, abandoned.  
 
3.2.5 Reduction of the nitro group of 4-(tert-butoxycarbonylamino-2-nitronaphthalen-
1-yl trifluoromethanesulfonate (43) 
 
The purpose of having the iodine at position-1 of the key intermediate 67 is to exploit the 
reactivity of iodine towards a cyclisation reaction to form the five-membered pyrrolidine ring 
of the CBI drug. The question was, therefore, asked as to whether triflate can take up this role. 
If that was the case, then reduction of the nitro group of 43, followed by protection, will give 
an intermediate compound capable of undertaking the role of the desired key intermediate 67. 
Efforts to reduce the nitro group of 43 included hydrogenation with palladium on charcoal 
catalyst and the use of sodium dithionite as the reducing agent (Scheme 17). These, however, 
gave complex product mixtures which could not be separated. Reduction of the nitro group 
may have well occurred but the presence of the triflate group in such a close proximity to the 
exposed amine can lead to transfer of the triflate group to the amine giving a range of possible 
products. One way of avoiding the transfer of triflate to the amino group will be to carry out 
the reaction in acidic medium so as to trap the amino group as the protonated form and 
thereby reduce its nucleophilicity. This method runs the risk of causing the deprotection of the 
acid-labile Boc group. The use of tin(II) chloride to reduce the nitro group of 43 was tried but 











3.2.6 Masking of the phenol group  
 
Protection of the phenolic group of 42 before reduction of the nitro group followed by 
orthogonal protection of the formed amino group, was another idea investigated (Scheme 18). 
The protecting group of the phenol will then be removed and the exposed hydroxy group 
converted to a triflate group. This compound can then be investigated for cyclisation to form 
the pyrolidine ring of the proposed CBI drug after alkylation at the N2-position with 
appropriate alkylating group. Treatment of compound 42 with silylating agents, such as 
chlorotrimethylsilane and hexamethyldisilazane, in different reaction conditions, however, 
failed to give 48 but instead resulted in recovered starting material (Scheme 18). 
 
3.2.7 Unexpected formation of a quinone imine on reduction of tert-butyl N-(4-
hydroxy-3-nitronaphthalen-1-yl)carbamate (42) 
 
The challenges faced resulted in another strategy being investigated. This involved reduction 
of the nitro group of 42 followed by selective protection of the amino group and then triflation 
of the phenolic group. Reducing agents such as catalytic hydrogenation and sodium dithionite 
were used in reducing 42 (Scheme 19). This resulted in the reduction of the nitro group but 
also oxidation of the product to give the quinone imine 50 as the E-isomer. This was 
confirmed by the observation of a correlation between the Boc-protons and the C3 proton of 
50 on a NOESY spectrum.  It was suspected that exposure of the reduced product to air was 
Scheme 19: Formation of quinone imine. Reagents and conditions: i. Na2S2O4, K2CO3, CH2Cl2/H2O, N2, 
35C, 16 h; ii. (CF3CO)2O, Pri2NEt, CH2Cl2, 0C to r.t., 16 h. 
Scheme 18: Attempted silylation of 42. Reagents and conditions: i. ClSiMe3, Pri2NEt, CH2Cl2, N2, 40C, 16 
h; ii. hexamethyldisilazane, DMF, N2, 80C, 48 h; iii. ClSiMe3, imidazole, THF, Ar, r.t., 24 h.  
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responsible for this oxidation. Reduction of the nitro group of 42 and protection of the 
intermediate amine in the absence of air was attempted. This involved reduction of 42 using 
sodium dithionite in a biphasic dichloromethane / water system under nitrogen. Once 
reduction was complete, the organic phase, which should contain the product, was syringed 
out and placed under nitrogen. Treatment of the mixture with trifluoroacetic anhydride under 
basic conditions should then give 51. This, however, resulted in the oxidised product 52. A 
literature search to ascertain the possibility of reducing 50/52 to regenerate the phenolic group 
was undertaken. Although no specific method was found for the reduction of a quinone imine, 
it was observed that quinones could be reduced to the hydroquinones using a range of 
reducing agents including sodium dithionite135, 136 and Raney nickel.137  However, since the 
reduction of 42 had been effected by sodium dithionite but still resulted in the oxidised 
product 50 and also the failure to synthesise 51 led to the thinking that, even if reduction of 50 
or 52 were possible, this would revert back to its oxidised form on exposure to air and 
therefore this idea was abandoned. 
 
3.2.8 Attempted reduction of the nitro group(s) of 1-iodo-2,4-dinitronaphthalene (54) 
and the synthesis of N,N’-bis(tert-butoxycarbonyl)-1-iodonaphthalene-2,4-
diamine (25) 
Due to the challenges faced, efforts were made to introduce the iodine onto the naphthalene 
ring of 24 to give 54 before reduction of the nitro groups (Scheme 20). This will allow 
attempted selective reduction of the para-nitro group with the aid of the bulky iodine 
shielding the ortho-nitro group from reduction. Protection of the para-amino group will be 
followed by reduction of the ortho-nitro group using more vigorous reductive conditions. This 
will allow orthogonal protection of the ortho-amino group to give the key intermediate 67. 
Alternatively, reduction of both nitro groups of 54 will still present the possibility of 
selectively protecting one of the amino groups followed by orthogonal protection of the other. 
Synthesis of 25 will be pursued if the above strategies fail. This will allow the exploration of 
selective deprotection / re-protection of 25 to access the orthogonally protected 1-iodo-
naphthalene-2,4-diamine key intermediate. Investigation into these possibilities was 




3.2.8.1 Synthesis of 1-iodo-2,4-dinitronaphthalene (54)  
The synthesis of 54 was achieved in two steps, the first being triflation at oxygen to give 53 
(Scheme 20). Nucleophilic aromatic substitution was then undertaken with iodide to give 54. 
Unlike the failed SNAr reaction of compound 43 (Scheme 14), compound 53 has two 
activating nitro groups at the ortho- and para-positions to the triflate. The enhanced activation 
increases the electrophilicity of the C1 to nucleophilic attack rather than the sulfur atom of the 
triflate group. The reaction was studied in ethyl acetate and in acetone, with acetone giving a 
higher yield (74%) than in ethyl acetate (66%). This might be due to the greater solubility of 
sodium iodide in acetone. 
 
3.2.8.2 Attempted reduction of the 4-nitro group of 1-iodo-2,4-dinitronaphthlene (54) 
Compound 54 was exposed to the same reaction conditions that allowed selective reduction of 
the 4-nitro group of 24 (Scheme 14). It was hoped that selective reduction of one of the nitro 
groups could be achieved. Efforts to reduce selectively the 4-nitro group of 54 using tin(II) 
chloride in acidic ethanol resulted in a mixture of products which included the de-iodinated 
Scheme 20: Attempted reduction of the nitro group(s) of 54 and the synthesis of 25. Reagents and conditions: 
(F3CSO2)2O, Et3N, CH2Cl2, 0C to r.t., 2 h; ii. NaI, EtOAc, reflux, 2 h; iii. SnCl2.2H2O, conc. aq. HCl, EtOH, 
r.t., 16 h;   iv. Pt/C(1%), H2, THF, 20 h; v. Pd/C(10%), NaBH4, MeOH, THF, 0C, 4 h; vi. SnCl2.2H2O, 
EtOAc, reflux, 1 h; vii. Boc2O, THF, reflux, 16 h; viii. NIS, pTsOH.H2O, THF/MeOH, −78C to r.t., 4h. 
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diamine 58 (Scheme 20). Prolonged reaction time was needed for progression of the reaction, 
probably due to poor solubility of 54, and the product mixture formed was difficult to 
separate. The inability to reduce selectively the 4-nitro group of 54 supports the role of the 
hydroxy group at the C1 position of 24 in the selective reduction of the nitro group (Scheme 
14). 
 
3.2.8.3 Reductive de-iodination 
Reduction of both nitro groups without loss of iodine was also attempted. Various reagents 
were considered for the reduction of 54. This difficult reduction can also result in de-
iodination.138 Hydrogenation in the presence of palladium-on-charcoal in a range of solvents 
(methanol, tetrahydrofuran, acetic acid) gave the de-iodinated diamine 58 (Scheme 20). It was 
hoped that the use of acetic acid as a solvent will make the mixture more acidic and reduce 
the possibility of dehalogenation which proceeds more effectively under basic conditions.139 
This was, however, not the case as de-iodination still occurred. Sodium borohydride was used 
as a source of a fixed number of equivalents of hydrogen. Sodium borohydride degrades to 
generate hydrogen which gets adsorbed onto palladium on carbon to reduce the nitro groups. 
This is a form of hydrogenation but with the ability to control the amount of hydrogen 
present. The use of sodium borohydride (2 eq.), however, remarkably resulted in selective de-
iodination to give 57 without reduction of the nitro groups. Platinum is said to be better at 
preserving halogens during hydrogenation combined with a fast rate of nitro group 
reduction.138, 140   Platinum-on-carbon (5% and 1%) together with hydrogen or sodium 
borohydride were used but either resulted in de-iodination together with reduction of the nitro 
groups (5% Pt/C) or was unreactive (1% Pt/C).  
 
3.2.8.4 The synthesis of N,N’-bis(tert-butoxycarbonyl)-1-iodonaphthalene-2,4- diamine 
(25) 
The difficulty encountered with efforts to reduce the nitro groups selectively meant that a new 
strategy was needed to circumvent these challenges. Synthesis of the key intermediate 67 
without orthogonal protection of the amino groups was pursued (Scheme 20). Once 
synthesised, efforts will then be made to ascertain the possibility of selective deprotection / re-
protection. Reduction of the nitro groups of 54 with concomitant de-iodination was carried 
out using tin(II) chloride. Protection of the amines with di-tert-butyl dicarbonate gave 59, 
which was readily isolated. Regioselective acid-catalysed electrophilic iodination of 59 with 
N-iodosuccinimide gave the aryl iodide 25 in a yield of 71%.79  
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3.2.9 Acidic de-iodination of N,N’-bis(tert-butoxycarbonyl)-1-iodonaphthalene-2,4-
diamine (25) 
Selective removal of one of the Boc-protection groups was attempted by treating 25 with 
dilute trifluoroacetic acid (0.85% v/v) in dichloromethane at room temperature (Scheme 21).    
 
An overall amount of 4 equivalent of the trifluoroacetic acid solution was added over 7 d. 
Isolation and purification of the product showed that de-iodination had occurred without 
deprotection to form 59 [experiment conducted by Wenyi Wang].141 Efforts were then made 
to remove both Boc groups and then exploit the steric hindrance provided by the iodine to re-
protect the 4-amino group selectively. Initial attempts to remove both Boc groups involved 
the use of trifluoroacetic acid at 0C. This, however, gave the de-iodinated diamine product 
58. Hydrogen chloride in dioxane (4.0 M) was then used with the view that the product 
formed after deprotection will precipitate as an hydrochloride salt and perhaps stop the de-
iodination step. This product would then be quickly treated with di-tert-butyl dicarbonate to 
protect the 4-amino group selectively. This procedure resulted in a de-iodinated 
monoprotected product product 62 in a low yield (6%). 
 
Assuming that deprotection with hydrogen chloride in dioxane had gone to completion, along 
with de-iodination, this observation suggested that selective protection of the N2-amine of 58 
Scheme 21: Acidic de-iodination. Reagents and conditions: i. CF3CO2H (upto 4 equiv), CH2Cl2, r.t., 7 d; ii.
CF3CO2H, 0C, 1.5 h; iii. (a). HCl / dioxane (4 M), r.t. 45 min, (b). Boc2O, Pri2NEt, THF, N2, r.t, 10 d. 
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was possible.  It also meant that the N2-amine in absence of the iodine was more reactive 
since it is more sterically accessible. Protection of the N4-amine of 62 with a bulkier 
protecting group (e.g. benzyloxycarbonyl group), followed by electrophilic iodination at C1 
will provide an intermediate with the potential of selective alkylation at N2. This could then 
be used as the key intermediate in the synthesis of the proposed CBI. Having a smaller and 
more electronegative protecting group at N2 and a bulkier and less electronegative group at N4 
is, however, much more desirable.  
 
3.2.10 Synthesis of the naphthalene key intermediate (67) 
The observation of the ability to protect 1,3-naphthalenediamine 58 selectively gave a new 
direction to the synthesis of the key intermediate 67. This selective protection has also been 
achieved by the treatment of 58 with 2-(tert-butoxycarbonyloxyimino)-2-phenylacetonitrile to 
give 62 at a yield of 8%.142 The N2-amine of 58 will be protected by a smaller and more 
electronegative protecting group compared to the orthogonal protection at the N4-amino 
group. Having a smaller protecting group at the N2-amine will give greater accessibility to the 
alkylating agent and also with a more electronegative protecting group, the remaining proton 
at N2 will be more acidic allowing easier deprotonation and selective alkylation. The chosen 
protecting group at N2 was trifluoroacetyl and the orthogonal protection for the 4-amino group 
will be tert-butylcarbonyl.  
   
The synthesis of the key intermediate 67 began by reduction of commercially available 1,3-
dinitronaphthalene 57 to the diamine 58, which was treated with one equivalent of 
trifluoroacetic anhydride in the presence of diisopropylethylamine at 0C in dry 
tetrahydrofuran (Scheme 22). This unfortunately gave the di-protected compound 63 in 26% 
Scheme 22: Synthesis of the key intermediate 67. Reagents and conditions: i. 10% Pd-C, H2, THF, r.t., 16 h; 
ii. (CF3CO)2O, Pri2NEt, dry THF, N2, 0C → 20C, 16 h; iii. NIS, pTsOH.H2O, dry THF, N2, −78C → 20C, 
20 h; iv. dilute (CF3CO)2O in dry THF (1.1% v/v), Pri2NEt, dry THF, N2, 0C → 20C, 16 h; v. aq. NaOH (5 
M), THF, r.t., 105 min. vi. Boc2O, dry THF, reflux, 16 h. 
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yield and recovered starting material. Repeating the reaction in pyridine led to isolation of the 
same product 63 and unreacted starting material. Electrophilic iodination of 63 to form 64 will 
give a product that can be explored for selective deprotection in basic conditions with the 
hope of de-iodination not occurring. An attempt to undertake an electrophilic iodination of 63 
to give 64, however, failed. The presence of the electron-withdrawing trifluoroacetamide 
protection rather than Boc protection as in 59 may be responsible for the lack of progress of 
this electrophilic iodination. The absence of a monoprotected product in the attempted 
selective protection of 58 using trifluoroacetic anhydride was an interesting observation. This 
was despite the use of one equivalent of anhydride. One would expect statistically that there 
should be at least some mono-protected compound(s). Trifluoroacetic anhydride is a very 
reactive electrophile and even weaker nucleophiles react with it. Ethyl trifluoroacetate was 
therefore used as a milder electrophile with the hope of promoting monoprotection.  
 
Compound 58 in tetrahydrofuran was treated with ethyl trifluoroacetate in basic conditions. 
This reagent, however, proved very unreactive even when used in excess at room temperature. 
The use of trifluoroacetic anhydride was revisited. It was thought that part of the reason for 
exclusive di-protected product was due to adding the anhydride as a neat liquid which created 
a local high concentration leading to the di-protected compound 63. Compound 58 was 
therefore treated with dilute trifluoroacetic anhydride in tetrahydrofuran (~1.1% v/v), added 
dropwise over 2 h at 0C. This interestingly led to isolation of the desired product 65 in a 
yield of 15% together with the di-protected compound 63 and recovered starting material 58. 
Several attempts were made to optimise this process including the use of different solvents 
(e.g. dimethylformamide, dichloromethane), different temperatures (e.g. −30C, −70C) and 
different concentrations of trifluoroacetic anhydride in tetrahydrofuran. These resulted in di-
protection or gave a similar percentage yield of the mono-protected product. Temperatures 
lower than 0C did not have a significant effect on the yield of the desired product and the use 
of DMF resulted in the di-protected product 64 only.  
 
Despite the modest yield of 65, the di-protected compound could be deprotected with a 
nucleophilic base (e.g. NaOH, NH3) and recycled to give the starting material 58. 
Deprotection of 63 to 58 was initially done using aqueous ammonia (35%) and methanol as 
the solvent. Solubility issues as well as the volatile nature of ammonia meant that this reaction 
took a long time to give the desired product, even after heating (50C). Besides, one by-
product of this reaction is trifluoroacetamide which necessitates purification of the product. 
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Due to these reasons, aq. sodium hydroxide was used to deprotect 63. This method results in 
trifluoroacetate ion as the by-product which is easily extracted into the aqueous layer during 
work-up. Protection of the N4-amine of 65 was achieved with the bulkier and less 
electronegative tert-butoxycarbonyl protecting group to give 66. Electrophilic iodination with 
N-iodosuccinimide gave 67, the key intermediate in the synthesis of the alkylating unit of the 
CBI drug. 
 
3.2.11 NMR investigation into the de-iodination of iodonaphthalenediamines in acidic 
media 
One of the major unexpected result in the synthesis of the key intermediate 67 was the de-
iodination of 1-iodonaphthalene-2,4-diamine under acidic conditions. For instance, the use of 
dilute trifluoroacetic acid in dichloromethane (0.85% v/v, one equivalent) in an attempt to 
deprotect 25 regioselectively resulted in de-iodination without removal of the Boc groups 
(Scheme 21). The rationale for this experiment had been to remove only one of the Boc 
groups. Regardless of which Boc group was removed, an appropriate orthogonal protection 
could be carried out on the exposed amine to obtain a compound that could fulfil the role of 
the key intermediate 67. Furthermore, when the concentration of the acid (trifluoroacetic acid 
or hydrogen chloride) was increased in an attempt to cleave the Boc-protection groups of 25, 
this also resulted in de-iodination, in addition to loss of the Boc groups. These fascinating 
observations where de-iodination occurred in acidic media led to the design of a series of 
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The first major identifiable compound was the deprotected compound 68 with the iodine still 
intact (Scheme 23). This compound was fairly stable after 2 h at 0C giving a yield of ~90% 
by NMR. The NMR showed the existence of a minor product in addition to 68 at this 
temperature. Raising the temperature of the spectrometer probe to 20C resulted in the 
emergence of a new compound which was identified as the Wheland-like intermediate 69.  
This compound became the dominant product after 2 h at 20C, giving a yield of ~> 90% with 
the remaining ~10% being compound 68. This suggested that an equilibrium existed between 
68 and 69, favouring 69 at this temperature. A new peak corresponding to the proton at 
position-1 of 69 was observed at δ 6.51 in the proton NMR spectrum (Figure 38). This peak 
correlated by HSQC with a sp3 carbon peak at δ 9.76 in 13C NMR spectrum in contrast to the 
sp2 13C NMR peak of δ 101.74 corrresponding to C1 of 68. The upfield shifts observed for 69 
are due to: 
 Loss of aromaticity by formation of the Wheland-like intermediate;  
 The shielding effect of the iodine;  
 The stabilisation of the positive charge.  
 
There was a significant change in chemical shift of the proton at position-3 from δ 8.11 in 68 
to δ 6.05 in 69 (Figure 38) and a corresponding change in 13C chemical shifts of δ 116.88 in 
68 to δ 91.48 in 69. Compound 69 was quite stable in this solution at 20C even after 7 d. 
However, all attempts to isolate 69 gave 58 through collapse of the Wheland intermediate 
with loss of an equivalent of I+. To enhance our understanding of this de-iodination process, 
the above experiment was repeated with 25 using CF3CO2D / CDCl3. Again, the first 
compound formed was the deprotected product 70 followed by formation of the tetrahedral 
cationic species 71 on warming to 20C (Scheme 23). Figure 39 shows a series of 1H NMR 
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3.2.11.2 Wheland-like intermediates from naphthalene-1,3-diamine in acidic media 
  
In order to ascertain if the observed Wheland intermediates were due to the presence of iodine 
at position-1, compound 58 was subjected to the same reaction conditions as above at 20C. 
Exposure of 58 to CF3CO2H / CDCl3 gave 73 and 74 in an equilibrium ratio of 4:1 which 
stayed constant even after 7 d (Scheme 24). Of particular interest in 74 was the observation of 
a CH2 peak at δ 4.13 in the proton NMR spectrum, which correlated with a peak at δ 33.28 in 
the 13C NMR spectrum. This was confirmed with a phase-sensitive HSQC and DEPT analysis 
(Figure 40). 
Scheme 24: Reactions of 58 with CF3CO2H and with CF3CO2D in CDCl3, showing Wieland-like intermediates. 
Reagents: i. CF3CO2H / CDCl3 (3:1); ii. CF3CO2D / CDCl3 (3:1); iii. aq. work-up. 
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3.2.11.3 De-iodination of tert-butyl N-(4-iodo-3-trifluoroacetamidonaphthalen-1-
yl)carbamate (67) in acidic media 
  
To investigate the influence of a non-acid-labile electron-withdrawing group at N2, compound 
67 was added to a mixture of CF3CO2H / CDCl3 (3:1) at 0C for 2 h to give the Boc-
deprotected 77. This after warming to 20C for 48 h gave the deiodianated compound 78 
without observation of a Wheland-like intermediate. A transient Wheland-like intermediate 
might be involved but the equilibrium concentration in this case is too low for it to be 
observed. This compound was confirmed by the existence of an extra 1H peak at δ 8.29 
corresponding to the new proton at position-1 of 78.  
 
The experiment was repeated with CF3CO2D / CDCl3 to give 79 initially and then 80 on 
warming to 20C. Compound 79 did not show any significant incorporation of deuterium at 
position-3 at 0C, with this signal integrating to almost one proton in the spectra. Initial 1H 
NMR spectra after ~15 min of warming to 20C showed the presence of both 79 and 80. The 
spectra showed that a significant amount of deuterium (72%) was incorporated at position-3 
of 79. Significant incorporation of deuterium also occurred at position-1 (80%) and position-3 
(69%) of 80 at 15 min. Keeping the reaction mixture at 20C for 48 h led to the complete 
conversion of 79 to 80. Increased incorporation of deuterium also occurred at position-1 
(86%) and position-3 (82%) of 80. The N2-amide proton of 79 and 80 was extensively 
exchanged with deuterium (95-100%) owing to its acidic nature. In regards to the proposal of 
intra-molecular transfer of protium / deuterium from N2 to the position-1 carbon, the 
observation of a very high level of deuteration at position-1 of 80 after just 15 min of 
warming re-affirms this claim. With the N2-amide proton extensively exchanged with 
deuterium, one will expect that if the intra-molecular theory was true then there should be a 
Scheme 25: Reactions of 67 with CF3CO2H and with CF3CO2D in CDCl3, showing Wheland-like intermediates. 
Reagents: i. CF3CO2H / CDCl3 (3:1); ii. CF3CO2D / CDCl3 (3:1); iii. aq. work-up. 
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butyl protected trifluoroacetic acid 85 is subjected to further deprotection in the acidic media 
and and subsequent β-elimination giving further opportunities for deuterium incorporation. 
The end result is multiple deuterium incorporation which leads to multiple splitting in the 13C 
NMR corresponding to the tert-butyl primary carbons (Figure 43). Tert-butyl was therefore a 
potential source of inter-molecular protons contributing to the new proton observed in the 
Wheland intermediates. 
 
3.2.11.5 Proposed mechanism for de-iodination of 1-iodonaphthalen-2,4-diamine (68) via 
Wheland intermediate 
  
Scheme 26 shows the proposed mechanism for the de-iodination of 1-iodonaphthalene-2-
diamine 68. Proton transfer from N2 to C1 of 68, causes loss of aromaticity leading to the 
Wheland-like intermediate 69. The source of the new proton in the Wheland intermediate, has 
an intra-molecular origin. Nucleophilic abstraction of the iodine and restoration of aromaticity 
leads to the de-iodinated product 58. The nucleophile responsible for trapping the iodine as I+-
equivalent is likely to be the trifluoroacetate ion. However, when the solutions were left for 
prolonged days (~7 d) the colour turned dark red, suggesting the presence of I2. The loss of 
iodine is accelerated by the presence of electron-withdrawing group on the ring, such as 
trifluoroacetamido as in 77 → 78. Electron-withdrawing groups make the iodine more 
electrophilic pushing the reaction towards the de-iodinated product. This means the Wheland 
intermediate becomes less stable as seen in 77 → 78 (79 → 80) where this intermediate was 
not observed by NMR.  
 
Electrophilic aromatic substitution proceeds via a -complex, which eventually converts to a 
“-complex” also known as Wheland intermediate. Charge transfer UV/vis absorption of 
several -complexes  has been used in their identification as well as crystallography.143 The 
majority of these intermediates are transient and unstable due to their rapid deprotonation 
making it difficult to observe them by NMR. The Wheland intermediates tend to be observed 
only by femtosecond time-resolved laser absorption spectroscopy. Few compounds such as 
Scheme 26: Proposed mechanism of de-iodination of 1-iodonaphthalen-2,4-diamine. 
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1,3,5-trimethylbenzene and hexamethylbenzene reacts with NO2+BF3- at -70C under super-
acidic conditions to give Wheland intermediates that are observable by NMR. These 
intermediates are unstable at higher temperatures and therefore decompose on warming.144, 145 
Wheland intermediates with carboranyl counter ions have also been isolated and observed by 
NMR.146-148 Furthermore, molecules with both Wheland-like cations and Meisenheimer-like 
anions have been isolated.149 Efforts to understand why de-iodination of Boc-protected 
naphthlenediamines occurs during the synthesis of the key intermediate 67 of the alkylating 
subunit of the proposed CBI drugs, have led to the observation of the first Wheland-like 
intermediates derived from amino-naphthalenes. These cations are very stable, even at room 
temperature and decompose on isolation. The Wheland intermediates are stabilised by 
delocalisation of the positive charge involving both nitrogens. In addition, the Wheland 
intermediate with iodine 71 is further stabilised by the transformation of the sp2 hybridised C1 
to sp3 hybridised carbon which help to relieve the steric compression between the bulky 
iodine and the peri 8-H.  These experiments have provided an insight into why de-iodination 
is a major challenge in the acidic deprotection of Boc-protected iodo-naphthalenediamines.  
 
3.2.12 Sharpless epoxidation 
With the synthesis of 67, the next step was to alkylate the N2 of 67 with an alkylating unit that 
could participate in a cyclisation step to form the pyrrolidine ring of the proposed CBI drug 3. 
The first of such groups to be introduced was an epoxide. Sharpless epoxidation150 was 
employed in the enantioselective synthesis of the epoxy alcohol 90 (Scheme 29). This method 
provides 2,3-epoxy alcohols with high enantioselectivity. Depending on the tartrate 
enantiomer used, selective synthesis of a particular enantiomer of the epoxy alcohol can be 
attained. When the alkene unit is in plane of drawing with the hydroxymethyl substituent at 
the lower right corner, as shown in Scheme 27, the delivery of the epoxide oxygen occurs 
either from the top (D-(−)-diethyl tartrate), or from underneath the plane (L-(+)-diethyl 
tartrate) regardless of the substituent pattern.150 This method allows the selective synthesis of 




For instance, epoxidation of (E)-buten-2-ol with D-(−)-diethyl tartrate gives the 2R,3R 
enantiomer, whilst the use of L-(+)-diethyl tartrate gives the 2S,3S enantiomer.151 The 2R,3R 
epoxy alcohol was selected since this configuration eventually leads to a CBI drug with a 
configuration (1S,10R), which has been shown to have superior cytotoxicity.81 The use of the 
methylepoxy alcohol 90 in the synthesis of the alkylating subunit of the proposed CBI drug 
will lead to the introduction of an extra stereogenic centre (10R), which is absent in the 
natural products. The extra methyl group is introduced in order to reduce the chance of direct 
alkylation by the seco-CBI of DNA, which would be detrimental to the design of prodrugs.125 
Analogues incorporating the (+) (1S,10R) diasteroisomer of the alkylating subunit has been 
found to be more active compared to the (−) (1R,10S) diasteroisomer.81 It has also been 
observed that, when the two sterogenic centres are syn (1S/10S or 1R/10R) the seco-CBI drug 
possess a low toxicity and not suitable for development as a prodrug.124  
 
Alkylation of the N2 of 67 with 2R,3S-3-methyl-2-(4-nosyloxymethyl)oxirane will be 
followed by opening of the epoxide in a metal-mediated cyclisation. This is proposed to go 
via the lithium coordinated transition state 88 (Scheme 28). Attack of the epoxide carbon 
occurs in an anti-fashion causing inversion of configuration at the stereogenic centre involved 











Commercially available buten-2-ol 89 (E/Z mixture 19:1), was added to a mixture of titanium 
tetraisopropoxide and D-(−)-diethyl tartrate, followed by tert-butyl hydroperoxide (TBHP) 
(Scheme 29). The titanium tetraisopropoxide and D-(−)-diethyl tartrate react together to form 
a catalyst complex which helps deliver the oxygen from TBHP to the double bond. 
  
The original procedure for the Sharpless epoxidation, which included an alkaline hydrolysis 
step, is said to be difficult when the produced epoxy alcohol is water-soluble and/or volatile, 
as in 90. In such situations, very poor yields are observed since it is difficult to extract the 
epoxy alcohol into organic phases.150, 152  A modified work-up without an alkaline hydrolysis 
step, designed for water-soluble epoxides, was used but this still led to majority of the product 
being lost, resulting in very low yields.152 Precipitation of excess reagents with Et2O followed 
by filtration and chromatographic purification gave 90 in a yield of 50%.153 Compound 90 
was then nosylated to give 91. Repeated recrystallisation to raise the enantiomeric purity gave 
the enantiopure 91 in an overall yield of 11% (68% ee in reference to literature value81). The 
challenges met during the synthesis of 91 and the low yield attained led to the synthesis of 93 
which could be easily accessed from the commercially available homochiral epoxy alcohol 
92. In this way, 93 could be used to establish the feasibility of the chemistry in the synthesis 
Scheme 28: Metal mediated cyclisation with lithium coordinated transition state. 
Scheme 29: Sharpless epoxidation. Reagents and conditions: i. Ti(O-Pri)4, D-(−)-diethyl tartrate, dry tert-butyl 




of the pyrrolidine ring of the proposed CBI drug before committing the precious supply of 91. 
R-Glycidol 92 was nosylated under basic conditions to give 93 (> 99% ee in reference to 
literature value154). The importance of having the nosylate leaving group is that it makes the 
exocyclic CH2 of the epoxide a more powerful electrophile than the CH2 of the oxirane. In 
this way, attack of nucleophiles will take place exclusively at the exocyclic CH2, with clean 
SN2 displacement of the nosylate retaining the stereochemical configuration at the oxirane. 
With weaker leaving groups, such as chloride, initial attack of a nucleophile will be at the 
oxirane CH2, opening the oxirane; the alkoxide formed will attack the exocyclic CH2, leading 
to introduction of a CH2-oxirane unit but with inversion of configuration. Intermediate-
strength leaving groups, such as tosylate, proceed by both mechanisms, leading to loss of 
stereochemical integrity.41 Synthesising the nosylates of the epoxides also produces a solid 
that can be purified by repeated recrystallisation to raise the enantiopurity. Tietze et al.81 have 
reported that the chloride, mesylate, triflate and the nonaflate are difficult to purify compared 
to the nosylate.  
 
3.2.13 Selective N2-alkylation of tert-butyl N-(1-iodo-2-(trifluoroacetamidonaphthalen-4-
yl)carbamate (67) 
  
One of the reasons for having orthogonal protections on the amino groups of 67 was to allow 
a selective alkylation to take place at N2. The proton on the trifluoroacetamide group is more 
acidic, due to the electron-withdrawing trifluoroacetamide group, compared to the Boc 
protected N4-amine. Therefore, by careful selection of a suitable base, selective deprotonation 
of N2 with subsequent alkylation with 93 can be achieved. In addition, the bulky nature of the 
Boc-group in comparison to the trifluoroacetamide protecting group should allow selective 
alkylation of the nitrogen of the trifluoroacetamide of 67. Selective N2-alkylation of 67 was 
investigated to give 95 (Scheme 30). The base used initially for deprotonation of the N2 
proton was potassium t-butoxide.  Several attempts using this base in different reaction 
conditions (e.g. r.t., 50 → 70°C, 2 h → 72 h), however, did not give the desired product 95. 
Even the use of excess reagents did not give the product but instead the starting material was 
recovered in all cases. Monitoring by thin layer chromatography suggested that the epoxide 
















93 was being consumed in the reaction. There is therefore a possible chance of a nucleophilic 
attack by potassium t-butoxide on 93, consuming it and resulting in no alkylation of 67.  This 
was despite a sequential addition of potassium t-butoxide to 67 before addition of the epoxide 
93. The base was changed to potassium carbonate. The pKa of the conjugate acid of the 
carbonate anion lies between the pKa of NHCOCF3 and NHBoc and therefore selective 
deprotection of the former is always likely to take place. Besides, the bulky nosylate group of 
93 will aid in the selective N2-alkylation. The low solubility of K2CO3 in acetone also means 
that a two-phase reaction takes place reducing the chance of nucleophilic attack of the oxirane 
nosylate by the carbonate anion. The reaction of 67 with 93 gave two compounds. The initial 
interpretation was that these could be due to regioselective alkylation. Mass spectrometry 
confirmed that these compounds were isomers and each contained only one oxiranylmethyl 
group. Furthermore, 2D NMR spectroscopy (HMBC, NOESY) confirmed that, in both 
compounds, the oxiranylmethyl group was located at the N2-amide group and not the Boc-
amide group. In the 1H NMR spectrum of one isomer, there was evidence of the existence of 
two rotameric forms about the F3COC—N2 amide bond in a ratio 1.3:1.  This dispelled the 
idea that the two separated compounds could be rotamers about this bond. It was concluded 
that the two compounds were diasteroisomers of 95. The diastereoisomers 95a and 95b 
(Figure 44) were obtained in yields of 34% and 39%, respectively (i.e. 73% overall yield).  
 
Despite the existence of only one overt chiral centre in 95, the bulky iodine at position-1 
restricts rotation around the C2—N2 single bond giving two atropisomers. The naphthyl ring 
adopts an orientation perpendicular to the plane of the trifluoroacetamide creating a virtual 
chiral centre at the middle of the N-aryl bond (Figure 44).81, 155 The atropisomers did not 
interconvert, meaning there existed two separable diastereoisomers both containing the same 
configuration at the oxirane. Unfortunately, it was not possible to identify the configurations 
at the virtual chiral centres of the two diastereoisomers. Observation of such atropisomerism 
in related compounds has been made by Tietze et al.155 where they showed that removal of the 
iodine resulted in a single isomer and also cyclising the two atropisomers resulted in a single 
product with same configuration. Selective alkylation of the N2-amide was therefore achieved 
Figure 44: Atropisomerism arising from restricted rotation about the N-aryl bond caused by the bulky iodine. 
96 
 
in good yield despite the use of excess potassium carbonate (4 eq.) which was needed for 
completion of reaction.  
 
3.2.14 Metal-mediated cyclisation 
 
The next step was to undertake a metal-mediated cyclisation of 95a and 95b to give 96 
(Scheme 31). A study by Tietze et al.81 showed that higher-order cuprate Li2Cu(CN)Me2 and 
the zinc organyl Li2Zn(SCN)Me3 were the best reagents for metallation in a similar 
cyclisation reaction. Lithium reagents were chosen due to the ability of lithium to coordinate 
with the oxygen of the epoxide to form a sterically fixed transiton state 88 (Scheme 28). There 
are two possible site of attack on the epoxide to form either 5-exo-trig 96 and/or the 6-endo-
trig products 100 (Scheme 32). However, Teitze et al. observed that in their cyclisation 
reactions, only the 5-exo-trig products were formed.81 Formation of the 6-endo-product is not 
detrimental, since substituting the hydroxy group with a better leaving group followed by 
Boc-deprotection will trigger spirocyclisation to generate the essential pyrrolidine ring and the 




















Scheme 31: Attempted metal mediated cyclisation. Reagents and conditions: i. MeLi, CuCN, dry THF,  
−78C → 25C, 72 h; ii. ZnCl2, ButLi, 3-bromopropene, N2, −78C → 40C, 72 h; iii. ZnCl2, ButLi, N2, 





Li2Cu(CN)Me2 was prepared in situ by addition of MeLi to CuCN. This was treated with 
compound 95a or 95b with the aim of replacing the iodine with copper and allowing the aryl-
copper to attack the oxirane to give 96. However, the sole product was 97, the result of loss of 
the trifluoroacetyl group (Scheme 31). This was attributed to the highly nucleophilic cyanide / 
methyl ion. The NMR of 97 showed the existence of conformers. This is likely to be due to 
slow rotation around the carbamate N-C(O) bond and the N2-epoxide bond. The use of 
dilithium tetra-tert-butylzincate (But4ZnLi2) was investigated. First of all, this reagent was 
tested for its ability to substitute an iodine on 4-iodophenol 98 with a propenyl group (Scheme 
31). Dilithium tetra-tert-butylzincate was prepared in situ by adding tert-butyllithium to zinc 
chloride. 4-Iodophenol 98 was then added to allow iodine → zinc exchange followed by 
addition of 3-bromopropene. The first attempt using 1.1 equivalent of dilithium tetra-tert-
butylzincate resulted in recovered starting material as the acidic phenolic proton was 
deprotonated rather than the desired halogen → zinc exchange.  The procedure was repeated 
with two equivalents of dilithium tetra-tert-butylzincate to compensate for the presence of the 
acidic phenolic proton of 98. This modification led to the synthesis of 99 and suggested that 
this method could work with 95.157  Compound 95a and 95b were exposed to the same 
conditions with excess dilithium tetra-tert-butylzincate to compensate for the acidic Boc-
carbamate proton. This, however, resulted in a complex product mixture that could not be 
separated. It is possible that removal of the N-H of 95a / 95b results in an unstable product 
leading to decomposition of the compound. It has also been reported that the electron-rich 
naphthalene ring tend to slow down metal-halogen exchange even in the case of naphthyl 
iodide and thus proton abstraction from the Boc-amide is favoured.41  
Scheme 32: Possible 5-exo-trig and 6-endo-trig cyclisation products and spirocyclisation of the endo-product 
to generate the pyrrolidine ring and the electrophilic cyclopropane ring. 
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3.2.15 Free-radical cyclisation 
A new approach to the synthesis of the pyrrolidine ring of the alkylating subunit of the 
proposed CBI drug was needed. The route of trying to synthesis an enantiopure CBI drug had 
to be suspended. A racemic synthesis of the pyrrolidine ring was pursued. This involved 
selective alkylation of the N2-amide with 3-bromopropene followed by free-radical 
cyclisation.   
  
An initial attempt to synthesise 104 using similar conditions as used in the synthesis of 95 
(four equivalents of potassium carbonate, allyl bromide) gave the di-alkylated product 103. 
This suggests that steric hindrance between the Boc group of 67 and the bulky nosylated 
epoxide 93 contributed to the selective synthesis of 95 (Scheme 30). Compared to 94, 3-
bromopropene is small enough to gain access to the Boc-amide nitrogen as well as the N2-
amide nitrogen. The NMR of 103 showed the presence of two diastereoisomers, probably due 
to the slow rotation about the C-NBoc and C-NCOCF3 bond (Figure 45).  
Scheme 33: Free radical cyclisation with TEMPO trap. Reagents and conditions: i. K2CO3, 3-bromopropene, 
acetone, N2, 50C, 16 h; ii. KOBut, 3-bromopropene, THF, N2, 20C → 50C, 16 h; iii. TEMPO, Bu3SnH, 60C, 
135 min; iv. aq. NaOH (5.0 M), THF, r.t., 105 min. 
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3.3 Synthesis of the non-alkylating subunit of proposed CBI drug. 
The non-alkylating subunit of the ant-tumour antibiotics is essential for their biological 
activity. The initial non-covalent binding of the anti-tumour antibiotics to double-stranded 
DNA is mediated by the non-alkylating subunit. The extent of binding by this subunit 
determines the potency and toxic effects of these agents. For instance, the ability of CC-1065 
to cause delayed death and also its high potency have been attributed to its non-alkylating 
subunit.49, 75  The non-alkylating subunit chosen for the proposed CBI drug was 5-(2-
dimethylaminoethoxy)indole-2-carboxylic acid (DMAI). This subunit is devoid of the delayed 
death effect of CC-1065 which has been attributed to the presence of the two ethylene 
moieties and the terminal amide moiety present in the non-alkylating subunit.45, 49 It is also 
simpler to synthesise and its ability to form salts enhances aqueous solubility of the 
synthesised compound.80, 81 Total synthesis of this subunit was undertaken by adopting a 
Fisher-like indole synthesis. 
 
3.3.1 Fisher-like indole synthesis 
The Fisher synthesis of indoles involves the condensation of an arylhydrazine with a ketone, 
whilst an aryldiazonium salt replaces the arylhydrazine in the modified Fisher-like indole 
synthesis. Furthermore, the nucleophile in this Fisher-like indole synthesis is the enol 
tautomer of the ketone whilst in Fisher indole synthesis the nucleophile is the arylhydrazine. 
Compound 110 was prepared by Fisher-like indole synthesis from the substituted aniline 109 
(Scheme 34). 
 
A Williamson ether synthesis was used to generate the nitrophenyl ether 108. The highly 
acidic phenolic proton of 4-nitrophenol 107 was removed by potassium hydroxide. This base 
will also liberate 2-chloro-N,N-dimethylethylamine from its hydrochloride salt; this amine 
has a mustard structure and will be in equilibrium with the 1,1-dimethylaziridinium ion. This 
Scheme 34: Synthesis of ethyl 5-(2-dimethylaminoethoxy)-1H-indole-2-carboxylate 110. Reagents and 
conditions: i. (a). KOH, EtOH, r.t.  (b). Me2NCH2CH2Cl, toluene, reflux, 17 h; ii. SnCl2, HCl, 0C → r.t., 19 h;
iii. NaNO2/HCl, -20C then ethyl 2-methyl-3-oxobutanoate/NaOAc, 20C, 16 h, then HCl/EtOH/reflux, 30 min. 
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powerful electrophile reacts readily with the phenoxide to give 108.  Reduction of the nitro 
group of 108 using tin(II) chloride in acid medium gave the aniline 109 at a yield of 88%. 
Compound 109 was diazotised with sodium nitrite in the presence of an acid catalyst. The 
acid initially reacts with the sodium nitrite to give the reactive nitroso species (NO+). This 
then attacks the lone pair on the primary amine of 109, followed by dehydration to yield the 
diazonium salt. Scheme 35 shows the proposed mechanism for the formation of the indole 
ring of 110. 
 
Treatment of the diazonium salt 113 with ethyl 2-methyl-3-oxobutanoate 112 in the presence 
of the weak base sodium acetate gives a hydrazone 116. The arylhydrazone tautomerises to 
the enamine 117 which then undergoes [3,3]-sigmatropic rearrangement and re-aromatisation 
of the benzene ring to give an aminal 120. Acid-catalysed decomposition of the aminal with 
the release of ammonia allows the loss of a proton and the formation of the aromatic indole 
Scheme 35: Proposed mechanism of the synthesis of 110 via a diazonium intermediate rather than the usual 
hydrazine intermediate of Fisher indole synthesis.   
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110 at the modest yield of 15%. This synthesis of the indole 110 proved very challenging. The 
initial conditions for this reaction were diazotisation at 0°C, followed by treatment with ethyl 
2-methyl-3-oxobutanoate for 1 h. This, however, did not give the desired product, even after 
increasing reaction time to 2 h. Finally, diazotisation was carried out at −20°C, which 
provided the desired product but at a low yield. Attempted optimisation by using excess 
reagents (NaNO2 / HCl) or using a stronger acid (H2SO4) at the diazotisation step did not have 
any significant effect on the yield. As part of the work-up, the product had to be extracted 
with hot hexane in the presence of decolourising charcoal. Adsorption on the charcoal is one 
of the ways by which aromatic products may be lost. Furthermore, the last step of the 
synthesis involved heating the mixture with ethanolic HCl. The presence of water in this step 
will inevitably lead to hydrolysis of the ethyl ester group to produce the indole acid. This will 
then be easily lost in the water layer during basic work-up. The challenges faced with the 
Fisher-like synthesis meant that a different approach was needed in the efficient synthesis of 
110.  
 
3.3.2 Synthesis of 5-(2-dimethylaminoethoxy)indole-2-carboxylic acid (DMAI) (127) 
  
When the indole-2-carboxylic acid 124 became commercially available, a new and shorter 
approach to the synthesis of 110 was adopted (Scheme 36). This involved esterification of 
124, followed by Williamson ether synthesis to alkylate the phenolic hydroxyl group to 
introduce the O-(2-dimethylamino)ethyl unit. Hydrolysis of the ester should then give the 
Scheme 36: Synthesis of DMAI. Reagents and conditions: i. sat. Ethanolic HCl, N2, reflux, 1 h; ii. (a) SOCl2, 
EtOH, 80C, 1 h; (b) sat.  ethanolic HCl, reflux, 4-16 h; iii. 2-chloro-N,N-dimethylamine hydrochloride, K2CO3, 















































desired indole carboxylic acid 127 to couple to 106. Esterification of the carboxylic group of 
124 was initially attempted using para-toluenesulfonic acid to activate the carboxylic group to 
nuleophilic attack by ethanol. Analysis of the crude products formed suggested the presence 
of some desired product 125, starting material 124 and a possible dimer of 124. Compound 
124 in ethanol was treated with thionyl chloride under reflux conditions. Thionyl chloride 
reacts with ethanol to generate hydrochloric acid which then catalyses the esterification. This 
procedure, however, resulted in a poor yield of 125 (3%) and a range of side products. The 
use of ethanolic-hydrogen chloride for the esterification was investigated by boiling 2-(indol-
3-yl)acetic acid 122 in saturated ethanolic hydrogen chloride to give 123 at 82% yield. 
Extension of this procedure to compound 124 gave 125 at a yield of 92%. In one instance of 
the synthesis of 125 using ethanolic-hydrochloric acid, the reaction was allowed to run 
overnight (16 h). This resulted in the formation of the side product 126 (~10%) as well as the 
desired product 125 (Scheme 36). Ethanol is protonated by hydrochloric acid to form an 
electrophilic ethyloxonium ion. Nucleophilic attack at this ion by the phenolic hydroxy group 
gives 126 with the loss of water. Compound 125 was then alkylated with 2-chloro-N,N-
dimethylethylamine to give 110 in 80% yield. Basic ester hydrolysis of 110 gave the required 



















3.4 Coupling of the alkylating and non-alkylating subunits 
  
With the synthesis of the alkylating subunit 106 and the non-alkylating subunit 127 of the 
proposed CBI drug having been achieved, the next step in the synthetic process was to couple 
the two together. Initial efforts to synthesise 128 via the acid chloride of 127 failed, resulting 
with recovery of starting material, despite the use of 4-dimethylaminopyridine as a catalyst 
(Scheme 37). The use of the coupling agent, N-(3-dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (EDC.HCl) was tried but this attempt also failed even after 
extending the reaction time. The preactivation of carbodiimide coupling agents relies on 
protonation of the carbodiimide by the carboxylic acid.158 The unhindered basic amino group 
present in 106 is likely to interfere with this preactivation step by being preferentially 
protonated. Thus initial preactivation before addition of 106 is desirable. Carpino et al.158 
have also observed that the neutral diisopropylcarbodiimide (DIC) is more effective compared 
to other carbodiimide coupling agents with protonated / quartenised tertiary amino groups 
(e.g. EDC.HCl). Coupling using diisopropylcarbodiimide and 1-hydroxybenzotriazole to 
preactivate 127 before addition of 106 was therefore investigated. The indolecarboxylic acid 
127 was pre-treated with diisopropylcarbodiimide and 1-hydroxybenzotriazole to allow 
formation of the active benzotriazolyl ester. Compound 106 was then coupled to the 
Scheme 37: Coupling of the alkylating subunit 106 and the DMAI subunit 127. Reagents and conditions: i.
N,N-diisopropylcarbodiimide, HOBt, DMF, N2, 0C → 40C, 18 h. 
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benzotriazolyl ester to give 128 at a satisfactory yield of 64%. Despite the precautions taken 
by sequential addition of compounds / reagents, mass spectrometry suggested that a small 
amount of the alkylating subunit 106 had reacted with the carbodiimide to give the guanidine 
129 [MS (ES+) m/z 580.4250 (M + 1) (C34H54N5O3 requires 580.4227)]. 159 
 
3.5 Reductive removal of the 2,2,6,6-tetramethylpiperidine protecting group 
  
The next step in the synthesis of the proposed CBI drug was to remove the masking 2,2,6,6-
tetramethylpiperidinyl group by reductive cleavage of the N-O bond. This involved the use of 
zinc dust as the reducing agent in acidic conditions. Several attempts in tetrahydrofuran / 
acetic acid / water or ammonium chloride / methanol with excess zinc dust did not result in 
significant reaction. Activation of the zinc by stirring in aqueous hydrogen chloride (10%) 
was therefore undertaken; the activated dust was added to 128 in a solvent mixture of 
tetrahydrofuran / acetic acid / water at a ratio of 1:3:1. This procedure led to the complete 
reductive removal of the tetramethylpiperidinyl group. However, side products 130, 131 and 
132 as well as the desired product 133 were formed (Scheme 38). The side products could be 
Scheme 38: i. Reduction of 2,2,6,6-tetramethylpiperidine. Reagents and conditions: i. THF/AcOH/H2O 
1:3:1, activated Zn dust, 70C, 23 h; ii. THF/AcOH/H2O 3:1:1, activated Zn dust, 70C, 16 h. 
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converted back to the desired product by either protecting the amino group and/or hydrolysing 
the acetyl group. The use of a high proportion of acetic acid and the sequence of addition of 
reagents was thought to be responsible for the problems encountered. The Boc group is acid-
labile and thus may be prone to destruction by acetic acid. The acetylation of the hydroxy 
group is facilitated by Zn2+ ions formed, which act as Lewis acids catalysing the 
esterification. As a result of these problems, the reaction was repeated with smaller proportion 
of acetic acid (i.e. tetrahydrofuran / acetic acid / water 3:1:1) and sequential addition of 
reagents with acetic acid being the last to be added. This gave 133 at a yield of 71% without 
side products.  
 
3.6 Activation of the proposed seco-CBI drug 
   
Substitution of the pendant hydroxy group of 133 with a better leaving group is required to 
aid Winstein cyclisation of the seco-drug to form the reactive cyclopropane ring needed for 
potency. Substitution of the hydroxy group of 133 with chlorine to form 135 was initially 
Scheme 39: Activation of seco-CBI drug. Reagents and conditions: i. MsCl, Et3N, DMF, N2, 0C, 1 h then LiCl, 
20C, 3 d; ii. MsCl, pyridine, N2, 0C, 1 h then LiCl, 20C, 7 d; iii. HCl in dioxane (4.0 M), 20C, 2 h. 
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attempted under Appel reaction conditions81 using triphenylphosphine and tetrachloromethane 
in dry dimethylformamide (Scheme 39). Scheme 40 shows the proposed reaction mechanism.  
  
The source of the chlorine in the Appel reaction is the tetrachloromethane. 
Triphenylphosphine 137 initially reacts with tetrachloromethane 138 forming the intermediate 
phosphonium salt 139 and trichloromethane anion 140. The trichloromethane anion 
deprotonates the hydroxy group of 133, yielding the alkoxide 141 and forming chloroform as 
the side product. Nucleophilic attack of the phosphonium salt 139 by the alkoxide 141 gives 
the oxyphosphonium intermediate 142. The oxygen is converted into a leaving group 
followed by SN2 displacement by the in situ generated chloride ion to form the desired 
product 135. The reaction also releases triphenylphosphine oxide as a co-product. This 
reaction was, however, unsuccessful with 133 (Scheme 39). Mass spectrometry showed the 
presence of triphenylphosphine oxide and suggested that there was another source of oxygen 
reacting with the reagent. This led to pre-drying the solvent with molecular sieves to remove 
any trace of water and carrying the reaction under N2 atmosphere. A large excess of 
triphenylphosphine was also used with the aim of compensating for any additional source of 
oxygen present. However, the reaction did not proceed even after raising the temperature. The 
limited solubility of compound 133 in organic solvents meant that this method of chlorination 
could not be pursued with other solvents.  
 









































Thionyl chloride was then investigated as a method to convert the –CH2OH into –CH2Cl. The 
use of this acidic reagent meant that steps had to be taken to protect the Boc group of 133. 
Compound 133 in dry dimethylformamide was treated with triethylamine and thionyl 
chloride. The basic triethylamine should serve to shield the Boc group from acidic 
deprotection. This method also failed to yield 135 giving rise to a complex product mixture in 
which the components could not be identified.  
 
The next trial was to treat 133 with methanesulfonyl chloride in the presence of triethylamine. 
The idea was that, once the alkyl mesylate had formed, the chloride ions from the 
triethylamonium salt will then displace the mesylate group to yield 135. Monitoring by mass 
spectrometry showed that the mesylation step was successful whilst the substitution with 
chloride failed. Tetra-butyl ammonium chloride was then added to the mixture to increase the 
concentration of chloride ions. This, however, also failed to yield the chloro product 135. The 
reaction was repeated and lithium chloride was used as the source of excess chloride ions. 
Purification and characterisation of the product formed, however, surprisingly showed that, in 
addition to the desired formation of the –CH2Cl group, the Boc-protection had been lost and 
the exocyclic nitrogen had condensed with a derivative of N,N-dimethylformamide to give the 







Dimethylformamide reacts with the excess mesyl chloride to give the imidate anhydride 144. 
Nucleophilic attack at 144 by the Boc-amine anion 145 gives the intermediate 146. Loss of 
methanesulfonate gives 147. The Boc-protecting group is then lost to give the 
dimethylformimidamide 134, driven by quench of the iminium cation. The reaction was 
repeated with pyridine as the solvent. Mesylation followed by substitution of the mesylate 
with chlorine afforded 135 at a good yield of 66%. Treatment of 135 with hydrogen chloride 
in dioxane removed the Boc-protecting group to give the final seco-CBI drug as the 
dihydrochloride salt 136. Biological evaluations were undertaken on 136 to assess its DNA-








3.7 Calf-thymus DNA melting assay 
The temperature at which double stranded DNA unwinds and unzips (denatures) is a useful 
tool to assess the binding of drugs to DNA. DNA absorbs light in the UV region due to the 
presence of the aromatic bases adenine, thymine, guanine and cytosine. Stacking interactions, 
hydrogen bonding and hydrophobic effects between the bases are responsible for the helical 
and compact nature of DNA. The compact nature of duplex DNA limits the resonance of the 
aromatic rings in the UV region and thus the DNA absorbs at a lower intensity. As 
denaturation of DNA occurs (e.g. by heating), the duplex structure unwinds and unzips to 
form single-stranded DNA (Scheme 42).  
 
The bases become unstacked in the process, as hydrogen bonds are broken allowing higher 
intensity of absorbance. When denaturation of DNA is effected by increase in temperature, 
this is also referred to as melting. The temperature at which the absorbance is 50% of the 
maximum is referred to as the transition-melting temperature (Tm).160 At this temperature, 
50% of the DNA is denatured. Modification of the DNA structure by binding to molecules 
causes a change in the Tm value.  For instance, agents that bind to and stabilise the DNA 
double helix (e.g. doxorubicin) increase the Tm, whilst agents that destabilise DNA (e.g. 
benzoacronycine derivatives) reduces the Tm.161 The extent of increase / decrease of Tm is 
correlated to the strength of interaction between the agent and DNA.  
 
Melting temperature measurements using calf-thymus DNA were undertaken to investigate 
the effect of the proposed CBI drug 136 on dsDNA. Calf-thymus DNA was treated with a 
Scheme 42: The melting of double stranded DNA by increasing temperature. 
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range of concentrations of 136 and allowed to incubate for 1 h. The amount of drug needed 
per molar equivalent to dsDNA (9.06 × 10-5 M) was calculated using the equation below: 
 
Volume of sample = Molar concentration of diluted DNA × Volume of diluted DNA × MW of 
drug sample × Molar equivalent required (0.01 → 0.6) 
 
The mixtures were slowly heated up to 95C to denature the DNA with continuous 
monitoring of UV absorption at 256 nm. An initial investigation to determine the appropriate 
time of incubation of the drug with DNA involved incubating 136 at 0.1 molar equivalents 
(MEq) for 1 h and 24 h with calf-thymus DNA. The results obtained showed that there was no 
significant difference between the data at the two incubation times and that binding to DNA 
and subsequent alkylation by 136 was a relatively fast process. This highlights the rapid 
nature of the Winstein cyclisation of 136 at near neutral pH to form the highly reactive 
cyclopropane ring leading to subsequent alkylation.  Based on this result, subsequent tests 
were carried out with a 1 h incubation time. Figure 46 shows a graph for the normalised 
absorbance against temperature for the different concentrations of 136. 
 
The normalised absorbance is calculated by subtracting the control absorbance (Buffer + 
DMSO + dsDNA) from the test absorbance (buffer + DMSO + dsDNA + 136). Plotting this 
against temperature gives a sigmoid curve. The rightward shift of the sigmoid curve on 
increasing the concentration of 136 shows an increasing Tm. This confirms that 136 binds to 






























Figure 46: Normalised melting curve for 136 at different molar equivalents (MEq). 
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double-stranded DNA and that the effect of this binding is to stabilise the dsDNA. 
Destabilising agents should cause a reduction in Tm upon increasing the concentration. As the 
temperature is increased, the absorbance initially rises very slowly. At this point, the majority 
of the DNA is in the duplex form, tightly held together by hydrogen bonds. At a characteristic 
temperature, there is a sudden rise in absorbance. This reflects the melting of dsDNA into 
single strands. As all the dsDNA are melted, the absorbance becomes constant causing the 
curve to plateau. At this point, the bases constituting DNA are fully unstacked and at 
maximum resonance and thus have maximum UV absorbance. The mid-point of the sigmoid 
curve is the Tm but this is best visualised by plotting the first derivative curves of the 
normalised absorbance curves (Figure 47). 
  
The first derivative of the melting curves (Figure 47) is obtained by plotting the change in 
absorbance / change in temperature against temperature. This gives a bell-shaped curve, the 
peak (midpoint) of it being the Tm for the particular concentration of drug. There is a general 
increase (rightward shift) of the peak of the curves which corresponds to an increase in Tm 
with concentration. The measured melting temperature of calf-thymus DNA in absence of 136 
(control) was 68.4C. The effect of increased concentration of 136 on the change in melting 
temperature is shown in Figure 48.  
  
Figure 47: First derivative melting curve for 136 at varying molar equivalents (MEq). 











































As the concentration of 136 increases per given concentration of DNA (9.06 × 10-5 M), there 
is a rise in melting temperature until saturation of the DNA binding sites occurs. The results 
above from the DNA-binding assay show that the proposed CBI drug is capable of binding to 
DNA. The effect of the drug is brought about by its ability to stabilise the double-stranded 
DNA. This should interfere with cellular processes such as transcription and translation of 
DNA, leading to cell death. ∆Tm can be used to assess how strongly an agent binds to DNA. 
For instance CC-1065 has been predicted to have a maximum ∆Tm value of > 31.5 deg. C at a 
DNA : drug ratio of 6.9 (0.14 MEq).43 This high ∆Tm suggests that CC-1065 binds very 
strongly to DNA. This is in agreement with the observation that CC-1065 binds irreversibly 
with DNA under aqueous physiological conditions.73 This irreversible DNA binding has been 
linked to the high cytotoxicity caused by CC-1065 and also its ability to cause delayed death. 
The maximum near-saturation ∆Tm observed for the proposed CBI drug 136 is approximately 
13.0 deg. C at a DNA : drug ratio of 1.6 (0.6 MEq) which is  similar to the clinically used 
cytotoxic agent, doxorubicin (∆Tm = 18 deg. C).43 The unnatural enantiomers of the anti-
tumour antibiotics have been shown to possess a lower DNA alkylation efficiency compared 
to the natural enantiomers. For instance (−)-duocarmycin SA alkylates DNA at a 
concentration ten times lower than that required by (+)-duocarmycin SA.61 The significant 
evlevation of the Tm of calf-thymus DNA by 136 despite being the racemate suggests that this 
compound is highly efficient at DNA alkylation. 
 
Figure 48: Tm shift against molar equivalent (MEq) of proposed CBI drug 136. 

































3.8 Cell viability assay 
In order to test the cytotoxicity of the synthesised drug 136, an MTS assay was carried out. 
This is a chromogenic assay to test cell viability. Mitochondrial reductase enzymes in viable 
cells are able to convert the MTS tetrazolium reagent into the coloured aqueous soluble 
formazan product (Scheme 43).162  
  
The amount of formazan produced (colour intensity) is proportional to the number of viable 
cells and can be measured at 490 nm.162, 163 This assay requires fewer steps compared to its 
precursor, the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. 
The MTT assay produces a crystalline fomazan dye which needs an extra step to dissolve 
before recording of the absorbance at 590 nm.164 Cytotoxic agents cause reduction in the 
number of viable cells and therefore a diminution in formazan levels. This effect should be 
proportional to the concentration of the cytotoxic agent. 
  
The inhibitory effect of 136 on prostate cancer cell lines was investigated using LNCaP cells. 
LNCaP cells are a PSA-producing human prostate cancer cell line which is also androgen 
sensitive.165 A range of concentrations of 136 (1 nM → 1 µM) was added to LNCaP cells in a 
96-well plate. Incubation at 37C in a humidified atmosphere containing 5% CO2 (v/v) was 
carried out for 3 d. The number of viable cells was quantified using the MTS reagent and 
measuring the absorbance of the produced formazan at 490 nm. In reference to the control cell 
number, the results were expressed as percentage inhibition against the concentration of 136 
(Figure 49). 




The inhibitory effect of the racemate of 136 on LNCaP cells was observed even at a very low 
concentration (1 nM). Approximately 60% inhibition occurred at 20 nM of drug 
concentration. The preliminary IC50 for this compound as a racemate was 18.0 nM 
highlighting the extreme potency of 136. This correlates well with the ability of 136 to 
alkylate DNA and inhibit cellular processes. The natural S-enantiomer of 136 is expected to 
have an even higher cytotoxicity. In vitro studies have shown that the natural S-enantiomer of 
the analogues of the anti-tumour antibiotics have superior potency compared to the R-
enantiomers.166 Furthermore, in vivo studies of hypoxia-selective nitro analogues of the anti-
tumour antibiotics indicated that the R-enantiomer was inactive whilst the S-enantiomer 
showed significant cytotoxicity greater than the racemate as expected.166 The reduced 
cytotoxicity of the R-enantiomer has been linked to the different steric interactions with 
double-stranded DNA.167 Future enantiomeric purification of 136 to isolate the required 
stereoisomer should therefore give a molecule with extreme potency. 
 
In order to estimate the cytotoxic effect of the proposed prodrug, the Boc-protected compound 
135 was subjected to the MTS assay. LNCaP cells were treated with a range of concentrations 
of 135 (100 nM → 100 µM) and incubated under the same conditions as described above. The 
results were presented as percentage inhibition of LNCaP cell viability against the 
concentration of 135 (Figure 50). 
 
Figure 49: Inhibitory effect of 136 on LNCaP cells ±SD. 


































Overall, a given concentration of 135 resulted in lower percentage inhibition compared to 136 
at the same concentration. For instance at a concentration of 100 nM, 136 resulted in 91% 
inhibition whilst 135 caused 36% inhibition. The preliminary IC50 recorded for this compound 
was 218 nM which is approximately 10-fold lower than the IC50 of 136. This highlights the 
importance of the seco precursor 136 being able to undergo Winstein cyclisation to form the 
highly electrophilic cyclopropane ring (Figure 51). 
  
With the Boc-protection, the electron density of the 5-amino group is reduced and thus the 
Winstein cyclisation is slowed or prevented from happening, leading to reduced activity. It 
has been suggested that the ideal ratio of cytotoxicity between a prodrug and the 
corresponding drug (QIC50) [QIC50 = IC50 (prodrug) ⁄ IC50 (prodrug + activating enzyme)] 
should exceed 1000.87  The lower observed ratio (~10) between 135 and 136 can be attributed 
to the fact that the measured cytotoxicities are only preliminary results and therefore further 
Figure 51: Winstein cyclisation by the proposed seco-CBI. 
Figure 50: Inhibitory effect of 135 on LNCaP cells ±SD. 
































tests would be required to verify the potency of these drugs. Besides, the higher than expected 
cytotoxicity of 135, could be due to the Boc-protecting group being cleaved allowing 
spirocyclisation to form the more reactive cyclopropane ring. Slow cyclisation of the Boc-
protected compound 135 may also be responsible. Alternatively, direct alkylation of the DNA 
by the Boc protected seco compound 135 without formation of the cyclopropane ring may 
account for the higher than expected cytotoxicity. The type of a prodrug is also very 
important. For instance, when a β-D-galactoside prodrug was subjected to in vitro cytotoxicity 
assay against human bronchial carcinoma cells of line A549, it was observed to have a lower 
cytotoxicity than the active drug by a factor of just 80 whilst a benzyl analogue of the same 
drug showed a lower cytotoxicity by a factor of 1600 compared to the active drug.125 
Compound 135 as a carbamate prodrug is not as stable as the proposed amide prodrug that 
would be synthesised by coupling of 136 to a PSA-cleavable peptide. Non-enzymatic 
cleavage of the carbamate group occurs easier than an amide bond. Having an amide prodrug 
as well as coupling of the drug to the bulky peptide and polymer will further reduce the 
cytotoxicity of the prodrug and give a higher QIC50 value.  
 
3.9 Peptide synthesis 
With the synthesis of the active drug 136, the next step involved the synthesis of the PSA-
cleavable peptide intended to be used in the development of the prodrug. The amino-acid 
sequence Ser-Lys-Leu-Gln is claimed to be the minimal sequence required for recognition 
and cleavage by PSA.99 The protected sequence Fmoc-Ser(Bn)-Ser(Bn)-Lys(Cbz)-Leu-Gln-
OH  containing the minimum required sequence was synthesised as a substrate for PSA. An 
attempt was made to use solution-phase peptide synthesis to make the peptide. Difficulties 
mainly due to the presence of the primary amide side-chain of Gln, often affect solution phase 
synthesis of Gln-containing peptides.168 These include limited solubility of the Gln reagent 
and the produced peptide which leads to purification problems. Unwanted side-reactions, such 
as dehydration at the γ-carboxamide of Gln to produce the corresponding nitrile or cyclisation 
of carboxy-activated Nα-protected Gln to Nα-protected α-aminoglutarimides, can occur during 




In order to avoid unwanted side-chain reactions of Gln and enhance solubility of Gln 
containing peptides, a range of sterically bulky protecting groups of the Gln side-chain have 
been used. These include 4-methoxybenzyl169 2,4-dimethoxybenzyl169, 170 2,4,6-
trimethoxybenzyl171 tetralin-1-yl,172 monomethoxybenzhydryl,173 trityl174, 175 and 
monomethyltrityl.176 2-Nitrobenzyl has also been used as a photo-cleavable protection.177 All 
of these protecting groups have the disadvantage of being atom-inefficient, with the bulky 
protecting groups containing many atoms and producing involatile side-products upon 
removal. In order to avoid the solubility issues and undesired reactions presented by Gln 
during solution-phase peptide synthesis, efforts were made to mask the primary amide side-
chain of Gln as the nitrile. Compatibility of the nitrile protection strategy with other 
protecting groups was also studied.178 These studies will then inform on the use of nitrile-Gln 
in the solution-phase synthesis of the proposed PSA-cleavable peptide. 
 
3.9.1 Formation of Fmoc-aminoglutarimide 
 
PGα PGα PGα
Scheme 44: Dehydration of Gln to form the nitriles 153 or the glutarimides 154. 
Scheme 45: Formation of Fmoc-aminoglutarimide. Reagents and conditions: i. DCC, dry pyridine, N2, r.t., 3 h; 
ii. (CF3CO)2O, dry pyridine, THF, N2, 0C 6 h. 
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Dehydration of the Gln primary amide side-chain was attempted using Fmoc-Gln-OH 155 as 
a model substrate. Fmoc-Gln-OH 155 in pyridine was treated with the dehydrating agent, 
dicyclohexylcarbodiimide (DCC) at room temperature.179 This led to the cyclised dehydrated 
product, the imide 157, at 48% yield, rather than the desired product of dehydration of 
primary amide 156 (Scheme 45). Treatment of 155 with pyridine and trifluoroacetic 
anhydride180 also resulted in 157 at 59% yield. Scheme 46 provides mechanisms for these 
cyclisation reactions.  
  
Pyridine deprotonates the carboxylic acid group of 155 to form the carboxylate anion. This 
reacts with DCC to form the acyl isourea. Intra-molecular attack at the activated carbonyl of 
the acylisourea by the weakly nucleophilic nitrogen of the primary amide results in the 
cyclised imide, with dicyclohexylurea as the powerful leaving group. 
 








Scheme 46: Mechanism for formation of Fmoc-glutarimide with DCC and with trifluoroacetic anhydride. 
Scheme 47: Dehydration of the side-chain amide of Gln to give the nitrile. Reagents and conditions: i. DCC, 
dry pyridine, N2, r.t., 16 h. 
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With the difficulties encountered with Fmoc-Gln-OH 155, a different Nα-protected Gln was 
used to test if the presence of the Fmoc-protecting group had any influence in the formation of 
the glutarimide 157. Interestingly, treatment of Cbz-Gln-OH 162 with DCC in pyridine gave 
the nitrile 163 at 82% yield (Scheme 47). This result suggested that, the Fmoc protecting 
group favours the cyclisation reaction whilst the Cbz protecting group favours the formation 
of the nitrile. Scheme 48 shows a proposed mechanism in the synthesis of 163.  
  
After the formation of the isourea “mixed anhydride” 164, removal of a proton from the side-
chain amide leads to the formation of the imidate. Cyclisation to form the pyranone ring 166, 
followed by base-catalysed elimination then gives the nitrile 163.  
 
Beauchard et al.178 invstigated the ability to incorporate Gln(CN) into peptide chains and also 
its compatibility with other protecting groups (Scheme 49) [experiments conducted by Anne 
Beauchard].  





To test the ability to couple Gln(CN) to a growing peptide chain, the dipeptide L-Leu-D-
Ser(OBut)-OMe 169 was synthesised. Cbz-L-Leu-OH 167 was coupled with D-Ser(OBt)OMe 
using benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) as the 
coupling agent. Initial nucleophilic attack of the positively charged phosphorus atom of 
PyBOP by the carboxylate anion of 167 forms the phosphonium ester, eliminating 
benzotriazolate anion in the process. This anion subsequently substitutes the phosphonium 
ester to give the more reactive benzotriazole ester, which then reacts with D-Ser(OBut)-OMe 
to give 168 in an excellent yield of 95%. Hydrogenolysis of 168 removed the Cbz group to 
give the dipeptide 169 L-Leu-D-Ser(OBut)-OMe. This was then coupled with N-Cbz-β-
cyanomethyl-L-Ala 163 using O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium 
hexafluorophosphate (HATU) to test compatibility of this coupling method with the nitrile 
Scheme 49: Incorporation Gln(CN) into a growing peptide chain and its compatibility with other protecting 
groups. Reagents and conditions: i. D-Ser(OBut)-OMe, PyBOP, Et3N, CH2Cl2, r.t  24 h  (ii) H2, Pd/C, MeOH, 
r.t. 16 h; iii. 163, HATU, Pri2NEt, CH2Cl2, r.t. 20 h; iv. 167, PyBOP, Et3N, CH2Cl2, r.t. 2 d; v. aq. H2O2, 































































































































group. This afforded the protected tripeptide 170 at a yield of 77% demonstrating that 
Gln(CN) can be added easily to growing peptide chain. Removal of the Cbz protecting group 
was effected with hydrogen and palladium-on-carbon catalyst to give 171 without any sign of 
competing reduction of the nitrile group. Coupling of 171 with Cbz-L-Leu-OH 167 led to the 
protected peptide 172 showing that peptide coupling at the N-terminus of Gln(CN) are 
efficient. Regeneration of Gln was achieved via mild hydration with hydroperoxide under 
basic conditions to give 173 without hydrolysis to the acid (Glu) or hydrolysis of the methyl 
ester. To test the stability / compatibility of the nitrile in acidic conditions, removal of the tert-
butyl protection of 172 was undertaken using trifluoroacetic acid to give 174. Condensation of 
174 with 2,2-dimethoxypropane under acid catalysis gave 175 which contains both the C-
terminal D-Dmo residue (which can be considered as a masked D-Ser, a pseudoproline) and 
the β-cyanomethyl-L-Ala (masked Gln). The tert-butyl group of Cbz-Gln(CN)-Leu-D-
Ser(OBut)-OMe 170 was also removed under acidic conditions, followed by condensation 
with 2,2-dimethoxypropane to give 177. Scheme 50 gives a further demonstration of the 
compatibility of Gln(CN) in solution-phase peptide synthesis. 
 
The protected dipeptide Cbz-Gln(CN)-Ala-OMe 178 was prepared by coupling L-Ala-OMe 
with Cbz-Gln(CN)-OH 163 using PyBOP. Hydrogenolysis of the N-terminal Cbz-protecting 
group of 178 afforded 179 (Scheme 50). Careful monitoring of the hydrogenolysis was 
needed since prolonged reaction time resulted in reduction of the nitrile group to form 182 
followed by a possible cyclisation to form 183 (Figure 52). Reducing the reaction time from 
16 h to 2 h allowed the synthesis of 179 without reduction of the nitrile. When this compound 
Scheme 50: Compatibility of Gln(CN) with  Cbz and Boc protecting groups. Reagents and conditions: i. L-Ala-
OMe.HCl, Pri2NEt, PyBOP, r.t., 3 d; ii. 10% Pd-C, H2, MeOH, r.t., 2 h iii. Boc-L-Ala-OH, Pri2NEt, HATU, DMF, 
r.t., 2 h; iv. aq. 35% H2O2, aq. 1 M NaOH, MeOH, 0C, 6 h. 
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was left at room temperature overnight, NMR spectra suggested that some of the compound 
had cyclised to give the diketopiperazine 184 (Figure 52).  
  
Synthesis of Boc-Ala-Gln(CN)-Ala-OMe 180 was achieved by immediate coupling of 179 to 
Boc-L-Ala-OH using HATU as the coupling agent (Scheme 50). Hydration of the nitrile 
group of 180 with the hydro-peroxide anion had to be carried out carefully to avoid side 
reactions. Carrying out the reaction at room temperature using hydrogen peroxide / sodium 
hydroxide resulted in hydrolysis of the methyl ester group as well as hydration of the nitrile. 
The reaction was repeated with the hindered base potassium tert-butoxide and urea hydrogen 
peroxide in methanol. At room temperature, no progression of the reaction occurred 
highlighting the reduced reactivity of the reagents. Heating the reaction at 40C resulted in 
hydration of the nitrile but also hydrolysis of the methyl ester. The use of 
diisopropylethylamine as a base with aqueous hydrogen peroxide or urea hydrogen peroxide 
resulted in a mixture of products. The reaction had to be carried out at 0C with sequential 
addition of aqueous hydrogen peroxide and sodium hydroxide and the mixture carefully 
neutralised at this temperature before bringing to room temperature to avoid hydrolysis of the 
ester. Neutralisation with aqueous hydrogen chloride proved problematic due to the risk of 
losing the Boc-protecting group. Sodium thiosulfate was therefore used to quench the 
reaction. Careful hydration of the nitrile 180 without disruption of the N-Boc protection and 
the methyl ester was achieved using 35% w/w aqueous hydrogen peroxide and 1 M aqueous 
sodium hydroxide in methanol to afford 181 at a modest yield of 23%. This low yield was 
mainly due to slow progression of the reaction since the majority of the starting material was 
recovered. Longer reaction time or the use of excess reagents should improve the yield.  
Figure 52: Possible products from prolonged hydrogenolysis of Cbz-Gln(CN)-Ala-OMe. 
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3.9.3 Hydration of terminal Gln nitrile group 
After proving the concept of masking the side-chain amide of Gln as a nitrile, within the 
peptide chain, the possibility of regenerating the amide side-chain was investigated when 
Gln(CN) is the C-terminal amino-acid. This is important because, in the proposed PSA-
cleavable pentapeptide to be synthesised, Gln is the C-terminal amino-acid. Attempted 
hydration of Cbz-Gln(CN)-OH 163 using aqueous hydrogen peroxide and sodium hydroxide 
resulted in hydrolysis of  the nitrile group completely to the carboxylate (Scheme 51). 
  
The proposed mechanism (Scheme 51) suggests an intra-molecular nucleophilic attack by the 
α-carboxylate of 163 to form imino-oxotetrahydropyran 185. This seems to out-compete the 
inter-molecular attack of the nitrile group by hydroperoxide ion. Nucleophilic attack by 
hydroxide ion on the imidate 185 results in a tetrahedral intermediate 186 from which 
ammonia leaves to yield the cyclic anhydride 187. Further nucleophilic attack by hydroxide 
ion yields Cbz-Glu-OH 188. This result suggested that the strategy of hydrating Gln(CN) at 
the C-terminus of the proposed PSA-cleavable peptide, Ser-Ser-Lys-Leu-Gln, will not be 
useful. A decision was therefore made to use solid-phase peptide synthesis to circumvent the 
difficulties presented by Gln when used in solution phase peptide synthesis. 
 




3.9.4 Solid-phase peptide synthesis 
 
Solid-phase peptide synthesis allows sequential coupling of α-protected-amino and side-
chain-protected amino-acids onto an insoluble polymeric support (Scheme 52). Removal of 
the protection from the α-amine allows subsequent amino-acids to be added using a coupling 
agent or pre-activated amino-acid derivative. The synthesised peptide is attached to the 
polymer via a linker through the C-terminus of the peptide. Cleavage of the peptide from the 
resin and followed by removal of the protecting groups gives the desired peptide. One 
advantage of solid-phase synthesis over solution phase peptide synthesis is that it allows 
excess reagents to be washed out of the reaction at each coupling stage, obviating the need for 
purification at each step of the synthesis. Besides, the use of dimethylformamide means that 
masking the side-chain primary amide group of Gln is not necessary as Gln is soluble in 
dimethylformamide. Peptides was synthesised using standard Fmoc solid-phase peptide 
synthesis [benzotriazol-1-yloxy-trispyrrolidino-phosphonium hexafluorophosphate (PyBOP) / 
N,N-diisopropylethylamine (Pri2NEt) couplings]. 2-Chlorotrityl chloride polystyrene resin 
was used to enable mild acidolytic cleavage of the peptide from the 2-chlorotrityl linker 
without removal of the N-terminal Fmoc protecting group or the side-chain protecting groups. 
This resin also avoids epimerisation making it ideal for synthesis of sensitive residues. The 
bulk of the trityl linker also helps to prevent formation of diketopiperazines from dipeptide 
intermediates.181 Furthermore, other side-reactions such as reattachment of residues during 
acidic cleavage and side-chain deprotection, are minimised.182 
 
Scheme 52: Solid phase peptide synthesis cycle and coupling of amino-acids to 2-chlorotrityl chloride resin. 
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3.9.4.1 Synthesis of Fmoc-Ser(Bn)-Ser(Bn)-Lys(Cbz)-Leu-Gln-OH (189) 
   
The synthesis of 189 began by loading Fmoc-Gln-OH onto 2-chlorotrityl chloride polystyrene 
under anhydrous conditions, using excess Pri2NEt, a non-nucleophilic tertiary amine base to 
generate the more nucleophilic carboxylate. The nucleophilic carboxylate group attacks the 
aliphatic carbon of 2-chlorotrityl chloride to substitute the chlorine atom with an ester group. 
The remaining trityl chloride units of the resin were capped by treatment with methoxide to 
substitute the chlorine with a methoxy group. This prevents reaction of subsequent amino-
acids directly with the resin. The loading attained was 73%. In each cycle, the Fmoc-
protection was removed by treatment of the resin with piperidine (20% v/v in DMF) and the 
remaining amino-acids (Fmoc-Leu-OH, Fmoc-Lys(Cbz), Fmoc-Ser(OBn) ( 2), respectively 
were added stepwise using PyBOP as the coupling reagent to activate the carboxy component 
of the Nα-protected amino-acid. The side-chain protections of Fmoc-Ser(OBn) and Fmoc-
Lys(Cbz) was chosen to ensure orthogonality with the cleavage of the N-terminal Fmoc-
protecting group and also the C-terminal chlorotrityl group. The benzyl and carboxybenzyl 
protections can be removed under the same conditions which will reduce the number of 
different deprotection reactions required. These cycles yielded the resin-bound Fmoc-
protected pentapeptide, which was cleaved from the resin with 1% v/v trifluoroacetic acid in 
dichloromethane to give the required protected pentapeptide 189 in 93% yield. Trifluoroacetic 
acid serves as a source of protons to protonate the carbonyl group at the C-terminal of the 
resin-bound peptide. This results in the cleavage of the trityl O-bond and release of the 
peptide. The process also results in generation of the highly stabilised chloro trityl 
carbocation, which can be trapped with scavengers (e.g. triisopropylsilane). The use of 
scavengers is only important when highly nucleophilic groups are present in the peptide 



























residue (e.g. Trp, Met, Tyr, Cys). If these nucleophilic groups are absent / protected, then the 
use of scavengers becomes unnecessary.181 
 
3.10 Synthesis of 1-benzyloxyisoquinolin-5-amine (193) as a model drug 
To test the proposed polymeric prodrug system for release of an aromatic amine such as the 
seco-CBI 136, a model drug was synthesised. This will enable the assessment of the ease of 
coupling aromatic amine directly to the peptide 189 and also whether PSA can selectively 
cleave the peptide-drug conjugate at the planned site. The model drug 193 was chosen due to 
its structural similarities to the proposed CBI drug. Besides, the model drug is non-toxic 
unlike α-naphthylamine which is the obvious choice as a model drug but is implicated in 
bladder cancer.183 Furthermore, once coupled to the pentapeptide 189, the benzyl group of the 
model drug together with Bn and Cbz group of the pentapeptide 189 would be cleaved in one 
step affording the delivery of 5-aminoisoquinolin-1-one, a well-known PARP-1 inhibitor.184-
187   
  
The model drug 193 was made by firstly nitrating 1-chloroisoquinoline 190 to give 191 at a 
yield of 66%. It was important to protonate and deactivate fully 190 before addition of the 
nitrating reagents to ensure selective nitration at the C5 position.184 The next step was a SNAr 
nucleophilic substitution (addition / elimination reaction) of the 1-chlorine with a benzyloxy 
group. This was effected by reaction of 191 with sodium benzyloxide under anhydrous 
conditions to give 192. Selective reduction of the nitro group without loss of the OBn was 
tried with different reagents, including tin(II) chloride, palladium on carbon / sodium 
borohydride and palladium on carbon / ammonium formate. The reaction was tried at 0C, 
room temperature and under reflux to determine the optimum conditions. All the conditions, 
however, resulted in reductive removal of the benzyl group to give 5-aminoisoquinolin-1-one 
(5-AIQ) 194 as well as the desired product 193. Palladium on carbon / sodium borohydride 
Scheme 53: Synthesis of 5-AIQ-model drug. Reagents and conditions: i. H2SO4 / HNO3, 0C for 2 h then r.t. 
for 10 min; ii. benzyl alcohol, NaH, dry DMF, r.t. for 15 min then 100C for 2 h; iii. MeOH, Pd/C, NaBH4 r.t. 
for 30 min then HCl. 
128 
 
were selected to reduce the nitro group of 192 due to the ability to control the number of 
hydrogen equivalents added in order to limit the reduction of the benzyl group. This allowed 
the synthesis of 193 at a yield of 33%.  
 
3.11 Coupling of model drug to peptide 
 
An attempt was made to couple the synthesised model drug 193 with the peptide 189. The 
pentafluorophenyl active ester 195 was synthesised using pentafluorophenol with 
dicyclohexylcarbodiimide (DCC) as the coupling reagent. DCC served to activate the 
carboxylate group of 189 to nucleophilic attack by the in situ generated pentafluorophenoxide. 
Mass spectrometry confirmed that the pentafluorophenyl ester 195 was formed [m/z: 
1264.5141 (M + H)]. Owing to purification difficulties as well as instability of the 
pentafluorophenyl ester, an attempt was made to couple the model drug 193 directly to the 
crude pentafluorophenyl ester to give 196. This, however, failed and also caused loss of the 
Fmoc group in some cases. PyBOP-activated 189 was also investigated to couple the model 
drug but this failed too.  
 
Scheme 54: Coupling of proposed PSA-cleavable peptide 189 to 5-AIQ derivative 193. Reagents and 


































3.12 Synthesis of 4-methoxynaphthalen-1-amine (200) as a model drug 
The challenges faced with coupling of 193 to the peptide led to the synthesis of a new model 
drug. 4-Aminonaphthalen-1-ol hydrochloride 31 was considered as a candidate to convert into 
a model drug. Silyl protection is known to be selective for hydroxy groups over amines due to 
the stability of the silicon-oxygen bond. Silyl protection of the phenolic group of 31 with 
chlorotrimethylsilane to give 197, however, failed.  
 
The next idea was to acetylate the amino group of 31 followed by protection of the phenolic 
group and then deacetylation to yield the model drug 200.  Due to risk of O-acetylation in the 
presence of excess base, as observed with 2-nitro-4-aminonaphthalen-1-ol 40 (Scheme 14), 
only one equivalent of triethylamine was used to free the amino group of 31. Even if non-
selective acetylation should occur, the O-acetyl group, being an ester, should be easier to 
hydrolyse without cleavage of the N-acetyl group. Acetylation of the amino group of 31 with 
acetyl chloride gave a mixture of several products. Purification resulted in the isolation of 198 
at a very low yield (~2%). It was thought that the acetyl chloride might have been too reactive 
resulting in formation of several products. Acetylation of 31 was therefore effected with 
acetic anhydride to give 198 at a yield of 93%.188 Methylation of the phenolic group of 198 
was carried out using methyl iodide with potassium carbonate as the base, giving rise to 199. 
Acidic hydrolysis of the N-acetyl group 199 gave 4-methoxynaphthalen-1-amine 200 as the 
new model drug. The next step was to couple this model drug to the proposed PSA-cleavable 
peptide 189. 
 
Scheme 55: Synthesis of naphthalene-based model drug. Reagents and conditions: i. (a) Chlorotrimethyl 
silane, imidazole, THF, Ar, r.t., 24 h; (b) Chlorotrimethyl silane, Et3N, dry DMF, N2, 72 h; ii. (a) Acetyl 
chloride, Et3N, THF, N2, r.t., 30 min; (b) Ac2O, Et3N, MeOH, 50C, 1 h; iii. MeI, K2CO3, acetone, reflux, 16 h; 
iv. aq. HCl (3.0 M), MeOH, 90C, 4 h. 
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3.13 Coupling of 4-methoxynaphthalen-1-amine to proposed PSA-cleavable 
peptide  
  
Coupling of 4-methoxynaphthalen-1-amine 200, was initially attempted with 
pentafluorophenol and DCC or 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
hydrochloride (EDC.HCl). This procedure, however, did not yield the desired results. 
Activation with EDC.HCl / hydroxybenzotriazole was then employed. The carboxyl group of 
189 reacts with the EDC.HCl to form the O-acylurea which can react with 4-
amethoxynaphthalen-1-amine to yield the product. The use of carbodiimide coupling agents 
in peptide synthesis tends to be associated with oxazolone formation leading to epimerisation. 
Hydroxybenzotriazole acts to reduce epimerisation by reacting with the O-acylurea to give the 
benzotriazole active ester which enhances reactivity by encouraging / stabilising the 
approaching amine via hydrogen bonding.159  Nucleophilic substitution of the benzotriazolyl 
ester by 200 gave the crude peptide-model drug 201 (Scheme 56). As mentioned before, the 
unprotected primary amide side-chain of Gln results in solubility issues during solution-phase 
peptide synthesis. Purification of 201 therefore proved very challenging. The peptide-model 
Scheme 56: Synthesis of Fmoc-peptide-model drug conjugate. Reagents and conditions: i. 4-
Methoxynaphthalen-1-amine 200, EDC.HCl, HOBt, DMF, N2, 0C → 20C, 2 d; ii. HBr in AcOH (33%), 20C,  
2 h then Et2O; iii. HBr in AcOH (33%), 20C, 2 h then MeOH. 
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drug conjugate did not have appreciable solubility in either organic or aqueous solvents. 
Extraction and chromatography could therefore not be used to purify 201. The insolubility of 
the peptide was, however, exploited in its purification by repeated trituration with Et2O and 
hot methanol affording 201 at a yield of 78%. Deprotection of acid-labile Cbz and benzyl 
protecting groups of 201 was effected with hydrogen bromide in acetic acid. Precipitation of 
the deprotected peptide (now a hydrobromide salt at the Lys side-chain) interestingly gave a 
product with a mass of eighty-four units higher than the expected mass. NMR investigation 
into this showed that both the serine β-hydroxy groups had been acetylated. Clearly, the 
hydrogen bromide was a strong enough acid to catalyse the esterification with solvent acetic 
acid under these conditions to give 202. The deprotection of 201 was repeated using the same 
reagents, hydrogen bromide in acetic acid. After completion of the reaction, methanol was 
added to methanolyse the acetate esters to give 203. Compound 203 was then subjected to 
enzyme assay to assess the ability of PSA to cleave the model drug. 
 
3.14 Study on the PSA-catalysed cleavage of Fmoc-Ser-Ser-Lys-Leu-Gln-4-
methoxynaphthalenamide 
The ability of PSA to cleave the peptide and release the model drug was investigated. 
Compound 203 (~2 mM) was incubated with PSA (10 mM) at 37C. The reaction was carried 
out in 50 mM Tris-HCl and 140 mM NaCl buffer at pH 7.4. These conditions were chosen in 
an attempt to mimic physiological conditions. A control experiment was also set up without 
the enzyme to make sure that cleavage is due to the action of PSA. Samples were taken at 
different time intervals and added to a solution of ZnCl2 (20 mM) to precipitate the enzyme. 
Centrifugation followed by HPLC analysis of the supernatant, however, did not detect any 
product or starting material. The absence of product or starting material in the supernatant led 
to the conclusion that the starting materials / product do not have sufficient aqueous 
solubility. This was supported by the observation that precipitates formed in the reaction 
mixture about 2 h into the experiment. The collected precipitates after centrifugation were 
suspended in methanol to dissolve the peptide. Analysis of the supernatant, however, showed 
that cleavage by the enzyme had not occurred, as only starting material 203 was detected. The 
lack of cleavage was attributed to the precipitation of the starting material during the 
experiment. The insolubility of the peptide-model drug conjugate 203 was attributed to the 
Fmoc-protecting group. The synthesis of peptide-model drug conjugate without the Fmoc-
protecting group was pursued. 
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3.15 Synthesis of Ser-Ser-Lys-Leu-Gln-(4-methoxynaphthalen-1-yl)amide 
 
Treatment of 201 with piperidine removed the Fmoc-protection to give 204. The benzyl-type 
protecting groups in the side-chains were then removed with hydrogen bromide / acetic acid, 
to give 205 (63%). This peptide-model drug conjugate was then subjected to enzyme assay to 
ascertain if PSA could release the model drug directly from the peptide. 
 
 
Scheme 57: Synthesis of peptide-model drug conjugate 205. Reagents and conditions: i. Piperidine / DMF 1:5, 












































































3.16 Study on PSA-cleavage of Ser-Ser-Lys-Leu-Gln-(4-methoxynaphthalen-1-
yl)amide 
Compound 205 (~2 mM) was incubated with PSA (10 mM) at 37C. The reaction was carried 
out in 50 mM Tris-HCl and 140 mM NaCl buffer at pH 7.4. A control experiment was also set 
up to make sure that cleavage was due to the action of PSA. Samples were taken at different 
time intervals and added to a solution of ZnCl2 (20 mM) in other to precipitate the enzyme. 
The mixture stayed clear throughout the experiment, indicating the enhanced water solubility 
of 205 compared to 203. HPLC analysis at 280 nM and 220 nM of the supernatant over 7 d, 
however, showed the presence of only starting material. This observation could be due to a 
number of reasons. Firstly, the activity of the enzyme was not ascertained before the 
experiments. Very low activity of the enzyme will require higher amounts to be used in order 
to observe cleavage. Carrying out an activity test of PSA using the commercially available 
PSA substrate, Mu-His-Ser-Ser-Lys-Leu-Gln-AMC, would help clarify this. Furthermore, it is 
possible that the proposed peptide is not a substrate for PSA. However, this reason is unlikely 
since from literature it has been established that the HSSKLQ is cleavable by PSA.99 
Denmeade et al. also showed that shorter amino-acid sequences SKLQ and KLQ were both 
cleavable by PSA.99 Synthesis of the polymeric prodrug system was pursued further with 
coupling of the peptide-model drug to poly(ethylene glycol). This together with 205 can then 
be tested against a new batch of active PSA. 
 
3.17 The synthesis of polymeric peptide-model drug  
Polymeric prodrugs enable the exploitation of the EPR effect when used to treat solid tumours 
like prostate cancer. The polymer serves to increase the molecular weight of the prodrug and 
thus restricts its diffusion across blood vessels of healthy tissues whilst allowing easy 
diffusion across the leaky blood vessels of cancer tissues. The size of the polymer means there 
is reduced renal excretion. This together with the fact that solid tumours have poor lymphatic 
drainage systems, promotes selective accumulation of drugs at tumour sites, thereby reducing 
unwanted side-effects.112, 114 The proposed prodrug system for the delivery of potent anti-
tumour agents consists of a polymer, the linking peptide and the active drug. With the 
synthesis of the peptide-model drug conjugate, the next step in the synthesis is to couple the 




The polymer chosen is this instance is poly(ethylene glycol) (PEG). This polymer is widely 
used in pharmaceuticals due to its non-toxicity, non-immunogenicity and its ability to 
improve the water solubility of drugs.120-122 The proposed ideal molecular weight needed for 
the exploitation of EPR effect is said to be ~20 KDa.114 Linear PEG (~5 KDa) was chosen to 
establish the chemistry with the aim of eventually using PEG (~20 KDa). Furthermore, 
coupling was made to only one end of the linear PEG. The hydroxy group of the 






























































































Scheme 58: Synthesis of polymeric peptide prodrug. Reagents and conditions:  i. 4-Nitrophenyl 
chloroformate, Et3N, 1,2-dichloroethane, 20C, 16 h; ii. Et3N, dry DMF, N2, 20C, 8 d; iii. HBr in acetic acid, 
20C, 2 h then MeOH. 
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terminal serine (~3.62 → 4.12) when compared to the uncoupled peptide 204. This confirmed 
that this N-terminal amino-acid had been acylated. 
 
3.18 Investigation into the use of molecular clip 
PSA, as an endopeptidase, tend to cleave peptide bonds between amino-acids. A study by 
Denmeade et al., however, showed that PSA was able to cleave 7-amino-4-methyl coumarin 
directly from a PSA-cleavable peptide.99 This led to the synthesis of the pentapeptide 189 and 
the subsequent coupling to a model drug and enzyme assay of this prodrug system. In order to 
deal with a situation whereby an active PSA fails to cleave a drug directly from the 
pentapeptide, a heptapeptide [Fmoc-Ser(Bn)-Ser(Bn)-Lys(Cbz)-Leu-Gln-Leu-D-Ser-OH] was 
synthesised with the intention of inserting a dipeptide molecular clip (Leu-Dmo) between the 
PSA-cleavable peptide (SSKLQ) and the attached drug. This will allow PSA to cleave 
between Gln and Leu followed by subsequent cyclisation to release the drug (Scheme 59).  
  
The rate of cyclisation of dipeptide linkers is based on the proportion in the cis-amide 
conformation.83, 104 5,5-Dimethyl-4-oxaproline (Dmo) have been found to force peptides into 
a 100% cis-amide conformation allowing rapid cyclisation to form diketopiperazine.106, 108 
Insertion of a molecular clip containing the Dmo unit between the PSA-cleavable peptide and 
the model drug will allow rapid intra-molecular cyclisation of the dipeptide linker to release 
the drug once the peptide is cleaved by PSA.83 The pseudoproline dipeptide linker, Leu-R-
Dmo was selected as the molecular clip to investigate due to the proven ability to generate the 
Dmo unit within a growing peptide.109 The Dmo will initially be introduced as a C-terminal 
D-Ser in the heptapeptide (SSKLQLS). Intraresidual N,O-acetalisation of the side-chain 
hydroxy group and the preceding amide nitrogen of D-Ser with 2,2-dimethoxypropane should 
Scheme 59: Proposed mechanism for the release of seco-CBIs by PSA-cleavage and spontaneous cyclisation. 
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generate the R-Dmo unit. L-Leu-R-Dmo corresponds to the L,S series of Dmt (5,5-dimethyl-
4-thiaprolin) pseudoproline. The L,S-Dmt molecular clips have been shown to cyclise at a 
faster rate than the L,R-Dmt series.105, 106 The rate of cyclisation of the cis-pseudoproline 
dipeptide molecular clips further depends on the conformation about the Cα of the N-terminal 
amino-acids (Scheme 60).   
 
Dipeptide molecular clips must adopt conformer 211A rather than other conformers such as 
211B where the reacting amine is pointing away from the target carbonyl. Conformer 221A 
was shown to be more sterically accessible in the L,S series of Aaa-Dmt (corresponding to L-
Aaa-R-Dmo) facilitating rapid cyclisation and expulsion of drug.106 Use of Leu-R-Dmo 
should therefore lead to rapid release of drug. Leu has been chosen as part of the proposed 
dipeptide molecular clip because it has been shown to be essential for cleavage by PSA at the 
appropriate site. For instance, replacement of Leu with Val in the synthesis of the PSA-
cleavable peptide, Ser-Ser-Lys-Leu-Gln-Val-Dmt caused PSA to release Gln-Val-Dmt rather 
than the desired Val-Dmt. This meant rapid cyclisation to release drug attached to the C-
terminal was not possible.105  
 
Scheme 60: Confromations of Leu-R-Dmo molecular clip. 
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3.19 Synthesis of Fmoc-Ser(Bn)-Ser(Bn)-Lys(Cbz)-Leu-Gln-Leu-D-Ser-OH 
   
The heptapeptide (Scheme 61) was made by solid-phase synthesis. Cleavage from the 2-
chlorotrityl chloride linker with trifluoroacetic acid (1% v/v) led to 213 (89%) with the tert-
butyl protecting group intact whilst cleavage with trifluoroacetic acid (50%) gave 214 without 
loss of other protecting groups.  
 


































































3.20 The synthesis of 5,5-dimethyl-4-oxaproline (Dmo) molecular clip 
 
The C-terminal D-Ser of 214 had been introduced as a precursor to Leu-R-Dmo molecular 
clip. The next steps studied conversion of the D-Ser into the R-Dmo pseudoproline in the 
protected heptapeptide 214 to give 215. Intraresidual N,O-acetalisation of the side-chain 
hydroxy group and the preceding amide nitrogen of D-Ser was attempted with 2,2-
dimethoxypropane (DMP) applying catalytic amounts of para-toluenesulfonic acid (pTsOH). 
The first attempt was carried out in toluene under microwave conditions but this resulted in 
decomposition of the peptide. The same result was obtained when the reaction was repeated 
under reflux using a Dean-Stark apparatus. One possibility for this failure was thought to be 
the poor solubility of 215 in the solvent used (toluene). The solvent was changed to 
dimethylformamide / dichloromethane and the reaction repeated for longer periods of time 
(up to 96 h). This, however, gave only decomposed products as well as starting materials. 
Aggregation of the peptide was thought to be one of the reasons why this reaction was 
unsuccessful. This means the site of reaction is sterically hindered and therefore the 2,2-








Figure 56: Structure of Fmoc-Ser(Bn)-Ser(Bn)-Lys(Cbz)-Leu-Gln-Leu-R-Dmo. 
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The tetrapeptide 216 was synthesised to ascertain the ability to generate Dmo within a shorter 
peptide chain (Scheme 62).  
 
Intraresidual N,O-acetalisation was tested on this compound using 2,2-dimethoxypropane and 
para-toluensulfonic acid. At 40C for 3 d, traces of the desired product 217 were observed by 
mass spectrometry, together with decomposed products. Repeating this reaction at a higher 
temperature (70C) led to no detectable product. This suggests that the peptide is not stable at 
higher temperatures and, therefore, this reaction should be tested at lower temperatures. Using 
a shorter peptide chain in the synthesis of the molecular clip might also be advantageous. 
Although regioselective insertion of pseudoproline systems into complex peptides such as 
cyclosporine C has been achieved,189  most pseudoprolines have been synthesised as 
dipeptides. One way of dealing with this will therefore be to synthesise the Dmo unit on a 
shorter peptide chain with protection at the C-terminal carboxyl group.109  The synthesis of 
the molecular clip as the dipeptide (Leu-R-Dmo) to be coupled to the remaining amino-acids 
should, however, be avoided. This is because rapid cyclisation into the diketopiperazine is 
likely to occur making it difficult to couple to other amino-acids.106 Synthsising the molecular 
clip within a tripeptide as in 177 or a tetrapeptide as in 175 (Scheme 49) will allow one to 
couple the remaining amino-acids employing solution-phase synthesis. In this instance since 
Gln is not a terminal amino-acid, it can be masked as the nitrile to aid solubility. The nitrile 
can be hydrated to the amide without running the risk of over hydration to the carboxylate.178  
Synthesis of 215 will be followed by coupling to the model drug 200 and removal of the 
Scheme 62: Synthsis of the Dmo motif. Reagents and conditions: i. Dimethoxypropane, pTSOH, DMF, 
40C, 72 h. 
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protecting groups to test the peptide-molecular clip-drug conjugate for enzymatic cleavage. 
This peptide-molecular clip-drug-conjugate will further be coupled to poly(ethylene glycol) 
and then subjected to more in vitro assays. 
 
The total synthesis of an analogue of the anti-tumour antibiotics has been achieved and 
biological evalution undertaken to confirm its potency. The development of the polymeric 
prodrug system saw the synthesis of the model drug 200 which was coupled to the proposed 
PSA-cleavable peptide 189. The peptide-model drug conjugate was further coupled to 
poly(ethylene glycol) to form the polymeric prodrug system. Enzymatic assay to test the 
ability of PSA to cleave the drug directly from the peptide, however, faced various challenges. 
This led to the synthesis of the heptapeptide 214 with the intention of inserting a molecular 
clip between the PSA-cleavable peptide and the drug. Insertion of the pseudoproline 
molecular clip (Leu-R-Dmo) into the heptapeptide 214 to give 215, however, failed. This has 
mainly been attributed to the steric bulk of the heptapeptide with a plan to synthesise the Dmo 
motif on a shorter peptide chain. Future synthesis of 215 will allow coupling to the model 
drug 200 followed by deprotection to give a peptide-Dmo-drug conjugate that can be 
investigated as to whether PSA can cleave. A successful cleavage by PSA will lead to the 
synthesis of polymer-peptide-molecular clip-drug conjugate and subsequent testing against 
PSA. Once the polymeric-peptide prodrug system is proven, the seco-CBI drug 136 will be 
conjugated with the peptide and the polymer and investigated for PSA triggered release from 

















4 Conclusion  
Conventional chemotherapeutic agents have significant limitations which impedes their 
ability to control tumour growth in patients. These limitations have been mainly attributed to 
their lack of selective targeting of cancerous cells over normal cells. CBI anti-tumour 
antibiotics represent synthetically accessible chemotherapeutic agents with high potency and 
novel mode of action.70, 78, 156, 190 The ability to deliver these drugs selectively to prostate 
tumours will not only address the limitations of current chemotherapeutic agents but will also 
present a new mode of targeting cancerous cells.  
 
Synthesis of the proposed seco-CBI drug 136 was addressed in two parts, namely, synthesis 
of the alkylating subunit and synthesis of the non-alkylating subunit. The key naphthalene 
intermediate, tert-butyl N-(1-iodo-2-(trifluoroacetamidonaphthalen-4-yl) carbamate 67 with 
iodo at C1 and orthogonally protected N2- and N4-amines was essential for the synthesis of 
the alkylating subunit. One of the main challenges faced in the synthesis of 67 was unintended 
de-iodination of 1-iodo-2,4-naphthalendiamines. Attempted acidic removal of the tert-
butoxycarbonyl groups of N,N’-bis(tert-butoxycarbonyl)-1-iodonaphthalene-2,4-diamine 25 
led to either selective de-iodination to give 59 or de-iodination with deprotection to give 
naphthalene-1,3-diamine 58 (Scheme 21). This observation triggered an extensive NMR 
studies to ascertain the reason for de-iodination. At 0C, it was observed that 1-
iodonaphthalene-2,4-diamine was stable in trifluoroacetic acid whilst, at 20C, an unexpected 
Wheland-like intermediate in the de-iodination process was observed. It was also observed 
that the source of the new proton in the Wheland-like intermediate had an intra-molecular 
origin. The findings that 1-iodonaphthalen-2,4-diamine was stable in trifluoroacetic acid at 
0C led to an effort to trap this compound as the salt and then protect the N4-amino group 
with tert-butoxycarbonyl (Boc). This, however, led to the isolation of the de-iodinated 
product, tert-butyl N-(1-aminonaphthalen-3-yl) carbamate 62, with Boc-protection at the N2-
amino group (Scheme 21).  
 
This result showed that preventing de-iodination in these compounds was too difficult and 
also gave a new direction in the synthesis of 67. It was thought that de-iodination occurred 
first to give naphthalene-1,3-diamine, which then underwent selective protection at the N2-
amino group to give 62. This suggested that the N2-amino group was more reactive than the 
N4-amino group, probably due its higher steric accessibility. Besides, it was found that 
naphthalene-1,3-diamine 58 could be monoprotected with 2-(tert-butoxycarbonyloxyimino)-
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2-phenylacetonitrile to give 62 but at a low yield of 8%.142 Introduction of trifluoroacetyl 
protection at the N2-amino group of 58 and tert-butoxycarbonyl at the N4-amino group was 
followed by electrophilic iodination to give 67. Selective alkylation at the N2-amide of 67 
followed by free-radical cyclisation with TEMPO trap and basic removal of the trifluoroacetyl 
group allowed coupling to the 5-(2-dimethylaminoethoxy)indole-2-carboxylic acid  non-
alkylating subunit 127. Reductive removal of 2,2,6,6-tetramethylpiperidine followed by 
substitution of the exposed hydroxy group with chlorine gave the Boc-protected CBI drug 
135. Acidic removal of the Boc group gave the final seco-CBI drug as its dihydrochloride salt 
136. 
 
Calf-thymus DNA melting assay of the synthesised CBI drug 136 was carried out. This 
confirmed that 136 binds and alkylates double stranded DNA very efficiently to bring about 
its cytotoxic effects. This effect was observed as an increase in the melting temperature (Tm) 
of dsDNA by as much as 13 deg. C, comparable to the Tm of the known cytotoxic agent, 
doxorubicin (Tm = 18 deg. C). This was despite 136 being the racemate. The (−)-unnatural 
enantiomers of the anti-tumour antibiotics tend to have a reduced DNA alkylation efficiency 
compared to the (+)-natural enantiomers.61 The significant elevation of the Tm of calf-thymus 
DNA by 136 therefore suggests that this compound is highly efficient at DNA alkylation. 
 
Preliminary MTS assay of the racemic seco-CBI drug 136 demonstrated that it was a potent 
cytotoxin, with an IC50 of 18 nM in LNCaP cells. The cytotoxic effect of the Boc-protected 
seco-CBI-drug 135 was measured as a rough prediction of the effect of conjugating the seco-
CBI drug 136 to the PSA-cleavable peptide to form a prodrug. The observed preliminary IC50 
was 218 nM showing an approximate ten-fold reduction in cytotoxicity compared to the 
unprotected drug. This suggested that the prodrug concept is viable. The high IC50 of 135 was 
attributed to the labile Boc-protection at N4. This meant that Winstein cyclisation was 
probably occurring to form the highly reactive cyclopropane ring, essential for cytotoxicity. 
The proposed peptide prodrug will form a more stable amide prodrug and therefore avoid 
unintended cyclisation of the seco-CBI. This should in turn reduce the cytotoxicity of the 
prodrug and increase the QIC50.87 
 
Investigation into a polymeric prodrug system involved firstly the synthesis of the proposed 
PSA-cleavable peptide SSKLQ. Initial attempts to synthesise this peptide via solution phase 
was met with solubility problems mainly due to the presence of the unprotected amide side-
chain of glutamine. This group was successfully masked as the nitrile to improve solubility 
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and reduce the chance of side-reactions. Although this effort proved effective in situations in 
which the glutamine is not a terminal amino-acid, attempted hydration of the nitrile when the 
glutamine is a terminal amino-acid resulted in conversion to glutamic acid rather than 
glutamine. This proved that this technique of masking the amide side-chain of glutamine as a 
nitrile in the synthesis of the pentapeptide, SSKLQ, was not going to work. Solid-phase 
peptide synthesis was therefore adopted in the synthesis of the pentapeptide 189. 4-
Methoxynaphthalen-1-amine 200 was coupled to the C-terminal of the pentapeptide as a 
model peptide-drug conjugate. A model polymer-peptide-drug conjugate was also synthesised 
by coupling of the model drug 200 to the C-terminal of the pentaptide followed by coupling to 
poly(ethylene glycol) at the N-terminal. Testing of the ability of PSA to cleave the amide 
bond between glutamine and the model drug was carried out with the peptide-model drug 
conjugate. Preliminary results from his assay, however, showed that cleavage did not occur 
and suggested the need to optimise the assay.  
 
In order to deal with a situation whereby PSA is unable to cleave the drug directly from the 
peptide, investigations were made into the insertion of self-immolative molecular clip 
between the drug and the peptide. The heptapeptide SSKLQLS was synthesised to investigate 
this proposal. Intra-residual N,O-acetalisation of the side-chain hydroxy group and the 
preceding amide nitrogen of the C-terminal D-Ser to generate the L-Leu-R-Dmo molecular 
clip, however, proved difficult. This was attributed to the bulky nature of the peptide and the 
possibility of aggregation leading to steric hinderance. Investigation into the use of a shorter 
peptide chain to generate the Dmo unit showed great promise as the desired product was 
detected by mass spectrometry. Dmo synthesis is quite problematic since though it requires 
acid catalysis, the cleavage of this molecular clip is also effected by acidic conditions. 5,5-
Dimethyl-L-proline (dmP)191 might be an alternative if the synthesis of Dmo becomes 
problematic. This pseudoproline (dmP) acts in similar fashion to Dmo but its carbocyclic 
framework renders it completely stable to acidic conditions. Synthesis of the molecular clip 
and its incorporation into the peptide will give a PSA-cleavable peptide that can be coupled to 
the model drug and polymer. PSA cleavage assays of the polymeric prodrug with the 
molecular clip and that without the molecular clip will be compared to assess the best system 
for efficient drug release. The most efficient system will then be adopted to synthesise the 
polymeric prodrug of the seco-CBI 136. Further biological evaluations will then be carried 
out with PSA-producing prostate cells to check the efficiency of activation of the polymeric 
prodrug system. The results from such studies will then be used as a guide in optimising the 





Chemical reagents were purchased from Sigma-Aldrich, Fluka, and Novabiochem. TLC was 
carried out on Merck aluminium backed TLC plates Silicagel 60 F254 and viewed using UV 
light ( = 254 nm). Reverse phase (RP) TLC was performed with RP-18 F254s pre-coated 
aluminium sheets (0.27 mm thickness). Column chromatography was carried on silica gel 60 
(35 – 70 micron).  Reverse phase chromatography was carried out using VersaPak C18 
(spherical) 23 × 110 mm (bed. wt., 30 g) cartridge. NMR data were obtained on either a 
Varian Mercury VX (400 MHz for 1H and 100 MHz for 13C) or a Bruker Avance III 
spectrometer (500 MHz for 1H, 125 MHz for 13C and 470 MHz for 19F). The chemical shifts 
are recorded in parts per million (ppm). A single mean value of chemical shift is given for 
multiplets arising from proton(s) in the same chemical environment whilsts a range value is 
given for the chemical shift of multiplets arising from protons of different chemical 
environments.  Mass spectrometry was carried out on a micrOTOFTM from Bruker Daltonics 
(Bremen, Germany) using an electrospray source (ESI-TOF). Melting points were obtained 
using a Reichert-Jung heated-stage microscope. Optical rotations were measured at ambient 
temperature using an Optical Activity Ltd AA-10 polarimeter in a cell volume of 5 mL and 
specific rotations are given in 10-1 deg. mL g-1. IR spectra were recorded on a Perkin-Elmer 
782 infra-red spectrometer using liquid films between NaCl discs or solids as KBr discs and 
values are given in cm-1. Analytical RP-HPLC was performed on a Dionex HPLC system 
(system 1) equipped with a Dionex UltiMate 3000 HPLC system with a Phenomenex Gemini 
5µm C-18 (150 × 4.6 mm) column with a flow rate of 1.0 mL min-1. Detecting was at λ= 
214, 220, 254, 280 nm.  Mobile phase A was 0.1% (v/v) TFA in water and mobile phase B 
was 0.1% TFA in acetonitrile. Gradient 1 was T = 0 min, A = 95%; T = 10 min, A = 5%. 
Gradient 2 was T = 0 min, A = 95%; T = 20 min, A = 5%. Preparative RP-HPLC was 
performed on a Dionex HPLC system equipped with a Phenomenex Gemini 5µm C-18 (250 x 
30 mm) with a flow rate of 22.5 mL min-1. Mobile phase A was 0.1% TFA in water and 
mobile phase B was 0.1% TFA in acetonitrile. Gradient was T = 0 min, A = 95%; T = 20 min, 
A = 5%. Centrifugation was carried out using Eppendorf MiniSpin centrifuge at 13400 rpm 
unless otherwise specified. Experiments were conducted at room temperature unless 
otherwise stated. Solvents were evaporated under reduced pressure. Solutions in organic 




Reagents for biological experiments were obtained from the Sigma-Aldrich Chemical Co. 
Fisher Ltd or Invitrogen and were of at least biochemical grade. Aqueous solutions were made 
in 18.2 Mega-Ω.cm-1 Milli-Q water and pH adjusted with HCl or NaOH solutions as 
appropriate. The pH was monitored using a Corning pH meter 240 and Corning general 
purpose combination pH electrode, calibrated at pH 7.0 and 10.0 or 4.0 at ambient room 
temperature. Reagents and plasticware were sterilised where required by autoclaving at 121°C 
for 15 minutes or were purchased already sterilised. Temperature-sensitive reagents were 
filtered through a 0.2 µ filter. Tissue culture experiments were carried out in a sterile hood. 
 
The human prostate cancer cell line LNCaP (Sigma-Aldrich) was cultured in Dulbecco’s 
Modiﬁed Eagle’s Medium (DMEM) supplemented with high glucose (4.5 g L-1), 20% (v/v) 
foetal bovine serum (FBS), penicillin (100 U mL-1) and streptomycin sulfate (100 μg mL-1) at 
37C in humidified atmosphere containing 5% (v/v) CO2. The MTS assay is based on the 
reagent: Promega ‘Cell Titer 96® Aqueous One Solution Cell Proliferation Assay’.192 
Centrifugation was carried out using Jouan B3.11 centrifuge at 1300 rpm unless otherwise 
specified. Perkin Elmer Lambda 40 UV/VIS spectrometer fitted with Perkin Elmer PTP-6 
(Peltier Temperature Programmer) was used to monitor DNA melting temperature. 
 
5.2 Benzyl N-(4-hydroxynaphthalen-1-yl)carbamate (32) 
 A suspension of 4-amino-1-naphthol hydrochloride 31 (224 mg, 1.1 mmol) 
in THF (30 mL) was stirred at −70C under N2. Potassium tert-butoxide (1.1 
mL of 1.0 M solution in THF, 1.1 mmol) was added dropwise over a 10 min 
period. The resulting mixture was warmed to −10°C and stirred for 1 h. The 
mixture was cooled again to −70°C and benzyl chloroformate (216 mg, 1.3 mmol) was added. 
The mixture was warmed gradually to 20C and was stirred overnight. The solvent was 
evaporated. The residue was dissolved in EtOAc and washed with water and brine. Drying, 
evaporation and chromatography (petroleum ether / EtOAc 1:1) gave 32 (207 mg, 62%) as a 
purple solid: Rf = 0.2 (petroleum ether / EtOAc 1:1); 1H NMR [(CD3)2SO) (COSY / 
NOESY)]  5.20 (2 H, s, Ph CH2), 6.90 (1  H, d, J = 8.0 Hz, Naph 3-H), 7.33 (1 H, d, J = 8.0 
Hz, Naph 2-H), 7.37-7.58 (7 H, m, Naph 6,7-H2 + Ph H5), 7.93 (1 H, d, J = 7.8 Hz, Naph 8-
H), 8.20 (1 H, dd, J = 8.7, 1.5 Hz, Naph 5-H), 9.29 (1 H, brs, NH), 10.15 (1 H, s, OH); 13C 
NMR [(CD3)2SO) (HSQC / HMBC)]  65.63 (Ph CH2), 107.31 (Naph 3-C), 122.25 (Naph 5-
C), 122.68 (Naph 8-C), 123.66 (Naph 2-C), 124.59 (Naph 1-C or 7-C or Ph 4-C), 124.69 
(Naph 7-C or 1-C or Ph 4-C), 124.73 (Ph 4-C or Naph 1-C or 7-C), 126.09 (Naph 6-C), 
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127.84 (Ph 3,5-C2), 128.38 (Ph 2,6-C2), 130.18 (Naph 4a,8a-C2), 137.05 (Ph 1-C), 151.33 
(Naph 4-C), 155.32 (C=O).  
 
5.3 Naphthalene-1,4-dione (35) 
4-Amino-1-naphthol hydrochloride 31 (67.6 mg, 0.35 mmol) was dissolved in 
trifluoroacetic acid (10 mL) and stirred at −20°C. Potassium nitrate (35.5 mg, 
0.35 mmol) was added dropwise over 5 min. The mixture was then allowed to 
stir at −20°C for 30 min and then poured onto ice. Extraction with EtOAc, 
drying and chromatography (CH2Cl2 / EtOAc 3:2) gave 35 (41.4 mg, 75%) as a buff solid: Rf 
= 0.8 (CH2Cl2 / EtOAc 6:1); mp 124-126C (lit.193 125-127°C); 1H NMR [(CD3)2SO) 
(COSY)]  7.14 (2 H, s, 2,3-H2), 7.93 (2 H, m, 6,7-H2), 8.04 (2 H, m, 5,8-H2); 13C NMR 
[(CD3)2SO) (HSQC / HMBC)]  125.83 (5,8-C2), 131.53 (4a,8a-C2), 134.18 (6,7-C2), 138.70 
(2,3-C2), 184.80 (1,4-C2); MS (ES+) m/z 159.0446 (M + 1) (C10H7O2 requires 159.0446).  
 
5.4 4-Amino-2-nitronaphthalen-1-ol (40) 
2,4-Dinitronaphthalen-1-ol  24 (5.04 g, 22 mmol) was stirred in conc. aq. 
HCl (20 mL) and EtOH (10 mL) for 1 h during the addition of SnCl2.2H2O 
(15.04 g, 66.64 mmol) in EtOH (20 mL), keeping the temperature < 30°C. 
The mixture was stirred for 17 h at 20C. The suspension was filtered and 
and the collected solid washed with EtOH / aq. conc. HCl (3:2). The yellow solid was 
partitioned between EtOAc and water and extracted several times with EtOAc. The organic 
layer was washed with brine and dried. Evaporation and chromatography (CH2Cl2) gave 40 
(3.11 g, 71%) as a pale red solid: Rf = 0.5 (CH2Cl2); mp 160-161C (lit.130 mp 160C); IR νmax  
3418, 3337 (OH, NH); 1H NMR (CDCl3)  3.98 (2 H, s, NH2), 7.26 (1 H, s, 3-H), 7.64 (1 H, 
ddd, J = 8.2, 7.0, 1.1 Hz, 7-H), 7.74 (1 H, ddd, J = 8.2, 6.9, 1.3 Hz, 6-H), 7.83 (1 H, d, J = 8.4 
Hz, 5-H), 8.53 (1 H, dd, J = 8.3, 0.6 Hz, 8-H), 11.92 (1 H, s, OH); 13C NMR (CDCl3) (HSQC 
/ HMBC)  100.54 (3-C), 121.42 (5-C), 125.65 (8a-C), 125.92 (8-C), 127.15 (7-C), 127.90 (2-
C), 129.56 (4a-C), 130.87 (6-C), 135.18 (4-C), 150.11 (1-C); MS (ES+) m/z 203.0466 (M - H) 








5.5 4-Amino-2-nitronaphthalen-1-yl tert-butyl carbonate (41) 
4-Amino-2-nitronaphthalene-1-ol 40 (53.8 mg, 0.26 mmol) was dissolved 
in CH2Cl2 (10 mL) and stirred under N2. Boc2O (60.2 mg, 0.28 mmol) in 
CH2Cl2 (5 mL) was added, followed by addition of DMAP (24.6 mg, 0.20 
mmol) in CH2Cl2 (2 mL); the mixture was stirred at 20C for 30 min. The 
mixture was washed with water, brine and dried. Evaporation and chromatography (CH2Cl2) 
gave 41 (13.6 mg, 17%) as a yellow solid: Rf = 0.4 (CH2Cl2); 1H NMR (CDCl3)  1.60 (9 H, 
s, But), 4.34 (2 H, s, NH2), 7.29 (1 H, s, 3-H), 7.62-7.66 (2 H, m, 6,7-H2), 7.79-7.82 (1 H, m, 
5-H), 8.13-8.16 (1 H, m, 8-H); 13C NMR [(CDCl3) (HSQC / HMBC)]  27.60 (CMe3), 84.87 
(CMe3), 102.48 (3-C), 121.22 (5-C), 124.15 (8-C), 126.12 (4a-C), 128.14 (6-C), 128.20 (8a-
C), 128.67 (7-C), 133.79 (4-C), 137.91 (2-C), 141.07 (1-C), 150.94 (C=O).  
 
5.6 tert-Butyl (4-hydroxy-3-nitronaphthalen-1-yl)carbamate (42) 
 4-Amino-2-nitronaphthalen-1-ol 40 (0.56 g, 2.7 mmol) was stirred in dry 
THF (20 mL) under N2. Boc2O (3.04 g, 14 mmol) in dry THF (5 mL) was 
added and the mixture was boiled under reflux for 20 h. The mixture was 
cooled and the solvent was evaporated. The residue was partitioned 
between CH2Cl2 and water and extracted with CH2Cl2, followed by washing with brine and 
drying. Evaporation and chromatography (petroleum ether / EtOAc 9:1) gave 42 (0.74 g, 
89%) as an orange solid: Rf = 0.4 (EtOAc / petroleum ether 1 : 4); mp 175-177ºC; IR νmax 
3338 (NH, OH), 3259 (NH, OH), 1687 (C=O), 1525 (NO2);  1H NMR [(CDCl3) (NOESY)]  
1.55  (9 H, s, But), 6.59 (1 H, br s, NH), 7.65 (1 H, ddd, J = 8.2, 7.0, 1.1 Hz, 6-H), 7.77 (1 H, 
ddd, J = 8.2, 6.9, 1.2 Hz, 7-H), 7.87 (1 H, d, J = 8.4 Hz, 8-H), 8.33 (1 H, s, 2-H), 8.56 (1 H, 
dd, J =  8.4, 0.5 Hz, 5-H), 12.11 (1 H, s, OH); 13C NMR [(CDCl3) (HSQC / HMBC)]  28.31 
(CMe3), 81.31 (CMe3), 112.82 (2-C), 121.46 (8-C), 125.45 (8a-C), 125.83 (4-C), 125.91 (4a-
C), 127.25 (6-C), 127.55 (3-C), 131.56 (7-C), 152.98 (1-C), 153.50 (C=O); MS (ES+) m/z 











Compound 42 (808 mg, 2.7 mmol), was stirred in dry pyridine (20 mL) 
under N2 at 0C for 15 min. Trifluoromethanesulfonic anhydride (0.70 mL, 
1.2 g, 4.2 mmol) was added dropwise during 45 min and the mixture was 
stirred for 30 min at 0C. The mixture was then allowed to warm to 20C 
during 10 min. Water was added and the mixture extracted with EtOAc. Drying, evaporation 
and chromatography (CH2Cl2 → CH2Cl2 / EtOAc 1:1→ EtOAc)  gave 43 (942 mg, 81%) as a 
yellow solid: Rf = 0.8 (CH2Cl2); mp 110-111°C; IR νmax 3435 (NH), 1737 (C=O); 1H NMR 
[(CDCl3) (NOESY)]  1.59 (9 H, s, But), 7.19 (1 H, s, NH), 7.78-7.82 (2 H, m, 6,7-H2), 7.96 
(1 H, dd, J = 6.5, 3.0 Hz, 5-H), 8.29 (1 H, dd, J = 6.5, 3.3 Hz, 8-H), 8.73 (1 H, s, 3-H); 13C 
NMR [(CDCl3) (HSQC / HMBC)]  28.20 (CMe3), 82.54 (CMe3), 110.52 (3-C),  118.42 (q, J 
= 321.2 Hz, CF3), 121.34 (5-C), 125.19 (8-C), 127.13 (8a-C), 127.51 (4a-C), 129.35 (6-C or 
7-C), 130.12 (7-C or 6-C), 132.72 (2-C), 134.61 (4-C), 143.02 (1-C), 152.20 (C=O); 19F NMR 
(CDCl3) δ -72.55 (s, CF3); MS (ES+) m/z 459.0484 (M + Na) (C16H15F3N2NaO7S requires 
459.0450).  
 
5.8 Attempted nucleophilic displacement of the triflate group of 43 with iodide 
Compound 43 (89.9 mg, 0.21 mmol) was stirred in DMF (20 mL) and NaI (63.1 mg, 0.46 
mmol) was added. The mixture was stirred at 80°C overnight and then at 90°C for 2 h. The 
solvent was evaporated and the residue was suspended in water. Extraction with EtOAc, 
washing with sat. aq. Na2S2O3, drying and evaporation gave 42 (50.2 mg, 80%) with 
properties as above. 
 
5.9 Attempted reduction of the triflate group of 43 
 
METHOD A 
Compound 43 (41.9 mg, 96 µmol), magnesium (4.1 mg, 0.17 mmol) and Pd/C (10%, 4.5 mg) 
were placed in a flask and placed under Ar. Dry MeOH (10 mL) was introduced via a syringe 
and the reaction was stirred at 20C for 16 h. Filtration through Celite®, evaporation and 






Compound 43 (122 mg, 0.28 mmol) in DMF (5 mL) was treated with Ph3P (3.66 mg, 14 
µmol), palladium acetate (1.70 mg, 7.6 µmol), Et3N (0.12 mL, 87 mg 0.84 mmol) and formic 
acid (0.02 mL, 24 mg, 0.56 mmol). The mixture was stirred at 65°C for 16 h, diluted with 
water, extracted with EtOAc, dried and evaporated. Chromatography (CH2Cl2) gave 42 (66 
mg, 78%) as an orange solid with properties as above. 
 
5.10 (E)-tert-Butyl (3-amino-4-oxonaphthalen-1(4H)-ylidene)carbamate (50) 
Compound 42 (66 mg, 0.22 mmol) was stirred vigorously with Pd/C (10%, 
36.5 mg) in MeOH (20 mL) under H2 for 1.5 h. The suspension was 
filtered through Celite® and the solvent was evaporated to give 50 (51 mg, 
84%) as a dark brown solid: Rf = 0.3 (CH2Cl2); mp 155-156°C; IR νmax 
3331 (NH), 1704 (C=O); 1H NMR (CDCl3)  1.61 (9 H, s, But), 5.06 (2 H, s, NH2), 6.10 (1 H, 
s, 2-H), 7.58 (1 H, t, J = 7.2 Hz, 6-H), 7.65 (1 H, t, J = 6.9 Hz, 7-H), 8.09 (1 H, d, J = 7.6 Hz, 
5-H), 8.29 (1 H, d, J = 7.7 Hz, 8-H); 13C NMR [(CDCl3) (HSQC / HMBC)]  28.23 (CMe3), 
82.26 (CMe3), 99.01 (2-C), 125.78 (8-C), 126.33 (5-C), 130.41 (4a-C), 131.27 (6-C), 133.62 
(7-C), 134.84 (8a-C), 144.84 (3-C), 157.13 (1-C), 162.94 (Boc C=O), 180.70 (4-C); MS (ES+) 
m/z 567.2262 (2 M + Na) (C15H16N2NaO3 requires 567.2220), 295.1052 (M + Na) 




K2CO3 (178 mg 1.3 mmol) and sodium dithionite (198 mg, 1.1 
mmol) in water (4 mL) were added dropwise to 42 (75 mg, 0.25 
mmol) in CH2Cl2 (8 mL) and water (1 mL) under N2. Stirring was 
continued for 16 h at 35°C. The mixture was dried and filtered. The 
filtrate was cooled to 0°C. Pri2NEt (580 mg, 4.5 mmol) was added followed by dropwise 
addition of trifluoroacetic anhydride (315 mg, 1.5 mmol). The mixture was stirred at 0C for 
15 min then allowed to warm to 20C. Stirring was continued for 2 h. The mixture was 
washed with water and brine and dried. Evaporation and chromatography (petroleum ether / 
EtOAc 9:1) gave 52 (39 mg, 42%) as a yellow solid: Rf = 0.6 (petroleum ether / EtOAc 4:1); 
mp 122-123°C; IR νmax 3290, 3097 (NH), 1744 (C=O); 1H NMR (CDCl3)  1.66 (9 H, s, But), 
7.71 (1 H, ddd, J = 9.0, 7.7, 1.9 Hz, 6-H), 7.78 (1 H, ddd, J = 8.9, 7.4, 1.5 Hz, 7-H), 8.13 (1 H, 
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s, 2-H), 8.19 (1 H, dd, J = 7.7, 1.1, Hz, 5-H), 8.36 (1 H, dd, J = 7.8, 0.9 Hz, 8-H), 9.17 (1H, s, 
NH); 13C NMR [(CDCl3) (HSQC / HMBC)]  28.13 (CMe3), 84.22 (CMe3), 114.57 (2-C), 
114.72 (q, J = 288.4 Hz, CF3), 126.11 (8-C), 127.12 (5-C), 129.40 (4a-C), 132.45 (6-C), 
133.67 (3-C), 134.80 (7-C), 135.00 (8a-C), 155.28 (Boc C=O), 155.57 (q, J = 39.2 Hz, 
CF3C=O), 161.36 (1-C), 178.63 (4-C); 19F NMR (CDCl3) δ -75.76 (s, CF3); MS (ES-) m/z 
367.0941 (M - H) (C17H14F3N2O4 requires 367.0906).  
 
5.12 2,4-Dinitronaphthalen-1-yl trifluoromethanesulfonate (53) 
2,4-Dinitronaphthalen-1-ol 24 (501 mg, 2.14 mmol) and Et3N (562 mg, 5.6 
mmol) in CH2Cl2 (10 mL) were cooled in an ice bath and treated dropwise 
with trifluoromethanesulfonic anhydride (784 mg, 2.8 mmol). The mixture 
was stirred at 20C for 2 h under N2. Aq. HCl (0.5 M, 10 mL) was added 
in one portion and the mixture was stirred for 30 min. The aqueous phase was separated and 
extracted with CH2Cl2. The combined organic phases were washed with sat. aq. NaHCO3 and 
brine. Drying, evaporation and chromatography (CH2Cl2) gave 53 (484 mg, 62%) as a yellow 
solid: Rf = 0.9 (CH2Cl2); mp 117-119°C (lit.79 mp 105-107°C); IR νmax 1532 (NO2), 1365 
(SO2-O-), 1349 (NO2); 1H NMR [(CD3)2SO] δ 7.72 (1 H, ddd, J = 8.2, 7.1, 1.0 Hz, 7-H), 7.91 
(1 H, ddd, J = 8.4, 7.0, 1.4 Hz, 6-H), 8.51 (1 H, d, J = 8.4 Hz, 8-H), 8.57 (1 H, d, J = 8.6 Hz, 
5-H), 8.87 (1 H, s, 3-H); 13C NMR [(CD3)2SO) (HSQC / HMBC)] δ 120.65 (q, J = 322.3 Hz, 
CF3), 122.31 (3-C), 123.32 (5-C), 125.58 (8-C), 127.49 (2-C), 127.76 (8a-C, 7-C), 128.00 (4a-
C), 133.09 (6-C), 134.75 (4-C), 158.70 (1-C); 19F NMR (CDCl3) δ -71.85 (s, CF3).  
 
5.13 1-Iodo-2,4-dinitronaphthalene (54) 
2,4-Dinitronaphthalen-1-yl trifluoromethanesulfonate 53 (4.28 g, 11.7 
mmol) was heated under reflux with NaI (5.99 g, 40 mmol) in acetone 
(170 mL) for 2 h. The evaporation residue, in EtOAc, was washed with 
sat. aq. Na2S2O3 and dried. Evaporation and chromatography (CH2Cl2) 
gave 54 (2.98 g, 74%) as yellow solid: Rf = 0.8 (CH2Cl2 / petroleum ether 
1:1); mp 183-186C (lit.79 mp 194-195°C); IR νmax 1530 (NO2), 1333(NO2); 1H NMR 
[(CD3)2SO)] δ 7.98 (2 H, m, 6-H, 7-H), 8.32 (1 H, dd, J = 7.1, 1.7 Hz, 5-H), 8.52 (1 H, dd, J = 
7.7, 2.0 Hz, 8-H), 8.73 (1 H, s, 3-H); 13C NMR [(CD3)2SO) (HSQC / HMBC)] δ 102.55 (1-C), 
117.53 (3-C), 123.35 (5-C), 124.01 (4a-C), 131.39 (6-C), 132.32 (7-C), 135.07 (8-C), 135.12 
(8a-C), 147.21 (4-C), 151.91 (2-C).  
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5.14 Naphthalene-1,3-diamine (58) 
1,3-Dinitronaphthalene 57 (44.1 mg, 0.20 mmol) was stirred in THF (10 
mL) and 10 % Pd-C (10 mg) added. The mixture was stirred under H2 for 
16 h. The mixture was filtered through Celite® and the solvent evaporated 
to give 58 (32 mg, 100%) as a dark solid: Rf = 0.3 (EtOAc / CH2Cl2 1:4); 1H NMR (CDCl3)  
3.71 (2 H, s, NH2), 4.08 (2 H, s, NH2), 6.23 (1 H, d, J = 2.1 Hz, 2-H), 6.50 (1 H, d, J = 1.9 Hz, 
4-H), 7.18 (1 H, ddd, J = 8.2, 6.8, 1.2 Hz, 7-H), 7.34 (1 H, ddd, J = 8.0, 6.8, 1.0 Hz, 6-H), 
7.53 (1 H, d, J = 8.2 Hz, 5-H), 7.64 (1 H, d, J = 8.4 Hz, 8-H); 13C NMR [(CDCl3) (HSQC / 
HMBC)]  100.67 (4-C), 100.58 (2-C), 118.65 (8a-C), 120.67 (8-C), 121.36 (7-C), 126.39 (5-
C or 6-C), 126.42 (6-C or 5-C), 136.01 (4a-C), 143.28 (1-C), 144.71 (3-C). 
 
5.15 N,N’-Bis(tert-butoxycarbonyl)naphthalene-1,3-diamine (59) 
1-Iodo-2,4-dinitronaphthalene 54 (1.05 g, 2.9 mmol) and SnCl2.2H2O 
(9.84 g, 44 mmol) in EtOAc (100 mL) were heated under reflux for 17 
h. The mixture was added to ice and NaHCO3 was added until the 
aqueous layer was basic. The mixture was extracted with EtOAc, washed with water and 
dried. Evaporation gave crude naphthalene-1,3-diamine 58. This material was boiled under 
reflux with Boc2O (3.11 g, 14.2 mmol) in THF (30 mL) for 17 h. Evaporation and 
chromatography (CH2Cl2) gave 59 (769 mg, 74%) as a pale buff solid: Rf = 0.7 (CH2Cl2); mp 
127-130°C (lit.79 mp 129-131°C); IR νmax 3254 (NH), 1716 (C=O), 1685 (C=O); 1H NMR 
[(CDCl3) (NOESY)]  δ 1.54 (9 H, s, But),  1.56 (9 H, s, But), 6.63 (1 H, s, NH), 6.91 (1 H, s, 
NH), 7.34 (1 H, ddd, J = 8.1, 6.8, 1.3 Hz, 7-H), 7.44 (1 H, ddd, J = 7.9, 6.9, 1.1 Hz, 6-H), 7.73 
(1 H, d, J = 8.2, 8-H), 7.77 (2 H, m, 4,5-H2), 7.93 (1 H, s, 2-H); 13C NMR [(CDCl3) (HSQC / 
HMBC)] δ 28.37 (2 × CMe3), 80.63 (CMe3), 80.92 (CMe3), 110.65 (2-C, 5-C), 119.69 (8-C), 
122.5 (8a-C), 124.41 (7-C), 126.49 (6-C), 128.52 (4-C), 133.76 (1-C), 134.82 (5a-C), 135.81 
(3-C), 152.76 (C=O), 153.13 (C=O).  
 
5.16 N,N’-Bis(tert-butoxycarbonyl)-1-iodonaphthalene-2,4-diamine (25) 
Compound 59 (417 mg, 1.28 mmol) was treated with N-
iodosuccinimide (431 mg, 1.9 mmol) and TsOH.H2O (457 mg, 2.4 
mmol) in THF / MeOH (14 mL, 1:1) at −78°C. The mixture was 
allowed to slowly warm to 20C over 4 h and was then diluted with aq. 
Na2S2O3 (5%) and stirred at 20C for 15 min. The mixture was extracted with EtOAc. The 
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combined organic extracts were dried and the solvents were evaporated. Chromatography 
(CH2Cl2) gave 25 (400 mg, 71%) as a pale buff solid: Rf = 0.4 (CH2Cl2); mp 166-168°C (lit.79 
mp 154-156°C); IR νmax 3384 (NH), 3229 (NH), 1733(C=O), 1683 (C=O); 1H NMR [(CDCl3)] 
δ 1.55 (9 H, s, But), 1.57 (9 H, s, But), 6.86 (1 H, s, 4-NH), 7.17 (1 H, s, 2-NH), 7.43 (1 H, dd, 
J = 6.9, 1.1 Hz, 6-H), 7.51 (1 H, dd, J = 6.8, 1.1 Hz, 7-H), 7.76 (1 H, d, J = 8.2 Hz, 5-H), 8.09 
(1 H, d, J = 8.4 Hz, 8-H), 8.62 (1 H, s, 3-H); 13C NMR [(CDCl3) (HSQC / HMBC)] δ 28.38 (2 
× CMe3), 81.03 (CMe3), 81.28 (CMe3), 87.36 (1-C), 113.71 (3-C), 121.40 (5-C), 124.88 (4a-
C), 125.32 (6-C), 128.15 (7-C), 132.58 (8-C), 134.65 (4-C or 8a-C), 134.82 (8a-C or 4-C), 
138.22 (2-C), 152.68 (C=O), 153.21 (C=O).  
 
5.17 Selective de-iodination of N,N’-Bis(tert-butoxycarbonyl)-1-iodonaphthalene-
2,4-diamine (25) 
Compound 25 (51.9 mg, 0.11 mmol) in CH2Cl2 (10 mL) was stirred with CF3CO2H in CH2Cl2 
(1.0 mL, 8.5µL mL-1, 0.11 mmol). The mixture was stirred for 7 d. Additional CF3CO2H in 
CH2Cl2 (1.0 mL, 8.5µL mL-1, 0.11 mmol) was added at 48 h, 72 h, 96 h and 120 h. The 
mixture was diluted with water and extracted with CH2Cl2. Drying, evaporation and 
chromatography (CH2Cl2) gave 59 (28.2 mg, 72%) as a pale buff solid with properties as 
above. 
 
5.18 tert-Butyl N-(1-aminonaphthalen-3-yl)carbamate (62) 
Compound 25 (287 mg, 0.56 mmol) was stirred with HCl in dioxane 
(4.0 M, 10 mL) for 45 min. The solid was collected by filtration, washed 
with HCl in dioxane (4.0 M) and dried to give a brown solid (157 mg). 
This material (54 mg) was suspended in dry THF (2 mL) and stirred 
under N2. Pri2NEt (0.10 mL, 77 mg, 0.60 mmol) was added, followed by dropwise addition of 
Boc2O (34 mg, 0.16 mmol) in dry THF (1.0 mL) during 15 min. The reaction was stirred 
under N2 for 10 d. Water was added and the mixture was concentrated under reduced 
pressure. The mixture was extracted with EtOAc. The extract was washed with water and sat. 
aq. Na2S2O3. Drying, evaporation and chromatography (CH2Cl2 / EtOAc 9:1) gave 62 (8.1 
mg, 6%) as a yellow solid: 1H NMR [(CDCl3) (NOESY)]  1.54 (9 H, s, But), 6.57 (1 H, s, 
NH), 6.90 (1 H, s, 2-H), 7.29 (1 H, s, 4-H), 7.32 (1 H, ddd, J = 8.2, 6.9, 1.2 Hz, 7-H), 7.40 (1 
H, ddd, J = 7.9, 6.9, 1.0 Hz, 6-H), 7.68 (1 H, d, J = 8.1 Hz, 5-H), 7.71 (1 H, d, J = 8.4 Hz, 8-
H); 13C NMR [(CDCl3) (HSQC / HMBC)]  28.35 (CMe3), 80.52 (CMe3), 102.52 (2-C), 
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105.75 (4-C), 120.50 (8a-C), 120.58 (8-C), 122.39 (7-C), 126.48 (6-C), 127.88 (5-C), 134.94 
(4a-C), 136.41 (3-C), 142.81 (1-C), 152.78 (C=O); MS (ES+) m/z 281.1269 (M + Na) 
(C15H18N2NaO2 requires 281.1266), 259.1443 (M + H) (C15H19N2O2 requires 259.1447).  
 
5.19 1,3-Bis(trifluoroacetamido)naphthalene (63) 
Compound 58 (32.0 mg, 0.20 mmol) was stirred in dry THF (2 mL) 
under N2 at 0°C. Pri2NEt (0.14 mL, 104 mg, 0.81 mmol) was added 
followed by dropwise addition of trifluoroacetic anhydride (0.03 mL, 
45.3 mg, 0.20 mmol) during 30 min. The reaction was stirred at 0C 
and allowed to warm slowly to 20C over 16 h. Water was added to the reaction and the 
solvent was evaporated. The residue was dissolved in EtOAc. This solution was washed with 
water and brine. Drying, evaporation and chromatography (CH2Cl2 / EtOAc 19:1) gave 63 (19 
mg, 26%) as a yellow solid: Rf 0.8 (CH2Cl2);  mp 214-216ºC; IR νmax 3345, 3258 (NH), 1716 
(C=O); 1H NMR [(CD3)2SO) (NOESY)]  7.66 (2 H, m, 6,7-H2), 7.91 (2 H, m, 2,8-H2), 8.06 
(1 H, m, 5-H), 8.40 (1 H, d, J = 1.8 Hz, 4-H), 11.62 (2 H, s, NH); 13C NMR [(CD3)2SO) 
(HSQC / HMBC)]  115.73 (q, J = 288.7 Hz, CF3), 116.12 (q, J = 288.7 Hz, CF3), 118.18 (4-
C), 118.73 (2-C), 122.41 (8-C), 126.33 (8a-C), 126.46 6-C or 7-C), 127.39 (7-C or 6-C), 
128.28 (5-C), 131.40 (4a-C), 133.39 (3-C), 133.59 (1-C), 154.82 (q, J = 37.1 Hz, C=O), 
156.03 (q, J = 36.7 Hz, C=O); 19F NMR [(CD3)2SO] δ -73.85 (3 F, s, CF3), -73.72 (3 F, s, 
CF3); MS (ES-) m/z 349.0442 (M - H) (C14H7F6N2O2 requires 349.0412).  
 
5.20 N-(1-aminonaphthalen-3-yl)-2,2,2-trifluoroacetamide (65) 
Compound 58 (1.29 g, 8.16 mmol) was stirred in dry THF (100 mL) 
under N2 at 0°C. Pri2NEt (5.70 mL, 4.23 g, 32.6 mmol) was added 
followed by dropwise addition of a solution of trifluoroacetic 
anhydride (1.13 mL, 1.71 g, 8.16 mmol) in dry THF (100 mL) during 
2 h. The mixture was allowed to slowly warm to 20°C during 16 h. The solvent was 
evaporated and the residue dissolved in EtOAc. This solution was washed with water and 
brine. Drying, evaporation and chromatography (petroleum ether / EtOAc 9:1 → 1:1) gave 65 
(309 mg, 15%) as a buff solid: Rf = 0.5 (CH2Cl2 / EtOAc 4:1); mp 168-169°C; IR νmax 3482, 
3374, 3324 (NH), 1721, 1706 (C=O); 1H NMR [(CD3)2SO)]  5.99 (2 H, s, NH2), 7.01 (1 H, 
d, J = 2.0 Hz, 2-H), 7.39 (1 H, ddd, J = 8.2, 6.8, 1.3 Hz, 7-H), 7.47 (1 H, ddd, J = 8.1, 6.8, 1.2 





Hz, 8-H), 11.17 (1 H, s, NH); 13C NMR [(CD3)2SO) (HSQC / HMBC)]  101.31 (2-C), 
106.51 (4-C), 115.88 (q, J = 289.0 Hz, CF3), 120.89 (8a-C), 122.24 (8-C), 123.46 (7-C), 
126.34 (6-C), 127.78 (5-C), 134.09 (4a-C), 134.67 (3-C), 145.56 (1-C), 154.41 (q, J = 36.6 
Hz, C=O); 19F NMR [(CD3)2SO] δ -73.69 (s, CF3); MS (ES+) m/z 277.0554 (M + Na) 
(C12H9F3N2NaO requires 277.0565).  
 
5.21 tert-Butyl N-(3-trifluoroacetamidonaphthalen-1-yl)carbamate (66) 
Compound 65 (330 mg, 1.30 mmol) was boiled under reflux with 
Boc2O (1.43 g, 6.55 mmol) in dry THF (10 mL) under N2 for 16 h. 
Evaporation and chromatography (petroleum ether  petroleum 
ether / EtOAc 19:1) gave 66 (381 mg, 83%) as a pale buff solid.  
Rf  = 0.4 (petroleum ether / EtOAc 4:1); mp 206-208ºC; IR νmax 3297 (NH), 3244 (NH), 1711 
(C=O), 1683 (C=O); 1H NMR [(CD3)2SO) (NOESY)]  1.57 (9 H, s, But), 7.54 (1 H, td, J = 
6.8, 1.4 Hz, 7-H), 7.58 (1 H, td, J = 6.8, 1.2 Hz, 6-H), 7.94 (1 H, d, J = 8.1 Hz, 5-H), 8.00 (1 
H, d, J = 2.0 Hz, 2-H), 8.13 (1 H, d, J = 8.2 Hz, 8-H), 8.20 (1 H, d, J = 1.8 Hz, 4-H), 9.39 (1 
H, s, NHBoc), 11.50 (1 H, s, NHCOCF3); 13C NMR [(CD3)2SO) (HSQC / HMBC)]  28.13 
(CMe3), 79.26 (CMe3)), 114.63 (2-C), 114.73 (4-C), 115.79 (q, J = 288.8 Hz, CF3), 122.64 (8-
C), 125.27 (8a-C), 125.33 (7-C), 126.75 (6-C), 128.03 (5-C), 133.52 (4-C), 133.56 (3-C), 
134.92 (1-C), 153.76 (Boc C=O), 154.68 (q, J = 37.1 Hz, CF3C=O); 19F NMR [(CD3)2SO] δ -
73.76 (s, CF3); MS (ES+) m/z 377.1120 (M + Na) (C17H17F3N2NaO3 requires 377.1089). 
 
5.22 tert-Butyl N-(1-iodo-2-(trifluoroacetamidonaphthalen-4-yl)carbamate (67) 
Compound 66 (336 mg, 0.95 mmol) in dry THF (10 mL) was cooled to 
−78C and stirred under N2. NIS (309 mg, 1.4 mmol) in dry THF (2.0 
mL) was added followed by TsOH.H2O (370 mg, 1.9 mmol) in dry 
THF (2.0 mL). The temperature of the mixture was allowed to rise 
slowly to 20C over 20 h. The reaction was quenched by addition of sat. aq. NaHCO3. The 
mixture was diluted with water and extracted with EtOAc. Drying, evaporation and 
chromatography (petroleum ether  petroleum ether / EtOAc 4:1) gave 67 (344 mg, 75%) as 
a pale buff solid: Rf = 0.6 (CH2Cl2); mp 198-199C; IR νmax 3323, 3209 (NH), 1721 (C=O), 
1698 (C=O); 1H NMR [(CDCl3) (NOESY)]  1.57 (9 H, s, But), 6.95 (1 H, s, Boc NH), 7.54-
7.61 (2 H, m, 6,7-H2), 7.82 (1 H, d, J = 8.1 Hz, 5-H), 8.14 (1 H, d, J = 8.6 Hz, 8-H), 8.58 (1 
H, s, NHCOCF3), 8.71 (1 H, s, 3-H); 13C NMR [(CDCl3) (HSQC / HMBC)]  28.31 (CMe3), 
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81.63 (CMe3), 89.87 (1-C), 113.26 (3-C), 115.77 (q, J = 289.3 Hz, CF3), 121.09 (5-C), 125.43 
(4a-C), 126.86 (6-C), 128.73 (7-C), 133.17 (8-C), 134.52 (8a-C), 134.90 (4-C), 135.20 (2-C), 
152.82 (Boc C=O), 155.05 (q, J = 38.0 Hz, CF3C=O); 19F NMR [(CD3)2SO] δ -74.13 (s, CF3); 
MS (ES+) m/z 503.0100 (M + Na) (C 17H16F3IN2NaO3 requires 503.0055), 498.0542 (M + 
+NH4) (C17H20F3IN3O3 requires 498.0500). 
 
5.23 Wheland-like intermediates in the de-iodination of N,N’-Bis(tert-
butoxycarbonyl)-1-iodonaphthalene-2,4-diamine (25) in acidic media 
To compound 25 (14.7 mg, 28 µmol) was added a mixture of CDCl3 (0.15 mL) and CF3CO2H 
(0.45 mL) at 0C. The sample was transferred to an NMR spectrometer, with the probe pre-
cooled to 0°C. The mixture was kept at 0C for 2 h to give 68. The mixture was allowed to 
slowly warm to 20C and kept at this temperature for 2 h to give 69.  
 
5.23.1 1-Iodonaphthalene-2,4-diammonium (68) 
1H NMR (CF3CO2H / CDCl3 3:1)  7.95 (1 H, t, J = 8.5 Hz, 6-H), 7.98 (1 
H, t, J = 7.0 Hz, 7-H), 8.05 (1 H, d, J = 8.0 Hz, 5-H), 8.11 (1 H, s, 3-H), 
8.48 (1 H, d, J = 8.5 Hz, 8-H);  13C NMR [(CF3CO2H / CDCl3 3:1) (HSQC 
/ HMBC)]  101.74 (1-C), 116.88 (3-C), 120.91 (5-C), 126.58 (4a-C), 
127.73 (4-C), 129.30 (2-C), 131.75 (6-C), 132.30 (7-C), 134.69 (8-C), 135.92 (8a-C). 
 
5.23.2 2-Imino-1-iodo-1,2-dihydronaphthalen-4-ammonium (69) 
1H NMR (CF3CO2H / CDCl3 3:1)  6.05 (1 H, s, 3-H), 6.51 (1 H, s, 1-H), 
7.58 (1 H, t, J = 7.4 Hz, 6-H), 7.70 (1 H, t, J = 7.4 Hz, 7-H), 7.75 (1 H, d, 
J = 7.8 Hz, 8-H), 7.84 (1 H, d, J = 8.0 Hz, 5-H); 13C NMR [(CF3CO2H / 
CDCl3 3:1) (HSQC / HMBC)]  9.76 (1-C), 91.48 (3-C), 121.68 (4a-C), 
124.18 (5-C), 129.94 (6-C), 131.47 (8-C), 134.99 (7-C), 141.24 (8a-C), 164.01 (4-C), 173.43 
(2-C).  
 
The above reaction was repeated using CF3CO2D to investigate the source of proton in the 
Wheland-like intermediate 69. To compound 25 (14.7 mg, 28 µmol) was added a mixture of 
CDCl3 (0.15 mL) and CF3CO2D (0.45 mL) at 0C. The sample was transferred to an NMR 
spectrometer, with the probe pre-cooled to 0°C. The mixture was kept at 0C for 2 h to give 
70. The mixture was allowed to slowly warm to 20C and kept at this temperature for 2 h to 
158 
 
give 71. An attempt to undertake mass spectrometry on sample 71 resulted in the 
identification of 72. 
 
5.23.3 Deuterated 1-iodonaphthalene-2,4-diammonium (70) 
1H NMR (CF3CO2D / CDCl3 3:1)  7.95 (1 H, t, J = 8.5 Hz, 6-H), 7.98 (1 
H, t, J = 7.0 Hz, 7-H), 8.05 (1 H, d, J = 8.0 Hz, 5-H), 8.11 (0.3 H / 0.7 D, 
s, 3-H), 8.48 (1 H, d, J = 8.5 Hz, 8-H);  13C NMR [(CF3CO2D / CDCl3 
3:1) (HSQC / HMBC)]  101.62 (1-C), 116.88 (3-C), 120.95 (5-C), 
126.66 (4a-C), 127.75 (4-C), 129.38 (2-C), 131.78 (6-C), 132.29 (7-C), 
134.73 (8-C), 136.03 (8a-C). 
 
5.23.4 Deuterated 2-imino-1-iodo-1,2-dihydronaphthalen-4-ammonium (71) 
1H NMR (CF3CO2D / CDCl3 3:1)  6.06 (0.07 H / 0.93 D , s, 3-H), 6.50 
(0.2 H / 0.8 D, s, 1-H), 7.59 (1 H, t, J = 7.8 Hz, 6-H), 7.70 (1 H, t, J = 
7.5 Hz, 7-H), 7.76 (1 H, d, J = 7.8 Hz, 8-H), 7.84 (1 H, d, J = 8.0 Hz, 5-
H); 13C NMR [(CF3CO2D / CDCl3 3:1) (HSQC / HMBC)]  9.55 (t, J = 
22.9 Hz, 1-C), 90.64 (m, 3-C), 121.66 (4a-C), 124.19 (5-C), 129.98 (6-
C), 131.48 (8-C), 135.02 (7-C), 141.18 (8a-C), 163.75 (4-C), 173.09 (2-C). 
 
5.23.5 Deuterated naphthalene-1,3-diamine (72) 
MS (ES+) m/z 159.0921 (32.8%)  (M + H) (C10H11N2 requires 
159.0922), 160.0991 (M + H) (86.1%) (C10H10DN2 requires 160.0985), 
161.1054 (M + H) (100%) (C10H9D2N2 requires 161.1048), 162.1114 
(M + 1) (55%) (C10H8 D3N2 requires 162.1111). 
 
5.24 Wheland-like intermediates from naphthalene-1,3-diamine in acidic media 
To naphthalene-1,3-diamine 58 (14.7 mg, 67 µmol) was added a mixture of CDCl3 (0.15 mL) 
and CF3CO2H (0.45 mL) at 0C. The sample was transferred to an NMR spectrometer, with 
the probe pre-cooled to 0°C. The mixture was kept at 0C for 20 min to give 73. The reaction 







5.24.1 Naphthalene-1,3-diammonium (73) 
1H NMR (CF3CO2H / CDCl3 3:1)  7.87 (1 H, t, J = 8.8 Hz, 6-H), 7.91 (1 
H, t, J = 7.7 Hz, 7-H), 7.98 (1 H, d, J = 2.0 Hz, 2-H), 8.04 (1 H, d, J = 8.1 
Hz, 8-H), 8.10 (1 H, d, J = 8.8 Hz, 5-H), 8.21 (1 H, d, J = 1.6,  4-H); 13C 
NMR [(CF3CO2H / CDCl3 3:1) (HSQC / HMBC)]  116.65 (2-C), 119.99 
(8-C), 125.51 (3-C), 125.96 (4-C), 126.64 (8a-C), 127.33 (1-C), 129.90 (5-C), 130.56 (6-C), 
131.20 (7-C), 134.27 (4a-C). 
 
5.24.2 3-Imino-3,4-dihydronaphthalen-1-ammonium  (74) 
1H NMR (CF3CO2H / CDCl3 3:1) δ 4.13 (2 H, s, 4-H2), 6.02 (1 H, s, 2-H), 
7.51 (1 H, d, J = 7.8 Hz, 5-H), 7.57 (1 H, t, J = 7.7 Hz, 7-H), 7.71 (1 H, t, J 
= 7.6 Hz, 6-H), 7.82 (1 H, d, J = 8.1 Hz, 8-H); 13C NMR [(CF3CO2H / 
CDCl3 3:1) (HSQC/ HMBC)]  33.28 (4-C), 93.53 (2-C), 123.03 (8a-C), 
123.15 (8-C), 128.83 (7-C), 129.27 (5-C), 134.33 (6-C), 136.63 (4a-
C).165.70 (1-C), 171.90 (3-C). 
 
The above procedure was repeated using CF3CO2D.  To naphthalene-1,3-diamine 58 (14.7 
mg, 67 µmol) was added a mixture of CDCl3 (0.15 mL) and CF3CO2D (0.45 mL) at 20C for 
6 d to give a mixture of 75 and 76. NMR showed deuterium exchange at 2-C and 4-C. 
 
5.24.3 Deuterated naphthalene-1,3-diammonium (75) 
1H NMR (CF3CO2D / CDCl3 3:1)  7.90 (1 H, t, J = 7.0 Hz, 6-H), 7.94 (1 
H , t, J = 7.0 Hz, 7-H), 8.05 (0.2 H / 0.8 D, s, 2-H/D), 8.10 (1 H, d, J = 
8.3 Hz, 8-H), 8.14 (1 H, d, J = 8.0 Hz, 5-H), 8.28 (0.2 H / 0.8 D, s, 4-
H/D); 13C NMR [(CF3CO2D / CDCl3 3:1) (HSQC / HMBC)]  116.63 (2-
C), 120.07 (8-C), 125.17-125.31 (3-C), 125.75 (brt, 4-CD), 126.04 (4-
CH), 126.74 (8a-C), 127.11-127.18 (1-C), 129.90-129.95 (5-C), 130.59 (6-C), 131.27 (7-C), 
134.30, 134.35 (4a-C). 
 
5.24.4 Deuterated 3-imino-3,4-dihydronaphthalen-1-ammonium  (76) 
1H NMR (CF3CO2D / CDCl3 3:1) δ 4.11 (0.4 H / 1.6 D, s, 4-CHD), 
6.04 (0.25 H / 0.75 D, s, 2-H/D), 7.55 (1 H, d, J = 7.8 Hz, 5-H), 7.61 (1 
H, t, J = 7.8 Hz, 7-H), 7.74 (1 H, t, J = 7.6 Hz, 6-H), 7.87 (1 H, d, J = 
8.2 Hz, 8-H);  13C NMR [(CF3CO2D / CDCl3 3:1) (HSQC / HMBC)] δ 
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32.74 (sextet, J = 20.0 Hz,  4-C),  92.98 (t, J = 24.5 Hz, 2-CD), 93.21 (t, J = 24.5 Hz, 2-CH), 
123.04 (8a-C), 123.21 (8-C), 128.84 (7-C), 129.29 (5-C), 134.42 (6-C), 136.66 (m, 4a-C), 
165.72 (1-C), 171.84 (3-C). 
 
5.25 De-iodination of tert-butyl (4-iodo-3-(2,2,2-trifluoroacetamido)naphthalen-1-
yl)carbamate (67) in acidic media 
To compound 67 (16.2 mg, 34 µmol) was added a mixture of CDCl3 (0.15 mL) and CF3CO2H 
(0.45 mL) at 0C. The sample was transferred to an NMR spectrometer, with the probe pre-
cooled to 0°C. The mixture was kept at 0C for 2 h to give 77.   
 
5.25.1 N-(4-Ammonium-1-iodonaphthalen-2-yl)-2,2,2-trifluoroacetamide (77) 
1H NMR (CF3CO2H / CDCl3) δ 7.84 (1 H, t, J = 7.5 Hz, 6-H), 7.88 
(1 H, t, J = 7.5 Hz, 7-H), 7.97 (1 H, d, J = 8.2 Hz, 5-H), 8.44 (1 H, d, 
J = 8.6 Hz, 8-H), 8.57 (1 H, s, 3-H), 9.24 (1 H, s, NH); 13C NMR 
[(CF3CO2H / CDCl3) (HSQC / HMBC)] δ 99.94 (1-C), 116.71 (3-C), 
120.59 (5-C), 125.47 (4a-C), 126.84 (4-C), 130.40 (6-C), 131.41 (7-C), 133.68 (2-C), 134.58 
(8-C), 135.78 (8a-C), 158.21 (q, J = 39.5 Hz, CF3C=O). 
 
The above procedure was repeated with CF3CO2D to give 79 at 0°C. The temperature of the 
reaction was allowed to rise from 0C → 20ºC and kept at 20C for 7 d to give 80 with 
deuterium exchange at 2-C and 4-C. 
 
5.25.2 Deuterated N-(4-ammonium-1-iodonaphthalen-2-yl)-2,2,2-trifluoroacetamide 
(79) 
1H NMR (CF3CO2D / CDCl3 3:1)  7.84 (1 H, t, J = 7.3 Hz, 6-H), 7.88 
(1 H, t, J = 7.2 Hz, 7-H), 7.96 (1 H, d, J = 8.2 Hz, 5-H), 8.44 (1 H, d, J 
= 8.4 Hz, 8-H), 8.59 (1 H, s, 3-H); 13C NMR [(CF3CO2D / CDCl3 3:1) 
(HSQC / HMBC)]  99.79 (1-C), 116.64 (3-C), 120.56 (5-C), 125.41 








5.25.3 Deuterated N-(1-ammoniumnaphthalen-3-yl)-2,2,2-trifluoroacetamide (80) 
1H NMR (CF3CO2D / CDCl3 3:1) δ 7.76-7.80 (2 H, m, 6,7-H2),  7.95 
(1 H, m, 8-H), 8.04 (1 H, m, 5-H), 8.20 (0.2 H / 0.8 D, s 2-H), 8.29 
(0.1 H / 0.9 D, s, 4-H), 9.31 (0.05 H / 0.95 D, s, NH); 13C NMR 
[(CF3CO2H / CDCl3 3:1) (HSQC / HMBC)]  116.48 (brt, 2-C), 
119.63 (8-C), 122.32-122.90 (brt, 4-C), 125.15 (8a-C), 125.91 (1-C), 
129.74 (6-C), 129.79 (5-C), 129.80 (7-C), 131.42 (3-C), 134.81 (4a-C), 157.58 (q, J = 39.1 
Hz, CF3C=O). 
 
5.26 Entrapment of tert-butyl cation by trifluoroacetic acid 
In each case where deprotection of Boc occurred in the NMR experiments described above, 
NMR showed that the But group of 25 and 67 was trapped by the acid to give But 
trifluoroacetate 81. When CF3CO2D was used, it was observed that incorporation of 
deuterium in But occurred to give 82. 
 
5.26.1 tert-Butyl 2,2,2-trifluoroacetate (81) 
1H NMR (CF3CO2H / CDCl3 3:1)  1.63 (9 H, s, But); 13C NMR [(CF3CO2H / 
CDCl3 3:1) (HSQC)]  27.02 (CMe3), 90.67 (CMe3), 159.45 (q, J = 41.9 Hz, 
C=O). 
 
5.26.2 Deuterated tert-butyl 2,2,2-trifluoroacetate (82) 
1H NMR (CF3CO2D / CDCl3 3:1)  1.61 (CH2D), 1.63 (CH3); 13C NMR 
[(CF3CO2D / CDCl3 3:1) (HSQC)]  26.76 (tt, J = 19.9, 3.5 Hz, CH2D), 
27.03 (t, J = 3.5 Hz, CH3), 90.64 (t, J = 5.4 Hz, CCH3(CH2D)2), 159.53 (q, J = 42.0 Hz, 
C=O). 
 
5.27 (2R,3R)-3-Methyloxiran-2-yl)methanol (90) 
Dry CH2C12 (200 mL) was stirred at −23°C under N2. To this was added 
titanium tetraisopropoxide (5.94 mL, 5.68 g, 20 mmol) and (−)-diethyl D-
tartrate (3.42 mL, 4.12 g, 20 mmol). The mixture was stirred for 5 min and buten-2-ol 89 (1.7 
mL, 1.44 g, 20 mmol) and anhydrous tert-butyl hydroperoxide (7.3 mL, 5.5 M in decane, 40 
mmol) were added. The mixture was kept at −20°C for 20 h. To this cold mixture was added 
Et2O (200 mL) and the mixture was stirred until a homogeneous solution was obtained. Sat. 







Celite® and the solvent was evaporated from the filtrate at 20C. Chromatography (Et2O / 
petroleum ether 1:1 → 4:1) gave 90 (872 mg, 50%) as a colourless oil: Rf = 0.5 (Et2O / 
petroleum ether 1:4); IR νmax  3412 (OH), 3020 (ring CH), 1255 (C-O). 1H NMR (CDCl3)  
1.20 (3 H, d, J = 5.2 Hz, Me), 2.76 (1 H, dt, J = 5.0, 2.6 Hz, 2-H), 2.89 (1 H, dq, J = 10.5, 2.3 
Hz, 3-H), 3.21 (1 H, br, OH), 3.45 (1 H, dd, J = 12.5, 4.7 Hz, 1-H), 3.72 (1 H, dd, J = 12.5, 
2.1 Hz, 1-H). 
 
5.28  2R,3S (3-Methyloxiran-2-yl)methyl 4-nitrobenzenesulfonate (91) 
4-Nitrobenzene-1-sulfonyl chloride (903 mg, 4.1 mmol) was 
added portionwise to a stirred solution of 90 (367 mg, 4.2 mmol) 
and Et3N (0.6 mL, 436 mg, 4.3 mmol) in toluene (10 mL) at 
0°C. Stirring was continued for 30 min at 20C and then the 
mixture was filtered through Celite®. The solvent was evaporated and the residue was purified 
by column chromatography (petroleum ether / Et2O 1:1) to give 91 (688 mg, 61%) as a 
mixture of diastereoisomers. This was dissolved in Et2O (60 mL) and after removal of about 
50% solvent, the white precipitate (the racemate) was filtered off and the solvent was 
evaporated from the mother liquor. Two crystallisation from Et2O afforded 91 (121.6 mg, 
11%) as a white solid: Rf = 0.6 (petroleum ether / Et2O 1:1); mp 65-66°C (lit.81 65-65.5°C); 
[α]18D  +26.9°  (c = 0.41%, CHCl3, 67.7% ee), (lit.81 [α]25D +39.68° (c = 0.8, CHCl3,  99.8% 
ee); 1H NMR (CDCl3)  1.31 (3 H, d, J = 5.2 Hz, Me), 2.88-2.95 (2 H, m, 2 × CH), 4.05 (1 H, 
dd, J = 11.4 , 6.2 Hz, SOCH), 4.40 (1 H, dd, J = 11.4, 3.2 Hz, SOCH), 8.11 (2 H, d, J = 8.7 
Hz, Ar 2,6-H2), 8.40 (2 H, d, J = 8.7 Hz, Ar 3,5-H2); 13C NMR [(CDCl3) (HSQC / HMBC)]  
16.84 (Me), 52.60 (CH), 55.23 (CH), 71.23 (CH2), 124.40 (Ar 3,5-C2), 129.22 (Ar 2,6-C2), 
141.66 (Ar 1-C), 150.82 (Ar 4-C); MS (ES+) m/z 296.0213 (M + Na) (C10H11NNaO6S 
requires 296.0205).  
 
5.29 (S)-Oxiran-2-ylmethyl 4-nitrobenzenesulfonate (93) 
Et3N (2.3 mL, 1.67 g, 16 mmol) was stirred with R-
oxiranylmethanol 92 (0.90 mL, 1.00 g, 14 mmol) in toluene at 0°C. 
This was followed by portionwise addition of 4-
nitrobenzenesulfonyl chloride (3.16 g, 14 mmol). The mixture was 
then stirred at 20C for 30 min. The suspension was filtered through Celite®. The solvent was 
evaporated and the residue was dissolved in CH2Cl2. This solution was washed with aq. 
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H2SO4 (2%), sat. aq. NaHCO3 and brine. Drying and evaporation gave a pale yellow solid. 
The solid was dissolved in dry toluene (20 mL) and the resulting suspension warmed to 
~55°C. Hexane was added dropwise till the solution turned cloudy. The resulting solution was 
cooled to 20C overnight and then cooled to 0C for 2 h with stirring. The suspension was 
filtered through sintered funnel and the precipitate was washed with hexane. Drying gave 93 
(1.69 g, 40%) as a white solid: Rf = 0.7 (Et2O); mp 82-83°C (lit.154 mp 84-86°C); [α]18D   + 
33.3°(c = 0.65%, CHCl3, > 99% ee), (lit.154 [a]25D + 26.5° (c = 2.45, CHCl3, 82 % ee]; IR νmax 
3107, 3074 (ring CH); 1H NMR (CDCl3)  2.60 (1 H, dd, J = 4.7, 2.5 Hz, 3-H), 2.83 (1 H, t, J 
= 4.4 Hz, 3-H), 3.20 (1 H, m, 2-H), 4.02 (1 H, dd, J =11.6,  6.4 Hz, SOCH), 4.46 (1 H, dd, J = 
11.6, 2.9 Hz, SOCH), 8.12 (2 H, m, Ph 2,6-H2), 8.40 (2 H, m, Ph 3,5-H2); 13C NMR [(CDCl3) 
(HSQC / HMBC)]  44.42 (3-C), 48.61 (2-C), 71.62 (SOCH2), 124.43 (Ph 3,5-C2), 129.24 




Compound 67 (21 mg, 43 µmol), K2CO3 (26 mg, 0.19 mmol) and R-
oxiran-2-ylmethyl 4-nitrobenzenesulfonate 93 (17 mg, 66 µmol) were 
stirred in acetone (20 mL) at 50C and stirred under N2 for 3 d. Sat. aq. 
NaHCO3  was added to the mixture, which was extracted with EtOAc. 
The organic phase was washed with brine and dried. Evaporation and 
chromatography (petroleum ether / EtOAc 19:1  9:1) gave 95 as two seperable 
diastereoisomers. Diastereoisomer 1, (7.8 mg, 34%) as a yellow oil: Rf = 0.4 (petroleum ether 
/ EtOAc 4:1). Diastereoisomer 2, (9.08 mg, 39%) as a pale yellow oil: Rf = 0.5 petroleum 
ether / EtOAc 4:1). With diastereoisomer 2, two rotamers about the F3COC—N were evident 
by NMR in the ratio 1.3:1 (A:B).  
 
MS (ES+) m/z 537.0504 (M +H) (C20H21F3IN2O4 requires 537.0498). 
 
Diastereoisomer 1  
1H NMR [(CDCl3) (NOESY)]  1.55 (9 H, s, But), 2.78 (1 H, dd, J = 4.7, 2.6 Hz, oxirane 3-H-
), 2.95 (1 H, t, J = 4.5 Hz, oxirane 3-H), 3.49 (1 H, m, oxirane 2-H), 4.30 (1 H, dd, J = 12.2, 
6.2 Hz, CHNCOCF3), 4.71 (1 H, dd, J = 12.2, 2.8 Hz, CHNCOCF3), 6.70 (1 H, s, NH), 7.47 
(1 H, t, J = 7.7 Hz, 6-H), 7.57 (1 H, m, 7-H), 7.63 (1 H, s, 3-H), 7.76 (1 H, d, J = 8.4 Hz, 5-
H), 8.19 (1 H, d, J = 8.5 Hz, 8-H); 13C NMR [(CDCl3) (HSQC / HMBC)]  28.29 (CMe3), 
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44.85 (oxirane 3-C), 48.89 (oxirane 2-C), 69.29 (CH2NCOCF3), 81.25 (CMe3), 85.75 (1-C), 
110.89 (3-C), 115.72 (q, J = 284.6 Hz, CF3), 120.33 (5-C), 123.42 (4a-C), 125.48 (6-C), 
128.25 (7-C), 132.53 (8-C), 134.43 (4-C), 134.95 (8a-C), 145.08 (2-C), 152.71 (C=O Boc); 





1H NMR [(CDCl3) (NOESY)]  1.56 (9 H, s, But), 2.56 (1 H, dd, J = 4.8, 2.5 Hz, oxirane 3-
H), 2.84 (1 H, m, oxirane 3-H), 3.17 (1 H, dd, J = 14.3, 7.1 Hz, CHNCOCF3), 3.44 (1 H, m, 
oxirane 2-H), 4.63 (1 H, dd, J = 14.3, 3.9 Hz,  CHNCOCF3), 6.99 (1 H, s, NH), 7.63-7.67 (2 
H, m, 6,7-H2), 7.85-7.87 (1 H, m, 5-H), 8.18 (1 H, s, 3-H), 8.31 (1 H, m, 8-H); 13C NMR 
[(CDCl3) (HSQC / HMBC)]  28.33 (CMe3), 45.67 (oxirane 3-C), 49.31 (oxirane 2-C), 54.66 
(CH2NCOCF3), 81.64 (CMe3), 99.03 (1-C), 115.88 (q, J = 288.4 Hz, CF3), 118.47 (3-C), 
120.59 (5-C), 125.80 (4a-C), 128.05 (6-C), 128.78 (7-C), 134.42 (8-C), 135.06 (8a-C), 135.09 
(4-C), 140.80 (2-C), 152.43 (Boc C=O), 157.09 (q, J = 36.5 Hz, F3CC=O); 19F NMR (CDCl3) 
δ -68.52 (s, CF3).  
 
Rotamer B 
1H NMR [(CDCl3) (NOESY)]  1.56 (9 H, s, But), 2.45 (1 H, dd, J = 4.6, 2.4 Hz, oxirane 3-
C), 2.84 (1 H, m, oxirane 3-H), 3.34 (1 H, m, oxirane 2-H), 3.38 (1 H, dd, J = 13.6, 5.8 Hz, 
CHNCOCF3), 4.55 (1 H, dd, J = 13.8, 4.6 Hz, CHNCOCF3), 6.99 (1 H, s, NH), 7.63-7.67 (2 
H, m, 6,7-H2), 7.86 (1 H, m, 5-H), 8.06 (1 H, s, 3-H), 8.31 (1 H, m, 8-H); 13C NMR [(CDCl3) 
(HSQC / HMBC)]  28.30 (CMe3), 46.70 (oxirane 3-C), 48.02 (oxirane 2-C), 53.29 
(CH2NCOCF3), 81.68 (CMe3), 99.45 (1-C), 115.88 (q, J = 288.4 Hz, CF3),), 118.47 (3-C), 
120.55 (5-C), 125.80 (4a-C), 128.13 (6-C), 128.86 (7-C), 134.55 (8-C), 135.09 (4-C), 135.11 
(8a-C), 140.32 (2-C), 152.43 (Boc C=O), 157.20 (q, J = 38.1 Hz, F3CC=O); 19F NMR 









MeLi in Et2O (1.6 M, 0.24 mL, 0.39 mmol) was added dropwise (~5 min) 
to a stirred suspension of CuCN (17.4 mg, 0.19 mmol) in dry THF (0.6 mL) 
at −78C under N2 and the mixture was stirred for 5 min. The mixture was 
brought to −40C and stirred for 30 min. After cooling again to −78C, 
compound 95 (65.6 mg, 0.12 mmol) in dry THF (0.6 mL) was added 
dropwise and stirring was continued at −78C. The mixture was allowed to warm gradually 
and was stirred at 25C for 3 d. Water was added to the mixture and EtOAc was used to 
extract product. The organic phase was washed with brine. Drying, evaporation and 
chromatography (petroleum ether / EtOAc 9:1) gave 97 (Conformer A:B 1:1.4) (39.4 mg, 
73%) as a yellow solid: Rf = 0.7 (EtOAc / petroleum ether 1:4); mp 127-128°C; IR νmax 3389, 
3336 (NH), 3082 (ring CH ), 1699 (C=O); MS (ES+) m/z 463.0522 (M + Na) (C18H21IN2 
NaO3 requires 463.0495).  
 
Conformer A 
1H NMR [(CDCl3) (NOESY)]  1.56 (9 H, s, But), 2.78 (1 H, d, J = 2.7 Hz, NHCH2CHOCH), 
2.86 (1 H, d, J = 4.0 Hz, NHCH2CHOCH), 3.27 (1 H, m, NHCH2CHOCH2), 3.51 (1 H, dd, J 
= 6.2, 4.6 Hz, NHCHCHOCH2), 3.75 (1 H, dd, J = 5.7, 3.5 Hz,  NHCHCHOCH2), 4.87 (1 H, 
t, J = 5.8 Hz, oxirane NH), 6.93 (1 H, s, Boc NH), 7.26 (1 H, ddd, J = 8.1, 6.8, 1.1 Hz, 6-H), 
7.45 (1 H, ddd, J = 8.1, 6.8, 1.2 Hz, 7-H), 7.62 (1 H, d, J = 8.2 Hz, 5-H), 7.74 (1 H, s, 3-H), 
7.99 (1 H, dd, J = 8.6, 0.6 Hz, 8-H); 13C NMR [(CDCl3) (HSQC / HMBC)]  28.32 (CMe3), 
45.38 (NHCH2CHOCH2), 45.44 (NHCH2CHOCH2), 50.82 (NHCH2CHOCH2), 78.88 (1-C), 
80.91 (CMe3), 105.08 (3-C), 120.13 (5-C), 120.74 (4a-C), 122.63 (6-C), 128.10 (7-C), 131.02 
(8-C), 135.03 (4-C), 135.59 (8a-C), 145.84 (2-C), 152.84 (C=O).  
 
Conformer B 
1H NMR [(CDCl3) (NOESY)]  1.56 (9 H, s, But), 2.77 (1 H, d, J = 2.6 Hz, NHCH2CHOCH), 
2.84 (1 H, d, J = 4.0 Hz, NHCH2CHOCH), 3.25-3.29 (1 H, m, NHCH2CHOCH2), 3.55 (1 H, 
dd, J = 6.2, 4.6 Hz, NHCHCHOCH2), 3.71 (1 H, dd, J = 5.7, 3.5 Hz,  NHCHCHOCH2), 4.87 
(1 H, t, J = 5.8 Hz, oxirane NH), 6.93 (1 H, s, Boc NH), 7.26 (1 H, ddd, J = 8.1, 6.8, 1.1 Hz, 
6-H), 7.45 (1 H, ddd, J = 8.1, 6.8, 1.2 Hz, 7-H), 7.62 (1 H, d, J = 8.2 Hz, 5-H), 7.74 (1 H, s, 3-
H), 7.99 (1 H, dd, J = 8.6, 0.6 Hz, 8-H); 13C NMR [(CDCl3) (HSQC / HMBC)]  28.32 
(CMe3), 45.38 (NHCH2CHOCH2), 45.44 (NHCH2CHOCH2), 50.82 (NHCH2CHOCH2), 78.88 
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(1-C), 80.91 (CMe3), 105.08 (3-C), 120.13 (5-C), 120.74 (4a-C), 122.63 (6-C), 128.10 (7-C), 
131.02 (8-C), 135.03 (4-C), 135.59 (8a-C), 145.84 (2-C), 152.84 (C=O).  
 
5.32 Preliminary study using But4ZnLi2 as a reagent for cyclisation of terminal 
epoxides 
 
5.32.1 4-(Prop-2-enyl)phenol (99) 
ZnCl2 in THF (0.7 M, 4.10 mL, 2.9 mmol) was added to dry THF (5 mL) under N2. 
ButLi in pentane (1.7 M, 6.70 mL, 11 mmol) was added dropwise to the solution at  
−78C; the solution was brought to 0C and stirred for 30 min. 4-Iodophenol 98 (285 
mg, 1.3 mmol) in dry THF (5 mL) was added dropwise to the solution at −78C. The 
mixture was warmed to 20C and stirred for 2 h. 3-Bromopropene (780 mg, 6.45 
mmol) was added and the mixture was stirred at 40C for 3 d. After cooling to 20C, the 
reaction was quenched with sat. aq. NH4Cl and the mixture was diluted with aq. HCl (2 M). 
The mixture was extracted with Et2O. The organic layer was washed with brine and dried. 
Evaporation gave crude 99 as a brown oil (200 mg). NMR showed a mixture of product 
(66%) and starting material (33%): 1H NMR (CDCl3)  3.32 (2 H, d, J = 6.6 Hz, Pr 1-H2), 
5.05 (2 H, m,  Pr 3-H2), 5.93 (1 H, ddt, J = 16.6, 11.9, 6.7 Hz, Pr 2-H), 6.77 (2 H, d, J = 9.4 
Hz, Ph 2,6-H2), 7.05 (2 H, d, J = 9.4 Hz, Ph 3,5-H2); 13C NMR [(CDCl3) (HSQC / HMBC)]  
38.30 (Pr 1-C), 114.27 (Ph 2,6-C2), 114.41 (Pr 3-C), 128.67 (Ph 3,5-C2), 131.17 (4-C), 136.84 




Compound 67 (99.4 mg, 0.21 mmol), K2CO3 (119 mg, 0.83 mmol) 
and 3-bromopropene (0.06 mL, 84 mg, 0.69 mmol) in acetone (15 
mL) were stirred at 50°C under N2 for 16 h. Sat. aq. NaHCO3 was 
added and mixture was extracted with EtOAc. Washing with brine, 
drying and evaporation gave 103 (diastereoisomers A / B 1.4:1) (115 
mg, 99%) as a yellow oil: Rf = 0.7 (petroleum ether / EtOAc 4:1); IR 





Diasteroisomer A  
1H NMR [(CDCl3) (COSY)]  1.23 (9 H, br, But), 3.71 (1 H, dd, J = 14.4, 8.3 Hz, 
CF3CONCH), 3.83 (1 H, dd, J = 14.9, 7.4 Hz, BocNCH), 4.64 (1 H, m, BocNCH), 4.98-5.21 
(5 H, m, 2 × propenyl 3-H, CF3CONCH), 5.85-5.94 (2 H, m, 2 × propenyl 2-H), 7.11 (1 H, s, 
3-H), 7.61-7.68 (2 H, m, 6,7-H2), 7.80-7.85 (1 H, m, 5-H), 8.29-8.32 (1 H, m, 8-H); 13C NMR 
[(CDCl3) (HSQC / HMBC)]  27.88 (CMe3), 52.45 (BocNCH2), 53.69 (CF3CONCH2), 80.78 
(CMe3), 105.48 (1-C), 115.94 (q, J = 289.4 Hz, CF3), 118.46 (BocNCH2CHCH2), 120.92 
(CF3CONCH2CHCH2), 123.57 (5-C), 128.11 (3-C), 128.52 (6-C or 7-C), 128.91 (7-C or 6-C), 
130.31 (CF3CONCH2CHCH2), 130.99 (4a-C), 133.37 (BocNCH2CHCH2), 133.87 (8-C), 
135.71 (8a-C), 139.39 (2-C), 139.86 (4-C), 154.53 (Boc C=O), 156.50 (q, J = 35.0 Hz, 
CF3C=O); 19F NMR (CDCl3) δ -68.65 (s, CF3).  
 
Diastereoisomer B 
1H NMR [(CDCl3) (COSY)]  1.23 (9 H, br, But), 3.76 (1 H, dd, J = 14.4, 8.0 Hz, 
CF3CONCH), 3.95 (1 H, dd, J = 14.7, 7.1 Hz, BocNCH), 4.4.53 (1 H, m, BocNCH), 4.98-
5.21 (5 H, m, 2 × propenyl 3-H, CF3CONCH), 5.85-5.94 (2 H, m, 2 × propenyl 2-H), 7.11 (1 
H, s, 3-H), 7.61-7.68 (2 H, m, 6,7-H2), 7.80-7.85 (1 H, m, 5-H), 8.29-8.32 (1 H, m, 8-H); 13C 
NMR [(CDCl3) (HSQC / HMBC)]  28.11 (CMe3), 52.45 (BocNCH2), 53.69 (CF3CONCH2), 
80.78 (CMe3), 105.48 (1-C), 115.94 (q, J = 289.4 Hz, CF3), 118.46 (BocNCH2CHCH2), 
120.92 (CF3CONCH2CHCH2), 123.42 (5-C), 127.79 (3-C), 128.52 (6-C or 7-C), 128.91 (7-C 
or 6-C), 130.31 (CF3CONCH2CHCH2), 130.99 (4a-C), 133.37 (BocNCH2CHCH2), 133.87 (8-
C), 135.71 (8a-C), 139.39 (2-C), 139.86 (4-C), 154.39 (Boc C=O), 156.42 (q, J = 36.0 Hz, 
CF3C=O); 19F NMR (CDCl3) δ -68.58 (s, CF3).  
 
5.34 tert-Butyl N-(1-iodo-2-(N-(prop-2-enyl) 2,2,2-trifluoroacetamido)naph-
thalen-4-yl)carbamate (104) 
Compound 67 (1.22 mg, 2.5 mmol) was stirred in THF (10 mL) and 
potassium tert-butoxide (318 mg, 2.8 mmol) added. This was stirred at 
20C under N2 for 30 min followed by addition of 3-bromopropene 
(0.700 mL, 973 mg, 8.04 mmol). The mixture was stirred for 2 h and 
heated to 50C overnight. Sat. aq. NaHCO3 was added. Extraction 
with EtOAc, drying, evaporation and chromatography (petroleum ether → petroleum ether / 
EtOAc 19:1) gave 104 as diastereoisomer A (yellow oil, 750 mg, 57%): Rf = 0.4 (petroleum 
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ether / EtOAc 4:1), and diastereoisomer B (yellow solid, 200 mg, 15%): Rf = 0.5 (petroleum 
ether / EtOAc 4:1); mp 146-147°C.                                                                                                                       
 
Diastereoisomer A 
1H NMR [(CDCl3) (NOESY)]  1.55 (9 H, s, But), 3.82 (1 H, dd, J = 14.5, 7.6 Hz, propenyl 
1-H), 4.96 (1 H, dd, J = 14.5, 5.6 Hz, propenyl 1-H), 5.18 (1 H, dq, J = 18.0, 1.3 Hz, propenyl 
3-H TRANS) 5.22 (1 H, dq, J = 11.0, 1.0 Hz, propenyl 3-H CIS), 5.92-5.98 (1 H, m, propenyl 2-
H), 7.01 (1 H, s, NH), 7.7.61-7.67 (2 H, m, 6,7-H), 7.83-7.87 (1 H, m, 5-H), 7.93 (1 H, s, 3-
H), 8.28-8.32 (1 H, m, 8-H); 13C NMR [(CDCl3) (HSQC / HMBC)]  28.27 (CMe3), 54.00 
(propenyl 1-C), 81.56 (CMe3), 115.89 (q, J = 288.7 Hz, CF3), 118.90 (3-C), 120.59 (propenyl 
3-C), 120.66 (5-C), 127.92 (6-C or 7-C), 128.67 (7-C or 6-C), 130.30 (propenyl 3-C), 134.38 
(8-C), 134.70 (8a-C), 135.39 (4-C), 140.14 (2-C), 152.45 (Boc C=O), 156.53 (q, J = 36.5 Hz, 
F3CC=O); 19F NMR (CDCl3) δ -68.55 (s, CF3); MS (ES+) m/z 559.0154 (M + K) 
(C20H20F3IN2KO3 requires 559.0107); 543.0437 (M + Na) (C20H20F3IN2NaO3 requires 
543.0368); 521.0516 (M + H) (C20H21F3IN2O3 requires 521.0549); 486.9814 [(M-But) + Na)] 
(C16H12F3IN2NaO3 requires 486.9742).  
 
Diastereoisomer B  
1H NMR [(CDCl3) (NOESY)]  1.56 (9 H, s, But), 3.95 (1 H, dd, J = 14.2, 7.4 Hz, propenyl 
1-H), 4.84 (1 H, dd, J = 14.2, 6.1 Hz, propenyl 1-H), 5.12 (1  H, dd, J = 17.0, 1.3 Hz, 
propenyl 3-H TRANS), 5.21 (1 H, dd, J = 10.1, 1.1 Hz, propenyl 3-H CIS), 5.91-5.97 (1 H, m, 
propenyl 2-H), 7.27 (1 H, s, NH), 7.51 (1 H, dd, J = 8.2, 6.9, 1.2 Hz, 6-H), 7.60 (1 H, dd, J = 
8.3, 6.9, 1.3 Hz, 7-H), 7.67 (1 H, d, J = 8.3 Hz, 5-H), 8.17 (1 H, d, J = 8.1 Hz, 8-H), 8.27 (1 
H, s, 3-H); 13C NMR [(CDCl3) (HSQC / HMBC)]   27.30 (CMe3), 53.30 (propenyl 1-C), 
80.76 (CMe3), 91.92 (1-C), 115.16 (q, J = 288.6 Hz, CF3), 119.84 (3-C), 120.03 (propenyl 3-
C), 121.93 (5-C), 125.63 (6-C), 126.43 (4a-C), 127.97 (7-C), 129.49 (propenyl 2-C), 131.56 
(8-C), 134.31 (4-C), 135.26 (8a-C), 136.78 (2-C), 151.32 (Boc C=O), 156.35 (q, J = 36.3 Hz, 
CF3C=O); 19F NMR (CDCl3) δ -68.20 (CF3); MS (ES+) m/z 559.0149 (M + K) 
(C20H20F3IN2KO3 requires 559.0107); 543.0371 (M + Na) (C20H20F3IN2NaO3 requires 









Compound 104 (38.1 mg, 73 µmol) in benzene (2.0 mL) was treated 
sequentially with TEMPO (35.7 mg, 0.23 mmol) and Bu3SnH (0.020 
mL, 21 mg, 73 µmol). The mixture was heated to 60C and stirred at 
this temperature for 135 min. Additional Bu3SnH (0.020 mL, 21 mg, 
73 µmol) was added at 30 min, 60 min and 90 min. Evaporation and 
chromatography (petroleum ether / EtOAc 49:1  19:1) gave 105 
(24.1 mg, 60%) as a yellow solid: Rf = 0.6 (petroleum ether / EtOAc 
19:1); mp 160-161°C; IR νmax 3364, 3129, 3266 (NH), 1700 (C=O); 1H NMR [(CDCl3) 
(NOESY)]  0.90 (3 H, s, piperidine Me), 1.00 (3 H, s, piperidine Me), 1.07 (3 H, s, 
piperidine Me), 1.20 (3 H, s, piperidine Me), 1.25, (1 H, m, piperidine 4-H), 1.29 (1 H, m, 
piperidine 3-H or 5-H), 1.35 (1 H, m, piperidine 3-H or 5-H), 1.42 (1 H, m, piperidine 3-H or 
5-H), 1.54 (1 H, m, piperidine 4-H), 1.54 (9 H, s, But), 1.66 (1 H, m, piperidine 3-H or 5-H), 
3.83 (1 H, t, J = 8.8 Hz, NOCH), 3.99 (1 H, m, 1-H), 4.08 (1 H, dd, J = 8.9, 4.3 Hz, NOCH), 
4.30 (1 H, t, J = 8.7 Hz, 2-H), 4.61 (1 H, d, J = 10.9 Hz, 2-H), 6.10 (1 H, s, NH), 7.47 (1 H, t, 
J = 7.8 Hz, 7-H), 7.53 (1 H, t, J = 7.6 Hz, 8-H), 7.81 (1 H, d, J = 8.3 Hz, 9-H), 7.90 (1 H, d, J 
= 8.4 Hz, 6-H), 8.79 (1 H, s, 4-H); 13C NMR [(CDCl3) (HSQC / HMBC)]  16.97 (piperidine 
4-C), 19.97 (piperidine Me), 20.05 (piperidine Me), 28.30 (CMe3), 32.92 (piperidine Me), 
32.96 (piperidine Me), 39.52 (piperidine 3-C or 5-C), 39.60  (piperidine 5-C or 3-C), 39.86 
(1-C), , 52.42 (2-C), 59.88 (piperidine 2,6-C2), ~77.26 (NOCH2), 81.05 (CMe3), 111.17 (4-C), 
116.20 (q, J = 288.1 Hz, CF3), 122.15 (6-C), 123.13 (9b-C), 124.01 (9-C), 125.36 (7-C), 
125.52 (5a-C), 127.06 (8-C), 129.77 (9a-C), 134.19 (5-C), 139.56 (3a-C), 153.34 (Boc C=O), 
154.28 (q, J = 37.5 Hz, CF3C=O); 19F NMR (CDCl3) δ -72.21 (s, CF3); MS (ES+) m/z 
572.2804 (M + Na) (C29H38F3N3NaO4 requires 572.2712), 550.2937 (M + H) (C29H39F3N3O4 
















Compound 105 (70.4 mg, 0.13 mmol) was dissolved in THF (4 mL) and aq. 
NaOH (5 M, 4 mL) added. The mixture was stirred at 20C for 105 min. 
Water was added to the mixture and extracted with EtOAc. Washing with 
brine, drying and evaporation gave 106 (60.7 mg, 100%) as a yellow oil: Rf 
=  0.35 (petroleum ether / EtOAc 9:1); IR νmax 3376 (NH), 1715 (C=O); 1H 
NMR [(CDCl3) (NOESY)]  1.06 (3 H, s, piperidine Me), 1.14 (6 H, s, 
piperidine Me), 1.16 (3 H, s, piperidine Me), 1.16-1.42 (6 H, m, piperidine 
3,4,5-H6), 1.54 (9 H, s, But), 3.70-3.75 (2 H, m, 2-H2), 3.80-3.90 (2 H, m, 1-H, NOCH), 4.00 
(1 H, dd, J = 7.6, 4.2 Hz, NOCH), 6.86 (1 H, s, Boc NH), 7.20 (1 H, t, J = 7.5 Hz, 7-H or 8-
H), 7.38 (1 H, t, J = 7.1 Hz, 8-H or 7-H), 7.51 (1 H, s, 4-H), 7.69 (2 H, d, J = 8.6 Hz, 6,9-H2); 
13C NMR [(CDCl3) (HSQC / HMBC)]  17.07 (piperidine 4-C), 20.07 (piperidine Me), 20.26 
(piperidine Me), 28.33 (CMe3), 32.93 (piperidine Me), 33.34 (piperidine Me), 39.45 
(piperidine 3-C or 5-C), 39.59 (piperidine 5-C or 3-C), 41.05 (1-C), 51.29 (2-C), 59.63 
(piperidine 2-C or 6-C), 59.72 (piperidine 6-C or 2-C), 76.68-77.32 (NOCH2), 80.54 (CMe3), 
105.52 (4-C), 116.77 (5a,9b-C2), 120.98 (6-C or 9-C), 121.52 (7-C or 8-C), 123.23 (9-C or 6-
C), 126.29 (8-C or 7-C), 131.41 (9a-C), 133.52 (5-C), 149.40 (3a-C), 153.34 (C=O); MS 
(ES+) m/z 476.2924 (M + Na) (C27H39N3NaO3 requires 476.2810), 454.3107 (M + H) 
(C27H40N3O3 requires 454.3070).  
 
5.37 N,N-Dimethyl-2-(4-nitrophenoxy)ethylamine (108) 
KOH (5.17 g, 92 mmol) in dry EtOH (40 mL) was added to 4-
nitrophenol 107 (14.2 g, 0.10 mol) in dry EtOH (30 mL). 
Filtration, washing (cold dry EtOH) and drying gave potassium 
4-nitrophenoxide (16.1 g, 89%) as an orange solid. NaOH (4.28 g, 73 mmol) in water (25 mL) 
was added to 2-chloro-N,N-dimethylethylammonium chloride (12.6 g, 88 mol) in water (50 
mL). The mixture was saturated with NaCl and extracted with toluene (5  50 mL). The 
combined toluene fractions were dried over KOH and added to a suspension of potassium 4-
nitrophenoxide (14.0 g, 83 mmol) in toluene (80 mL). The mixture was heated under reflux 
for 17 h. Cooling, filtration and evaporation gave 108 (10.4 g, 63%) as a yellow oil: Rf = 0.2 
(EtOAc / petroleum ether 1:1); IR νmax 1517.34 (NO2); 1H NMR (CDCl3) δ  2.26 (6 H, s, 
NMe2), 2.69 (2 H, t, J = 5.6 Hz, NCH2), 4.08 (2 H, t, J = 5.6 Hz, OCH2), 6.88 (2 H, d, J = 9.3 
Hz, Ph 2,6-H2), 8.08 (2 H, d, J = 9.3 Hz, Ph 3,5-H2); 13C NMR (CDCl3) δ 45.76 (NMe2), 
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57.87 (NCH2), 66.65 (OCH2), 114.78 (Ph-C2), 125.75 (Ph-C2), 141.48 (Ph-Cq), 163.88 (Ph-
Cq). A sample was converted to the HCl salt and recrystallised (PriOH): mp 165-166°C (lit.194 
mp PriOH 166-167°C); 1H NMR [(CD3)2SO] δ 2.81 (6 H, s, NMe2), 3.53 (2 H, t, J = 5.1 Hz, 
NCH2), 4.51 (2 H, t, J = 5.1, OCH2), 7.20 (2 H, d, J = 9.2 Hz, Ph 2,6-H2), 8.20 (2 H, d, J = 9.2 
Hz, Ph 3,5-H2); 13C NMR [(CD3)2SO) (HSQC / HMBC)] δ 42.68 (NMe2), 54.91 (NCH2), 
63.17 (OCH2), 115.34 (Ph 2,6-C2), 125.81 (Ph 3,5-C2), 141.36 (Ph 1-C), 162.72 (Ph 4-C).  
 
5.38 2-(4-Aminophenoxy)-N,N-dimethylethylamine (109) 
Compound 108 (160 mg, 0.76 mmol) was added dropwise to 
conc. aq. HCl (2.0 mL, 66 mmol) and SnCl2.2H2O (626 mg, 2.8 
mmol). The mixture was stirred at 0C for 30 min and then at 
room temperature for 19 h. The mixture was made basic by addition of conc. aq. NaOH, then 
extracted four times with CH2Cl2. The combined organic phase was washed with water and 
dried and the solvent was evaporated to give 109 (120 mg, 88%) as a buff oil: Rf = 0.6 
(MeOH / CH2Cl2 1:9); IR υmax 3397 (NH), 3302 (NH), 3204 (NH); 1H NMR (CDCl3) δ 2.29 
(6 H, s, NMe2), 2.65 (2 H, t, J = 5.8 Hz, NCH2), 3.96 (2 H, t, J = 5.8 Hz, OCH2), 6.58 (2 H, d, 
J = 8.8 Hz, Ph 3,5-H2), 6.72 (2 H, d, J = 8.8 Hz, Ph 2,6-H); 13C NMR (CDCl3) δ 45.83 (2 C, 2 
 Me), 58.43 (NCH2), 66.74 (OCH2), 115.82 (Ph 2,6-C), 116.36 (Ph 3,5-C), 140.22 ( Ph 4-
C), 151.78 (Ph 1-C).  
 
5.39 Ethyl 5-(2-dimethylaminoethoxy)-1H-indole-2-carboxylate (110) 
Compound 109 (1.07 g, 5.9 mmol) in water (10 mL) and 
conc. aq. HCl (3.0 mL) was diazotised at −20°C with 
NaNO2 (476 mg, 6.9 mmol) in water (2.0 mL). The cold 
solution was added in one portion to a vigorously stirred ice-cold mixture of ethyl 2-methyl-3-
oxobutanoate (895 mg, 6.2 mmol), NaOAc (5.18 g, 63 mmol), EtOH (8.0 mL) and ice (7.0 g). 
The mixture was stirred at 20C for 16 h and then cooled to 0°C, basified by slow addition of 
Na2CO3 and extracted with CH2Cl2. The organic layers were combined and washed with 
water and dried. The evaporation residue was extracted with hot hexanes in the presence of 
decolourising charcoal and the solvent was evaporated from the clarified solution. The 
residue, in EtOH (4.0 mL), was treated with sat. ethanolic HCl (3.0 mL) and heated under 
reflux for 30 min. The evaporation residue was partitioned between dilute aq. Na2CO3 and 
CH2Cl2. The organic layer was washed with water and sat. brine and dried. Evaporation and 
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recrystallisation gave 110 (25 mg, 15%): Rf = 0.3 (EtOAc / MeOH 1:1); mp 108-109 (lit.80 
mp 110°C); IR νmax 3315 (NH), 1687 (C=O); 1H NMR (CDCl3)  1.39 (3 H, t, J = 7.1 Hz, 
OCH2Me), 2.35 (6 H, s, NMe2), 2.76 (2 H, t, J = 5.8 Hz, (Me)2NCH2CH2), 4.10 (2 H, t, J = 
5.8 Hz, (Me)2NCH2CH2), 4.39 (2 H, q, J = 7.1 Hz, OCH2Me), 6.99 (1 H, dd, J = 8.9, 2.4 Hz, 
6-H), 7.07 (1 H, d, J = 2.4 Hz, 4-H), 7.12 (1 H, dd, J = 2.1, 0.8 Hz, 3-H), 7.28 (1 H, d, J = 8.9 
Hz, 7-H), 9.30 (1 H, s, NH); 13C NMR [(CDCl3) (HSQC / HMBC)]  14.32 (OCH2Me), 45.83 
(NMe2)), 58.38 (Me)2NCH2CH2), 60.82 (OCH2Me), 66.57 (Me)2NCH2CH2), 103.67 (4-C), 
108.13 (3-C), 112.69 (7-C), 117.37 (6-C), 127.74 (2-C), 127.89 (3a-C), 132.42 (7a-C), 153.83 
(5-C), 162.01 (C=O). 
 
5.40 Preliminary test of the use of ethanolic HCl for esterification  
 
5.40.1 Ethyl 2-(1H-indol-3-yl)acetate (123). 
Indole-3-acetic acid 122 (122 mg, 0.70 mmol), was stirred in conc. 
ethanolic HCl (20 mL) and heated under reflux for 1 h. The solvent was 
evaporated and the mixture was dissolved in EtOAc. This solution was 
washed with sat. aq. NaHCO3 and brine. Drying and evaporation yielded 
123 (116 mg, 82%) as a pale buff oil: 1H NMR (CDCl3)  1.28 (3 H, t, J = 7.0 Hz, Me), 3.78 
(2 H, s, indole CH2), 4.19 (2 H, q, J = 7.1 Hz, OCH2), 7.08 (1 H, s, indole 2-H), 7.15 (1 H, t, J 
= 7.5 Hz, indole 6-H), 7.21 (1 H, t, J = 7.5 Hz, indole 5-H), 7.31 (1 H, d, J = 8.0 Hz, indole 7-
H), 7.60 (1 H, d, J = 7.8 Hz, indole 4-H), 8.14 (1 H, br, NH); 13C NMR [(CDCl3) (HSQC / 
HMBC)]  14.19 (Me), 31.39 (indole CH2), 60.77 (OCH2), 108.38 (indole 3-H), 111.19 
(indole 7-H), 118.81 (indole 4-H), 119.54 (indole 5-H), 122.06 (indole 6-H), 123.11 (indole 
2-H), 127.21 (indole 3a-C), 136.12 (indole 7a-C), 172.21 (C=O). 
 
5.41 Ethyl 5-hydroxy-1H-indole-2-carboxylate (125) 
 
METHOD A 
SOCl2 (1 mL, 1.64 g, 14 mmol) was added dropwise to 5-hydroxy-
1H-indole-2-carboxylic acid 124 (116mg, 0.66 mmol) in absolute 
ethanol (10 mL). This mixture was boiled under reflux at 80C for 1 
h. The mixture was allowed to cool to room temperature. The solvent was evaporated and the 
crude mixture, in EtOAc, was washed with aq.  NaHCO3 (5%) and with brine. Drying and 








5-Hydroxy-1H-indole-2-carboxylic acid 124 (1.53 g, 8.6 mmol) was heated under reflux in 
conc. ethanolic HCl (100 mL) under N2 for 4 h. The solvent was evaporated and the residue 
dissolved in EtOAc. This was washed with water and brine. Drying, evaporation and 
chromatography (CH2Cl2 → CH2Cl2 / EtOAc 4:1) gave 125 (1.64, 92%) as a white solid:  
 
Rf = 0.8 (EtOAc); mp 152-154°C (lit.195 146-148°C); IR νmax 3316, 3209 (OH, NH), 1696 
(C=O); 1H NMR [(CD3)2SO]  1.38 (3 H, t, J = 7.1 Hz, Me), 4.37 (2 H, q, J = 7.1 Hz, CH2), 
6.86 (1 H, dd, J = 8.8, 2.4 Hz, 6-H), 6.97 (1 H, d, J = 2.3 Hz, 4-H), 7.00 (1 H, dd, J = 2.1, 0.8 
Hz, 3-H), 7.32 (1 H, d, J = 8.8Hz, 7-H), 8.93 (1 H, s, OH), 11.60 (1 H, s, NH). 13C NMR 
[(CD3)2SO]  14.29 (Me), 60.17 (CH2), 104.43 (4-C), 106.66 (3-C), 113.07 (7-C), 116.15 (6-
C), 127.36 (2-C or 3a-C), 127.44 (3a-C or 2-C), 132.21 (7a-C), 151.34 (5-C), 161.30 (C=O). 
 
5.42 Ethyl 5-ethoxy-1H-indole-2-carboxylate (126) 
5-Hydroxy-1H-indole-2-carboxylic acid 124 (2.00 g, 11 mmol) was 
boiled under reflux in conc. ethanolic HCl (25 mL) under N2 for 16 
h. The solvent was evaporated and the residue in EtOAc was washed 
with water and brine. Drying, evaporation and chromatography (CH2Cl2 → CH2Cl2 / EtOAc 
4:1) gave 126 ( 236 mg, 10%) as a white solid: Rf = 0.7 (petroleum ether / EtOAc 1:1) ; mp 
147-148°C; 1H NMR (CDCl3)  1.41 (3 H, t, J = 7.2 Hz, ester Me), 1.43 (3 H, t, J = 7.0 Hz, 
ether Me), 4.06 (2 H, q, J = 7.0 Hz, ether CH2), 4.40 (2 H, q, J = 7.1 Hz, ester CH2), 6.99 (1 
H, dd, J = 8.9, 2.4 Hz, 6-H), 7.07 (1 H, d, J = 2.4 Hz, 4-H), 7.13 (1 H, dd, J = 2.1, 0.9 Hz, 3-
H), 7.30 (1 H, d, J = 9.0 Hz, 7-H), 8.89 (1 H, s, NH); 13C NMR [(CDCl3) (HSQC / HMBC)]  
14.33 (ester Me), 14.87 (ether Me), 60.31 (ester CH2), 63.93 (ether CH2), 103.65 (4-C), 
108.13 (3-C), 112.60 (7-C), 117.34 (6-C), 127.81 (2-C), 127.85 (3a-C), 132.16 (7a-C), 153.92 
(5-C), 161.89 (C=O); MS (ES+) mz 256.0957 (M + Na) (C13H15NNaO3 requires 256.0950), 
234.1125 (M + H) (C13H16NO3 requires 234.1130). 
 
5.43 Ethyl 5-(2-dimethylaminoethoxy)-1H-indole-2-carboxylate (110) 
To a solution of ethyl-5-hydroxy-1H-indole-2-carboxylate 
125 (1.68 g, 8.2 mmol) in CHCl3 (40 mL) was added 2-
chloro-N,N-dimethylamine hydrochloride (1.77 g, 12.0 
mmol), K2CO3 (3.40 g, 25 mmol) and water (8 mL) in sequence. The stirred solution was 
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placed in an oil bath at 65°C and the temperature was slowly raised to 80.5°C (~1°C per 
5min) over 65 min and the mixture was stirred for 16 h. The reaction mixture was cooled to 
room temperature and the phases were separated. The volume of the organic phase was 
reduced to 25% of its original volume by evaporation. The residue was combined with the 
aqueous phase and diluted with water and toluene. The organic layer was separated and 
washed with water and extracted with aq. HCl (1.0 M). The acidic phase was washed with 
toluene, cooled to 0°C, basified (~pH 12) by addition of aq. NaOH (4.0 M) and extracted with 
toluene. The organic extract was washed with water and brine and dried and the solvent was 
evaporated to give 110 as a white solid (1.81 g, 80%) with properties as above (Section 5.39).  
 
5.44 5-(2-(Dimethylamino)ethoxy)-1H-indole-2-carboxylic acid (127) 
A mixture of 110 (609 mg, 2.2 mmol) and Cs2CO3 (2.50 g, 
7.7 mmol) in MeOH (12 mL) and water (6 mL) was heated 
at reflux for 2 h. The mixture was evaporated to dryness. 
The residue was dissolved in water, and adjusted to pH 6.5 with aq. HCl (1.0 M). The mixture 
was placed in a refrigerator overnight and then in ice for 2 h. The resulting crystalline solid 
was collected, washed with ice-cold water and acetone to give 127 (419 mg, 77%) as a white 
crystalline solid: Rf = 0.1 (EtOAc / MeOH 1:1); A portion of the product was treated with 
HCl in 1,4-dioxane (4.0 M) and EtOAc. Filtration gave the HCl salt of the product as a white 
solid: mp 238-239C (lit.166 mp 237-239C); IR νmax 3380, 3240 (OH, NH), 1593 (C=O); 1H 
NMR [(CD3)2SO]  2.37 (6 H, s, NMe2), 2.81 (2 H, t, J = 5.7 Hz, (Me)2NCH2CH2), 4.12 (2 H, 
t, J = 5.8 Hz, (Me)2NCH2CH2), 6.91 (1 H, dd, J = 8.9, 2.4 Hz, 6-H), 6.95 (1 H, d, J = 1.5 Hz, 
3-H), 7.14 (1 H, d, J = 2.3 Hz, 4-H), 7.35 (1 H, d, J = 8.9 Hz, 7-H), 11.50 (1 H, s, NH); 13C 
NMR [(CD3)2SO) (HSQC / HMBC)]  45.04 (NMe2), 57.39 (Me)2NCH2CH2), 65.66 
(Me)2NCH2CH2), 103.18 (4-C), 106.06 (3-C), 113.21 (7-C), 115.50 (6-C), 127.27 (3a-C), 

















Compound 127 (101 mg, 0.41 mmol) and HOBt (125 mg, 0.81 
mmol) were stirred in dry DMF (10 mL) at 0C under N2. N,N-
diisopropylcarbodiimide (0.13 mL, 106 mg, 0.81 mmol) was 
added via a syringe and the mixture was stirred for 1 h at 0C. 
Compound 106 (203 mg, 0.37 mmol) in dry DMF (10 mL) was 
added. The reaction mixture was allowed to warm slowly to 20C 
overnight and heated at 40C for 2 h. Sat. aq. NaHCO3 was added 
and the mixture was extracted with EtOAc. The extract was 
washed with water and brine. Drying, evaporation and chromatography (EtOAc → EtOAc / 
MeOH / Et3N 90:10:0.1) gave 128 (163 mg, 64%) as a yellow oil: IR νmax 3447 (NH), 1727, 
1693 (C=O); 1H NMR [(CDCl3) (NOESY)]  0.88 (3 H, s, piperidine Me), 1.00 (3 H, s, 
piperidine Me), 1.04 (3 H, s, piperidine Me), 1.17 (3 H, s, piperidine Me), 1.24-1.50 (6 H, m, 
piperidine 3,4,5-H6), 1.54 (9 H, s, But), 2.45 (6 H, s, NMe2), 2.88 (2 H, t, J = 5.5 Hz, 
OCH2CH2N(CH3)2), 3.87 (1 H, t, J = 8.8 Hz, NOCH), 4.03-4.07 (1 H, m, 1-H), 4.13 (1 H, dd, 
J = 9.0, 4.8 Hz, NOCH), 4.17 (2 H, t, J = 5.6 Hz, OCH2CH2N(CH3)2), 4.60 (1 H, t, J = 9.1 
Hz, 2-H), 4.81 (1 H, dd, J = 10.2, 1.2 Hz, 2-H), 6.90 (1 H, s, Boc NH), 7.00 (1 H, s, indole 7-
H), 7.02 (1 H, dd, J = 8.9, 2.4 Hz, indole 6-H), 7.13 (1 H, d, J = 2.1 Hz, indole 3-H), 7.36 (1 
H, d, J = 8.9 Hz, indole 7-H), 7.42 (1 H, t, J = 7.5 Hz, 7-H), 7.50 (1 H, t, J = 7.2 Hz, 8-H), 
7.84 (1 H, d, J = 8.2 Hz, 9-H), 7.89 (1 H, d, J = 8.5 Hz, 6-H), 8.90 (1 H, s, 4-H), 9.52 (1 H, s, 
indole NH); 13C NMR [(CDCl3) (HSQC / HMBC)]  16.94 piperidine 4-C), 20.01 (piperidine 
Me), 20.16 (piperidine Me), 28.30 (CMe3), 33.02 (piperidine Me), 33.07 piperidine Me), 
39.48 (piperidine 3-C or 5-C), 39.53 (piperidine 5-C or 3-C), 40.20 (1-C), 45.51 (NCH3)2), 
54.66 (2-C), 58.06 (OCH2CH2N(CH3)2), 59.77 (piperidine 2-C or 6-C), 59.82 (piperidine 6-C 
or 2-C), 66.14 (OCH2CH2N(CH3)2), 77.64 (NOCH2), 80.69 (CMe3), 103.71 (indole 3-C), 
105.58 (indole 4-C), 111.95 (4-C), 112.61 (indole 7-C), 116.79 (indole 6-C), 122.13 (6-C), 
122.62 (9b-C), 123.91 (9-C), 124.47 (7-C), 126.60 (8-C), 128.31 (indole 3a-C), 130.07 (9a-
C), 130.99 (5a-C), 131.26 (indole 7a-C), 133.71 (5-C), 141.39 (3a-C), 153.50 (indole 5-C + 
indole C=O), 160.23 (Boc C=O); MS (ES+) m/z 706.3970 (M + Na) (C40H53N5NaO5 requires 




5.46 Reductive removal of the 2,2,6,6-tetramethylpiperidine protecting group 
To compound 128 (123.28 mg, 0.18 mmol) was added THF (2 mL), AcOH (6 mL), H2O (2 
mL) and activated zinc dust (353.52 mg, 5.41 mmol) in a pressure tube equipped with 
magnetic stir bar. The reaction mixture was heated to 70°C for 2 h followed by a further 
addition of activated zinc dust (354 mg, 5.4 mmol) and heated to 70C for 21 h. After cooling 
to room temperature and diluted with THF, the organics were filtered through Celite® and 
concentrated in vacuo. Chromatography (EtOAc → EtOAc / MeOH / Et3N 95:5:0.1) gave two 
fractions each with a mixture of compounds. First fraction (14.01 mg) consisted of 130 and 



































MS (ES+) m/z 587.2945 (M + 1)
(C33H39N4O6 requires 587.2870)
MS (ES+) m/z 487.2432 (M + 1)
(C28H31N4O4 requires 487.2345)
MS (ES+) m/z 445.2328 (M + 1)
(C26H29N4O3 requires 445.2240)




5.47  (5-(tert-Butoxycarbonylamino)-3-(5-(2-dimethylaminoethoxy) indole-2-
carbonyl)-2,3-dihydro-1H-benzo[e]indol-1-yl)methyl acetate (130) 
The mixture of 130 and 131 (14.0 mg) and Boc2O (62.8 mg) were 
boiled under reflux in dry THF (10 mL) under N2 overnight. 
Evaporation and chromatography (EtOAc → EtOAc / MeOH / 
Et3N 90:10:0.1) gave 130 as a pale buff solid (14.53 mg): mp 
170-171°C; Rf = 0.3 (EtOAc / MeOH 1:1); 1H NMR [(MeOD) 
(NOESY)]  1.61 (9 H, s, But), 2.03 (3 H, s, OAc), 2.46 (6 H, s, 
NMe2), 2.88 (2 H, t, J = 5.4 Hz, CH2NMe2), 4.10 (1 H, dd, J = 
10.8, 8.0 Hz, CHOAc), 4.19 (2 H, t, J = 5.4 Hz, OCH2CH2NMe2), 
4.16-4.22 (1 H, m, 1-H), 4.59 (1 H, dd, J = 10.8, 3.6 Hz, CHOAc), 4.68 (2 H, d, J = 4.4 Hz, 2-
H), 7.04 (1 H, dd, J = 9.0, 2.4 Hz, indole 6-H), 7.11 (1 H, s, indole 3-H), 7.23 ( 1 H, d, J = 2.1 
Hz, 4-H), 7.45 (1 H, d, J = 8.9 Hz, indole 7-H), 7.51 (1 H, ddd , J = 8.2, 6.8, 1.0 Hz, 7-H), 
7.60 (1 H, ddd, J = 8.0, 6.8, 1.0 Hz, 8-H), 8.01 (1 H. d, J = 8.3 Hz, 9-H), 8.08 (1 H, d, J = 8.5 
Hz, 6-H); 13C NMR [(MeOD) (HSQC / HMBC)]  20.73 (OAc), 28.78 (CMe3), 41.13 (1-C), 
45.82 (NMe2), 56.45 (2-C), 59.27 (CH2NMe2), 66.48 (CH2OAc), 67.12 (OCH2CH2NMe2), 
81.30 (CMe3), 104.65 (indole 4-C), 107.35 (indole 3-C), 114.01 (indole 7-C), 115.05 (4-C), 
117.67 (indole 6-C), 123.93 (9b-C), 124.64 (6-C, or 9-C), 124.71 (9-C or 6-C), 125.87 (7-C), 
127.90 (5a-C), 128.21 (8-C), 129.37 (indole 3a-C), 131.54 (9a-C), 132.06 (indole 2-C), 
133.70 (indole 7a-C), 135.96 (indole 5-C), 142.52 (indole 3a-C), 154.91 (indole 5-C), 156.70 
(Boc C=O), 162.89 (indole C=O), 172.77 (OAc C=O); MS (ES+) m/z 587.2945 (M + H) 
(C33H39N4O6 requires 587.2870). 
 
5.48 tert-Butyl N-(3-(5-(2-dimethylaminoethoxy) indole-2-carbonyl)-1-
(hydroxymethyl)-2,3-dihydro-1H-benzo[e]indol-5-yl)carbamate (133) 
To compound 128 (122.7 mg, 0.18 mmol) were added 
sequentially, THF (3.0 mL), H2O (1.0 mL), activated Zn dust 
(934 mg, 14.4 mmol, 80 eq.) and AcOH (1.0 mL). The mixture 
was heated at 70C in a sealed pressure tube overnight. After 
cooling to room temperature, the mixture was filtered through 
Celite® and the solvents were evaporated from the filtrate. Sat aq. 
NaHCO3 was added to the mixture and the suspension was 
extracted with EtOAc. The organic phase was washed with water 










90:10:0.1) gave 133 as an off-white solid (69.3 mg, 71%): Rf  = 0.2 (EtOAc / MeOH 1:1); mp 
219-220C; IR νmax 3567, 3423, 3293 (OH, NH), 1684 (C=O); 1H NMR [(CD3)2SO 
(NOESY)]  1.56 (9 H, s, But), 2.36 (6 H, s, NMe2), 2.79 (2 H, t, J = 5.7 Hz, CH2NMe2), 3.23 
(1 H, m, CHOH), 3.84-3.87 (1 H, m, CHOH), 4.02 (1 H, m, 1-H), 4.15 (2 H, t, J = 5.8 Hz, 
OCH2CH2NMe2), 4.74 (2 H, m, 2-H), 5.11 (1 H, br, OH), 6.98 (1 H, dd, J = 8.9, 2.4 Hz, 
indole 6-H), 7.18 (1 H, d, J = 1.7 Hz, indole 3-H), 7.24 (1 H, d, J = 2.3 Hz, indole 4-H), 7.46 
(1 H, d, J = 8.8 Hz, indole 7-H), 7.48 (1 H, t, J = 8.2 Hz, 7-H), 7.8 (1 H, t, J = 7.8 Hz, 8-H), 
7.96 (1 H, d, J = 8.3 Hz, 9-H), 8.06 (1 H, d, J = 8.4 Hz, 6-H), 8.58 (1 H, s, 4-H), 9.29 (1 H, s, 
Boc NH), 11.66 (1 H, s, indole NH); 13C NMR [(CD3)2SO) (HSQC / HMBC)]  28.16 
(CMe3), 42.81 (1-C), 45.35 (NMe2), 54 (2-C), 57.65 (CH2NMe2), 62.81 (CH2OH), 65.95 
(OCH2CH2NMe2), 78.95 (CMe3), 103.31 (indole 4-C), 105.35 (indole 3-C), 113.13 (indole 7-
C), 113.61 (4-C), 115.78 (indole 6-C), 123.38 (9b-C), 123.65 (9-C), 123.88 (6-C), 124.01 (7-
C), 125.78 (5a-C), 126.62 (indole 2-C), 129.72 (9a-C), 131.08 (indole 3a-C), 131.66 (indole 
7a-C), 134.20 (5-C), 141.01 (3a-C), 152.90 (indole 5-C), 154.07 (Boc C=O), 160.26 (indole 
C=O); MS (ES+) m/z  567.2608 (M + Na) (C31H36N4NaO5 requires 567.258340), 545.2829 (M 




Compound 133 (29.6 mg, 54 µmol) was stirred in dry DMF (0.4 
mL) under N2 at 0°C. Et3N (38.0 µL, 27.6 mg, 0.27 mmol) was 
added dropwise, followed by dropwise addition of MsCl (13.0 
µL, 19.2 mg, 0.16 mmol). The mixture was stirred at 0°C for 1 h. 
LiCl (134 mg, 3.2 mmol) was added to the mixture which was 
stirred at 20C for 3 d. Water was added and the solvent was 
evaporated (< 30°C). Chromatography (EtOAc → EtOAc / 
MeOH / Et3N 95:5:0.1) gave 134 (21.3 mg, 76%) as a yellow 
solid: Rf = 0.2 (EtOAc / MeOH 1:1); mp 229-230°C; 1H NMR 
[(CDCl3) (NOESY)]  2.42 (6 H, s, OCH2CH2NMe2), 2.84 (2 H, t, J = 5.6 Hz, CH2NMe2), 
3.04 (3 H, br, NCHNMe), 3.10 (3 H, br, NCHNMe), 3.45 (1 H, t, J = 10.9 Hz, CHCl), 3.98 (1 
H, dd, J = 11.4, 3.1 Hz, CHCl), 4.10-4.18 (1 H, m, 1-H), 4.16 (2 H, t, J = 5.6 Hz, 
OCH2CH2NMe2), 4.63 (1 H, t, J = 8.6 Hz, 2-H), 4.78 (1 H, dd, J = 10.8, 1.5 Hz, 2-H), 7.00 (1 
H, d, J = 2.4 Hz, indole 6-H), 7.02 (1 H, d, J = 2.3 Hz, indole 3-H), 7.14 (1 H, d, J = 2.2 Hz, 
indole 4-H), 7.35 (1 H, d, J = 8.9 Hz, indole 7-H), 7.38 (1 H, t, J = 7.3 Hz, 7-H), 7.50 (1 H, 
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dd, J = 8.0, 1.1 Hz, 8-H), 7.67-7.69 (2 H, m, 9-H + NCHN(Me)2), 7.70 (1 H, s, 4-H), 8.47 (1 
H, d, J = 8.3 Hz, 6-H), 9.59 (1 H, s, indole NH). 13C NMR [(CDCl3) (HSQC / HMBC)]  
~35.0 (NCHNMe), ~40.0 (NCHNMe), 43.30 (1-C), 45.63 (OCH2CH2NMe2), 46.08 (CH2Cl), 
55.05 (2-C), 58.21 (OCH2CH2NMe2), 66.30 (OCH2CH2NMe2), 103.70 (indole 4-C), 104.68 
(4-C), 105.97 (indole 3-C), 112.63 (indole 7-C), 117.10 (indole 6-C), 118.26 (9b-C), 121.97 
(9-C), 123.64 (7-C), 125.76 (6-C), 127.26 (8-C), 127.81 (5a-C), 128.25 (indole 3a-C), 129.75 
(9a-C), 130.81 (indole 7-C), 131.36 (indole 7a-C), 142.03 (3a-C), 150.91 (5-C), 153.03 
(NCHNMe2), 153.66 (indole 5-C), 160.49 (indole C=O). Ms (ES+) m/z 520.2375 (M + H) 




Compound 133 (23.8 mg, 44 µmol) was stirred in dry pyridine 
(0.7 mL) under N2 at 0°C. Methanesulfonyl chloride (5.0 µL, 7.0 
mg, 61 µmol) was added dropwise and the mixture was stirred at 
0°C for 1 h. LiCl (92 mg, 2.2 mmol) was added and the mixture 
was warmed to 20C and was stirred for 7 d. EtOAc was added 
followed by sat. aq. NaHCO3. The mixture was extracted with 
EtOAc; the extract was washed with water and brine. Drying, 
evaporation and chromatography (EtOAc → EtOAc / MeOH / 
Et3N 980:20:1) gave 135 (16.3 mg, 66%) as a yellow solid: Rf = 0.3 (MeOH / EtOAc 1:1); 
mp > 250°C; 1H NMR [(CDCl3) (COSY / NOESY)]  1.55 (9 H, s, But), 2.37 (6 H, s, NMe2), 
2.78 (2 H, t, J = 5.7 Hz, CH2NMe2), 3.47 (1 H, t, J = 10.7 Hz, ClCH), 3.96 (1 H, dd, J = 11.2, 
2.9 Hz, , ClCH), 4.13 (2 H, t, J = 5.8 Hz, OCH2CH2NMe2), 4.14 (1 H, m, 1-H), 4.66 (1 H, t, J 
= 8.6 Hz, 2-H), 4.82 (1 H, dd, J = 10.7, 1.7 Hz, 2-H), 6.91 (1 H, s, Boc NH), 7.01 (1 H, d, J = 
1.4 Hz, indole 3-H), 7.04 (1 H, dd, J = 8.9, 2.4 Hz, indole 6-H), 7.14 (1 H, d, J = 2.2 Hz, 
indole 4-H), 7.35 (1 H, d, J = 8.9 Hz, indole 7-H), 7.45 (1 H, ddd, J = 8.3, 7.0, 1.1 Hz, 7-H), 
7.55 (1 H, ddd, J = 7.9, 6.8, 0.9 Hz, 8-H), 7.77 (1 H, d, J = 8.2 Hz, 9-H), 7.90 (1 H, d, J = 8.4 
Hz, 6-H), 8.92 (1 H, s, 4-H), 9.42 (1 H, s, indole NH). 13C NMR [(CDCl3)  (HSQC / 
HMBC)] 28.28 (CMe3), 43.40 (1-C), 45.84 (NMe2 + CH2Cl), 54.94 (2-C), 58.37 (CH2NMe2), 
66.59 (OCH2CH2NMe2), 80.92 (CMe3), 103.64 (indole 4-C), 105.90 (indole 3-C), 111.46 (4-
C), 112.59 (indole 7-C), 117.32 (indole 6-C), 120.77 (9b-C), 122.37 (6-C), 123.04 (9-C), 
124.71 (5a,7-C2), 127.23 (8-C), 128.24 (indole 3a-C), 129.68 (9a-C), 130.49 (indole 2-C), 
131.32 (indole 7a-C), 134.75 (5-C), 141.66 (3a-C), 153.28 (Boc C=O), 153.86 (indole 5-C), 
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160.41 (indole C=O); MS (ES+) m/z 565.2382 (M + H) (C31H3637ClN4O4 requires 565.2396), 
563.2443 (M + H) (C31H3635ClN4O4 requires 563.2425), 427.2157 [(M – (Boc + Cl) + H] 
(C26H27N4O2 requires 427.2134). 
 
5.51 5-Amino-1-chloromethyl-3-(5-(2-dimethylaminoethoxy)indole-2-carbonyl)-
2,3-dihydro-1H-benzo[e]indole dihydrochloride (136) 
HCl in 1,4-dioxane (4.0 M, 2mL) was added to 135 and the 
mixture stirred at 20C for 2 h. The solvent and excess HCl were 
evaporated at 20°C. The residue was triturated with acetonitrile 
and Et2O. Drying gave 136 (15.3 mg, 100%) as a buff solid: mp 
 > 250°C. A sample in EtOAc was washed with sat. aq. NaHCO3 
and brine. Drying and evaporation gave the free base as a yellow 
solid: Rf = 0.3 (EtOAc / MeOH 1:1); mp > 250 C; 1H NMR 
[(CD3)2SO) (NOESY)]  2.90 (6 H, d, J = 3.3 Hz, NMe2), 3.55 (2 
H , t, J = 4.2 Hz, CH2NMe2), 3.77 (1 H, dd, J = 11.0, 8.2 Hz, ClCH), 3.99 (1 H, dd, J = 11.1, 
3.1 Hz, ClCH), 4.15 (1 H, m, 1-H), 4.33 (2 H, t, J = 4.9 Hz, OCH2CH2NMe2), 4.52 (1 H, dd, J 
= 10.8, 1.5 Hz, 2-H), 4.75 (1 H, t, J = 10.7 Hz, 2-H), 7.00 (1 H, d, J = 8.8 Hz, indole 6-H), 
7.10 (1 H, d, J = 1.7 Hz, indole 3-H), 7.26 (1 H, d, J = 1.9 Hz, indole 4-H), 7.32 (1 H, t, J = 
7.9 Hz, 7-H), 7.45 (1 H, d, J = 8.9 Hz, indole 7-H), 7.48 (1 H, t, J = 7.4 Hz, 8-H), 7.75-7.80 (2 
H, m, 4,9-H2), 8.08 (1 H, d, J = 8.5 Hz, 6-H), 11.66 (1 H, s, indole NH); 13C NMR 
[(CD3)2SO) (HSQC / HMBC)]  41.40 (1-C), 42.89 (NMe2), 47.51 (ClCH2), 55.04 (2-C), 
55.67 (CH2NMe2), 62.70 (OCH2CH2NMe2), 99.50 (4-C), 104.01 (indole 4-C), 105.00 (indole 
3-C), 113.30 (indole 7-C), 115.54 (indole 6-C), 117.55 (9b-C), 120.67 (4a-C), 122.46 (7-C), 
123.05 (9-C), 123.37 (6-C), 126.91 (8-C), 127.11 (indole 2-C), 130.01 (9a-C), 131.52 (indole 
3a-C), 131.95 (indole 7a-C), 142.78 (5-C), 151.97 (indole 5-C), 157.90 (3a-C), 158.17 (C=O); 
MS (ES+) m/z 465.1910 (M + H) (C26H2837ClN4O2 requires 465.1871), 463.1874 (M + H) 















5.52  (9H-Fluoren-9-yl)methyl S-(2,6-dioxopiperidin-3-yl)carbamate (157) 
 
Method A 
Dry pyridine (15 mL) was stirred with Fmoc-L-Gln-OH 155 
(2.01 g, 5.46 mmol) under N2 for 20 min. DCC (1.73 g, 8.40 
mmol) in dry pyridine (5 mL) was added during 30 min and 
the mixture was stirred for 3 h. The reaction was filtered 
through Celite®. The solvent was evaporated to approximately half the volume and the 
mixture was filtered again (Celite®).  The solvent was evaporated and water was added. The 
suspension was kept at 4°C for 1 h. The suspension was filtered. Aq. HCl (6 M, 50 mL) was 
added and the suspension was extracted with EtOAc. The extract was washed with brine and 




Fmoc-L-Gln-OH 155 (1.55 g, 4.2 mmol) was suspended in dry THF (20 mL) and placed 
under N2. Dry pyridine (2.0 mL) was added and the mixture was stirred at 0°C. 
Trifluoroacetic anhydride (2.0 mL) was added dropwise during 45 min (keeping the 
temperature ≤ 5°C). The mixture was then stirred at 0°C for 6 h. The solvent was evaporated 
and the residue was suspended in water and EtOAc. Extraction with EtOAc, drying and 
chromatography (petroleum ether / EtOAc 1:1 → EtOAc) gave 157 (867 mg, 59 %) as a white 
solid:  
 
Rf  = 0.7 (EtOAc); mp 125-127ºC; IR νmax 3290 (NH), 3185(NH), 3083(NH), 1690 (C=O); 1H 
NMR [(CD3)2SO]  1.98-2.04 (2 H, m, Gln γ-H2), 2.56 (1 H, m, Gln β-H), 2.80 (1 H, dt, J = 
17.6, 6.2 Hz, β-H), 4.32 (1 H, t, J = 6.7 Hz, fluorene 9-H), 4.38-4.40 (3 H, m, Fmoc-CH2, Gln 
α-H), 7.40 (2 H, t, J = 7.4 Hz, fluorene 2,7-H2), 7.48 (2 H, t, J = 7.4 Hz, fluorene 3,6-H2), 7.72 
(1 H, d, J = 8.7 Hz, Fmoc NH), 7.78 (2 H, d, J = 7.3 Hz, fluorene 4,5-H2), 8.02 (2 H, d, J = 
7.5 Hz, fluorene 1,8-H2), 10.87 (1 H, brs, NH).  13C NMR [(CD3)2SO) (HSQC / HMBC)]  
24.28 (Gln γ-C), 30.94 (Gln β-C), 46.58 (fluorene 9-C), 50.71 (Gln α-C), 65.63 (Fmoc CH2), 
120.13 (fluorene 1,8-C2), 125.20 (fluorene 4,5-C2), 127.07 (fluorene 2,7-C2), 127.63 (fluorene 
3,6-C2), 140.73 (fluorene 4a,4b-C2), 143.81 (fluorene 8a,9a-C2), 156.08 (C=O), 172.37 
(C=O), 172.97 (C=O); MS (ES+) m/z 373.1174 (M + Na) (C20H18N2NaO4 requires 373.1164), 




5.53 S-2-(Benzyloxycarbonylamino)-4-cyanobutanoic acid (163) 
Cbz-L-Gln-OH 162 (4.11 g, 14.3 mmol) in dry pyridine (15 mL) 
was treated with DCC (3.03 g, 14.7 mmol) in dry pyridine (15 
mL), added in portions during 30 min. The mixture was stirred 
for 16 h and was then filtered through Celite®. Most of the 
solvent was evaporated and the suspension was filtered again. 
The remaining solvent was evaporated. Water was added to the residue followed by aq. HCl 
(2 M) until the pH was ca. 1. The mixture was extracted with EtOAc (3 ×) and dried. 
Evaporation and chromatography (EtOAc) gave 163 (3.06 g, 82%) as a colourless oil: Rf = 
0.3 (EtOAc); IR νmax 3320 cm-1 (NH, OH), 2251 cm-1 (C≡N), 1710 cm-1 (C=O); 1H NMR 
(CDCl3) δ 2.06 (1 H, m, 3-H), 2.29 (1 H, m, 3-H), 2.44 (2 H, t, J = 6.6 Hz, 4-H2), 4.43 (1 H, t, 
J = 6.7 Hz, 2-H), 5.10 (2 H, s, PhCH2), 5.62 (1 H, d, J = 7.2 Hz, NH), 7.34 (5 H, m, Ph-H5); 
13C NMR [(CDCl3) (HMBC / HMQC)]  13.57 (4-C), 21.01 (3-C), 52.62 (2-C), 67.46 
(PhCH2), 118.65 (CN), 128.14 (Ph 2,6-C2), 128.37 (Ph 3,5-C2), 128.58 (Ph 4-C), 135.68 (Ph 
1-C), 156.24 (N-C=O), 174.01 (CO2H); MS (ES+) m/z 285.0837 (M + Na) (C13H14N2NaO4 
requires 285.0851), 263.1022 (M + H) (C13H15N2O4  requires 263.1031).  
 
5.54 tert-Butyl N-(N-phenylmethoxycarbonyl-L-leucyl)-D-serine methyl ester 
(168) 
Cbz-L-Leu-OH 167 (670 mg, 2.5 mmol) and D-Ser(OBut)-OMe 
(1.00 g, 2.5 mmol) were stirred with benzotriazol-1-yl-oxytri-
pyrrolidinophosphonium hexafluorophosphate (PyBOP) (1.60 g, 
3.0 mmol) and Et3N (1.01 g, 10 mmol) in CH2Cl2 (30 mL) for 24 
h. The solution was washed with water, aq. citric acid (5%), aq. NaHCO3 and water. Drying, 
evaporation and chromatography (petroleum ether / EtOAc 7:3) afforded 168 (1.00 g, 95%) as 
a white powder: mp 83-84C; 1H NMR (CDCl3)  0.94 (6 H, d, J = 6.0 Hz, 2  Leu Me), 1.18 
(9 H, s, But), 1.52 (1 H, dd, J = 16.5, 8.5 Hz, Leu -H), 1.63-1.72 (2 H, m, Leu ,-H2), 3.55 
(1 H, dd, J = 9.2, 2.7 Hz, Ser -H), 3.73 (3 H, s, OMe), 3.79 (1 H, dd, J = 9.2, 2.7 Hz, Ser -
H), 4.25 (1 H, m, Leu -H), 4.68 (1 H, td, J = 8.3, 2.7 Hz, Ser -H), 5.12 (2 H, s, PhCH2), 
5.21 (1 H, d, J = 7.3 Hz, NH), 6.77 (1 H, d, J = 7.3 Hz, NH), 7.35 (5 H, s, Ph-H5); 13C-NMR 
[(CDCl3) (HMBC / HMQC)]  22.85 (Leu Me), 22.85 (Leu Me), 24.70 (Leu -C), 27.25 
(CMe3), 41.78 (Leu -C), 52.39 (OMe), 52.75 (Ser -C), 53.50 (Leu -C), 61.70 (Ser -C), 










170.65 (Ser C=O), 171.13 (Cbz C=O), 171.81 (Leu C=O); MS (ES+) m/z 445.2314 (M + Na) 
(C22H34N2NaO6 requires 445.2314), 423.2455 (M + H) (C22H35N2O6 requires 423.2495). 
 
5.55 tert-Butyl N-(L-leucyl)-D-serine methyl ester (169) 
Compound 168 (280 mg, 0.66 mmol) was stirred vigorously under 
H2 with Pd/C (10%, 30 mg) in MeOH (30 mL) for 16 h. Filtration 
(Celite) and evaporation gave 169 (250 mg, quant.) as a white 
powder: mp 145-146C; 1H NMR (CDCl3)  0.92 (3 H, t, J = 6.9 Hz, 
Leu Me), 0.93 (3 H, t, J = 6.9 Hz, Leu Me), 1.11 (9 H, s, But), 1.39 (1 H, d heptet, J = 9.1, 4.1 
Hz, Leu -H), 1.53 (2 H, br, NH2), 1.62-1.77 (2 H, m, Leu -H2), 3.39 (1 H, dd, J = 9.3, 4.1 
Hz, Leu -H), 3.53 (1 H, dd, J = 9.1, 3.3 Hz, Ser -H), 3.71 (3 H, s, OMe), 3.80 (1 H, dd, J = 
9.1, 3.0 Hz, Ser -H), 4.66 (1 H, td, J = 8.5, 3.0 Hz, Ser -H), 7.78 (1 H, d, J = 8.0 Hz, NH); 
13C NMR (CDCl3)  21.50 (Leu Me), 23.44 (Leu Me), 24.88 (Leu γ-C), 27.39 (CMe3), 44.03 
(Leu -C), 52.37(OMe), 52.58 (Ser -C), 53.61 (Leu -C), 62.12 (Ser -C), 73.42 (CMe3), 
171.17 (Ser C=O), 175.71 (Leu C=O). 
 
5.56  tert-Butyl N-(N-(S-2-phenylmethoxycarbonylamino-4-cyanobutanoyl)-L-
leucyl)-D-serine methyl ester (170) 
Compound 163 (900 mg, 3.43 mmol) and L-Leu-D-
Ser(But)-OMe 169 (1.00 g, 3.43 mmol) were stirred with 
2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate (HATU) (1.43 
g, 3.77 mmol) and Pri2NEt (885 mg, 6.86 mmol) in 
CH2Cl2 (80 mL) for 20 h. The solution was washed with water, aq. citric acid (5%), aq. 
NaHCO3 and water. Drying, evaporation and chromatography (EtOAc) gave 170 (1.14 g, 
77%) as a white powder: mp 95-96C; 1H NMR (CDCl3)  0.89 (3 H, d, J = 6.3 Hz, Leu Me), 
0.92 (3 H, d, J = 6.3 Hz, Leu Me), 1.12 (9 H, s, But), 1.53 (1 H, t, J = 7.8 Hz, Leu -H), 1.61-
1.68 (2 H, m, Leu -H2), 2.03 (1 H, ddd, J = 13.6, 7.6, 5.8 Hz, Gln(CN) β-H), 2.17 (1 H, 
ddd, J = 13.6, 7.6, 5.8 Hz, Gln(CN) β-H), 2.40 (2 H, t, J = 7.6 Hz, Gln(CN) γ-H2), 3.55 (1 H, 
dd, J = 9.0, 3.1 Hz, Ser -H), 3.71 (3 H, s, OMe), 3.77 (1 H, dd, J = 9.0, 3.1 Hz, Ser -H), 
4.45 (1 H, dd, J = 13.7, 7.5 Hz, Gln(CN) α-H), 4.55 (1 H, dd, J = 14.0, 7.5 Hz, Leu -H), 4.65 
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(1 H, dt, J = 8.2, 3.1 Hz, Ser -H), 5.88 (1 H, d, J = 7.6 Hz, CbzNH), 7.0 (1 H, d, J = 8.2 Hz, 
Ser NH), 7.18 (1H, d, J = 7.5 Hz, Leu NH); 13C NMR [(CDCl3) (HMBC / HMQC)]  13.35 
(Gln(CN) γ-C), 22.18 (Leu Me), 22.61 (Leu Me), 24.62 (Leu -C), 27.17 (CMe3), 28.44 
(Gln(CN) β-C), 40.64 (Leu -C), 51.61 (Leu -C), 52.46 (OMe), 52.95 (Ser -C), 53.23 
(Gln(CN) α-C), 61.49 (Ser -C), 67.19 (PhCH2), 73.40 (OCMe3), 119.19 (CN), 128.01 (Ph), 
128.18 (Ph), 128.48 (Ph), 135.95 (Ph 1-C), 156.07 (Cbz C=O), 170.38 (Gln(CN) C=O), 
170.61 (Leu C=O), 171.58 (Ser C=O); MS (ES+) m/z 533.2941 (M + H) (C27H41N4O7 requires 
533.2975). 
 
5.57 N-(N-(S-2-Amino-4-cyanobutanoyl)-L-leucyl)- tert-butoxycarbonyl-D-serine 
methyl ester (171) 
Compound 170 (820 mg, 1.54 mmol) was stirred vigorously 
under H2 with Pd/C (10%, 80 mg) in MeOH (80 mL) for 16 
h. Filtration (Celite) and evaporation gave 171 (640 mg, 
quant.) as a pale yellow oil: 1H NMR (CDCl3)  0.94 (3 H, d, 
J = 6.2 Hz, Leu Me), 0.96 (3 H, d, J = 6.2 Hz, Leu Me), 1.14 
(9 H, s, But), 1.57 (1 H, m, Leu -H), 1.65 (1 H, sextet, J = 6.2 Hz, Leu -H), 1.72 (1 H, m, 
Leu -H), 1.88 (1 H, m, Gln(CN) β-H), 2.13 (1 H, m, Gln(CN) β-H), 2.54 (2 H, dt, J = 10.2, 
6.6 Hz, Gln(CN) γ-H), 2.55 (2 H, dt, J = 10.2, 6.6 Hz, Gln(CN) γ-H), 3.49 (1 H, dd, J = 7.4, 
5.8 Hz, Gln(CN) α-H), 3.56 (1 H, dd, J = 9.0, 3.5 Hz, Ser -H), 3.74 (3 H, s, OMe), 3.79 (1 H, 
dd, J = 8.9, 3.1, Ser -H), 4.51 (1 H, ddd, J = 14.4, 8.6, 2.4 Hz, Leu -H), 4.65 (1 H, dt, J = 
8.2, 3.1 Hz, Ser -H), 6.88 (1 H, d, J = 8.2 Hz, Ser NH), 7.47 (1 H, d, J = 8.2 Hz, Leu NH); 
13C-NMR [(CDCl3) (HMBC / HMQC)]  13.98 (Gln(CN) γ-C), 22.14 (Leu Me), 22.74 (Leu 
Me), 27.21 (CMe3), 30.80 (Gln(CN) β-C), 40.76 (Leu -C), 51.23 (Leu -C), 52.41 (OMe), 
52.83 (Ser -C), 53.92 (Gln(CN) α-C), 61.58 (Ser C), 73.42 (CMe3), 119.41 (CN), 170.69 







butanoyl)-L-leucyl)-D-serine methyl ester (172) 
Cbz-L-Leu-OH 167 (210 mg, 0.80 mmol) and 171 
(320 mg, 0.80 mmol) were stirred with benzo-
triazol-1-yl-oxytripyrrolidinophosphonium 
hexafluorophosphate (PyBOP) (500 mg, 0.96 
mmol) and Et3N (323 mg, 3.20 mmol) in CH2Cl2 
(15 mL) for 2 d. The solution was washed with water, aq. citric acid (5%), aq. NaHCO3 and 
water. Drying, evaporation and chromatography (petroleum ether / EtOAc 7:3) afforded 172 
(390 mg, 75%) as a white powder: mp 152-154ºC; IR (Nujol) max 3304, 2239, 1758, 1705, 
1629 cm-1; 1H NMR (CDCl3)  0.91 (6 H, d, J = 6.2 Hz, 2  Leu Me), 0.94 (6 H, d, J = 6.2 
Hz, 2  Leu Me), 1.14 (9 H, s, But), 1.51-1.70 (6 H, m, 2  Leu -H + 2  Leu -H2), 2.02 (1 
H, m, Gln(CN) β-H), 2.23 (1 H, m, Gln(CN) β-H), 2.39 (2 H, t, J = 7.6 Hz, Gln(CN) γ-H2), 
3.57 (1 H, dd, J = 8.9, 3.1, Ser -H), 3.73 (3 H, s, OMe), 3.79 (1 H, dd, J = 38.9, 3.1, Ser -
H), 4.19 (1 H, m, Gln(CN) α-H), 4.53 (1 H, dd, J = 14.0, 7.6 Hz, Leu -H), 4.60 (1 H, m, Leu 
-H), 4.65 (1H, dt, J = 8.0, 3.2 Hz, Ser -H), 5.12 (2 H, s, PhCH2), 5.30 (1 H, d, J = 7.6 Hz, 
NH), 6.80-6.89 (3 H, br m, 3  NH), 7.35 (5 H, s, Ph-H5); 13C NMR [(CDCl3) (HMBC / 
HMQC)]  13.51 (Gln(CN) γ-C), 21.82 (Leu Me), 22.12 (Leu Me), 22.75 (Leu Me), 22.91 
(Leu Me), 24.71 (2  Leu -C), 27.25 (CMe3), 28.07 (Gln(CN) β-C), 40.62 (2  Leu -C), 
51.65 (Leu -C), 51.91 (Leu -C), 52.48 (OMe), 52.99 (Ser -C), 53.72 (Gln(CN) α-C), 
61.53 (Ser -C), 67.28 (PhCH2), 73.48 (CMe3), 119.28 (CN), 128.09 (Ph), 128.28 (Ph), 
128.57 (Ph), 136.04 (Ph 1-C), 156.46 (Cbz C=O), 169.79 (Ser C=O Ser), 170.60 (Gln(CN) 
C=O), 171.28 (Leu C=O), 172.56 (Leu C=O); MS (ES+) m/z 668.3610 (M + Na) 
(C33H51N5Na1O8 requires 668.3635). 
 
5.59 tert-Butyl N-(N-(N-(N-phenylmethoxycarbonyl-L-leucyl)-L-glutamyl)-L-
leucyl)-D-serine methyl ester (173) 
Aq. H2O2 (35%, 0.30 mL) was added to 172 (20 
mg, 30 mol) in aq. NaOH (0.5 M, 2.7 mL), 
followed by aq. NaOH (2.0 M, 0.2 mL). The 
mixture was stirred for 1 h at room temperature. 





























Extraction (CH2Cl2, thrice), drying and evaporation gave 173 (18.8 mg, 90%) as a white 
powder: mp 193-194C; IR (Nujol) 3292, 1623, 1540 cm-1;  1H NMR (CDCl3)  0.82 (6 H, d, 
J = 6.7 Hz, 2  Leu Me), 0.86 (6 H, d, J = 6.7 Hz, 2  Leu Me), 1.09 (9 H, s, But), 1.39-1.45 
(4 H, m, 2  Leu -H2), 1.59-1.60 (2 H, m, 2  Leu -H), 1.75 (1 H, m, Gln -H), 1.84-1.90 (1 
H, m, Gln -H), 2.08 (2 H, t, J = 7.2 Hz, Gln -H), 3.33 (3 H, s, OMe), 3.49 (1 H, dd, J = 9.0, 
3.9 Hz, Ser -H), 3.58 (1 H, dd, J = 9.4, 5.5 Hz, -H), 4.03 (1 H, m Leu -H), 4.25 (1 H, m, 
Gln -H), 4.33 (1 H, dd, J = 7.8, 3.9 Hz, Ser -H), 4.40 (1 H, m, Leu -H), 5.01 (1 H, d, J = 
13.0 Hz, PhCH), 5.02 (1 H, d, J = 13.0 Hz, PhCH), 6.74 (1 H, br, Gln -CONH), 7.20 (1 H, 
br, Gln -CONH), 7.31 (1 H, d, J = 8.6 Hz, Gln -NH), 7.35 (5 H, s, Ph-H5), 7.37 (1 H, d, J = 
8.8 Hz, Leu NH), 7.93 (1 H, d, J = 9.0 Hz, Leu NH), 7.97 (1 H, d, J = 7.8 Hz, Ser NH); 13C 
NMR [(CD3OD) (HMBC / HMQC)]  21.43 (Leu Me), 21.63 (Leu Me), 23.05 (2  Leu Me), 
24.04 (Leu -H), 24.16 (Leu -H), 27.13 (CMe3), 27.79 (Gln -C), 31.47 (Gln -C), 40.69 
(Leu -C), 41.18 (Leu -C), 50.78 (Leu -C), 51.87 (OMe), 52.00 (Gln -C), 52.74 (Ser -
C), 53.07 (Leu -C), 61.55 (Ser -C), 65.37 (PhCH2), 72.66 (CMe3), 127.63 (Ph 2,6-C2), 
127.76 (Ph 4-C), 128.34 (Ph 3,5-C2), 137.04 (Ph 1-C), 155.95 (Cbz C=O), 170.86 (Ser C=O), 
171.55 (Gln -C=O), 171.79 (Leu C=O), 172.31 (Leu C=O), 173.77 (Gln -C=O); MS (ES+) 
m/z 664.3968 (M + H) (C33H54N5O9 requires 664.3916). 
 
5.60 N-(N-(S-2-((N-Phenylmethoxycarbonyl-L-leucyl)amino)-4-cyanobutanoyl)-
L-leucyl)-D-serine methyl ester (174) 
Compound 172 (33 mg, 51 mol) was stirred with 
CF3CO2H (1.0 mL) and CH2Cl2 (1.0 mL) for 1 h. 
Evaporation gave 174 (41 mg, quant.) as a pale 
yellow oil: 1H NMR (CDCl3)  0.89 (6 H, d, J = 
6.9 Hz, 2  Leu Me), 0.90 (6 H, d, J = 6.9 Hz, 2  
Leu Me),1.55-1.70 (6 H, m, 2  Leu -H2 + 2  
Leu -H), 1.89-2.19 (2 H, m, Gln(CN) β-H2), 2.35-2.42 (2 H, m, Gln(CN) γ-H2), 3.72 (3H, s, 
OMe), 3.91 (1H, d, J = 11.0 Hz, Ser β-H), 4.05 (1H, dd, J = 12.1, 3.5 Hz, Ser -H), 4.26 (1 H, 
m, Gln(CN) α-H), 4.60 (2 H, s, PhCH2), 4.70 (1 H, dd, J = 11.3, 3.3 Hz, Leu -H), 4.99-5.16 
(2 H, m, Leu -H + Ser -H), 5.82 (1 H, d, J = 5.2 Hz, NH), 7.32 (5 H, m, Ph-H5), 7.59 (1 H, 






Compound 174 (32 mg, 54 mol) was boiled under 
reflux with 2,2-dimethoxypropane (28 mg, 0.27 
mmol) and TsOH (1.2 mg, 6 mol) in CH2Cl2 (2.0 
mL) under N2 for 19 h. Evaporation and 
chromatography (petroleum ether / EtOAc 1:4) gave 
175 (7.5 mg, 22%) as a pale yellow oil: 1H NMR (CDCl3)  0.88 (6 H, d, J = 6.0 Hz, 2  Leu 
Me), 0.91 (6 H , d, J = 5.5 Hz, 2  Leu Me), 1.49 (3 H, s, Dmo 2-Me), 1.52-1.57 (4 H, m, 2  
Leu -H2), 1.59-1.69 (2 H, m, 2  Leu -H), 1.64 (3 H, s, Dmo 2-Me), 1.98 (1 H, m, Gln(CN) 
β-H), 2.14 (1 H, m, Gln(CN) β-H), 2.30 (2 H, t, J = 7.2 Hz, Gln(CN) γ-H2), 2.72 (1 H, t, J = 
2.5 Hz, -H), 3.78 (3 H, s, OMe), 4.07-4.25 (3 H, m, Dmo 4,5-H3), 4.34 (1 H, t, J = 7.9 Hz, 
-H), 4.61 (1 H, dd, J = 11.6, 5.8 Hz, -H), 5.04 (1 H, d, J = 5.8 Hz, NH), 5.10 (2 H, s, 
PhCH2), 5.59 (1 H, d, J = 8.0 Hz, NH), 6.85 (1 H, d, J = 8.3 Hz, NH), 7.33 (5 H, s, Ph-H5); 
13C NMR [(CD3OD) (HMBC / HMQC)]  13.29 (Gln(CN) γ-C), 21.21 (Leu Me), 21.83 (Leu 
Me), 22.85 (Dmo 2-Me), 22.87 (Leu Me), 23.43 (Leu Me), 24.38 (Leu -C), 24.68 (Leu -C), 
24.85 (Dmo 2-Me), 27.81 (Gln(CN) β-C), 40.42 (Leu -C), 40.34 (Leu -C), 50.73 (-C), 
51.64 (-C), 52.82 (OMe), 53.72 (Dmo 5-C), 59.46 (-C), 67.07 (Dmo 4-C), 67.26 (PhCH2), 
96.73 (Dmo 2-C), 118.99 (CN), 128.15 (Ph 2,6-C2), 128.28 (Ph 4-C), 128.55 (Ph 3,5-C2), 
136.07 (Ph 1-C), 156.57 (C=O), 169.57 (C=O), 169.98 (C=O), 169.98 (C=O), 171.05 (C=O), 
172.57 (C=O); MS (ES+) m/z 652.3282 (M + Na) (C32H47N5Na1O8 requires 652.3322), 
630.3464 (M + H) (C32H48N5O8 requires 630.3502). 
 
5.62 N-(N-(S-4-Cyano-2-(phenylmethoxycarbonylamino)butanoyl)-L-leucyl)-D-
serine methyl ester (176) 
Compound 170 (200 mg, 0.37 mmol) was stirred with 
CF3CO2H (2.0 mL) and CH2Cl2 (2 mL) for 2 h. 
Evaporation afforded 176 (220 mg, quant.) as a yellow 
oil: 1H NMR (CDCl3) 0.87 (3 H, d, J = 5.2 Hz, Leu Me), 
0.88 (3 H, d, J = 5.2 Hz, Leu Me), 1.55-1.60 (3 H, m, Leu 
-H3), 1.95 (1 H, m, Gln(CN) β-H), 2.14 (1 H, m, 













11.3, 6.0 Hz, Ser -H), 3.99 (1 H, ddd, J = 11.3, 6.0, 3.6 Hz, Ser -H), 4.43 (1 H, t, J = 6.9 
Hz, Gln(CN) α-H), 4.57-4.72 (2 H, m, Leu -H + Ser -H), 5.07 (2 H, s, PhCH2), 6.29 (2 H, 
br, 2  NH), 7.31 (5 H, s, Ph-H5), 7.55 (1 H, t, J = 6.0 Hz, OH); 13C NMR (CDCl3)  13.46, 
14.12, 21.64, 22.69, 24.78, 28.75, 40.74, 50.97, 52.40, 53.24, 67.27, 119.01, 128.00, 128.12, 
128.27, 128.53, 135.84, 156.08, 170.15, 172.92; MS (ES+) m/z 477.2327 (M + H) 




Compound 176 (220 mg, 0.46 mmol) was boiled under 
reflux with 2,2-dimethoxypropane (240 mg, 2.3 mmol) and 
TsOH (9.6 mg, 50 mol) in CH2Cl2 (5.0 mL) under N2 for 
19 h. Evaporation and chromatography (petroleum ether / 
EtOAc 1:4) gave 177 (120 mg, 50%) as a pale yellow oil:  
1H NMR (CDCl3)  0.81 (3 H, d, J = 5.8 Hz, Leu Me), 0.90 (3 H, d, J = 6.3 Hz, Leu Me), 
1.54 (3 H, s, Dmo 2-Me), 1.44-1.64 (3 H, m, Leu -H3), 1.66 (3 H, s, Dmo 2-Me), 1.92 (1 
H, m, Gln(CN) β-H), 2.18 (1 H, m, Gln(CN) β-H), 2.40 (2 H, t, J = 7.0 Hz, Gln(CN) γ-H2), 
3.80 (3 H, s, OMe), 4.18 (2 H, dd, J = 9.4, 6.2 Hz, Dmo 5-H), 4.24 (1 H, d, J = 9.4 Hz, Dmo 
5-H), 4.32 (1 H, t, J = 8.6 Hz, Leu -H), 4.37 (1 H, m, Gln(CN) α-H), 5.05 (1 H, d, J = 5.8 
Hz, Dmo 4-H), 5.11 (2 H, s, PhCH2), 5.49 (1 H, d, J = 7.4 Hz, CbzNH), 6.60 (1 H, d, J = 6.6 
Hz, Leu NH), 7.35 (5 H, s, Ph-H5); 13C NMR [(CDCl3) (HMBC / HMQC)]  13.31 (Gln(CN) 
γ-C), 21.10 (Leu Me), 22.90 (Dmo 2-Me), 23.43 (Leu Me), 24.39 (Leu -C), 24.88 (Dmo 2-
Me), 28.52 (Gln(CN) β-C), 40.39 (Leu -C), 50.90 (Gln(CN) α-C), 52.82 (OMe), 53.20 (Leu 
-C), 59.44 (Dmo 4-C), 67.10 (Dmo 5-C), 67.42 (PhCH2), 96.76 (Dmo 2-C), 118.70 (CN), 
128.17 (Ph 2,6-C2), 128.39 (Ph 4-C), 128.60 (Ph 3,5-C2), 135.78 (Ph 1-C), 155.83 (Cbz C=O), 
169.56 (Gln C=O), 170.10 (Leu C=O), 171.01 (Dmo C=O); MS (ES+)  m/z: 539.2450 (M + 






5.64 Methyl S-2-(2-(benzyloxycarbonylamino)-4-cyanobutanamido)propanoate 
(178) 
Cbz-L-Gln(CN)-OH 163 (3.06 g, 11.7 mmol) was stirred with DMF 
(200 mL) and Pri2NEt (12 mL, 8.90 g, 69 mmol) and PyBOP (9.10 g, 
17.5 mmol) for 5 min. L-Ala-OMe.HCl (2.50 g, 17.9 mmol) was 
added and the mixture was stirred for 3 d.  The DMF was evaporated 
and the residue was extracted with EtOAc. The extract was washed 
with aq. NaHCO3 (5%) and brine, and was dried. Evaporation and chromatography 
(petroleum ether / EtOAc 1:1 → EtOAc) gave 178 (3.52 g, 87%) as a white solid: Rf = 0.9 
(EtOAc / MeOH 1:1); mp 157-158ºC; [α]18D -10.2º (c = 1.6%, DMF);  IR νmax 3303 (NH), 
2244 (C≡N), 1750 (C=O), 1693 (C=O), 1657 (C=O); 1H NMR [(CD3)2SO]  1.29 (3 H, d, J = 
7.5 Hz, Ala Me), 1.82 (1 H, m, Gln(CN) β-H), 1.96 (1 H, m, Gln(CN) β-H), 2.52 (2 H, m, 
Gln(CN) γ-H2), 3.62 (3 H, s, OMe), 4.11 (1 H, td, J = 8.6, 4.8  Hz , Gln(CN) α-H), 4.26 (1 H, 
qn, J = 7.3 Hz, Ala α-H), 5.03 (2 H, s, PhCH2), 7.34 (5 H, m, Ph-H5), 7.52 (1 H, d, J = 8.0 Hz 
Gln(CN) NH), 8.50 (1 H, d, J = 7.0 Hz, Ala NH). 13C NMR [(CD3)2SO) (HSQC / HMBC)]  
13.14 (Gln(CN) γ-C), 16.68 (Ala-Me), 27.63 (Gln(CN) β-C), 47.67 (Ala α-C), 51.95 (OMe), 
53.03 (Gln(CN) α-C), 65.57 (PhCH2), 119.94 (CN), 127.76 (Ph 2,6-C2), 127.85 (Ph 4-C), 
128.36 (Ph 3,5-C2), 136.87 (Ph 1-C), 155.93 (Cbz C=O), 170.79 (Gln(CN) C=O), 172.99 




Cbz-L-Gln(CN)-L-Ala-OMe 178 (357 mg, 1.03 mmol) was 
stirred vigorously with Pd/C (10% 36 mg) in MeOH (25 mL) 
under hydrogen for 2 h. Filtration (Celite®) and evaporation 
gave N-(S-2-amino-4-cyanobutanoyl)-L-alanine 179. This 
was added to Boc-L-Ala-OH (395 mg, 2.1 mmol), Pri2NEt 
(0.72 mL, 533 mg, 4.1 mmol) and HATU (822 mg, 2.2 mmol) in DMF (25 mL). The mixture 
was stirred for 2 h and the solvent was evaporated. The residue in EtOAc was washed with aq. 
NaHCO3 (5%), water and brine. Evaporation and chromatography (EtOAc / petroleum ether 
1:1 → EtOAc) gave 180 (252 mg, 64%) as a white solid: mp 175-176 ºC; [α]18D  -24.6 (c = 
0.80%, DMF); IR νmax 3318 (NH), 3279 (NH), 2250 (C≡N), 1673 (C=O); 1H NMR (CDCl3)  
1.37 (3 H, d, J = 7.1 Hz, Ala Me), 1.41 (3 H, d, J = 7.3 Hz, Ala Me), 1.43 (9 H, s, But), 2.02 
(1 H, m, Gln(CN) β-H), 2.26 (1 H, m, Gln(CN) β-H), 2.46 (2 H, m, Gln(CN) γ-H2), 3.71 (3 H, 
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s, OMe), 4.11 (1 H, m, Ala α-H), 4.51 (1 H, qn, J = 7.2 Hz, Ala α-H), 4.62 (1 H, td, J = 7.5, 
5.5 Hz, Gln (CN) α-H), 5.35 (1 H, br, BocNH), 7.01 (1 H, d, J = 7.2 Hz, Ala-OMe NH), 7.07 
(1 H, d, J = 8.1 Hz, Gln(CN) NH); 13C NMR [(CDCl3) (HSQC / HMBC)]  13.33 (Gln(CN) 
γ-C), 17.39 (Ala Me), 17.88 (Ala Me), 28.20 (CMe3), 28.34 (Gln(CN) β-C), 48.20 (Ala α-C), 
50.46 (Ala α-C), 51.62 (Gln(CN) α-C), 52.41 (OMe), 80.25 (CMe3), 119.28 (C≡N), 155.63 
(Boc C=O), 169.79 (Gln(CN) C=O), 172.84 (N-terminal Ala C=O), 173.42 (C-terminal Ala 
C=O): MS (ES+) m/z 407.2052 (M + Na) (C17H28N4NaO6 requires 407.1907).  
 
5.66 N-(N-(tert-Butoxycarbonyl)-L-alanyl)-L-glutaminyl)-L-alanine (181). 
Boc-L-Ala-L-Gln(CN)-L-Ala-OMe 180 (1.00 g, 2.6 mmol) 
in MeOH (50 mL) at 0°C was stirred with aq. H2O2 (35% 
w/w, 1.6 mL, 18.2 mmol) and aq. NaOH (1.0 M, 2.6 mL, 2.6 
mmol)  for 6 h. The reaction was quenched by addition of aq. 
Na2S2O3 (20%, 30 mL) and the methanol was evaporated. The residue was extracted with 
EtOAc; the organic solution was washed with brine and dried. Evaporation and 
chromatography (EtOAc → EtOAc / MeOH 4:1) gave 181 (243 mg, 23%) as a white solid: 
mp 193-194°C; [α]18D -26.4 (c = 0.85%, DMF); IR νmax 3420 (NH), 3306 (NH), 1747 (C=O), 
1660 (C=O); 1H NMR [(CD3)2SO] δ 1.16 (3 H, brd, J = 7.0 Hz, N-terminal Ala Me), 1.27 (3 
H, d, J = 7.5 Hz, C-terminal Ala Me), 1.37 (9 H, s, But), 1.72 (1 H, m, Gln β-H), 1.86 (1 H, m, 
Gln β-H), 2.10 (2 H, t, J = 7.0 Hz, Gln γ-H2), 3.62 (3 H, s, OMe), 3.96 (1 H, qn, J = 7.1 Hz, 
N-terminal Ala α-H), 4.28-4.35 (2 H, m, C-terminal Ala α-H + Gln α-H), 6.75 (1 H, s, Gln δ-
NH), 6.97 (1 H, d, J = 7.3 Hz, N-terminal Ala-NH), 7.21 (1 H, s, Gln δ-NH), 7.80 (1 H, d, J = 
8.0 Hz, Gln α-NH), 8.35 (1 H, d, J = 6.5 Hz, C-terminal Ala NH); 13C NMR ((CD3)2SO) 
(HSQC / HMBC) δ 16.79 (C-terminal Ala-Me), 18.05 (N-terminal Ala-Me), 28.17 (CMe3 + 
Gln β-C), 31.13 (Gln γ-C), 47.50 (C-terminal Ala α-C), 49.73 (N-terminal Ala α-C), 51.52 
(Gln α-C), 51.86 (OMe), 78.11 (CMe3), 155.09 (Boc C=O), 171.10 (Gln α-C=O), 172.48 (N-
terminal Ala C=O), 172.86 (C-terminal Ala C=O), 173.72 (Gln δ-C=O); 15N NMR 
[(CD3)2SO) (HSQC / HMBC)] δ 63.83 (BocN), 79.33 (Gln γ-CONH2), 85.20 (Gln α-N), 
91.03 (C-terminal Ala-N); MS (ES+) m/z 425.2166 (M + Na) (C17H30N4NaO7 requires 






5.67 N-Phenylmethoxycarbonyl-L-glutamic acid (188) 
Aq. H2O2 (35%, 1.5 mL) was added to 163 (110 mg, 0.42 mmol) in aq. 
NaOH (0.5 M, 15 mL), followed by aq. NaOH (2 M, 1.0 mL) and the 
mixture was stirred for 30 min. The mixture was cooled to 0ºC and the pH 
was adjusted to 2.0 with aq. HCl (1.0 M). Extraction (CH2Cl2, thrice), drying and evaporation 
gave 188 (120 mg, quant.) as a colourless viscous oil: IR (liquid film) max 3290, 1697 cm-1; 
1H NMR (CD3OD)  1.96 (1 H, m, -H), 2.19 (1 H, m, -H), 2.32 (1 H, m, -H), 2.40 (1 H, 
m, -H), 4.18 (1 H, m, -H), 4.88 (2 H, s, PhCH2), 5.09 (1 H, br, OH), 7.32 (5 H, s, Ph-H5); 
MS (ES+) m/z 282.1023 (M + H) (C13H16NO6 requires 282.0972). 
 
5.68 Solid phase peptide synthesis  
The Kaiser test was used to test for the presence / absence of free amino groups during 
deprotection or coupling. The resin is treated with ninhydrin in ethanol, phenol in ethanol and 
potassium cyanide in pyridine. A positive test (presence of free amino group) is indicated by a 
purple colour. To determine the resin loading after coupling the first amino-acid, the resin is 
treated with piperidine in DMF (1:4) (4 ×) for 3 min each time to cleave the Fmoc group. The 
absorbance of the dibenzofulvene-piperidine adduct is recorded at 301 nm against DMF and 
the loading of the first amino-acid on the resin calculated using Beer Lambert equation: 
 
A = C. ε. L, C = A / ε, C = n / v, n = (v  10-3) × C 
Therefore loading of resin (mol) = [(A301  v  10-3) / (ε301)] × F 
 
Where A301 is the absorbance at 301 nm minus the control reading, V is the volume (mL), ε301 
is the extinction coefficient at 301 nm (7800 M-1 cm-1) and F is the dilution factor. 
 
Peptides were synthesised using standard Fmoc solid-phase peptide synthetic protocols. The 
resin used was 2-chlorotrityl chloride polystyrene. Before starting a peptide synthesis, the 
resin was swollen in CH2Cl2 for about 5 min. Loading of the resin involved reaction with the 
appropriate Nα-Fmoc amino-acids (2 - 4 equiv.) in CH2Cl2 in the presence of iPr2NEt (6 
equiv.) for 2 h. The mixture was rinsed with DMF (5 ×) and CH2Cl2 (5 ×) followed by 
treatment with CH2Cl2 / MeOH / Pri2NEt (17:2:1) (3 × 15 min) to cap unreacted resin. 
Washing with DMF (5 ×) and CH2Cl2 (5 ×) followed by Fmoc deprotection by treating resin 
with piperidine in DMF (1:4) (4 ) for 3 min each time, yielded the desired loaded resin. 
Determination of the absorbance of the dibenzofulvene-piperidine adduct allowed estimation 
192 
 
of the percentage loading of the resin. The peptide chains were then assembled by sequential 
couplings of preactivated Nα-Fmoc amino-acids (2 - 3 equiv.) for 2 h. The preactivation was 
carried out manually in DMF by treatment with benzotriazol-1-yl-
oxytrispyrrolidinophosphonium hexafluorophosphate (PyBOP) (2 equiv.) and Pri2NEt (6 
equiv.) for 5 min. Removal of the Fmoc-protection was carried out by treatment with 
piperidine (20% in DMF) (5 × 3 min). The completeness of each coupling and Fmoc 
deprotection were verified by Kaiser test. A positive Kaiser test was usually followed by an 
additional coupling cycle. The protected peptides were cleaved from the resin with CF3CO2H 
(TFA) (1% in CH2Cl2), concentrated (~5 % of volume) and precipitated with water. Filtration 
and drying in a freeze drier / oven (40°C) gave the product. 
 
5.69 Fmoc-L-Ser(Bn)-L-Ser(Bn)-L-Lys(Cbz)-L-Leu-L-Gln-OH (189) 
 
Peptide 189 was synthesised on 2-chlorotrityl chloride polystyrene resin (1.05 g, 1.66 mmol) 
according to the general procedure (Section 5.68) described above to yield 189 (1.23 g, 93%) 
as a white solid: Rf  = 0.5 (EtOAc / MeOH 1:1); mp 192-195°C; IR νmax 3295 (NH, OH), 
1728-1635 (C=O); 1H NMR [(CD3)2SO) (COSY)] δ 0.83-0.92 (6 H, m, Leu Me2), 1.31-1.36 
(2 H, m, Lys γ-H2), 1.41-1.54 (5 H, m, Leu β-H2, + Lys β-H1, δ-H2), 162-1.68 (2 H, m, Leu γ-
H1 + Lys β-H1), 1.80-1.89 (1 H, m, Gln β-H), 1.95-2.04 (1 H, m, Gln β-H), 2.13-2.24 (2 H, m, 
Gln γ-H), 2.99 (2 H, m, Lys ε-H2), 3.62-3.74 (4 H, m, 2 × Ser β-H2), 4.22 ( 1 H, m, Gln α-H), 
4.31-4.42 (5 H, m, Fmoc-CH2 + fluorene 9-H  + Leu α-H + Lys α-H), 4.47-4.59 (5 H, m, 2 × 
SerOCH2Ph + Ser α-H ), 4.62-4.70 (1 H, m, Ser α-H), 5.05 (2 H, s, Cbz CH2), 6.88 (1 H, br, 
NH), 7.28-7.41 (18 H, m, 17 × Ar-H + NH), 7.46 (2 H, t, J = 7.4 Hz, 2 × Ar-H), 7.76-7.80 (3 
H, m, 2 × Ar-H + NH), 7.91-7.96 (3 H, m, 2 × Ar-H + NH),  8.11 (1 H, d, J = 7.7 Hz, NH), 
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8.20 (1 H, d, J = 7.4 Hz, Gln NH), 8.33 (1 H, d, J = 7.4 Hz, Ser NH), 12.63 (1 H, s, OH); 13C 
NMR [(CD3)2SO) (HSQC / HMBC)] δ 21.56 (Leu Me), 22.52 (Lys γ-C), 23.03 (Leu Me), 
24.01 (Leu γ-C), 26.78 (Gln β-C), 29.13 (Lys -C), 31.31 (Gln γ-C), 31.73 (Lys β-C), 38.83-
40.08 (Lys ε-C), 40.82 (Leu β-C), 46.58 (fluorene 9-C), 50.67 (Leu α-C), 51.52 (Gln α-C), 
52.55 (Lys α-C), 52.80 (Ser α-C), 54.67 (Ser α-C), 65.10 (Cbz OCH2Ph), 65.83 (Fmoc-CH2), 
69.74 (2 × Ser β-C), 71.98 (SerOCH2Ph), 72.08 (SerOCH2Ph), 120.09 (Ar-C), 125.30 (Ar-C), 
127.07 (Ar-C), 127.33 (Ar-C), 127.37 (Ar-C), 127.41 (Ar-C), 127.44 (Ar-C), 127.63 (Ar-C), 
127.74 (Ar-C), 128.13 (Ar-C), 128.16 (Ar-C), 128.32 (Ar-C), 137.23 (Cbz Ph 1-C), 138.09 
(Bn Ph 1-C), 138.14 (Bn Ph 1-C), 140.68 (2  Fmoc-Cq), 143.74 (Fmoc-Cq), 143.80 ((Fmoc-
Cq), 156.03 (Cbz C=O), 169.09 (Ser 2  C=O), 169.70 (Fmoc C=O), 171.00 (Lys C=O), 
171.92 (Leu C=O), 173.19 (CO2H), 173.49 (Gln δ-C=O); MS (ES+) m/z  1120.5117 (M + Na) 
(C60H71N7NaO13 requires 1120.5008), 1098.5283 (M + H) (C60H72N7O13 requires 1098.5189).  
 
5.70 Chloro-5-nitroisoquinoline (191) 
A mixture of conc. H2SO4 (1.37 g, 13.9 mmol) and conc. aq. HNO3 (70%, 1.20 
g, 13.1 mmol) at 0C was added to 1-chloroisoquinoline 190 (2.14 g, 13.1 
mmol) in conc. H2SO4 (10 mL) at 0C and the mixture was stirred at 0°C for 2 
h and at 20°C for 10 min before being poured onto ice-water. The solid was 
collected by filtration and dried to give 191 (1.80 g, 66%) as a yellow solid: Rf = 0.4 (MeOH / 
CH2Cl2 1:9); mp 178-181°C (lit.196 mp 187°C); IR νmax 1524 (NO2); 1H NMR (CDCl3)  
(COSY) δ 7.81 (1 H, t, J = 8.1 Hz, 7-H), 8.40 (1 H, dd, J = 6.2, 0.9 Hz, 4-H), 8.49 (1 H, d, J = 
6.1 Hz, 3-H), 8.56 (1 H, dd, J = 7.7, 1.1 Hz, 6-H), 8.74 (1 H, d, J = 8.5 Hz, 8-H); 13C NMR 
[(CDCl3) (HSQC / HMBC)] δ 115.80 (4-C), 126.98 (7-C), 127.54 (8a-C), 128.84 (6-C), 
130.35 (4a-C), 133.24 (8-C), 144.78 (3-C), 145.43 (5-C), 152.63 (1-C).                             
                                                                                                                                                                             
5.71 1-Benzyloxy-5-nitroisoquinoline (192)  
NaH (60% dispersion in mineral oil, 94 mg, 3.9 mmol) was added to benzyl 
alcohol (445 mg, 4.1 mmol) in dry DMF (10 mL). 1-Chloro-5-nitro-
isoquinoline 191 (407 mg, 2.0 mmol) was added and the mixture was stirred 
under N2 for 15 min at 20°C and at 100°C for 2 h. Water (50 mL) was added 
to the evaporation residue, which was then extracted with EtOAc (5  50 
mL). The combined organic phases were washed with brine and dried. 
Evaporation and chromatography (EtOAc / petroleum ether 1:9) yielded 192 (485 mg, 89%) 
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as a yellow solid: Rf = 0.9 (EtOAc / petroleum ether 1:9); mp 85-86°C; IR νmax 1522 (NO2); 
1H NMR [(CDCl3) (COSY)] δ 5.61 (2 H, s, CH2 ), 7.34-7.44 (3 H, m, Ph 3,4,5-H3), 7.53 (2 H, 
d, J = 7.3 Hz, Ph 2,6-H2), 7.61 (1 H, t, J = 8.2 Hz, 7-H), 8.02 (1 H, dd, J = 6.4, 0.8 Hz, 4-H), 
8.23 (1 H, d, J = 6.3 Hz, 3-H), 8.47 (1 H, dd, J = 7.8, 1.2 Hz, 6-H), 8.67 (1 H, dd, J = 8.3, 0.9 
Hz, 8-H); 13C NMR [(CDCl3) (HSQC / HMBC)] δ 68.58 (CH2), 110.00 (4-C), 120.89 (8a-C), 
125.08 (7-C), 128.12 (Ar-C), 128.18 (Ar-C), 128.30 (Ar-C), 128.60 (Ar-C), 130.69 (4a-C), 
131.28 (8-C), 136.67 (Ph 1-C), 143.74 (3-C), 144.82 (5-C), 160.43 (1-C); MS (ES+) m/z 
303.0729 (M + Na) (C16H12N2NaO3 requires 303.0746), 281.0895 (M + H) (C16H13N2O3 
requires 281.0926).  
 
5.72 1-Benzyloxyisoquinolin-5-amine (193) 
NaBH4 (381 mg, 10.1 mmol) in MeOH (5.0 mL) was added to 192 (698 mg, 
2.5 mmol) and Pd/C (10% 692 mg) in MeOH (25 mL) and the mixture was 
stirred for 30 min. Aq. HCl (1.0 M, 1.0 mL) was added and the mixture was 
filtered  through Celite®. The evaporation residue was partitioned between 
water and EtOAc. The product was extracted with EtOAc and the solution 
was dried. Evaporation and chromatography (petroleum ether / EtOAc 1:1) 
yielded 193 (206 mg, 33%) as a buff oil: Rf = 0.7 (EtOAc / petroleum ether 1:1); 1H NMR 
[(CDCl3) (COSY)] δ 5.66 (2 H, s, CH2), 6.95 (1 H, dd, J = 7.8, 0.8 Hz, 6-H), 7.17 (1 H, d, J 
=6.0 Hz, 4-H), 7.32-7.36 (2 H, m, 7-H, Ph 4-H), 7.40 (2 H, t, J = 7.5 Hz, Ph 3,5-H2), 7.54 (2 
H, d, J = 7.0 Hz, Ph 2,6-H2), 7.77 (1 H, d, J = 8.5 Hz, 8-H), 8.00 (1 H, d, J = 6.0 Hz, 3-H); 13C 
NMR [(CDCl3) (HSQC / HMBC)] δ 67.96 (CH2), 108.64 (4-C), 112.99 (6-C), 114.57 (8-C), 
120.49 (8a-C), 127.07 (7-C, Ph 4-C), 127.67 (4a-C), 127.75 (Ph 2,6-C2), 128.44 (Ph 3,5-C2), 
137.34 (Ph 1-C), 138.34 (3-C), 141.23 (5-C), 160.67 (1-C); MS (ES+) m/z 273.0974 (M + Na) 
(C16H14N2NaO requires 273.1004), 251.1161 (M + H) (C16H15N2O requires 251.1184).  
 
5.73 N-(4-Hydroxynaphthalen-1-yl)acetamide (198) 
4-Aminonaphthalen-1-ol hydrochloride 31 (1.01 g, 5.15 mmol) was stirred 
with Et3N (0.72 mL, 525 mg, 5.2 mmol) and Ac2O (0.49 mL, 530 mg, 5.2 
mmol) in MeOH (25 mL) at 50°C for 1 h. The solvent was evaporated. 
Chromatography (EtOAc / CH2Cl2 1:3) gave 198 (959 mg, 93%) as a pale 
pink solid: Rf = 0.4 (EtOAc); mp 184-186ºC (lit.197 mp 186-187°C); IR νmax  
3327, 3258 (OH, NH), 1652 (C=O); 1H NMR [(CD3)2SO) (NOESY)]  2.18 (3 H, s, Me), 
6.89 (1 H, d, J = 8.0 Hz, 3-H), 7.36 (1 H, d, J = 8.0 Hz, 2-H), 7.51 (1 H, ddd, J = 8.2, 6.8, 1.4 
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Hz, 6-H), 7.56 (1 H, ddd, J = 8.2, 6.8, 1.4 Hz, 7-H), 7.94 (1 H, d, J = 8.0 Hz, 8-H), 8.20 (1 H, 
dd, J = 8.0, 0.6 Hz, 5-H), 9.66 (1 H, s, NH), 10.11 (1 H, s, OH); 13C NMR [(CD3)2SO) (HSQC 
/ HMBC)]  23.12 (Me), 107.27 (3-C), 122.23 (5-C), 122.81 (8-C), 123.59 (2-C), 124.51 (6-
C), 124.70 (4a-C), 124.98 (1-C), 125.93 (7-C), 129.78 (8a-C), 151.16 (4-C), 168.86 (C=O); 
MS (ES-) m/z 200.0713 (M - H) (C12H10NO2 requires 200.0712).  
 
5.74 N-(4-Methoxynaphthalen-1-yl)acetamide (199) 
Compound 198 (211 mg, 1.05 mmol), K2CO3 (158 mg, 1.14 mmol) and MeI 
(70 µL, 149 mg, 1.05 mmol) in acetone (10 mL) were refluxed for 16 h. The 
solvent was evaporated. The residue in EtOAc, was washed with water, sat. 
aq. Na2S2O3 and brine. Drying, evaporation and chromatography (CH2Cl2 / 
EtOAc 3:2) gave 199 (189 mg, 80%) as a pale pink solid: Rf = 0.3 (CH2Cl2 / 
EtOAc 3:2); mp 185-187°C (lit.198 mp 186-186.5°C); IR νmax  3270 (NH), 1652 (C=O); 1H 
NMR [(CD3)2SO) (NOESY)]  2.20 (3 H, s, NCOMe), 4.02 (3 H, s, OMe), 7.00 (1 H, d, J = 
8.2 Hz, 3-H), 7.52 (1 H, d, J = 8.2 Hz, 2-H), 7.57 (1 H, ddd, J = 8.0, 6.8, 1.2 Hz, 6-H), 7.62 (1 
H, ddd, J = 8.1, 6.8, 1.3 Hz, 7-H), 8.01 (1 H, d, J = 7.9 Hz, 8-H), 8.23 (1 H, dd, J = 8.0, 1.2 
Hz, 5-H), 9.75 (1 H, s, NH); 13C NMR [(CD3)2SO) (HSQC / HMBC)]  23.19 (NCOMe), 
55.66 (OMe), 103.82 (3-C), 121.65 (5-C), 122.89 (8-C), 122.93 (2-C), 125.02 (4a-C), 125.27 
(6-C), 126.27 (7-C), 126.46 (1-C), 129.33 (8a-C), 152.63 (4-C), 168.91 (C=O); MS (ES-) m/z 
214.0890 (M - H) (C13H12NO2 requires 214.0868).  
 
5.75 4-Methoxynaphthalen-1-amine (200) 
A suspension of 199 (123 mg, 0.57 mmol) in aq. HCl (3.0 M, 9 mL) and 
MeOH (3 mL) was heated at 90°C for 4 h. The mixture was cooled to 20C. 
and sat. aq. NaHCO3 was added until the mixture was basic to universal 
indicator paper. The suspension was extracted with EtOAc. The extract was 
washed with water, brine and dried. Evaporation and chromatography (petroleum ether / 
CH2Cl2 1:4  CH2Cl2) gave 200 (83 mg, 83%) as a purple oil: Rf = 0.5 (CH2Cl2); 1H NMR 
[(CDCl3) (COSY)]  3.70 (2 H, s, NH2), 4.00 (3 H, s, Me), 6.68 (1 H, d, J = 8.0 Hz, 3-H), 
6.71 (1 H, d, J = 8.0 Hz, 2-H), 7.50 (2 H, m, 6-H,7-H), 7.82 (1 H, m, 8-H), 8.28 (1 H, m, 5-
H); 13C NMR [(CDCl3) (HSQC / HMBC)]  55.78 (Me), 104.50 (3-C), 109.61 (2-C), 120.95 
(8-C), 122.51 (5-C), 125.19 (4a-C), 125.21 (6-C or 7-C), 125.58 (7-C or 6-C), 126.14 (8a-C), 






Compound 189 (203 mg, 0.19 mmol) and 200 (67.9 mg, 0.39 mmol) were stirred in dry DMF 
(10 mL) and at 0°C. HOBt (42.6 mg, 0.28 mmol) and EDC.HCl (56.5 mg, 0.29 mmol) were 
added and the mixture was stirred for 2 d under N2 at room temperature. The DMF was 
evaporated and the residue was triturated with hot MeOH. Cooling at 0°C for 30 min, 
filtration, washing with MeOH and drying gave 201 (181 mg, 78%) as a pale purple solid: Rf 
= 0.50 (EtOAc / AcOH / MeOH 19:2:1); mp 227-228°C; 1H NMR [(CD3)2SO) (COSY)] δ 
0.82-0.93 (6 H, m, Leu Me2), 1.31 (2 H, br, Lys γ-H2), 1.39-1.40 (2 H, m, Lys δ-H2), 1.53-
1.56 (3 H, m, Leu β-H2, + Lys β-H1), 1.61-1.68 (2 H, m, Leu γ-H1 + Lys β-H1), 1.99-2.04 (1 
H, m, Gln β-H1), 2.11-2.15 (1 H, m, Gln β-H1), 2.27-2.31 (2 H, m, Gln γ-H2), 2.97-2.98 (2 H, 
m, Lys ε-H2), 3.62-3.73 (4 H, m, Ser β-H4), 4.01 (3 H, s, OMe), 4.27-4.43 (5 H, m, Fmoc 
CH2, Fmoc CH, Leu α-H, Lys α-H), 4.47-4.58 (6 H, m, 2 × SerOCH2, Ser α-H, Gln α-H), 
4.64-4.66 (1 H, m, Ser α-H), 5.04 (2 H, s, Cbz CH2), 6.92 (1 H, br, NH), 6.99 (1 H, d, J = 8.4 
Hz, Naph Ar-H), 7.26-7.50 (21 H, m, Fmoc Ar-H, Bn Ar-H, Naph Ar-H, 3 × NH), 7.53-7.61 
(2 H, m, 2 × Ar-H), 7.75-7.80 (3 H, m, 2 × Ar-H, NH), 7.93-8.02 (4 H, m, 3 × Ar-H, NH), 
8.08-8.15 (1 H, m, NH), 8.20-8.23 (2 H, m, Ar-H, NH), 8.29-8.33 (1 H, m, NH); 13C NMR 
[(CD3)2SO) (HSQC / HMBC)] δ 21.51 (Leu Me), 22.60 (Lys γ-C), 23.04 (Leu Me), 24.09 
(Leu γ-C), 27.44 (Gln β-C), 27.81 (Lys -C), 29.22 (Gln γ-C), 31.55 (Lys β-C), 38.82-40.07 
(2 C, Lys ε-C, Leu β-C), 46.55 (Fmoc CH), 50.87 (Leu α-C or Lys α-C), 51.14 (Lys α-C or 
Leu α-C), 52.83 (2 × Ser α-C), 54.66 (Gln α-C), 55.66 (OMe), 65.09 (Cbz CH2), 65.81 (Fmoc 
CH2), 69.74 (2 × Ser β-C), 72.06 (2 C, 2 × SerOCH2Ph), 103.72 (Naph Ar-C), 120.10 (Ar-C), 
121.67 (Ar-C), 122.83 (Ar-C), 123.11 (Ar-C), 124.99 (Ar-Cq), 125.30 (Ar-C), 125.81 (Ar-Cq), 




























129.39 (Ar-C), 137.22 (Cbz Cq), 138.13 (2 × Bn Cq), 140.68 (Ar-Cq), 145.07 (Fmoc Cq), 
152.89 (Naph 1-C), 156.02 (Cbz C=O), 169.20 (C=O), 169.75 (C=O), 170.93 (C=O), 171.33 
(C=O), 172.07 (C=O), 172.96 (C=O), 173.75 (C=O); MS (ES+) m/z 1253.6693 (M + H) 






Compound 201 (1.40 g, 1.1 mmol) was stirred with HBr in AcOH (33%, 10 mL) at 20C for 2 
h. Et2O was added and the precipitate was filtered and washed with Et2O. The solid residue 
was dried and triturated with hot MeOH. The solvent was cooled to 20C and placed at 0C 
for 30 min. The solid residue was collected by filteration and washed with cold MeOH. 
Drying gave 202 (0.89 g, 72%) as a white solid: mp 245-246°C; 1H NMR [(CD3)2SO) 
(COSY)] δ 0.89 (3 H, d, J = 6.4 Hz, Leu Me), 0.93 (3 H, d, J = 6.4 Hz, Leu Me), 1.35-1.37 (2 
H, m, Lys γ-H2), 1.57 (5 H, m, Leu β-H2, Lys β-H1, Lys δ-H2), 1.66-1.73 (2 H, m, Lys β-H1, 
Leu γ-H1), 2.03 (3 H, s, SerOCOCH3), 2.05 (3 H, s, SerOCOCH3), 2.03-2.14 (2 H, m, Gln β-
H2), 2.29 (2 H, m, Gln γ-H2), 2.79 (2 H, qn, J = 2.8 Hz,  Lys ε-H2), 4.03 (3 H, s, OMe), 4.11-
4.31 (5 H, m, 2 × Ser β-H2, Fmoc CH), 4.34-4.47 (5 H, m, Fmoc CH2, Leu α-H, Lys α-H, Ser 
α-H1), 4.56 (1 H, dd, J = 13.6, 7.5 Hz, Gln α-H), 4.66 (1 H, dd, J = 12.8, 7.0 Hz, Ser α-H1), 
6.92 (1 H, s, NH), 7.02 (1 H, d, J = 8.4 Hz, Naph 2-H), 7.37 (2 H, t, J = 7.4 Hz, 2 × Ar-H), 
7.41 (1 H, s, NH), 7.48 (3 H, t, J = 8.6 Hz, Naph 3-H,  2 × Ar-H), 7.59 (2 H, qn, J = 6.9 Hz, 2 
× Ar-H), 7.70 (3 H, s, Lys NH3+Br-), 7.78 (2 H, dd, J = 7.1, 0.31 Hz, 2 × Ar-H), 7.84 (1 H, d, 
J = 8.3 Hz, NH), 7.96 (3 H, d, J = 7.3 Hz, 3 × Ar-H), 8.10 (1 H, d, J = 7.6 Hz, NH), 8.25 (3 H, 
m, Ar-H, 2 × NH), 8.41 (1 H, d, J = 7.6 Hz, NH), 9.83 (1 H, s, NH); 13C NMR [(CD3)2SO)] δ 
(HSQC / HMBC) 20.63 (2 ×  SerOCOCH3), 21.49 (Leu Me), 22.12 (Lys γ-C), 23.09 (Leu 
Me), 24.11 (Leu γ-C), 26.56 (Lys -C), 27.85 (Gln β-C), 31.26 (Lys β-C), 31.49 (Gln γ-C), 
38.67 (Lys ε-C), 40.62 (Leu β-C), 46.57 (Fmoc CH), 51.00 (Leu α-C), 51.68 (Ser α-C), 52.31 
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(Lys α-C), 52.89 (Gln α-C), 53.58 (Ser α-C), 55.71 (OMe), 63.22 (Ser β-C), 63.33 (Ser β-C), 
65.82 (Fmoc CH2), 103.77 (Naph 2-C), 120.14 (2 × Ar-C), 121.69 (Ar-C), 122.79 (Ar-C), 
123.11 (Naph 3-C), 125.01 (Ar-Cq), 125.23 (2 × Ar-C), 125.41 (Ar-C), 125.79 (Ar-Cq), 
126.39 (Ar-C), 127.09 (2 × Ar-CH), 127.67 (2 × Ar-CH), 129.38 (Ar-Cq), 140.71 (2 × Ar-Cq), 
143.74 (2 ×Fmoc Ar-Cq), 152.89 (Naph 1-C), 155.97 (C=O), 168.20 (C=O), 169.04 (C=O), 
170.10 (SerOCOCH3), 170.16 (SerOCOCH3), 170.88 (C=O), 171.06 (C=O), 172.07 (C=O), 
173.72 (Gln δ-C=O); MS (ES+) m/z 1045.4515 (M + Na) (C53H66N8NaO13 requires 
1045.4647), 1023.4706 (M + H) (C53H67N8O13 requires 1023.4828), 981.4644 (M – OAc + H) 
(C51H65N8O12 requires 981.4722). 
 
5.78 Fmoc-Ser-Ser-Lys-Leu-Gln-N-(4-methoxynaphthalen-1-yl)amide (203) 
 
Compound 201 (76.5 mg, 0.061 mmol) was stirred with HBr in AcOH (33%, 5 mL) for 2 h. 
MeOH was added and excess reagent were evaporated. The solid residue was triturated 
several times with Et2O and dried to give a purple solid. Purification (~28.6 mg) by 
preparative HPLC gave 203 (14.2 mg, 48%) as a buff solid: Rt 11.81 min (0.1% TFA in water 
/ 0.1% TFA in acetonitrile, 95% → 5%, over 20 min); MS (ES+) m/z 961.4453 (M + Na) 
















Compound 201 (453 mg, 0.36 mmol) was stirred in piperidine / DMF (20 mL, 1:5) at 20C 
for 45 min. The solvent was evaporated and the residue was triturated with hot MeOH. The 
mixture was cooled to 0°C, filtered and the collected solid washed with cold MeOH. Drying 
gave 204 (304 mg, 82%) as an off white solid: Rf = 0.5 (EtOAc / MeOH / AcOH 9:1:1); mp 
225-226°C; 1H NMR [(CD3)2SO) (COSY)] δ 0.85 (3 H, d, J = 6.4 Hz, Leu Me), 0.89 (3 H, d, 
J = 6.4 Hz, Leu Me), 1.29-1.31 (2 H, m, Lys γ-H2), 1.41 (2 H, br, Lys δ-H2), 1.54-1.59 (3 H, 
m, Leu β-H2 + Lys β-H1), 1.62-1.71 (2 H, m, Leu γ + Lys β-H1), 2.01-2.14 (4 H, m, Gln β-H2 
+ NH2), 2.26-2.28 (2 H, m, Gln γ-H2), 2.96-3.00 (2 H, m, Lys ε-H2), 3.52-3.71 (5 H, m, 2 × 
Ser β-H2 +  Ser α-H1), 4.02 (3 H, s, OMe), 4.31-4.43 (2 H, m, Leu α-H + Lys α-H), 4.49-4.56 
(5 H, m, 2 × SerOCH2Ph + Gln α-H), 4.61 (1 H, br, Ser α-H), 5.04 (2 H, s, Cbz OCH2Ph), 
6.90 (1 H, s, NH), 7.00 (1 H, d, J = 8.3 Hz, Naph 2-H), 7.26 (1 H, t, J = 5.6 Hz, Cbz NH), 
7.33-7.42 (16 H, m, 10 × Bn Ar-CH + 5 × Cbz Ar-CH, NH), 7.49 (1 H, d, J = 8.2 Hz, Naph 3-
H), 7.56-7.58 (2 H, m, Naph 6,7-H2), 7.95-8.00 (2 H, m, Naph 5-H + NH), 8.19-8.23 (3 H, m, 
Naph 8-H + 2 × NH), 8.30 (1 H, br, NH), 9.80 (1 H, s, NH); 13C NMR [(CD3)2SO) (HSQC / 
HMBC)] δ 21.51 (Leu Me), 22.33 (Lys γ-C), 23.04 (Leu Me), 27.77 (Gln β-C), 29.07 (Lys δ-
C), 31.52 (Gln γ-C + Lys β-C), 38.83-40.09 (Leu β-C + Lys ε-C), 51.00 (Lys α-C or Leu α-
C), 52.88 (Ser α-C), 52.61 (Leu α-C or Lys α-C), 52.96 (Gln α-C), 54.63 (Ser α-C), 55.67 
(OMe), 65.09 (Cbz OCH2Ph), 69.93 (Ser β-C), 72.02 (2 × SerOCH2Ph), 72.43 (Ser β-C), 
121.65 (Naph 8-C), 122.79 (Naph 5-C), 123.06 (Naph 3-C), 124.99 (Naph 6-C or 7-C), 
125.38 (Naph 8a-C), 125.82 (Naph 4-C), 126.38 (Naph 7-C or 6-C), 127.37 (Ar-C), 127.44 
(Ar-C), 127.72 (Ar-C), 128.18 (Ar-C), 128.33 (Ar-C), 129.38 (Naph 4a-C), 137.22 (Cbz Ar- 
Cq), 138.09 (Bn Ar-Cq), 138.28 (Bn Ar-Cq), 152.86 (Naph 1-C), 155.83 (Cbz C=O), 169.32 
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(C=O), 170.90 (C=O), 171.32 (C=O), 172.12 (C=O), 172.76 (C=O), 173.67 (C=O); MS 
(ES+) m/z 1053.5064 (M + Na) (C59H70N8NaO11 requires 1053.5062, 1031.5296 (M + H) 
(C59H71N8O11 requires  1031.5242). 
 
5.80 Ser-Ser-Lys-Leu-Gln-N-(4-methoxynaphthalen-1-yl)amide (205) 
 
Compound 202 (330 mg, 0.32 mmol) was stirred with HBr in AcOH (33%, 4 mL) for 2 h at 
20C. MeOH was added and the solvent was evaporated. The solid residue was recrystallised 
(MeOH / EtOAc) to give 205 (176.41 mg, 63%) as a white solid: mp 224-225; 1H NMR 
[(D2O) (COSY)] δ 0.80 (3 H, d, J = 4.8 Hz, Leu Me), 0.85 (3 H, d, J = 5.0 Hz, Leu Me), 1.32 
(2 H, br, Lys γ-H2), 1.51-1.54 (2 H, m, Lys δ-H2), 1.59-1.61 (4 H, m, Leu β-H2 + Leu γ + Lys 
β-H1), 1.71 (1 H, m, Lys β-H1), 2.11 (1 H, m, Gln β-H1), 2.25 (1 H, m, Gln β-H1), 2.41-2.44 
(2 H, m, Gln γ-H2), 2.83-2.85 (2 H, m, Lys ε-H2), 3.80-3.81 (2 H, m, Ser β-H2), 3.92 (2 H, m, 
Ser β-H2), 3.96 (3 H, s, OMe), 4.14 (1 H, m, Ser α-H), 4.24 (1 H, t, J = 6.8 Hz, Lys α-H), 
4.30-4.32 (1 H, m, Leu α-H), 4.46 (1 H, m, Ser α-H), 4.51 (1 H, m, Gln α-H), 6.92 (1 H, d, J = 
8.1 Hz, Naph 2-H), 7.29 (1 H, d, J = 8.2 Hz, Naph 3-H), 7.52 (1 H, t, J = 7.0 Hz, Naph 7-H), 
7.56 (1 H, t, J = 6.7 Hz, Naph 6-H), 7.70 (1 H, d, J = 8.1 Hz, Naph 5-H), 8.20 (1 H, d, J = 8.1 
Hz, Naph 8-H); 13C NMR [(D2O) (HSQC / HMBC)] δ 20.88 (Leu Me), 21.96 (Leu Me), 24.34 
(Leu γ-C), 26.20 (Lys δ-C), 30.22 (Lys β-C), 31.26 (Gln γ-C), 39.09 (Lys ε-C), 39.57 (Leu β-
C), 52.71 (Leu α-C), 53.70 (Lys α-C + Gln α-C), 54.40 (Ser α-C), 55.42 (Ser α-C), 55.79 
(OMe), 60.14 (Ser β-C), 61.12 (Ser β-C), 104.21 (Naph 2-C), 122.06 (Naph 8-C), 122.17 
(Naph 5-C), 123.91 (Naph 4-C), 125.14 (Naph 8a-C), 125.39 (Naph 3-C) 126.13 (Naph 7-C), 
127.55 (Naph 6-C), 129.99 (Naph 4a-C), 154.61 (Naph 1-C), 168.00 (Ser C=O), 171.40 (Ser 
C=O), 173.40 (Gln C=O), 173.74 (Lys C=O), 174.81 (Leu C=O), 177.81 (Gln δ-C=O); Ms 






5.81 α-Methoxy-ω-(4-nitrophenoxy carbonyl)-polyoxyethylene (207) 
Monomethoxy-PEG-OH (Mw ~5000 g mol-1) 206 (1.0 g, 0.20 
mmol) was dissolved in toluene (20 mL) and dried by water-
toluene distillation. 1,2-Dichloroethane (2 mL), 4-nitrophenyl 
chloroformate (81.3 mg, 0.40 mmol) and Et3N (60 µL, 43.6 
mg, 0.43 mmol) were added sequentially. The mixture was stirred overnight at 20C. Et2O  
was added to form a white precipitate. Filtration and drying gave 207 (1.0 g, 97%) as a white 
solid: Rf = 0.3 (EtOAc / MeOH 1:1); 1H NMR (CDCl3) δ 3.35 (3 H, s, OMe), 3.43 (2 H, t, J = 
5.2 Hz, mPEG CH2), 3.52 (2 H, m, mPEG CH2), 3.61-3.72 (~434 H, m, mPEG CH2), 3.77-
3.78 (4 H, m, mPEG CH2), 4.41 (2 H, t, J = 4.5 Hz, mPEG CH2), 7.36 (2 H, d, J = 9.1 Hz, Ar 





Compound 204 (45.8 mg, 44 µmol) was stirred in dry DMF (1.0 mL) and Et3N (0.05 mL) 
added, followed by addition of mPEG-nitrophenyl ester 207 (205mg, 0.040 mmol). The 
mixture was stirred under N2 at 20C for 8 d. The solvent was evaporated. Reverse-phase 
chromatography (H2O / MeCN 99:1 →  5:95) and freeze drying gave 208 (123 mg, 52%) as a 
white solid: Rf = 0.7 (MeCN / MeOH 4:1); 1H NMR [(CD3)2SO) (COSY)] δ 0.85 (3 H, d, J = 
6.4 Hz, Leu Me), 0.89 (3 H, d, J = 6.4 Hz, Leu Me), 1.23-1.30 (2 H, m, Lys γ-H2), 1.39-1.41 
(Lys δ-H2), 1.51-1.59 (3 H, m, Leu β-H2 + Lys β-H1), 1.66-1.71 (2 H, m, Leu γ-H + Lys β-
H1), 1.96-2.04 (1 H, m, Gln β-H1), 2.12-2.16 (1 H, m, Gln β-H1), 2.27-2.31 (2 H, m, Gln γ-
H2), 2.97-2.99 (2 H, m, Lys ε-H2), 3.30 (3 H, s, mPEG OMe), 3.39 (2 H, t, J = 5.0 Hz, mPEG 
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CH2), 3.47-3.68 (~444 H, m, 2 × Ser β-H2 + mPEG 220 × CH2), 3.74 (2 H, t, J = 4.6 Hz, 
mPEG CH2), 4.02 (3 H, s, Naph OMe), 4.10-4.13 (1 H, Ser α-H), 4.31-4.45 (2 H, m, Leu α-H 
+ Lys α-H), 4.52-4.58 (5 H, m, Gln α-H  + 2 × SerOCH2Ph), 4.63-4.64 (1 H, m, Ser α-H), 
5.05 (2 H, s, Cbz OCH2Ph), 6.85 (1 H, s, NH), 6.99 (1 H, d, J = 9.0 Hz, Naph 2-H), 7.16-7.19 
(1 H, br, NH), 7.28-7.42 (15 H, m, 10 × Bn Ar-H,  5 × Cbz Ar-H), 7.50 (2 H, m, Naph 3-H, 
NH), 7.56-7.58 (2 H, m, Naph 6,7-H2), 7.96-7.98 (2 H, m, Naph 5-H, NH), 8.07 (1 H, d, J = 





Peptide 213 was synthesised on 2-chlorotrityl chloride polystyrene resin (1.09 g, 1.64 mmol) 
according to the general procedure (Section 5.68) as described above to yield 213 (1.27 g, 
89%) as a white solid: Rf = 0.7 (EtOAc / MeOH 1 :1);  mp 243-245°C; IR νmax 3287 (NH, 
OH), 1634 (C=O);  1H NMR [(CD3)2SO) (COSY)] δ 0.79-0.86 (12 H, m, 2 × Leu Me2), 1.10 
(9 H, s, But), 1.24 (2 H, m, Lys γ-H2), 1.36-1.46 (7 H, m, 2 × Leu β-H2 + Lys β-H1, δ-H2), 
1.57-1.62 (3 H, m, 2 × Leu γ-H + Lys β-H1), 1.75-1.77 (1 H, m, Gln β-H), 1.85-1.89 (1 H, m, 
Gln β-H), 2.09 (2 H, t, J = 7.7 Hz, Gln γ-H2), 2.94-2.95 (2 H, m, Lys ε-H2), 3.49-3.51 (1 H, m, 
D-Ser β-H1), 3.58-3.69 (5 H, m, 2 × L-Ser  β-H2 + D-Ser β-H1), 4.22-4.37 (7 H, m, Fmoc-
CH2, fluorene 9-H, Gln α-H, Leu α-H, D-Ser α-H, Lys α-H), 4.42-4.51 (6 H, m, 2× 
SerOCH2Ph, Leu α-H, L-Ser α-H), 4.60 (1 H, m, L-Ser α-H), 5.00 (2 H, s, Cbz CH2), 6.77 (1 
H, br, NH), 7.18-7.43 (20 H, m, 19 × Ar-H + NH), 7.63-7.74 (3 H, m, Fmoc Ar-H2 + NH), 
7.89-7.90 (4 H, m, Fmoc Ar-H2 + 2 × NH), 7.99-8.06 (3 H, m, 3 × NH), 8.23-8.34 (2 H, m, 2 































22.96 (Leu Me), 23.02 (Leu Me), 23.99 (Leu γ-C), 24.04 (Leu γ-C), 27.08 (CMe3), 27.75 (Gln 
β-C), 29.13 (Lys δ-C), 31.48 (Gln γ-C), 31.68 (Lys β-C), 40.19 (Lys ε-C), 40.75 (Leu β-C), 
41.20 (Leu β-C), 46.57 (fluorene 9-C), 50.72 (Leu α-C), 50.89 (Leu α-C), 51.98 (Gln α-C), 
52.56 (Lys α-C), 52.64 (Ser α-C), 52.76 (Ser α-C), 54.67 (L-Ser α-C), 61.51 (D-Ser β-C), 
65.09 (Cbz OCH2Ph), 65.82 (Fmoc CH2), 69.73 (2 × L-Ser β-C), 71.97 (SerOCH2Ph), 72.08 
(SerOCH2Ph), 72.65 (CMe3), 120.07 (Fmoc Ar-C), 125.28 (Fmoc Ar-C), 127.05 (Ar-C), 
127.30 (Ar-C), 127.35 (Ar-C), 127.39 (Ar-C), 127.42 (Ar-C), 127.61 (Ar-C), 127.70 (Ar-C), 
128.11 (Ar-C), 128.13 (Ar-C), 128.30 (Ar-C), 137.22 (Cbz Ph 1-C), 138.07 (Bn Ph 1-C), 
138.13 (Bn Ph 1-C), 140.67 (2 × Fmoc-Cq), 143.72 (Fmoc-Cq), 143.78 (Fmoc-Cq), 156.02 
(Cbz C=O), 169.10 (C=O), 169.67 (C=O), 170.21 (C=O), 170.73 (C=O), 171.12 (C=O), 
171.53 (C=O), 171.76 (C=O), 171.82 (C=O), 173.77 (Gln δ-C=O); (MS (ES+) m/z 1376.6879 
(M + Na) (C73H95N9NaO16 requires 1376.6795). 
 
5.84 Calf-thymus DNA melting assay199 
 
5.84.1 Buffer preparation 
NaH2PO4 (1.17 g, 9.75 mM), ethylenediaminetetraacetic acid (EDTA) disodium salt dihydrate 
(372 mg, 1.0 mM) and NaCl (438 mg, 7.5 mM) were dissolved in MilliQ water (0.8 L). The 
pH was adjusted to pH 7.0 using aq. NaOH (0.1 M) or aq. HCl (0.1 M) as required and Milli-
Q water added to produce 1 L. 
 
5.84.2 Calf thymus DNA solution preparation 
Calf thymus DNA stock solution was prepared by dissolving DNA in 9.75 mM phosphate 
buffer to a concentration of 1 mg mL-1. Once fully dissolved, the stock was diluted down until 
an absorbance of 0.6 at 256 nm was obtained. This was found to be approximately 1.6 mL of 
DNA stock made up to 50 mL with phosphate buffer (i.e. ~0.032 mg mL-1). 
 
5.84.3 Calculations 
The DNA concentration of the diluted DNA (9.06 × 10-5 M) was calculated using the 
following Beer-Lambert equation: 
 
Equation 1:  A = εcl 
Where: A = the absorbance of diluted calf thymus DNA at 256 nm 
ε = molar extinction of DNA (6600 M-1 cm-1);200, 201  
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c = molar concentration of DNA solution; 
l = path length in cm (in this case 1 cm cuvette). 
 
The volume of the drug sample solution needed to obtain the required molar equivalent (0.01 
→ 0.6) could be worked out using the following equation: 
 
Equation 2: Volume of sample = Molar concentration of diluted DNA × Volume of diluted 
DNA × MW of drug sample × Molar equivalent required  
 
5.84.4 Procedure 
Compound 136 (1.04 mg, 1.94 µmol) was dissolved in DMSO (1 mL) to make a stock 
solution (1.94 mM). Different volumes of the stock solution (corresponding to the range of 
molar equivalents given above (Equation 2) were added to the DNA (3 mL, 9.06 × 10-5 M) in 
the appropriate cells and incubated at room temperature for 1 h to allow alkylation of DNA. 
 
Samples in quartz cells consisted of: 
 Cell 1 (blank) → Buffer + DMSO (40 µL); 
 Cells 2 and 3 (positive control) → DNA + buffer + DMSO (40 µL); 
 Cells 4 and 5→Test compound + DNA + buffer + DMSO.  
 
All cells contained the same total volume of DMSO (40 µL). Since the test compound 
solution was prepared in DMSO, this had to be taken into account. The absorbance at 256 nm 
was monitored for each sample over the range of 40-95C at a rate of 0.5C per minute in a 1 
cm quartz cell  using a complete PC controlled spectrometer system by Perkin Elmer: Lambda 
BioDNA Melt system including PTP-6 temperature controlled programmer for simultaneous 
curves, UVTemplab software and in-cuvette temperature sensor. The thermal melting (Tm) of 
the calf thymus DNA was determined for samples in cells 2-5. ∆Tm = Tm of DNA-drug 
complex (cells 4 and 5) – Tm of DNA alone (cells 2 and 3). Tm values were calculated from the 







5.85 Anti-proliferative assay 
 
5.85.1 Preparation of cell suspension 
Medium was poured off the cells and the cells washed with PBS (5 mL). Trypsin/EDTA 
[(0.05% (w/v), 5 mL)] was added and the mixture placed at 37C until the cells detached. 
Medium (8 mL) was added to suspend the cells which were transferred to a Universal tube. 
The suspension was centrifuged at ~1300 rpm for 7 min using Jouvan B3.11 centrifuge at 
room temperature. The supernatant was removed and the cells re-suspended in medium (5 
mL). This was then diluted (~1 in 10) and the cells counted using a haemocytometer. Further 
dilution was made to give a suspension with the required number of cells per well for the 
experiment (2000 cells per well to be added in 50 µL). These seed densities had been 
determined previously to give an acceptable optical density value after 3 d incubation. 
 
5.85.2 Procedure202 
Cells (2000 per well) were seeded onto 96-well microtitre plates, allowed to attach for 2-4 h at 
37oC, in humidified atmosphere containing 5% (v/v) CO2 and then treated with various 
concentrations of test compounds (1 µM → 1 nM for 136 and 100 µM → 100 nM for 135).  
 
Quadruplicate samples were run by adding the following reagents: 
 Culture medium only (negative control) → 100 µL medium per well; 
 Cells suspension only (positive control) → 50 µL medium + 50 µL cell suspension; 
 Cells + 1% (v/v) DMSO vehicle → 50 µL of 2% (v/v) DMSO in medium + 50 µL cell 
suspension; 
 Cells + test compound in 1% (v/v) DMSO vehicle → 50 µL of drug at 2 × 
concentration with 2% (v/v) DMSO in medium + 50 µL cell suspension. 
 
Each well contained a final volume of 100 µL medium containing final vehicle concentration 
of 1% (v/v) DMSO and was incubated at 37°C, in a humidified atmosphere containing 5% 
(v/v) CO2 for 3 d. Cell viability was measured by chemical treatment with MTS reagent as 
recommended by the manufacturer (Promega, U.S.A),192 followed by incubation  at 37°C, in 
humidified atmosphere containing 5% (v/v) CO2 for 2-4 hours after which the absorbance of 
each well was measured at 490 nm using a VERSAmax microplate reader. The determination 
of IC50 data was calculated using a four parameter logistic curve and SigmaPlot 12 software 
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for windows. Means and standard deviations were calculated from background corrected 
absorbance. (MTS procedure was adopted from a protocol developed by Dr Pauline Wood.202) 
 
5.86 PSA-Cleavage Assay  
 
5.86.1 Buffer preparation 
Tris.HCl (788 mg, 50 mM), NaCl (818 mg, 140 mM) and were dissolved in Milli-Q water (80 
mL). The pH was adjusted to pH 7.4 using aq. NaOH (0.1 M) or aq. HCl (0.1 M) as required 
and Milli-Q water added to produce 100 mL. 
 
5.86.2 Procedure98, 100 
The peptide-model drug conjugate 203 or 205 (~2 mM) was incubated with PSA (10 µg mL-1) 
at 37C in 50 mM Tris.HCl and 140 mM NaCl, pH 7.4 buffer (500 µL). A control experiment 
without the enzyme was also set up. Samples (50 µL) were taken at different time intervals 
(up to 7 d) and added to ZnCl2 solution (final concentration 10 mM) to quench the reaction. 
Centrifugation (Eppendorf Mini-Spin centrifuge, 13400 rpm, 10 min) was followed by HPLC 
analysis of the supernatant on reverse-phase Phenomenex Gemini 5µm C-18 (150 × 4.6 mm) 
analytical column with gradient and flow-rate as described in Section 5.1. Detection was 




















1. Timms, B. G. Prostate development: A historical perspective. Differentiation 2008, 
76, 565-577. 
2. Wood, C. K.; Lockhart, J. S. Prostate cancer. Am. J. Nurs. 2000, 100, 47-51. 
3. Amin, M.; Khalid, A.; Tazeen, N.; Yasoob, M. Zonal anatomy of prostate. Annals 
2010, 16, 138-142. 
4. Laczko, I.; Hudson, D. L.; Freeman, A.; Feneley, M. R.; Masters, J. R. Comparison of 
the zones of the human prostate with the seminal vesicle: Morphology, 
immunohistochemistry, and cell kinetics. Prostate 2005, 62, 260-266. 
5. Kumar, V. L.; Majumder, P. K. Prostate gland: Structure, functions and regulation. 
Int. J. Urol. Nephrol. 1995, 27, 231-243. 
6. NHS Choices. Prostate disease-Introduction. http://www.nhs.uk/conditions/Prostate-
disease/Pages/Introduction.aspx (7 January 2013). 
7. Tindall, D. J.; Scardino, P. T. Recent advances in prostate cancer: basic science 
discoveries and clinical advances. World Scientific Publishing Co. Pte. Ltd: Singapore, 2011. 
8. NHS Choices. Prostate enlargement-Introduction. http://www.nhs.uk/Conditions/-
Prostate-enlargement/Pages/Introduction.aspx (7 January 2013). 
9. Chen, Y.; Zhang, X.; Hu, X.; Deng, Y.; Chen, J.; Li, S.; Zhang, C.; Wang, J.; Liu, Z.; 
Hao, Y.; Xiao, Y.; Yuan, J.; Xu, T.; Wang, X. The potential role of a self-management 
intervention for benign prostate hyperplasia. Urology 2012, 79, 1385-1389. 
10. Yoo, T. K.; Cho, H. J. Benign prostatic hyperplasia: From bench to clinic. Korean J. 
Urol. 2012, 53, 139-148. 
11. NHS Choices. Prostatitis-introduction. http://www.nhs.uk/Conditions/Prostatitis/-
Pages/Introduction.aspx (07 January 2013). 
12. Pluta, R. M.; Lynm, C.; Golub, R. M. Prostatitis. J. Am. Med. Assoc. 2012, 307, 527. 
13. Naber, K. G. Prostatitis. Nephrol. Dial. Transpl. 2001, 16, 132-134. 
208 
 
14. Clark, C. Protatitis. Pharm. J. 2004, 272, 511-514. 
15. Bott, S. R.; Birtle, A. J.; Taylor, C. J.; Kirby, R. S. Prostate cancer management: (1) 
An update on localised disease. Postgrad. Med. J. 2003, 79, 575-580. 
16. Heidenreich, A.; Bastian, P. J.; Bellmunt, J.; Bolla, M.; Joniau, S.; Mason, M. D.; 
Matveev, T.; Mottet, N.; van der Kwast, T. H.; Wiegel, T.; Zattoni, F. The updated EAU 
guidelines on prostate cancer. http://www.uroweb.org/fileadmin/guidelines/-
2012_Guidelines_large_text_print_total_file.pdf (8 January 2013). 
17. Damber, J.; Aus, G. Prostate cancer. Lancet 2008, 371, 1710-1721. 
18. Mazhar, D.; Waxman, J. Review: Prostate cancer. Postgrad. Med. J. 2002, 78, 590-
595. 
19. Hsing, A.; Chokkalingam, A. Prostate cancer epidemiology. Frontiers Biosci. 2006, 
11, 1388-1413. 
20. Crawford, E. D. Epidemiology of prostate cancer. Urology 2003, 62, 3-12. 
21. Eeles, R. A.; Olama, A. A. A.; Benlloch, S.; Saunders, E. J.; Leongamornlert, D. A.; 
Tymrakiewicz, M.; Ghoussaini, M.; Luccarini, C.; Dennis, J.; Jugurnauth-Little, S.; Dadaev, 
T.; Neal, D. E.; Hamdy, F. C.; Donovan, J. L.; Muir, K.; Giles, G. G.; Severi, G.; Wiklund, F.; 
Gronberg, H.; Haiman, C. A.; Schumacher, F.; Henderson, B. E.; Le Marchand, L.; 
Lindstrom, S.; Kraft, P.; Hunter, D. J.; Gapstur, S.; Chanock, S. J.; Berndt, S. I.; Albanes, D.; 
Andriole, G.; Schleutker, J.; Weischer, M.; Canzian, F.; Riboli, E.; Key, T. J.; Travis, R. C.; 
Campa, D.; Ingles, S. A.; John, E. M.; Hayes, R. B.; Pharoah, P. D. P.; Pashayan, N.; Khaw, 
K.-T.; Stanford, J. L.; Ostrander, E. A.; Signorello, L. B.; Thibodeau, S. N.; Schaid, D.; 
Maier, C.; Vogel, W.; Kibel, A. S.; Cybulski, C.; Lubinski, J.; Cannon-Albright, L.; Brenner, 
H.; Park, J. Y.; Kaneva, R.; Batra, J.; Spurdle, A. B.; Clements, J. A.; Teixeira, M. R.; Dicks, 
E.; Lee, A.; Dunning, A. M.; Baynes, C.; Conroy, D.; Maranian, M. J.; Ahmed, S.; 
Govindasami, K.; Guy, M.; Wilkinson, R. A.; Sawyer, E. J.; Morgan, A.; Dearnaley, D. P.; 
Horwich, A.; Huddart, R. A.; Khoo, V. S.; Parker, C. C.; Van As, N. J.; Woodhouse, C. J.; 
Thompson, A.; Dudderidge, T.; Ogden, C.; Cooper, C. S.; Lophatananon, A.; Cox, A.; 
Southey, M. C.; Hopper, J. L.; English, D. R.; Aly, M.; Adolfsson, J.; Xu, J.; Zheng, S. L.; 
Yeager, M.; Kaaks, R.; Diver, W. R.; Gaudet, M. M.; Stern, M. C.; Corral, R.; Joshi, A. D.; 
Shahabi, A.; Wahlfors, T.; Tammela, T. L. J.; Auvinen, A.; Virtamo, J.; Klarskov, P.; 
Nordestgaard, B. G.; Roder, M. A.; Nielsen, S. F.; Bojesen, S. E.; Siddiq, A.; FitzGerald, L. 
209 
 
M.; Kolb, S.; Kwon, E. M.; Karyadi, D. M.; Blot, W. J.; Zheng, W.; Cai, Q.; McDonnell, S. 
K.; Rinckleb, A. E.; Drake, B.; Colditz, G.; Wokolorczyk, D.; Stephenson, R. A.; Teerlink, 
C.; Muller, H.; Rothenbacher, D.; Sellers, T. A.; Lin, H.-Y.; Slavov, C.; Mitev, V.; Lose, F.; 
Srinivasan, S.; Maia, S.; Paulo, P.; Lange, E.; Cooney, K. A.; Antoniou, A. C.; Vincent, D.; 
Bacot, F.; Tessier, D. C.; Kote-Jarai, Z.; Easton, D. F. Identification of 23 new prostate cancer 
susceptibility loci using the iCOGS custom genotyping array. Nat. Genet. 2013, 45, 385-391. 
22. The breast cancer linkage consortium. Cancer risks in BRCA2 mutation carriers. J. 
Natl. Cancer Inst. 1999, 91, 1310-1316. 
23. Francis, J. C.; McCarthy, A.; Thomsen, M. K.; Ashworth, A.; Swain, A. Brca2 and 
Trp53 deficiency cooperate in the progression of mouse prostate tumourigenesis. PLoS 
Genetics 2010, 6, 1-9. 
24. Nelson, W. G.; De Marzo, A. M.; Isaacs, W. B. Review: Mechanisms of disease-
prostate cancer. N. Engl. J. Med. 2003, 349, 366-381. 
25. Kirby, R.; Madhavan, S. G. Prostate cancer. Surgery 2010, 28, 594-598. 
26. Coffey, D. S. Similarities of prostate and breast cancer: Evolution, diet, and estrogens. 
Urology 2001, 57, 31-38. 
27. Kumar, V.; Anderson, J. Prostate cancer. Surgery 2002, 20, 297-300. 
28. Lee, W. H.; Morton, R. A.; Epstein, J. I.; Brooks, J. D.; Campbell, P. A.; Bova, G. S.; 
Hsieh, W. S.; Isaacs, W. B.; Nelson, W. G. Cytidine methylation of regulatory sequences near 
the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc. 
Natl. Acad. Sci. USA 1994, 91, 11733-11737. 
29. Bastian, P. J.; Yegnasubramanian, S.; Palapattu, G. S.; Rogers, C. G.; Lin, X.; De 
Marzo, A. M.; Nelson, W. G. Molecular biomarker in prostate cancer: The role of CpG Island 
hypermethylation. Eur. Urol. 2004, 46, 698-708. 
30. Meeker, A. K.; Hicks, J. L.; Platz, E. A.; March, G. E.; Bennett, C. J.; Delannoy, M. 
J.; De Marzo, A. M. Telomere shortening is an early somatic DNA alteration in human 
prostate tumorigenesis. Cancer Res. 2002, 62, 6405-6409. 
210 
 
31. Meeker, A. K.; Hicks, J. L.; Iacobuzio-Donahue, C. A.; Montgomery, E. A.; Westra, 
W. H.; Chan, T. Y.; Ronnett, B. M.; De Marzo, A. M. Telomere length abnormalities occur 
early in the initiation of epithelial carcinogenesis. Clin. Cancer Res. 2004, 10, 3317-3326. 
32. Sommerfeld, H. J.; Meeker, A. K.; Piatyszek, M. A.; Bova, G. S.; Shay, J. W.; Coffey, 
D. S. Telomerase activity: A prevalent marker of malignant human prostate tissue. Cancer 
Res. 1996, 56, 218-222. 
33. Iwata, T.; Schultz, D.; Hicks, J.; Hubbard, G. K.; Mutton, L. N.; Tamara L. Lotan, T. 
L.; Bethel, C.; Lotz, M. T.; Yegnasubramanian, S.; Nelson, W. G.; Dang, C. V.; Xu, M.; 
Anele, U.; Koh, C. M.; Bieberich, C. J.; De Marzo, A. M. MYC overexpression induces 
prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells. PLoS 
ONE 2010, 5, 1-16. 
34. Nationl Institute for Health and Care Excellence (NICE). Prostate cancer: Diagnosis 
and treatment. National Collaborating Centre for Cancer: Cardiff, 2008; pp 1-186. 
35. Jain, S.; Bhojwani, A.; Mellon, J. Improving the utility of prostate specific antigen 
(PSA) in the diagnosis of prostate cancer: The use of PSA derivatives and novel markers. 
Postgrad. Med. J. 2002, 78, 646-650. 
36. Wood, N. Understanding treatment of prostate cancer. Pharm. J. 2009, 35-38. 
37. Zhang, T. Y.; Agarwal, N.; Sonpavde, G.; DiLorenzo, G.; Bellmunt, J.; Vogelzang, N. 
J. Management of castrate resistant prostate cancer-Recent advances and optimal sequence of 
treatments. Curr. Urol. Rep. 2013, 1-10. 
38. National Institute for Health and Care Excellence (NICE). Abiraterone for castration-
resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen. 
Centre for Health Technology Evaluation: 2012; pp 1-51. 
39. Suárez, C.; Morales-Barrera, R.; Ramos, V.; Núñez, I.; Valverde, C.; Planas, J.; 
Morote, J.; Maldonado, X.; Carles, J. Role of immunotherapy in castration-resistant prostate 
cancer (CRPC). Brit. J. Urol. Int. 2013, 1-10. 
40. Mukherji, D.; Temraz, S.; Wehbe, D.; Shamseddine, A. Angiogenesis and anti-
angiogenic therapy in prostate cancer. Crit. Rev. Oncol. Hematol. 2013, 87, 122-131. 
211 
 
41. Lajiness, J., P.; Boger, D., L. Asymmetric synthesis of 1,2,9,9a-
tetrahydrocyclopropa[c]benzo[e]indol-4-one (CBI). J. Org. Chem 2011, 76, 583-587. 
42. Wrasidlo, W.; Douglas, S.; Boger, D. Introduction of endonucleolytic DNA 
fragmentation and apoptosis by the duocarmycins. Bioorg. Med. Chem. 1994, 2 631-636. 
43. Li, L. H.; Swenson, D. H.; Schpok, S. L. F.; Kuentzel, S. L.; Dayton, B. D.; Krueger, 
W. C. CC-1065 (NSC298223), a novel antitumour agent that interacts strongly with double-
stranded DNA. Cancer Res. 1982, 42, 999-1004. 
44. Atwell, G. J.; Tercel, M.; Boyd, M.; Wilson, W. R.; Denny, W. A. Synthesis and 
cytotoxicity of 5-amino-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl)carbonyl]-1,2- 
dihydro-3H-benz[e]indole (amino-seco-CBI-TMI) and related 5-alkylamino analogues: New 
DNA minor groove alkylating agents. J. Org. Chem. 1998, 63, 9414-9420. 
45. Baraldi, P. G.; Cacciari, B.; Guiotto, A.; Romagnoli, R.; Zaid, A. N.; Spalluto, G. 
DNA minor-groove binders: Results and design of new antitumor agents. Farmaco 1999, 54, 
15-25. 
46. Mohamadi, F.; Spees, M. M.; Staten, G. S.; Marder, P.; Kipka, J. K.; Johnson, D. A.; 
Boger, D. L.; Zarrinmayeh, H. Total synthesis and biological properties of novel 
antineoplastic (chloromethyl)furanoindolines: An asymmetric hydroboration mediated 
synthesis of the alkylation subunits. J. Med. Chem. 1994, 37, 232-239. 
47. Nagamura, S.; Asai, A.; Kobayashi, E.; Gomi, K.; Saito, H. Studies on duocarmycin 
SA and its derivatives. Bioorg. Med. Chem. 1997, 5, 623-630. 
48. Tercel, M.; Atwell, G. J.; Yang, S.; Ashoorzadeh, A.; Stevenson, R. J.; Botting, K. J.; 
Gu, Y.; Mehta, S. Y.; Denny, W. A.; Wilson, W. R.; Pruijn, F. B. Selective treatment of 
hypoxic tumor cells in vivo: Phosphate pre-prodrugs of nitro analogues of the duocarmycins. 
Angew. Chem. Int. Ed. 2011, 50, 2606-2609. 
49. Wang, Y.; Jiang, J.; Jiang, X.; Cai, S.; Han, H.; Li, L.; Tian, Z.; Jiang, W.; Zhang, Z.; 
Xiao, Y.; Wright, S. C.; Larrick, J. W. Synthesis and antitumor activity evaluations of 
albumin-binding prodrugs of CC-1065 analog. Bioorg. Med. Chem. 2008, 16, 6552-6559. 
50. Parrish, J. P.; Kastrinsky, D. B.; Stauffer, F.; Hedrick, M. P.; Hwang, I.; Boger, D. L. 
Establishment of substituent effects in the DNA binding subunit of CBI analogues of the 
duocarmycins and CC-1065. Bioorg. Med. Chem. 2003, 11, 3815-3838. 
212 
 
51. Boger, D. L. The duocarmycins: Synthetic and mechanistic studies. Acc. Chem. Res. 
1995, 28, 20-29. 
52. Cacciari, B.; Romagnoli, R.; Baraldi, P. G.; DaRos, T. D.; Spalluto, G. CC-1065 and 
the duocarmycins: Recent developments. Expert Opin. Ther. Pat. 2000, 10, 1853-1871. 
53. Bhuyan, B. K.; Newell, K., A.; Crampton, S. L.; Von Hoff, D. D. CC-1065 (NSC 
298223), a most potent antitumor agent: Kinetics of inhibition of growth, DNA synthesis, and 
cell survival. Cancer Res. 1982, 42, 3532-3537. 
54. Pecere, T.; Gazzola, M. V.; Mucignat, C.; Parolin, C.; Vecchia, F. D.; Cavaggioni, A.; 
Basso, G.; Diaspro, A.; Salvato, B.; Carli, M.; Palù, G. Aloe-emodin is a new type of 
anticancer agent with selective activity against neuroectodermal tumors. Cancer Res. 2000, 
60, 2800-2804. 
55. Purnell, B.; Sato, A.; O’Kelley, A.; Price, C.; Summerville, K.; Hudson, S.; O’Hare, 
C.; Kiakos, K.; Asao, T.; Lee, M.; Hartley, J. A. DNA interstrand crosslinking agents: 
Synthesis, DNA interactions, and cytotoxicity of dimeric achiral seco-amino-CBI and 
conjugates of achiral seco-amino-CBI with pyrrolobenzodiazepine (PBD). Bioorg. Med. 
Chem. Lett. 2006, 16, 5677-5681. 
56. Howard, T. T.; Lingerfelt, B. M.; Purnell, B. L.; Scott, A. E.; Price, C. A.; Townes, H. 
M.; McNulty, L.; Handl, H. L.; Summerville, K.; Hudson, S. J.; Bowen, J. P.; Kiakos, K.; 
Hartleyd, J. A.; Leea, M. Novel furano analogues of duocarmycin C1 and C2: Design, 
synthesis, and biological evaluation of seco-iso-cyclopropylfurano[2,3-e]indoline (seco-iso-
CFI) and seco-cyclopropyltetrahydrofurano[2,3-f]quinoline (seco-CFQ) analogues. Bioorg. 
Med. Chem. 2002, 10, 2941-2952. 
57. Sato, A.; McNulty, L.; Cox, K.; Kim, S.; Scott, A.; Daniell, K.; Summerville, K.; 
Price, C.; Hudson, S.; Kiakos, K.; Hartley, J. A.; Asao, T.; Lee, M. A novel class of in vivo 
active anticancer agents: Achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone 
(seco-CBI) analogues of the duocarmycins and CC-1065. J. Med. Chem. 2005, 48, 3903-
3918. 
58. Kupchinsky, S.; Centioni, S.; Howard, T.; Trzupek, J.; Roller, S.; Carnahan, V.; 
Townes, H.; Purnell, B.; Price, C.; Handl, H.; Summerville, K.; Johnson, K.; Toth, J.; 
Hudson, S.; Kiakos, K.; Hartley, J. A.; Lee, M. A novel class of achiral seco-analogs of CC-
213 
 
1065 and the duocarmycins: Design, synthesis, DNA binding, and anticancer properties. 
Bioorg. Med. Chem. 2004, 12, 6221-6236. 
59. Darzynkiewicz, Z.; Juan, G.; Li, X.; Gorczyca, W.; Murakami, T.; Traganos, F. 
Cytometry in cell necrobiology: Analysis of apoptosis and accidental cell death (necrosis). 
Cytometry 1997, 27, 1-20. 
60. Boger, D. L.; Johnson, D. S. CC-1065 and the duocarmycins: Unraveling the keys to a 
new class of naturally derived DNA alkylating agents. Proc. Natl. Acad. Sci. USA 1995, 92, 
3642-3649. 
61. Boger, D. L.; Johnson, D. S. CC- 1065 and the duocarmycins : understanding their 
biological function through mechanistic studies. Angew. Chem. Int. Ed. Engl. 1996, 35, 1438-
1474. 
62. Wang, Y.; Yuan, H.; Wright, S. C.; Wang, H.; Larrick, J. W. Synthesis and 
cytotoxicity of a biotinylated CC-1065 analogue. BMC. Chem. Biol. 2002, 2, 1-4. 
63. Hurley, L. H.; Warpehoski, M. A.; Lee, C. S.; McGovren, J. P.; Scahill, T. A.; Kelly, 
R. C.; Mitchell, M. A.; Wicnienski, N. A.; Gebhard, I.; Johnson, P. D.; Bradford, V. S. 
Sequence specificity of DNA alkylation by the unnatural enantiomer of CC-1065 and its 
synthetic analogues. J. Am. Chem. Soc. 1990, 112, 4633-4649. 
64. Remers, W. A. The chemistry of antitumour antibiotics. John Wiley & Sons, Inc.: 
Canada, 1988; Vol. 2, p 154-161. 
65. Huang, W.; Xu, H.; Li, Y.; Zhang, F.; Chen, X.; He, Q.; Igarashi, Y.; Tang, G. 
Characterization of yatakemycin gene cluster revealing a radical S-adenosylmethionine 
dependent methyltransferase and highlighting spirocyclopropane biosynthesis. J. Am. Chem. 
Soc. 2012, 134, 8831-8840. 
66. Boger, D. L.; Mbini, P.; Tarby, C. M. Chemical and structural comparison of N-Boc-
CBQ and N-Boc-CBI: Identification and structural origin of an unappreciated but productive 
stability of the CC-1065 and duocarmycin SA alkylation subunits. J. Am. Chem. Soc. 1994, 
116, 6461-6462. 
67. Boger, D. L.; Garbaccio, R. M.; Jin, Q. Synthesis and evaluation of CC-1065 and 
duocarmycin analogues incorporating the Iso-CI and Iso-CBI alkylation subunits: Impact of 
relocation of the C-4 carbonyl. J. Org. Chem. 1997, 62, 8875-8891. 
214 
 
68. MacMillan, K. S.; Boger, D. L. Fundamental relationships between structure, 
reactivity, and biological activity for the duocarmycins and CC-1065. J. Med. Chem. 2009, 
52, 5771-5780. 
69. Boger, D. L.; Turnbull, P. Synthesis and evaluation of CC-1065 and duocarmycin 
analogs incorporating the 1,2,3,4,11,11a-hexahydrocyclopropa[c]naphtho[2,1-b]azepin-6-one 
(CNA) alkylation aubunit: structural features that govern reactivity and reaction 
regioselectivity. J. Org. Chem. 1997, 62, 5849-5863. 
70. Lajiness, J. P.; Boger, D. L. Synthesis and characterization of a cyclobutane 
duocarmycin derivative  incorporating the  1,2,10,11-tetrahydro-9H-
cyclobuta[c]benzo[e]indol-4-one (CbBI)  alkylation subunit. J. Am. Chem. Soc. 2010, 132, 
13936-13940. 
71. Boger, D. L.; Santillán, J., A.; Searcey, M.; Jin, Q. Synthesis and evaluation of 
duocarmycin and CC-1065 analogues containing modifications in the subunit linking amide. 
J. Org. Chem. 1999, 64, 5241-5244. 
72. Boger, D. L.; Santillán, A.; Searcey, M.; Jin, Q. Critical role of the linking amide in 
CC-1065 and the duocarmycins: Implications on the source of DNA alkylation catalysis. J. 
Am. Chem. Soc. 1998, 120, 11554-11557. 
73. Warpehoski, M. A.; Harper, D. E.; Mitchell, M. A.; Monroe, T. J. Reversibility of the 
covalent reaction of CC-1065 and analogs with DNA. Biochemistry 1992, 31, 2502-2508. 
74. Lee, C.; Gibson, N. W. DNA interstrand cross-links induced by the 
cyclopropylpyrroloindole antitumor agent bizelesin are reversible upon exposure to alkali. 
Biochemistry 1993, 32, 9108-9114. 
75. McGovren, J. P.; Clarke, G. L.; Pratt, E. A.; Dekoning, T. F. Preliminary toxicity 
studies with the DNA-binding antibiotic, CC-1065. J.  Antibiot. 1984, 37, 63-70. 
76. Aristoff, P. A.; Johnson, P. D.; Sun, D.; Hurleyt, L. H. Synthesis and biochemical 
evaluation of the CBI-PDE-I-dimer, a benzannelated analog of (+)-CC-1065 that also 
produces delayed toxicity in mice. J. Med. Chem. 1993, 36, 1956-1963. 
77. Boger, D. L.; Boyce, C.; Garbaccio, R.; Searcey, M.; Jin, Q. CBI prodrug analogs of 
CC-1065 and the duocarmycins. Synthesis 1999, 1505-1509. 
215 
 
78. Boger, D. L.; Ishizaki, T.; Sakya, S. M.; Munk, S. A.; Kitos, P. A.; Jin, Q.; Besterman, 
J. M. Synthesis and preliminary evaluation of (+)-CBI-indole2: An enhanced functional 
analog of (+)-CC-1065. Bioorg. Med. Chem. Lett. 1991, 1, 115-120. 
79. Yang, S.; Denny, W. A. A new short synthesis of 3-substituted 5-amino-1-
(chloromethyl)-1,2-dihydro-3H-benzo[e]indoles (amino-CBIs). J. Org. Chem. 2002, 67, 
8958-8961. 
80. Milbank, J. B. J.; Tercel, M.; Atwell, G. J.; Wilson, W. R.; Hogg, A.; Denny, W. A. 
Synthesis of 1-substituted 3-(chloromethyl)-6-aminoindoline (6-amino-seco-CI) DNA minor 
groove alkylating agents and structure-activity relationships for their cytotoxicity. J. M. 
Chem. 1999, 42, 649-658. 
81. Tietze, L. F.; Schuster, H. J.; Hampel, S. M.; Rühl, S.; Pfoh, R. Enantio- and 
diastereoselective synthesis of duocarmycine-based prodrugs for a selective treatment of 
cancer by epoxide opening. Chem. Eur. J. 2008, 14, 895-901. 
82. Atkinson, J. M.; Siller, C. S.; Gill, J. H. Tumour endoproteases: The cutting edge of 
cancer drug delivery? Brit. J. Pharmacol. 2008, 153, 1344-1352. 
83. Tranoy-Opalinski, I.; Fernandes, A.; Thomas, M.; Gesson, J. P.; Papot, S. Design of 
self-Immolative linkers for tumour-activated prodrug therapy. Anticancer Agents Med. Chem. 
2008, 8, 618-637. 
84. Papot, S.; Tranoy, I.; Tillequin, F.; Florent, J. C.; Gesson, J. P. Design of selectively 
activted anticancer prodrugs: Elimination and cyclisation strategies. Curr. Med. Chem. 
Anticancer Agents 2002, 2, 155-185. 
85. Kamal, A.; Tekumalla, V.; Raju, P.; Naidu, V. G. M.; Diwan, P. V.; Sistla, R. 
Pyrrolo[2,1-c][1,4]benzodiazepine-β-glucuronide prodrugs with a potential for selective 
therapy of solid tumors by PMT and ADEPT strategies. Bioorg. Med. Chem. Lett. 2008, 18, 
3769-3773. 
86. Bagshawe, K. D. Antibody directed enzymes revive anti-cancer prodrugs concept. 
Brit. J. Cancer 1987, 56, 531-532. 
87. Tietze, L. F.; Krewer, B. Antibody-Directed Enzyme Prodrug Therapy: A promising 
approach for a selective treatment of cancer based on prodrugs and monoclonal antibodies. 
Chem. Biol. Drug Des. 2009, 74, 205-211. 
216 
 
88. Tietze, L. F.; Schuster, H. J.; Schmuck, K.; Schuberth, I.; Alves, F. Duocarmycin-
based prodrugs for cancer prodrug monotherapy. Bioorg. Med. Chem. 2008, 16, 6312-6318. 
89. Niculescu-Duvaz, I.; Springer, C. J. Introduction to the background, principles, and 
state of the art in suicide gene therapy. Mol. Biotechnol. 2005, 30, 71-88. 
90. Singh, P.; LeBeau, A. M.; Lilja, H.; Denmeade, S. R.; Isaacs, J. T. Molecular insights 
into substrate specificity of prostate specific antigen through structural modeling. Proteins 
2009, 77, 984-993. 
91. Choi, K. Y.; Swierczewska, M.; Lee, S.; Chen, X. Protease-activated drug 
development. Theranostics 2012, 2, 156-178. 
92. Denmeade, S. R.; Nagy, A.; Gao, J.; Lilja, H.; Schally, A. V.; Isaacs, J. T. Enzymatic 
activation of a doxorubicin-peptide prodrug by prostate-specific antigen. Cancer Res. 1998, 
58, 2537-2540. 
93. Ferrieu-Weisbuch, C.; Michel, S.; Collomb-Clerc, E.; Pothion, C.; Deléage, G.; 
Jolivet-Reynaud, C. Characterization of prostate-specific antigen binding peptides selected by 
phage display technology. J. Mol. Recogn. 2006, 19, 10-20. 
94. Kumar, S. K.; Williams, S. A.; Isaacs, J. T.; Denmeade, S. R.; Khan, S. R. Modulating 
paclitaxel bioavailability for targeting prostate cancer. Bioorg. Med. Chem. 2007, 15, 4973-
4984. 
95. Michel, S.; Collomb-Clerc, E.; Geourjon, C.; Charrier, J. P.; Passagot, J.; Courty, Y.; 
Deléage, G.; Jolivet-Reynaud, C. Selective recognition of enzymatically active prostate-
specific antigen (PSA) by anti-PSA monoclonal antibodies. J. Mol. Recogn. 2005, 18, 225-
235. 
96. DiPaola, R. S.; Rinehart, J.; Nemunaitis, J.; Ebbinghaus, S.; Rubin, E.; Capanna, T.; 
Ciardella, M.; Doyle-Lindrud, S.; Goodwin, S.; Fontaine, M.; Adams, N.; Williams, A.; 
Schwartz, M.; Winchell, G.; Wickersham, K.; Deutsch, P.; Yao, S.-L. Characterization of a 
novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with 
prostate cancer. J. Clin. Oncol. 2002, 20, 1874-1879. 
97. DeFeo-Jones, D.; Garsky, V. M.; Wong, B. K.; Feng, D. M.; Bolyar, T.; Haskell, K.; 
Kiefer, D. M.; Leander, K.; McAvoy, E.; Lumma, P.; Wai, J.; Senderak, E. T.; Motzel, S. L.; 
Keenan, K.; Van Zwieten, M.; Lin, J. H.; Freidinger, R.; Huff, J.; Oliff, A.; Jones, R. E. A 
217 
 
peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate 
tumor cells positive for prostate-specific antigen in vivo. Nat. Med. 2000, 6, 1248-52. 
98. Mhaka, A.; Denmeade, S. R.; Yao, W.; Isaacs, J. T.; Khan, S. R. A 5-
fluorodeoxyuridine prodrug as targeted therapy for prostate cancer. Bioorg. Med. Chem. Lett. 
2002, 12, 2459-2461. 
99. Denmeade, S. R.; Lou, W.; Lövgren, J.; Malm, J.; Lilja, H.; Isaacs, J. T. Specific and 
efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen. 
Cancer Res. 1997, 57, 4924-4930. 
100. Denmeade, S. R.; Jakobsen, C. M.; Janssen, S.; Khan, S. R.; Garrett, E. S.; Lilja, H.; 
Christensen, S. B.; Isaacs, J. T. Prostate-specific antigen-activated thapsigargin prodrug as 
targeted therapy for prostate cancer. J. Natl. Cancer Inst. 2003, 95, 990-1000. 
101. Lee, D. I.; Sumbilla, C.; Lee, M.; Natesavelalar, C.; Klein, M. G.; Ross, D. D.; Inesi, 
G.; Hussain, A. Mechanisms of resistance and adaptation to thapsigargin in androgen-
independent prostate cancer PC3 and DU145 cells. Arch. Biochem. Biophy. 2007, 464, 19-27. 
102. Schuster, H. J.; Krewer, B.; von Hof, J. M.; Schmuck, K.; Schuberth, I.; Alves, B.; 
Tietze, L. F. Synthesis of the first spacer containing prodrug of a duocarmycin analogue and 
determination of its biological activity. Org. Biomol. Chem. 2010, 8, 1833-1842. 
103. Ge, Y.; Wua, X.; Zhang, D.; Hua, L. 3-Aminoxypropionate-based linker system for 
cyclization activation in prodrug design. Bioorg. Med. Chem. Lett. 2009, 19, 941-944. 
104. Manabe, S.; Machida, H.; Aihara, Y.; Yasunaga, M.; Itoa, Y.; Matsumur, Y. 
Development of a diketopiperazine-forming dipeptidyl Gly-Pro spacer for preparation of an 
antibody–drug conjugate. Med. Chem. Commun. 2013, 4, 792-796. 
105. Suaifan, G. A. R. Y.; Arafat, T.; Threadgill, M. D. Synthetic approaches to peptides 
containing the L-Gln-L-Val-D(S)-Dmt motif. Bioorg. Med.Chem. 2007, 15, 3474-3488. 
106. Suaifan, G. A. R. Y.; Mahon, M. F.; .; Arafat, T.; Threadgill, M. D. Effects of steric 
bulk and stereochemistry on the rates of diketopiperazins formation from N-aminoacyl-2,2-
dimethylthiazolidine-4-carboxamides (Dmt dipeptide amides)-a model for a new prodrug 
linker system. Tetrahedron 2006, 62, 11245-11266. 
218 
 
107. Brady, S. F.; Pawluczyk, J. M.; Lumma, P. K.; Feng, D.-M.; Wai, J. M.; Jones, R.; 
DeFeo-Jones, D.; Wong, B. K.; Miller-Stein, C.; Lin, J. H.; Oliff, A.; Freidinger, R. M.; 
Garsky, V. M. Design and synthesis of a pro-drug of vinblastine targeted at treatment of 
prostate cancer with enhanced efficacy and reduced systemic toxicity. J. Med. Chem. 2002, 
45, 4706-4715. 
108. Han, S.; Choi, K. N-Arylcarbonylpseudoprolines as tunable chiral derivatizing agents 
for the determination of the absolute configuration of secondary alcohols. Eur. J. Org. Chem. 
2011, 2011, 2920-2923. 
109. Wöhr, T.; Mutter, M. Pseudo-prolines in peptide synthesis: Direct insertion of serine 
and threonine derived oxazolidines in dipeptides. Tetrahedron Lett. 1995, 36, 3847-3848. 
110. Abedini, A.; Raleigh, D. P. Incorporation of pseudoproline derivatives allows the 
facile synthesis of human IAPP, a highly amyloidogenic and aggregation-arone polypeptide. 
Org. Lett. 2005, 7, 693-696. 
111. Wöhr, T.; Wahl, F.; Nefzi, A.; Rohwedder, B.; Sato, T.; Sun, S.; Mutter, M. Pseudo-
prolines as a solubilizing, structure-disrupting protection technique in peptide synthesis. J. 
Am. Chem. Soc. 1996, 118, 9218-9227. 
112. Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor vascular permeability 
and the EPR effect in macromolecular therapeutics: A review. J. Control. Release 2000, 65, 
271-284. 
113. Arias, J. L. Drug targeting strategies in cancer treatment. Mini-Rev. Med. Chem. 2011, 
11, 1-17. 
114. Bisht, S.; Maitra, A. Dextran–doxorubicin/chitosan nanoparticles for solid tumor 
therapy. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology 2009, 1, 
415-425. 
115. Cao, N.; Feng, S.-S. Doxorubicin conjugated to D-α-tocopheryl polyethylene glycol 
1000 succinate (TPGS): Conjugation chemistry, characterization, in vitro and in vivo 
evaluation. Biomaterials 2008, 29, 3856-3865. 
116. Marcus, Y.; Sasson, K.; Fridkin, M.; Shechter, Y. Turning low-molecular-weight 
drugs into prolonged acting prodrugs by reversible pegylation: A study with gentamicin. J. 
Med. Chem. 2008, 51, 4300-4305. 
219 
 
117. Seymour, L. W.; Ulbrich, K.; Steyger, P. S.; Brereton, M.; Subr, V.; Strohalm, J.; 
Duncan, R. Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs 
in the treatment of subcutaneous murine B16F10 melanoma. Brit. J. Cancer 1994, 70, 636-
641. 
118. Vasey, P.; Kaye, S.; Morrison, R.; Twelves, C.; Wilson, P.; Duncan, R.; Thomson, A.; 
Murray, L.; Hilditch, T.; Murray, T.; Burtles, S.; Fraier, D.; Frigerio, E.; Cassidy, J. Phase I 
clinical and pharmacokinetic study of PK1 [N-(2- hydroxypropyl)methacrylamide copolymer 
doxorubicin]: First member of a new class of chemotherapeutic agents-Drug-polymer 
conjugates. Clin. Cancer Res. 1999, 5, 83-94. 
119. Chandran, S. S.; Nan, A.; Rosen, D. M.; Ghandehari, H.; Samuel R. Denmeade, S. R. 
A prostate-specific antigen–activated N-(2-hydroxypropyl) methacrylamide copolymer 
prodrug as dual-targeted therapy for prostate cancer. Mol. Cancer Ther. 2007, 6, 2928-2937. 
120. Roberts, M. J.; Bentley, M. D.; Harris, J. M. Chemistry for peptide and protein 
PEGylation. Adv. Drug Deliver. Rev. 2002, 54, 459-476. 
121. Choi, H.; Chuna, M.; Lee, S. H.; Jang, M. H.; Kimb, H. D.; Jung, C. S.; Oh, S. Y. In 
vitro and in vivo study of poly(ethylene glycol) conjugated ketoprofen to extend the duration 
of action. Int. J. Pharmaceutics 2007, 341, 50-57. 
122. Greenwald, R. B.; Choe, Y. H.; McGuire, J.; Conover, C. D. Effective drug delivery 
by PEGylated drug conjugates. Adv. Drug Deliver. Rev. 2003, 55, 217-250. 
123. Veronese, F. M.; Schiavon, O.; Pasut, G.; Mendichi, R.; Andersson, L.; Tsirk, A.; 
Ford, J.; Wu, G.; Kneller, S.; Davies, J.; Duncan, R. PEG-doxorubicin conjugates: Influence 
of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor 
activity. Bioconjugate Chem. 2005, 16, 775-784. 
124. Tietze, L. F.; Major, F.; Schuberth, I.; Dirk A. Spiegl, D. A.; Krewer, B.; 
Maksimenka, K.; Bringmann, G.; Magull, J. Selective treatment of cancer: Synthesis, 
biological evaluation and structural elucidation of novel analogues of the antibiotic CC-1065 
and the duocarmycins. Chem. Eur. J. 2007, 13, 4396-4409. 
125. Tietze, L. F.; Herzig, T.; Fecher, A.; Haunert, F.; Schuberth, I. Highly selective 
glycosylated prodrugs of cytostatic CC-1065 analogues for antibody-directed enzyme tumor 
therapy. Chem. Biochem. 2001, 2, 758-765. 
220 
 
126. Boger, D. L.; Yun, W.; Teegarden, B. R. An improved synthesis of 1,2,9,9a-
tetrahydrocyclopropa[c]benz[e]indol-4-one (CBI): A simplified analogue of the CC-1065 
alkylation subunit. J. Org. Chem. 1992, 57, 2813-287. 
127. Boger, D. L.; Ishizaki, T. Synthesis of N-(tert-butyloxycarbonyl)-CBI, CBI, CBI-
CDPI1, and CBI-CDPI2: Enhanced functional analogues of CC-1065 incorporating the 
1,2,9,9a tetrahydrocyclopropa[c]benz[e]indol-4-one (CBI) left-hand subunit. J. Org. Chem. 
1990, 55, 5823-5832. 
128. Boger, D. L.; McKie, J. A. An eficient synthesis of 1,2,9,9a-tetrahydrocyclo-
propa[c]benz[e]indol-4-one (CBI): An enhanced and simplified analogue of the CC-1065 and 
duocarmycin alkylation subunits. J. Org. Chem. 1995, 60, 1271-1275. 
129. Tietze, L. F.; Major, F.; Schuberth, I. Antitumor agents: Development of highly potent 
glycosidic guocarmycin analogues for selective cancer therapy. Angew. Chem. Int. Ed. 2006, 
45, 6574–6577. 
130. Hodgson, H. H.; Smith, E. W. The mononitration of α-naphthol and of α-naphthyl 
methyl ether, and the monoreduction of 2,4-dinitro-1-naphthol. J. Chem. Soc. 1935, 671-674. 
131. Clayden, R.; Greeves, N.; Warren, S.; Wothers, P. Organic chemistry. Oxford 
university press: New York, 2001. 
132. Mori, A.; Mizusaki, T.; Ikawa, T.; T., M.; Monguchi, Y.; Sajiki, H. Mechanistic study 
of a Pd/C-catalyzed reduction of aryl sulfonates using Mg-MeOH-NH4OAc system. Chem. 
Eur. J. 2007, 13, 1432-1441. 
133. Peterson, G. A.; Kunng, F.-A.; McCallum, J. S.; Wulffe, W. D. Palladium catalyzed 
reduction of aryl triflates-Utilization in the synthesis of angelicin, olivin and chromomycinone 
from phenolsproduced in the benzannulation reaction of chromium carbenecomplexes. 
Tetrahedron Lett. 1987, 28, 1381-1384. 
134. Cacchi, S.; Ciattini, P. G.; Morera, E.; Ortar, G. Palladium-catalysed 
triethylammonium formate reduction of aryl triflates. A selective method for deoxygenation 
of phenols. Tetrahedron. Lett. 1986, 27, 5541-5544,. 
135. Morey, J.; Saá, J. M. Solid state redox chemistry of hydroquinones and quinones. 
Tetrahedron 1993, 49, 105-112. 
221 
 
136. Oatis, J., J. E.; Walle, T.; Daniell, H. B.; Gaffney, T. E.; Knapp, D. R. Synthesis of 4’-
hydroxypropranolol sulfate, a major non-β-blocking propranolol metabolite in man. J. Med. 
Chem. 1985, 28, 822-824. 
137. Barrero, A. F.; Alvarez-Manzaneda, E. J.; Chahboun, R.; Meneses, R. Raney nickel: 
An efficient reagent to achieve the chemoselective hydrogenation of α,β-unsaturated carbonyl 
compounds. Synlett 1999, 10, 1663-1666. 
138. Yang, J.; Xiong, C.; Han, X.; Zhou, L. Liquid phase hydrogenation of 
chloronitrobenzene to chloroaniline with PtM/CNTs (M=La, Ce, Pr, Nd and Sm) catalyst. 
Indian J. Chem. 2009, 48A, 1358-1363. 
139. Ben-David, Y.; Gozin, M.; Portnoy, M.; Milstein, D. Reductive dechlorination of aryl 
chlorides catalyzed by palladium complexes containing basic, chelating phosphines. J. Mol. 
Catal. 1992, 73, 173-180. 
140. Indra, A.; Rajamohanan, P. R.; Gopinath, C. S.; Bhaduri, S.; Lahiri, G. K. Selective 
hydrogenation of chloronitrobenzenes with an MCM-41 supported platinum allyl complex 
derived catalyst. Appl. Catal. A-Gen. 2011, 399, 117-125. 
141. Twum, E. A.; Woodman, T. J.; Wang, W.; Threadgill, M. D. Observation by NMR of 
cationic Wheland-like intermediates in the deiodination of protected 1-iodonaphthalene-2,4-
diamines in acidic media. Org. Biomol. Chem. 2013, 11, 6208-6214. 
142. Hawkings, M. J.; Greco, M. N.; Powell, E.; De Garvilla, L.; Maryanoff, B. E. Novel 
inhibitors of chymase. 2005. 
143. Houle, F. A.; Beauchamp, J. L. Photoelectron spectroscopy of methyl, ethyl, 
isopropyl, and tert-butyl radicals. Implications for the thermochemistry and structures of the 
radicals and their corresponding carbonium ions. J. Am. Chem. Soc. 1979, 101, 4067-4074. 
144. Rathore, R.; Kochi, J. K. Donor/acceptor organizations and the electron-transfer 
paradigm for organic reactivity. Adv. Phys. Org. Chem. 2000, 35, 193-318. 
145. Mascal, M.; Hansen, J. Design, synthesis and metal binding properties of a mixed-
donor macrobicycle. Chem. Commun. 1998, 355-356. 
222 
 
146. Olah, G. A.; Lin, H. C.; Mo, Y. K. Stable carbocations. CXXXIX. Nitro- and 
chlorohexamethylbenzeneium ions and 1-nitro- and 1-chloro-2,4,6-trifluoromesitylenium 
ions. J. Am. Chem. Soc. 1972, 94, 3667-3669. 
147. Reed, C. A.; Fackler, N. L. P.; Kim, K.-C.; Stasko, D.; Evans, D. R.; Boyd, P. D. W.; 
Rickard, C. E. F. Isolation of protonated arenes (Wheland intermediates) with BArF and 
carborane anions. A novel crystalline superacid. J. Am. Chem. Soc. 1999, 121, 6314-6315. 
148. Reed, C. A.; Kim, K.-C.; Stoyanov, E. S.; Stasko, D.; Tham, F. S.; Mueller, L. J.; 
Boyd, P. D. W. Isolating benzenium ion salts. J. Am. Chem. Soc. 2003, 125, 1796-1804. 
149. Boga, C.; Del Vecchio, E.; Forlani, L.; Mazzanti, A.; Lario, C. M.; Todesco, P. E.; 
Tozzi, S. Meisenheimer-Wheland complexes between 1,3,5-tris(N,N-dialkylamino)benzenes 
and 4,6-dinitrotetrazolo[1,5-a]pyridine. Evidence of reversible C−C coupling in the 
SEAr/SNAr reaction. J. Org. Chem. 2009, 74, 5568-5575. 
150. Katsuki, T.; Sharpless, K. B. The first practical method for asymmetric epoxidation. J. 
Am. Chem. Soc. 1980, 102, 5974-5976. 
151. Pickard, S. T.; Smith, H. E.; Polavarapu, P. L.; Black, T. M.; Rat, A.; Yang, D. 
Synthesis, experimental and ab initio theoretical vibrational circular dichroism, and absolute 
configurations of substituted oxiranes. J. Am. Chem. Soc. 1992, 114, 6850-6857. 
152. Rossiter, B. E.; Katsuki, T.; Sharpless, K. B. Asymmetric epoxidation provides 
shortest routes to four chiral epoxy alcohols which are key intermediates in syntheses of 
methymycin, erythromycin, leukotriene C-1, and disparlure. J. Am. Chem. Soc. 1981, 103, 
465-467. 
153. White, J. D.; Theramongkol, P.; Kuroda, C.; Engebrecht, J. R. Enantioselective total 
synthesis of (-)-monk acid C via carbosulfenylation of a dihydropyran. J . Org. Chem. 1988, 
53, 5909-5921. 
154. Klunder, J. M.; Onami, T.; Sharpless, K. B. Arenesulfonate derivatives of homochiral 
glycidol: Versatile chiral building blocks for organic synthesis. J. Org. Chem. 1989, 54, 1295-
1304. 
155. Tietze, L. F.; Schuster, H. J.; von Hof, J. M.; Hampel, S. M.; Colunga, J. F.; Michael 
John, M. Atropisomerism of aromatic carbamates. Chem. Eur. J. 2010, 16, 12678–12682. 
223 
 
156. Boger, D. L.; McKie, J. A.; Boyce, C. W. Asymmetric synthesis of the CBI alkylation 
subunit of the CC-1065 and duocarmycin analogues. Synlett 1997, 515-517. 
157. Furuyama, T.; Yonehara, M.; Arimoto, S.; Kobayashi, M.; Matsumoto, Y.; Uchiyama, 
M. Development of highly chemoselective bulky zincate complex. tBu4ZnLi2: Design, 
structure, and practical applications in small-/macromolecular synthesis. Chem. Eur. J. 2008, 
14, 10348-10356. 
158. Carpino, L. A.; El-Faham, A. The diisopropylcarbodiimide/1-hydroxy-7-
azabenzotriazole system: Segment coupling and stepwise peptide assembly. Tetrahedron 
1999, 55, 6813-6830. 
159. Valeur, E.; Bradley, M. Amide bond formation: Beyond the myth of coupling 
reagents. Chem. Soc. Rev. 2009, 38, 606-631. 
160. Reed, G. H.; Kent, J. O.; Wittwer, C. T. High-resolution DNA melting analysis for 
simple and efficient molecular diagnostics. Pharmacogenetics 2007, 8, 597-608. 
161. David-Cordonnier, M.-H.; Laine, W.; Lansiaux, A.; Rosu, F.; Colson, P.; de Pauw, E.; 
Michel, S.; Tillequin, F.; Koch, M.; Hickman, J. A.; Pierré, A.; Bailly, C. Covalent binding of 
antitumor benzoacronycines to double-stranded DNA induces helix opening and the 
formation of single-stranded DNA: Unique consequences of a novel DNA-bonding 
mechanism. Mol. Cancer Ther. 2005, 4, 71-80. 
162. Barltrop, J. A.; Owen, T. C.; Cory, A. H.; Cory, J. G. 5-(3-carboxymethoxyphenyl)-2-
(4,5-dimethylthiazolyl)-3-(4-sulfophenyl)tetrazolium, inner salt (MTS) and related analogs of 
3-(4,5-dimethylthiazolyl)-2,5-diphenyltetrazolium bromide (MTT) reducing to purple water-
soluble formazans as cell-viability indicators. Bioorg. Med. Chem. Lett. 1991, 1, 611-614. 
163. Malich, G.; Markovic, B.; Winder, C. The sensitivity and speciﬁcity of the MTS 
tetrazolium assay for detecting the in vitro cytotoxicity of 20 chemicals using human cell 
lines. Toxicology 1997, 124, 179-192. 
164. Wang, P.; Henning, S. M.; Heber, D. Limitations of MTT and MTS-based assays for 
measurement of antiproliferative activity of green tea polyphenols. PLoS ONE 2010, 5, 1-10. 
165. Reiter, R. J.; Tan, D. X.; Manchester, L. C.; Korkmaz, A.; Fuentes-Broto, L.; 
Hardman, W. E.; Rosales-Corral, S. A.; Qi, W. A walnut-enriched diet reduces the growth of 
LNCaP human prostate cancer xenografts in nude mice. Cancer Invest. 2013, 31, 365–373. 
224 
 
166. Tercel, M.; Lee, H. H.; Yang, S.; Liyanage, H. D. S.; Mehta, S. Y.; Boyd, P. D. W.; 
Jaiswal, J. K.; Tan, K. L.; Pruijn, F. B. Preparation and antitumour properties of the 
enantiomers of a hypoxia-selective nitro analogue of the duocarmycins. Chem. Med. Chem. 
2011, 6, 1860-1871. 
167. Boger, D. L.; Johnson, D. S.; Yun, W. (+)- And ent-(-)-duocarmycin SA and (+)- and 
ent-(-)-N-Boc-DSA DNA alkylation properties. Alkylation site models that accommodate the 
offset AT-rich adenine N3 alkylation selectivity of the enantiomeric agents. J. Am. Chem. Soc. 
1994, 116, 1635-1656. 
168. Isidro-Llobet, A.; Alvarez, M.; Albericio, F. Amino acid-protecting groups. Chem. 
Rev. 2009, 109, 2455-2504. 
169. Pietta, P. G.; Biondi, P. A.; Brenna, O. Comparative acidic cleavage of 
methoxybenzyl-protected amides of amino acids. J. Org. Chem. 1976, 41, 703-704. 
170. Marshall, G. R.; Pietta, P. G.; Cavallo, P. 2,4-Dimethoxybenzyl as a protecting group 
for glutamine and asparagine in peptide synthesis. J. Org. Chem. 1971, 36, 3966-3970. 
171. Henkel, B.; Zhang, L.; Goldammer, C.; Bayer, E. Combined solid phase and solution 
synthesis of the fully protected segment 74-99 of HIV 1-protease with the application of a 
new trityl-linker. Z. Naturforsch. B. 1996, 51, 1339-1346. 
172. Gita, P. M.; Yusuf, A. O.; Bhatt, B. M. Application of tetralinyls as carboxamide 
protecting groups in peptide synthesis. Bull. Chem. Soc. Ethiopia 1998, 12, 35-43. 
173. Franzen, H. M.; Nagren, K.; Grehn, L.; Langstrom, B.; Ragnarsson, U. Preparation 
and 11C-labelling of a substance P analogue containing D-tryptophan in positions 7 and 9. J. 
Chem. Soc. Perkin Trans. 1. 1988, 497-502. 
174. Sieber, P.; Riniker, B. Protection of carboxamide functions by the trityl residue. 
Application to peptide synthesis. Tetrahedron Lett. 1991, 32, 739-742. 
175. Lee, J. T.; Chen, D. Y.; Yang, Z.; Ramos, A. D.; Hsieh, J. J. D.; Bogyo, M. Design, 
syntheses, and evaluation of Taspase1 inhibitors. Bioorg. Med. Chem. Lett. 2009, 19, 5086-
5090. 
176. Jelinski, M.; Hamacher, K.; Coenen, H. H. C-Terminal 18F-ﬂuoroethylamidation 
exempliﬁed on [Gly-OH9] oxytocin. J. Label Compd. Radiopharm. 2002, 45, 217-229. 
225 
 
177. Ramesh, D.; Wieboldt, R.; Billington, A. P.; Carpenter, B. K.; Hess, G. P. Photolabile 
precursors of biological amides: Synthesis and characterization of caged o-nitrobenzyl 
derivatives of glutamine, asparagine, glycinamide, and γ-aminobutyramide. J. Org. Chem. 
1993, 58, 4599-4605. 
178. Beauchard, A.; Twum, E. A.; Lloyd, M. D.; Threadgill, M. D. S-2-Amino-4-
cyanobutanoic acid (β-cyanomethyl-L-Ala) as an atom-efficient solubilising synthon for L-
glutamine. Tetrahedron Lett. 2011, 52, 5311-5314. 
179. Ressler, C.; Ratzkin, H. Synthesis of β-cyano-L-alanine and γ-cyano-α-L-
aminobutyric acid, dehydration products of L-asparagine and L-glutamine; A new synthesis 
of amino acid nitriles. J. Org. Chem. 1961, 26, 3356-3360. 
180. Campagna, F.; Carotti, A.; Casin, G. A convenient synthesis of nitriles from primary 
amides under mild conditions. Tetrahedron Lett. 1977, 21, 1813-1816. 
181. Merck. Peptide synthesis. Novabiochem: 2008-2009. 
182. Bollhagen, R.; Schmiedberger, M.; Barlos, K.; Grell, E. A new reagent for the 
cleavage of fully protected peptides synthesised on 2-chlorotrityl chloride resin. J. Chem. 
Soc., Chem. Commun. 1994, 2559-2560. 
183. Purchase, I. F. H.; Kalinowski, A. E.; Ishmael, J.; Wilson, J.; Gore, C. W.; Chart, I. S. 
Lifetime carcinogenicity study of 1- and 2-naphthylamine in dogs. Brit. J. Cancer 1981, 44, 
892-901. 
184. Sunderland, P. T.; Woon, E. C. Y.; Dhami, A.; Bergin, A. B.; Mahon, M. F.; Wood, P. 
J.; Jones, L. A.; Tully, S. R.; Lloyd, M. D.; Thompson, A. S.; Javaid, H.; Martin, N. M. B.; 
Threadgill, M. D. 5-Benzamidoisoquinolin-1-ones and 5-(ω-carboxyalkyl)isoquinolin-1-ones 
as isoform-selective inhibitors of poly(ADP-ribose) polymerase 2 (PARP-2). J. Med. Chem. 
2011, 54, 2049-2059. 
185. McDonald, M. C.; Mota-Filipe, H.; Wright, J. A.; Abdelrahman, M.; Michael D. 
Threadgill, M. D.; Thompson, A. S.; Thiemermann, C. Effects of 5-aminoisoquinolinone, a 
water-soluble, potent inhibitor of the activity of poly(ADP-ribose) polymerase on the organ 




186. Cuzzocrea, S.; Mazzon, E.; Di Paola, R.; Genovese, T.; Patel, N. S. A.; Muià, C.; 
Michael D. Threadgill, M. D.; De Sarro, A.; Thiemermann, C. 5-Aminoisoquinolinone 
reduces colon injury by experimental colitis. N-S. Arch. Pharmacol. 2004, 370, 464-473. 
187. Chartterjee, P. K.; Chatterjee, B. E.; Pedersen, H.; Sivarajah, A.; Mcdonald, M. C.; 
Mota-Filipe, H.; Brown, P. A. J.; Stewart, K. N.; Cuzzocrea, S.; Threadgill, M. D.; 
Thiemermann, C. 5-Aminoisoquinolinone reduces renal injury and dysfunction caused by 
experimental ischemia/reperfusion. Kidney Int. 2004, 65, 499-509. 
188. Kesten, S. J.; Johnson, J.; Werbel, L. M. Antimalarial drugs. 61. Synthesis and 
antimalarial effects of 4-[(7-chloro-4-quinolinyl)amino]-2-[(diethylamino)methyl]-6-
alkylphenols and their Nω-oxides. J. Med. Chem. 1987, 30, 906-911. 
189. Keller, M.; Wöhr, T.; Dumy, P.; Patiny, L.; Mutter, M. Pseudoprolines in drug design: 
Direct insertion of pseudoproline systems into cyclosporin C. Chem. Eur. J. 2000, 6, 4358-
4363. 
190. Boger, D. L.; Boyce, C.; Garbaccio, R.; Searcey, M.; Jin, Q. CBI prodrug analogs of 
CC-1065 and the duocarmycins. Synthesis 1999, SI 1505-1509. 
191. van Lierop, B. J.; Jackson, W. R.; Robinson, A. J. 5,5-Dimethylproline dipeptides: An 
acid-stable class of pseudoproline. Tetrahedron 2010, 66, 5357-5366. 
192. CellTiter 96® AQueous One Solution Cell Proliferation Assay. Promega corporation 
2012, TB245, 1-12. 
193. Cui, L.-Q.; Liu, K.; Zhang, C. Effective oxidation of benzylic and alkane C-H bonds 
catalyzed by sodium O-iodobenzenesulfonate with oxone as a terminal oxidant under phase-
transfer conditions. Org. Biomol. Chem. 2011, 9, 2258-2265. 
194. Hunter, D. H.; Aponce, Y. 4-Iodophenylcholine: A potential myocardial imaging 
agent. Cancer J . Chem. 1984, 62, 2015-2018. 
195. Frecentese, F.; Fiorino, F.; Perissutti, E.; Severino, B.; Magli, E.; Esposito, A.; De 
Angelis, F.; Massarelli, P.; Nencini, C.; Viti, B.; Santagada, V.; Caliendo, G. Efficient 
microwave combinatorial synthesis of novel indolic arylpiperazine derivatives as 
serotoninergic ligands. Eur. J. Med. Chem. 2010, 45, 752-759. 
227 
 
196. Robinson, R. A. 1-Dialkylaminoalkylaminoisoquinolines. J. Am. Chem. Soc. 1947, 69, 
1939-1942. 
197. Jorgensen, E. C.; Slade, P. Thyroxine analogs. 20. Substituted 1- and 2-naphthyl 
ethers of 3,5-diiodotyrosine. J. Med. Chem. 1971, 14, 1023-1026. 
198. Cablewski, T.; Gurr, P. A.; Raner, K. D.; Strauss, C. R. A new, regioselective, tandem 
amidation reaction of electron-rich arenes. J. Org. Chem. 1994, 59, 5814-5817. 
199. A. Rabbani, A.; Khodabandeh, M. Studies on the binding of the alkylating agent sulfur 
mustard to calf thymus chromatin. Med. J. Islamic Rep. Iran. 1993, 7, 43-46. 
200. Zhang, P.; Chen, J.; Liang, Y. DNA binding, cytotoxicity, and apoptotic-inducing 
activity of ruthenium(II) polypyridyl complex. Acta Biochimica. Biophysica. Sinica. 2010, 42, 
440-449. 
201. Reichmann, M. E.; Rice, S. A.; Thomas, C. A.; Doty, P. A further examination of the 
molecular weight and size of desoxypentose nucleic acid. J. Am. Chem. Soc. 1954, 76, 3047-
3053. 
202. Ciupa, A.; De Bank, P. A.; Mahon, M. F.; Wood, P. J.; Caggiano, L. Synthesis and 
antiproliferative activity of some 3-(pyrid-2-yl)-pyrazolines. Med. Chem. Comm. (Suppl.) 
2013, 4, 956-961. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
